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Abstract  
The term ovarian cancer describes a set of distinct and heterogeneous 
diseases with an overall poor prognosis. Standard treatment strategies are 
limited and new novel therapies targeting the molecular pathways dysregulated 
in ovarian cancer are being explored with a goal of personalising provision of 
treatment, based upon accurate biomarker testing.    
There are two major challenges if progress is to continue with a measureable 
clinical impact. Firstly, the mechanism of action of emerging therapies must be 
understood with reliable biomarkers capable of accurately predicting response 
to therapy. Secondly, for biomarkers to be useful in their accurate prediction of 
response, a thorough understanding of how to test a patient is needed. As our 
understanding of inter- and intra-tumour heterogeneity grows, the ability to test 
a single sample of tumour that is representative becomes more challenging and 
it is likely that new clinical strategies for testing multiple areas of the same 
tumour, at multiple time points, are required if our understanding of tumour 
biology is to translate into survival benefit for patients. Detection and 
subsequent testing of circulating tumour cells may offer the ability to test cells 
representative of the entire tumour without the need for invasive testing but a 
clear understanding of the consequences of intra-tumoural heterogeneity is 
needed.  
This PhD aimed to address these challenges by firstly exploring the potential 
role of sapacitabine, a novel oral nucleoside analogue, for the treatment of 
ovarian cancer alongside the poly (ADP-ribose) polymerase (PARP) inhibitor 
rucaparib and platinum. Homologous recombination DNA repair functional 
status has been explored as a biomarker for their stratified use. Additionally, 
this project aimed to explore the feasibility of detecting circulating tumour cells 
in ovarian cancer using ImageStream technology, which combines flow 
cytometry with high resolution immunofluorescent microscopy. 
  
iii 
 
Acknowledgments 
Throughout my undergraduate and postgraduate medical training, I have been 
privileged to work under the supervision and mentorship of so many incredible 
people and I have always felt inspired to push myself to be able to contribute to 
my field. This PhD has pushed me to my absolute limits academically, 
physically and emotionally but it has also rewarded me in so many ways.  
This work has created a lifetime of further questions but it has only been 
possible because of the unbelievable support from friends and colleagues at the 
NICR and NGOC and my family and friends. Perhaps the most important 
people to thank are those women, alongside their families, who have battled 
ovarian cancer. I have been honoured to care for them and take pride in using 
their donated samples in order to contribute to forwarding the understanding 
and treatment of this devastating disease. Each ‘PCO’ sample represents a 
woman who selflessly considered others as she fought for her own health. This 
work is dedicated to all of these women and their families for their strength, 
determination and inspiration.   
I thank Richard and Nicola for their continuous support and guidance and 
apologise for the length of my acknowledgements - I still have not learnt to write 
concisely!  
I thank James, Mum, Dad and Becky as well as friends who have tirelessly 
supported me, encouraged me during busy times and forgiven my absence.  
I am grateful to all of my colleagues, in particular Aiste, Angelika, Peter, Barry, 
Laura and Fiona for their help and expertise in the lab and the North Terrace. 
Colleagues who have been actively involved in various parts of this project have 
been acknowledged separately within relevant chapters and publications. 
Thank you also to Emilia, who arrived just in time to become a helpful 
distraction!  
Finally, I thank the NGOC, Clovis and Cyclacel for funding this project. 
iv 
 
Contents 
Statement of Originality ................................................................................................................... i 
Abstract ....................................................................................................................... ii 
Acknowledgments ......................................................................................................................... iii 
Contents ........................................................................................................................................ iv 
List of Abbreviations ...................................................................................................................... ix 
List of Figures and Tables ............................................................................................................. xi 
Chapter 1: Introduction .............................................................................................. 1 
1.1. Ovarian Cancer ................................................................................................................... 2 
1.1.1. Epidemiology .................................................................................................... 2 
1.1.2. Risk Factors ...................................................................................................... 3 
1.1.3. Pathogenesis .................................................................................................... 5 
1.2. Current Classification System of Ovarian Cancer .............................................................. 8 
1.3. The Reclassification of Ovarian Cancer? ......................................................................... 11 
1.3.1. Why Should the Current Classification System be Updated? ........................ 11 
1.3.2. How Should Ovarian Cancer be Classified? .................................................. 12 
1.4. DNA Damage Repair (DDR) Pathways ............................................................................ 13 
1.4.1. Direct Repair by O6-methylguanine-DNA Methyltransferase (MGMT) ........... 14 
1.4.2. Base Excision Repair (BER) ........................................................................... 15 
1.4.3. Nucleotide excision repair (NER) .................................................................... 17 
1.4.4. Mismatch Repair (MMR) ................................................................................. 19 
1.4.5. Double Strand Break Repair (DSB) ................................................................ 22 
1.4.6. Non-Homologous End Joining (NHEJ) ........................................................... 22 
1.4.7. Homologous Recombination repair (HR) ........................................................ 23 
1.5. Other Pathways Important in Ovarian Cancer .................................................................. 28 
1.6. Current Treatment Strategies in Ovarian Cancer ............................................................. 31 
1.6.1. Ovarian Cancer Surgery ................................................................................. 31 
1.6.2. Tumour Sampling for Histological and Molecular Subtyping .......................... 32 
1.6.3. Chemotherapy ................................................................................................ 33 
1.6.4. Platinum .......................................................................................................... 34 
1.6.5. Second Line Agents ........................................................................................ 36 
1.7. Targeted Therapies for Ovarian Cancer? ......................................................................... 38 
1.7.1. Angiogenesis Inhibitor: Bevacizumab ............................................................. 38 
1.7.2. PARP Inhibitors ............................................................................................... 39 
1.8. Rationale for this Project ................................................................................................... 48 
Chapter 2. Hypothesis and Aims ............................................................................. 49 
2.1. Primary Cultures ............................................................................................................... 50 
2.2. Solid Tumour Culture and Heterogeneity ......................................................................... 51 
2.3. Sapacitabine ..................................................................................................................... 52 
2.4. Circulating Tumour Cells................................................................................................... 53 
  
v 
 
Chapter 3. Materials and Methods ........................................................................... 49 
3.1. General Equipment ........................................................................................................... 49 
3.2. Chemicals and Reagents .................................................................................................. 50 
3.3. General Laboratory Practice ............................................................................................. 53 
3.4. Cell Culture ....................................................................................................................... 53 
3.4.1. Cell lines ......................................................................................................... 53 
3.4.2. Primary Ovarian Ascitic Cancer Cells (PCO) ................................................. 56 
3.5. Cytotoxicity and Proliferation Assays ................................................................................ 59 
3.5.1. Colony Formation Assays ............................................................................... 59 
3.5.2. Growth Assay (Sulforhodamine B [SRB]) ....................................................... 60 
3.5.3. Growth Inhibition Assays ................................................................................ 61 
3.6. Homologous Recombination Repair Functional Assay .................................................... 63 
3.6.1. Principles of the Assay.................................................................................... 63 
3.6.2. Assay Protocol ................................................................................................ 65 
3.6.3. Immunofluorescence Microscopy: Focus Counting ........................................ 66 
3.7. 8-hydroxy-2’-deoxyguanosine: A functional BER assay ................................................... 67 
3.8. RNA Genome Expression Arrays ..................................................................................... 69 
3.9. PARP Assay ..................................................................................................................... 72 
3.10. Western Blotting ................................................................................................................ 74 
3.11. Clinical Definitions ............................................................................................................. 76 
3.12. Statistical Analysis ............................................................................................................ 76 
Chapter 4. Assessment of the Primary Ovarian Cancer (PCO) Culture Model and   
                  Exploration of Biological Markers of Clinical Survival ......................... 78 
4.1. Introduction: Primary Culture ............................................................................................ 78 
4.2. Aims .................................................................................................................................. 79 
4.3. Methods ............................................................................................................................ 80 
4.3.1. Characterisation .............................................................................................. 80 
4.3.2. Morphology ..................................................................................................... 80 
4.3.3. Immunofluorescence Characterisation Panel ................................................. 81 
4.3.4. Formal Histopathology .................................................................................... 84 
4.3.5. Surface Antigen Characterisation Timeline .................................................... 84 
4.3.6. Reducing Analysis Time of PCO cultures (Characterisation and HR Assay) . 84 
4.3.7. Cytocentrifugation ........................................................................................... 84 
4.3.8. Coverslip Cultures ........................................................................................... 85 
4.3.9. PCO culture, HR Functional Assay, Cell Proliferation, PARP Assays  
             and Gene Expression Methods ...................................................................... 85 
4.4. Results .............................................................................................................................. 86 
4.5. PCO Collection ................................................................................................................. 86 
4.6. Clinical Characteristics...................................................................................................... 86 
4.7. Characterisation ................................................................................................................ 87 
4.7.1. Original Characterisation Protocol and its Limitations .................................... 87 
4.7.2. Expanded Characterisation Panel .................................................................. 88 
4.7.3. CA125 Expression: Immunofluorescence vs. Immunohistochemistry ............ 90 
4.7.4. Epithelial Mesenchymal Transition (EMT) and PCO Phenotype .................... 92 
4.7.5. Stability of Characterisation Phenotype with Time and Passage ................... 93 
4.7.6. Morphology ..................................................................................................... 95 
4.8. PCO Culture Growth ......................................................................................................... 96 
4.8.1. Growth and HR Status .................................................................................... 97 
4.9. PCO-2 Cultures ................................................................................................................. 98 
4.9.1. PCO vs PCO-2 Antigen Characterisation ....................................................... 98 
4.9.2. PCO vs PCO-2 Growth ................................................................................. 100 
4.9.3. PCO vs. PCO-2 HR Status ........................................................................... 101 
4.10. Homologous Recombination DNA Repair Status of PCO Cultures ................................ 102 
  
vi 
 
4.11. Sensitivity to Cytotoxic Agents ........................................................................................ 103 
4.11.1. Selection of Methodology: SRB vs. WST-1 vs. Colony Formation vs.  
             Cell Counting ................................................................................................ 104 
4.11.2. SRB Assay to evaluate effect of cytoxtic agents on PCO cultures ............... 105 
4.11.3. Sensitivity to Rucaparib and Cisplatin by HR Status .................................... 108 
4.11.4. Sensitivity Rucaparib vs. Cisplatin ................................................................ 109 
4.12. Clinical Application of HR Assay ..................................................................................... 111 
4.12.1. Cytocentrifugation and Coverslip Culture ..................................................... 111 
4.12.2. PARP Activity as a Surrogate Assay for HR Function .................................. 113 
4.12.3. HR Gene Expression as a Surrogate for HR Function ................................. 116 
4.13. Alternative HR analysis ................................................................................................... 121 
4.13.1. Correlation of Focus Count With Rucaparib Sensitivity ................................ 122 
4.13.2. Correlation of Focus Count With Cisplatin Sensitivity .................................. 122 
4.13.3. Rad51 Alone as a Predictor of HR Function ................................................. 127 
4.14. Clinical correlations ......................................................................................................... 128 
4.14.1. HR Status as a Predictor of Survival ............................................................ 128 
4.14.2. Clinical vs. Ex Vivo Sensitivity to Platinum ................................................... 130 
4.14.3. Growth as a Predictor of Time to Relapse (PFS) ......................................... 132 
4.15. Summary ......................................................................................................................... 134 
4.16. Discussion ....................................................................................................................... 135 
Chapter 5. Inter- and Intra-tumoural Heterogeneity.............................................. 142 
5.1. Introduction ..................................................................................................................... 142 
5.1.1. Heterogeneity in Ovarian Cancer: What is Already Known? ........................ 143 
5.1.2. Reported Solid Culture Methodologies ......................................................... 146 
5.2. Aims ................................................................................................................................ 147 
5.3. Methods .......................................................................................................................... 148 
5.4. Results ............................................................................................................................ 148 
5.5. PCO Solid Culture Case Series ...................................................................................... 150 
5.5.1. Culture Success ............................................................................................ 150 
5.5.2. Patient Demographics................................................................................... 151 
5.6. Heterogeneity as a Prognostic Marker ........................................................................... 160 
5.7. HR of Ascites as a Prognostic Marker ............................................................................ 164 
5.8. Histology as a Prognostic Marker ................................................................................... 167 
5.9. Surgical Cytoreduction as a Prognostic Marker ............................................................. 167 
5.10. Longitudinal Sequential Samples ................................................................................... 168 
5.11. Discussion ....................................................................................................................... 173 
5.12. Conclusions .................................................................................................................... 181 
Chapter 6. Sapacitabine as a Therapeutic Agent in the Treatment of  
                  Ovarian Cancer ..................................................................................... 182 
6.1. Introduction ..................................................................................................................... 182 
6.2. Sapacitabine ................................................................................................................... 183 
6.2.1. Structure ....................................................................................................... 183 
6.2.2. Function and Mechanism of Action ............................................................... 183 
6.2.3. Sapacitabine and DNA Repair Pathways ..................................................... 186 
6.3. Aims ................................................................................................................................ 192 
6.4. Methods .......................................................................................................................... 192 
6.4.1. Cell lines ....................................................................................................... 193 
6.4.2. Growth Inhibition of BER Proficient and Deficient Cells by CNDAC With and 
Without Nucleoside Transport Inhibitors ....................................................... 193 
6.4.3. Development of an Assay of BER Function.................................................. 194 
6.4.4. Western Blotting ............................................................................................ 195 
  
vii 
 
6.5. Results ............................................................................................................................ 196 
6.5.1. Cell Lines ...................................................................................................... 196 
6.5.2. Assessing Cytotoxicity in PCO Samples ...................................................... 200 
6.5.3. Sensitivity of PCO to CNDAC, Cisplatin and Rucaparib in Relation to HR 
Status ............................................................................................................ 200 
6.5.4. HR and the Prediction of CNDAC Sensitivity................................................ 208 
6.5.5. CNDAC in Sequential or Combination Drug Regimes .................................. 209 
6.5.6. Investigation of Alternative DNA Repair Mechanisms as Possible 
Determinants of Sensitivity to CNDAC ......................................................... 210 
6.5.7. Base Excision Repair .................................................................................... 214 
6.5.8. Interaction of HR and BER Functional Status .............................................. 221 
6.5.9. Investigation of Uptake of CNDAC by Nucleoside Transporters Using 
Inhibitors ....................................................................................................... 222 
6.5.10. Expression of Proteins Implicated in CNDAC Sensitivity: ENT, dCK, CDA . 224 
6.5.11. BER Gene Expression as a Surrogate for BER Function ............................. 227 
6.6. Discussion ....................................................................................................................... 229 
6.6.1. Sapacitabine in the Treatment of Ovarian Cancer ....................................... 229 
6.6.2. HR as a Biomarker of Sensitivity to CNDAC ................................................ 230 
6.6.3. Interaction of Other Cellular Pathways in the Sensitivity to CNDAC ............ 232 
6.6.4. Cellular Uptake and Metabolism of CNDAC ................................................. 235 
6.7. Conclusions .................................................................................................................... 235 
Chapter 7. Circulating Tumour Cells in Ovarian Cancer ...................................... 236 
7.1. Introduction ..................................................................................................................... 236 
7.1.1. The Origin of CTCs ....................................................................................... 236 
7.1.2. Pharmacodynamic Biomarkers Using CTCs ................................................ 238 
7.1.3. CTCs vs Circulating DNA.............................................................................. 238 
7.1.4. CTCs in Ovarian Cancer ............................................................................... 240 
7.1.5. CTC Challenges ............................................................................................ 242 
7.1.6. CTC Detection Techniques ........................................................................... 243 
7.1.7. ImageStream ................................................................................................ 245 
7.2. Aims ................................................................................................................................ 246 
7.3. Method Development ...................................................................................................... 247 
7.3.1. Antibody Selection ........................................................................................ 247 
7.3.2. ImageStream Settings .................................................................................. 247 
7.3.3. Characterisation of OVCAR3 Cell Line and PCO Cultures .......................... 249 
7.3.4. Retrieval of Spiked ‘CTC’ .............................................................................. 251 
7.3.5. ImageStream Data Analysis Algorithm  ........................................................ 252 
7.3.6. Retrieval Results Without Enrichment .......................................................... 255 
7.3.7. Enrichment .................................................................................................... 256 
7.3.8. Enrichment Results ....................................................................................... 259 
7.3.9. Retrieval Results with Enrichment ................................................................ 259 
7.4. Results: Ovarian Cancer Patient Sample Results .......................................................... 262 
7.4.1. Enumeration .................................................................................................. 262 
7.4.3. CTC Enumeration and Survival .................................................................... 269 
7.4.4. Objects of Interest ......................................................................................... 270 
7.4.5. Healthy Volunteer Blood without spiked ‘CTC’ ............................................. 274 
7.4.6. ImageStream HR Assay ............................................................................... 274 
7.4.7. HR Assay in CTCs ........................................................................................ 277 
7.4.8. Imagestream for the characterisation of Ascites .......................................... 278 
7.4.9. Ascitic Fluid ................................................................................................... 280 
7.5. Summary ......................................................................................................................... 284 
7.6. Discussion ....................................................................................................................... 285 
7.6.1. Why are there so few CTCs in Ovarian Cancer? ......................................... 288 
7.6.2. Can ImageStream Assessment of Ascites make Real Time HR Assessment 
Possible? ...................................................................................................... 290 
7.7. Conclusions .................................................................................................................... 291 
  
viii 
 
Chapter 8: Discussion ............................................................................................ 292 
8.1. Summary of Results ........................................................................................................ 293 
8.2. A New Treatment Strategy for Ovarian Cancer .............................................................. 297 
8.3. Redefining Ovarian Cancer ............................................................................................ 299 
8.4. Ovarian Cancer Heterogeneity: Implications for Academia ............................................ 300 
8.5. Strengths and Weaknesses ............................................................................................ 300 
8.6. Future Work .................................................................................................................... 302 
Appendices ............................................................................................................. 304 
Appendix 1: PhD Publications ................................................................................................... 304 
Appendix 2: Published Abstracts .............................................................................................. 305 
Appendix 3: Oral Presentations ................................................................................................ 306 
Appendix 4: Poster Presentations ............................................................................................. 307 
Appendix 5: Consent Form for Tissue Collection...................................................................... 310 
References .............................................................................................................. 324 
 
  
ix 
 
List of Abbreviations 
Abbreviation Full Terminology Abbreviation Full Terminology 
3AB  3-Aminobenzamide ECL Enhanced chemiluminescence 
8-OHdG 8-oxo-7,8-dihydro-2’deoxyguanosine  ED  Effective dose 
8-oxoG 8-oxoguanine  EDTA Ethylenediaminetetraacetic acid 
Ab Antibody ELISA 
Enzyme-linked immunoabsorbent 
assay 
ADP Adenosine diphosphate ribose EMT Epithelial mesenchymal transition 
AKT Serine/threonine protein kinase ENT Equilibrative nucleoside transporter 
AML Acute myeloid leukaemia EOC Epithelial ovarian cancer 
ATCC American Tissue Culture Collection EORTC 
European Organisation for Research 
and Treatment of Cancer 
ATM Ataxia-telangiectasia-mutated kinase EpCAM Epithelial cell adhesion molecule 
ATP  Adenosine 5'-triphosphate FACS Fluorescence-activated cell sorting 
ATR  Human Ataxia telangiectasia-related FBS FBS Foetal bovine serum 
AUC Area under curve FCS  Fetal bovine serum 
BER Base excision repair FDA Food and drug association 
BRAF Serine/threonine-protein kinase B-Raf  FEN  Flap structure-specific endonuclease 
BRCA 1 Breast cancer susceptibility protein 1 FFPE Formalin-fixed paraffin-embedded 
BRCA 2 Breast cancer susceptibility protein 2 FIGO 
International Federation of 
Gynaecology and Obstetrics 
BSA  Bovine serum albumin FISH Fluorescent in situ hybridisation 
BSO Bilateral salpingo ophorectomy FITC Fluorescein isothiocynanate 
CA125 Cancer antigen 125 GI50 Growth inhibition (50%) 
CCD Charge coupled device GOG Gynaecological Oncology Group 
CDA Cytidine deaminase  Gy Gray (irradiation unit) 
CI 
Confidence interval / Combination 
index 
H&E Haematoxylin and eosin  
CK Cytokeratin H2AX H2A histone family, member X 
CLL Chronic lymphocytic lymphoma HCl Hydrochloric acid 
CML Chronic myeloid leukaemia HE4 Human epididymis protein 4 
CNDAC  
2-C-cyano-2-Deoxy-1-D-arabino-
pentofuranosylcytosine 
HEPES 
4-(2-hydroxyethyl)-1-
piperazineethanesulfoni acid 
CNddc 
2’-C-cyano-2’,3’-didehydro-2’,3’-
dideoxycytidine HGSC 
High grade serous cancer 
CTC Circulating tumour cell HK10 human Kallikrein 10 
DAPI 4’,6-diamidino-2-phenylindole HNPCC  
Hereditary non-polyposis colorectal 
cancer 
dCK Deoxycytidine kinase HR Homologous recombination 
DDR DNA damage response HRC 
Homologous recombination 
competent 
DMSO Dimethyl sulphoxide HRD Homologous recombination deficient 
DNA  Deoxyribonucleic acid HRP Horseradish peroxidase 
DNA-PK  DNA-dependent protein kinase HRT Hormone replacement therapy 
DP Dipyridamole HU Hydroxyurea 
DSB  Double strand break IC Inclusion cyst 
DT Doubling time IDS Interval debulking surgery 
x 
 
IP Intra-peritoneal  PCO Primary culture ovary 
IR Ionising radiation PCR  Polymerase chain reaction 
ITH Intra-tumour heterogeneity PE Phycoerythrin 
IV Intra-venous PFS Progression free survival 
KRAS 
Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
pH  Potential of hydrogen 
LC50 Lethal dose (50%) Pol  DNA polymerase 
LD Limiting dose PPV Positive predictive value 
LOH Loss of heterozygosity PTEN 
Gene encoding phosphatase and 
tensin homolog 
MAPK Mitogen-activated protein kinase RAD51 Rad 51 homolog 
MGMT  
O6-methylguanine-DNA 
methyltransferase 
RBC Red blood cell 
miRNA  MicroRNAs RCLB Red cell lysis buffer 
MMR Mismatch repair RCT Randomised controlled trial 
MOC31 Antibody to an epithelial glycoprotein  RECIST 
Response Evaluation Criteria in Solid 
Tumours 
MRN MRE11, Rad51, NBS1 complex RNA  Ribonucleic acid 
MSI Microsatellite instability ROC Receiver operating characteristic 
MUC16 Mucin 16 ROS Reactive oxygen species 
MX Methoxyamine RPM Revolutions per minute 
NACT Neoadjuvant chemotherapy RPMI  
Roswell Park Memorial Institute 
developed medium 
NAD+ Nicotinamide adenine dinucleotide SD Standard deviation 
NADH  Reduced form of NAD+ SEM Standard error of the mean 
NBMPR 
Nitrobenzylmercaptopurine 
ribonucleoside  
SLL Small lymphocytic lymphoma 
NER Nucleotide excision repair SNP Single nucleotide polymorphism 
NGOC 
Northern Gynaecological Oncology 
Centre 
SRB Sulforhodamine B 
NHEJ Non-homologous end joining SSB  Single strand break 
NHS National Health Service TAM Tumour-associated macrophage 
NICE National Institute for Clinical Excellence TCA  Trichloroacetic acid 
NPV Negative predictive value TCGA The Cancer Genome Atlas 
NSCLC Non-small cell lung cancer TMA Tissue microarray 
NT Nucleoside transporter TP53 
Gene encoding tumour suppressor 
protein (p53)  
OCP Oral contraceptive pill TZ Temozolomide 
OD  Optical density UV Ultraviolet 
OS Overall survival v/v by volume 
OSE Ovarian surface epithelium VEGF Vascular endothelial growth factor 
OVCAR Ovarian cancer w/v by weight 
p53 
Tumour suppressor protein encoded by 
TP53 gene 
WBC White blood cell 
PAR  Poly(ADP-ribose) polymer WST-1 Water soluble tetrazolium salts 
PARP Poly(ADP-ribose) polymerase WT Wild type 
PARPi Poly(ADP-ribose) polymerase inhibitor XRCC X-ray cross complementing 
PBS Phosphate buffered saline γH2AX Histone H2A variant X 
    
 
xi 
 
List of Figures and Tables 
Figure 1.1 - 1:  Ovarian Cancer, age-standardised five-year relative survival rates, England and 
Wales 1971-1995, England 1996-2009; Cancer Research UK. 
Figure 1.4 - 1:  Base excision repair pathway. 
Figure 1.4 - 2: Nucleotide excision repair pathway. 
Figure 1.4 - 3: Mismatch repair pathway. 
Figure 1.4 - 4: Non-homologous end joining pathway. 
Figure 1.4 - 5:  Homologous recombination pathway. 
Figure 1.6 - 1: Platinum-resistance definition by the Gynaecologic Oncology Group (GOG). 
Figure 1.7 - 1:  Synthetic lethality in HR defective tumours with PARP inhibition. 
Figure 3.4 - 1:  PCO collection flow chart for sample analysis. 
Figure 4.3 - 1:  PCO culture morphology reference Images. 
Figure 4.7 - 1:  PCO immunofluorescent characterisation panel. 
Figure 4.7 - 2: Concordant CA125 expression in PCO 158. 
Figure 4.7 - 3: Relationship between serum CA125 and CA125 protein expression detected by 
immunohistochemistry and immunofluorescence. 
Figure 4.7 - 4: 
Figure 4.8 - 1:  
Cytokeratin and vimentin co-expression in PCO 163. 
PCO growth. 
Figure 4.8 -  2: Growth rate PCO cultures by HR status results. 
Figure 4.9 -  1:  Doubling time for PCO vs. PCO-2 cultures. 
Figure 4.10 -  1: HR assay. Immunofluorescence detection of nuclear γH2AX (A) and Rad51 (B) 
in PCO 164. 
Figure 4.11 -  1:  Comparison of growth inhibition by rucaparib using SRB, WST-1 proliferation 
assays and cell counting in PCO 170. 
Figure 4.11 -  2: Rad51 foci count and growth inhibition by rucaparib and cisplatin. 
Figure 4.11 -  3:  Sensitivity to cisplatin and rucaparib stratified by HR Status. 
Figure 4.11 -  4:  Growth inhibition by rucaparib (A) and cisplatin (B) in PCO cultures by HR 
functional status. 
Figure 4.11 -  5:  Resistance to rucaparib and cisplatin. 
Figure 4.12 -  1:  PCO HR status: comparison of HR results following traditional culture technique 
vs. direct culture onto coverslips. 
Figure 4.12 -  2: Stimulated PARP activity in PCO. A: Immunoblot; B: Standard curve; C: 
Stimulated PAR activity expressed as mean (SD) PAR pmol/10
6
 cells. 
Figure 4.12 -  3: Correlation of PAR level and % survival 10 μM cisplatin (A) and 100 μM 
rucaparib (B). 
Figure 4.12 -  4: RNA expression of key components of the HR DNA repair pathway for 24 PCO 
samples.  
Figure 4.12 -  5: RNA expression of key components of the HR DNA repair pathway in PCO 
grouped by HR status, n=24.  
Figure 4.12 -  6: Correlation between PARP-1 RNA expression and sensitivity to rucaparib (% 
survival at 100 µM). 
Figure 4.13 -  1: Fold increase in Rad51 focus formation from control with subsequent HR 
classification. 
Figure 4.13 -  2: Correlation of γH2AX and Rad51 foci counts with % survival at 100 μM 
rucaparib. 
Figure 4.13 -  3: Correlation of γH2AX and Rad51 foci counts with % survival at 10 μM cisplatin. 
Figure 4.13 -  4:  ROC curve of ability of Rad51 foci count to predict HR function. 
  
xii 
 
Figure 4.14 -  6: Kaplan-meier survival curves for patients stratified by HR function of ascitic PCO 
cultures.  
Figure 4.14 -  7:  Ex vivo PCO culture sensitivity to cisplatin as a predictor of clinical sensitivity to 
platinum based chemotherapy. 
Figure 4.14 -  8: Correlation of PCO culture doubling time with PFS and OS. 
Figure 5.1 -1: Somatic evolution . 
Figure 5.4 -  1:  Fibroblast exclusion using selective seeding. 
Figure 5.5 -  1:  Solid PCO cultures. 
Figure 5.5 -  2:  Summary of characterisation antigen detection. 
Figure 5.5 -  3: 
 
PCO 179. Solid tumour biopsies taken from five intra-abdominal sites cultured, 
alongside ascites culture (A). (B) Intra-tumoural heterogeneity of antigen 
detection of EpCAM and CA125 using immunofluorescent microscopy. (C) 
Variable proliferation following 10-day exposure to rucaparib, assess using SRB 
assay. 
Figure 5.5 -  4:  PCO subculture doubling time. 
Figure 5.5 -  5: Growth comparison. A: HRC vs HRD; B: Ascites vs solid cultures. 
Figure 5.5 -  6:  Growth inhibition. 
Figure 5.6 -  1:  Kaplan-meier survival curves: heterogeneous HR cultures vs homogeneous HR 
cultures. 
Figure 5.6 -  2:  Cytoreductive surgical outcome by homogenous and heterogeneous functional 
groupings. 
Figure 5.7 -  1:  Kaplan-meier survival curves for PFS/OS by HR status (A), histological subtype 
(B) and outcome of cytoreductive surgery (C). 
Figure 5.10 -  1: Longitudinal sampling. 
Figure 5.12 -  1: Tumour evolution and intra-tumour heterogeneity. 
Figure 6.2 -  1: Structure of sapacitabine, CNDAC, gemcitabine and ara-C. 
Figure 6.2 -  2: Incorporation of CNDAC into DNA, β-elimination resulting in CNddC.  
Figure 6.2 -  3:  S-Phase stalled replication forks. 
Figure 6.2 - 4:  CNDAC metabolism. 
Figure 6.5 - 1:  Cytotoxicity of CNDAC and cisplatin in cell lines matched for BRCA1/2 
mutations. 
Figure 6.5 - 2: Sensitivity of each PCO culture to CNDAC (A), cisplatin (B), and rucaparib (C). 
Figure 6.5 - 3: Sensitivity to CNDAC, rucaparib and cisplatin stratified by HR status.  
Figure 6.5 - 4: Correlation studies between percentage survival at given concentrations of 
CNDAC, cisplatin and rucaparib. 
Figure 6.5 - 5:  Correlation of sensitivity of PCO cultures to cisplatin and CNDAC. 
Figure 6.5 - 6:  Resistance (A) and sensitivity (B) to CNDAC, cisplatin and rucaparib b. 
Figure 6.5 - 7:  ROC analysis for HR status and CNDAC sensitivity. 
Figure 6.5 - 8:  Cell proliferation by CNDAC (SRB assay) with matched cell lines for NHEJ, 
BER, and NER DNA repair. 
Figure 6.5 - 9: Inhibition of BER using methoxyamine. 
Figure 6.5 - 10: 8-OHdG baseline levels in PCO samples. 
Figure 6.5 - 11:  Correlation of 8-OHdG with CNDAC sensitivity. 
Figure 6.5 - 12: ROC 8-OHdG of 1.5 to predict CNDAC sensitivity. 
Figure 6.5 - 13: Incidence of BER and HR dysfunction in PCO cultures with corresponding 
grouped sensitivity to CNDAC. 
Figure 6.5 - 14:  CNDAC cell proliferation assays using AA8 and EM9 cell lines with addition of 
DP or NBMPR. 
Figure 6.5 - 15:  Western blot for protein expression of ENT1, CDA, dCK in PCO cultures. 
xiii 
 
Figure 6.5 - 16: RNA expression of key components of the BER DNA repair pathway in PCO 
grouped by BER status, n=24. 
Figure 7.3 - 1: Scatterplot showing the area and aspect ratio of OVCAR3 cell line sample 
(incubated with EpCAM, CK, CA125 and DRAQ5) based upon brightfield image 
(MO1). 
Figure 7.3 - 2: ImageStream cell line characterisation results. 
Figure 7.3 - 3: CTC analysis algorithm. 
Figure 7.3 - 4: CTC retrieval without WBC enrichment. 
Figure 7.3 - 5: EasySep™ CD45 depletion of WBC (STEMCELL Technologies, 2013). 
Figure 7.3 - 6: Comparison of depletion methods.  
Figure 7.3 - 7: Retrieval of malignant cells from whole blood. 
Figure 7.4 - 1:  CTC frequency and relation to stage of disease and extra-peritoneal disease. 
Figure 7.4 - 1: Cell plot of ovarian cancer CTC with nucleated cells (DRAQ5 nuclear stain) with 
variable expression of EpCAM, CK and CA125. 
Figure 7.4 - 2: CTC characterisation. 
Figure 7.4 - 3: Three representatives CTC from PCO 202. 
Figure 7.4 -  4: CTC area. 
Figure 7.4 -  5: Correlation of CTC frequency/ml with survival. 
Figure 7.4 -  6: Objects of interest from healthy volunteer sample. 
Figure 7.4 -  7: CTC from PCO 173, 180 and 213 showing CTC surrounded by WBC. 
Figure 7.4 -  8: ImageStream assessment of HR function in a panel of cell lines. 
Figure 7.4 -  9: γH2AX and Rad51 nuclear foci. 
Figure 7.4 -  10: Mean γH2AX  foci count in PCO cultures using ImageStream. 
Figure 7.4 -  11:  ImageStream antigen characterisation of PCO ascites. 
Figure 7.4 -  12: ImageStream characterisation of ascitic PCO samples. 
Figure 7.4 -  13: ImageStream cell plot of the major sub-populations of cells identified within the 
ascitic fluid of PCO209. A: EpCAM only. B: CK only. C: CA125 only. D: All. E: 
EpCAM and CK. F: EpCAM and CA125. G: CK and C A-125. 
Figure 7.4 -  14: γH2AX Foci in fresh ascites. 
Figure 8.2 - 1:  Schematic for the sequential Provision of Targeted Agents following Interim 
Tumour Sampling and Biomarker Testing 
Figure 9.1 - 1:  CA125 conjugation validation. 
Figure 9.2 - 1:  HR assay optimisation of nuclear, γH2AX and Rad51 foci masks. 
Figure 9.3 - 1:  
 
γH2AX focus dose response comparing three ImageStream masks with 
traditional immunofluorescent microscopy and manual counting. 
Figure 9.4 - 1: γH2AX foci following irradiation at different doses. Assessment of count using 
ImageStream. 
Figure 9.5 - 1: HR method optimisation in PCO cultures. 
  
  
xiv 
 
Table 1.1 - 1: FIGO (International Federation of Gynaecology and Obstetrics) surgical staging 
of ovarian cancer  with five-year stage-specific relative survival rates, Cancer 
Research UK. 
Table 1.1 -  2: Risk factors for ovarian cancer development. 
Table 1.1 -  3: Ovarian cancer classification with frequencies and common genetic mutations. 
Table 1.6 - 1: Randomised Controlled Trials (RCT) for chemotherapy treatment for ovarian 
cancer 
Table 1.6 - 2: Second line chemotherapy agents in the treatment of ovarian cancer 
Table 1.7 – 1: Clinical trials of olaparib and rucaparib PARPi. 
Table 3.4 - 1:  Cell lines. 
Table 3.6 -  1: Microscope settings for immunofluorescent HR assay. 
Table 3.8 – 1: HR genes analysed in RNA genome analysis. 
Table 3.8 – 2: BER genes analysed in RNA genome analysis. 
Table 4.3 – 1: Antibodies for the PCO immunofluorescent characterisation panel. 
Table 4.3 -  2: Immunofluorescence microscope settings for PCO culture characterisation. 
Table 4.6 -  1: Summary of PCO patient demographics. 
Table 4.7 -  1: Immunofluorescent characterisation timeline.  
Table 4.7 -  2: Histological subtype, characterisation antigen expression, HR DNA repair status 
in PCO cultures (n=61) stratified by morphological subtype. 
Table 4.9 -  1:  Immunofluorescent antigen characterisation of matched PCO and PCO-2 
cultures. 
Table 4.9 -  2: Summary of antigen expression of PCO and PCO-2 cultures. 
Table 4.9 -  3:  Functional HR status of paired PCO and PCO-2 cultures. 
Table 4.10 -  1: Functional HR status of PCO cultures by histological subtype. 
Table 4.11 -  1: Comparing cytotoxicity to rucaparib in a cell line panel by colony formation assay 
and proliferation assays.  
Table 4.11 -  2: Comparison of growth inhibition, determined by SRB assay, by rucaparib and 
cisplatin stratified by HR functional status. 
Table 4.12 -  1: PCO culture antigen characterisation.  
Table 4.14 -  1: Patient demographic data stratified by HR status. 
Table 5.4 -  1: Optimisation of solid culture methodology. 
Table 5.5 -  1: Solid tumour patient demographics. 
Table 5.5 – 2: Solid tumour morphological classification by histological subtype. 
Table 5.5 – 3: PCO solid tumour samples with HR status and corresponding sensitivities to 
rucaparib and cisplatin, determined using SRB cell proliferation assay. 
Table 5.6 - 1: Intra-tumoural heterogeneity of HR status and survival (PFS and OS). 
Table 5.6 – 2: PCO patient demograpghics with heterogeneity of HR function ordered by 
progression free and overall survival.    
Table 5.8 – 1:   Incidence of HRC and HRD by histological subtype. 
Table 5.9 – 1: The distribution of surgical outcome within the homogeneous and 
heterogeneous tumour groups. 
Table 6.2 - 1:   CNDAC in clinical trials. 
Table 6.4 – 1: Agents for the inhibition of BER or transporter protein, their mode of action and 
hypothesis for effect with simultaneous treatment with sapacitabine. 
Table 6.4 - 2:   Antibodies for western blot. 
Table 6.5 - 1:  Cell line panel: growth characteristics and cytotoxicity by CNDAC, rucaparib and 
cisplatin. 
Table 6.5 - 2:  Comparison of SRB with colony formation in cell lines matched for BRCA 1/2. 
Table 6.5 - 3:  CNDAC in combination with PARPi. 
xv 
 
Table 6.5 - 4:  Cell line panel used to explore the contribution of NHEJ, BER, NER, p53 and 
MMR in the sensitivity to CNDAC. 
Table 6.5 - 5:  Sensitivity to CNDAC and cisplatin assessed by proliferation assay in cell line 
panels matched for functional/defective DNA repair pathways. 
Table 6.5 - 6: Cytotoxic effect of methoxyamine (MX): Percentage survival AA8 and EM9 cells 
with addition of MX. 
Table 6.5 - 7: ROC analysis of predictability of 8-OHdG values to predict sensitivity to CNDAC. 
Table 6.5 - 8: Mean GI50 of paired cell lines following exposure to CNDAC with NBMPR or DP. 
Table 7.1 - 1 Differences between CTC and ctDNA analyses.  
Table 7.1 - 2: CTC detection technologies. 
Table 7.3 - 1: ImageStream laser and channel settings for flourochrome conjugated antibodies. 
Table 7.3 - 2: Characterisation of OVCAR3 cell line  using traditional fixed immunofluorescent 
microscopy and ImageStream. 
Table 7.3 – 3: Depletion methods. 
Table 7.4 - 1: Patient demographics and numbers of circulating tumour cells in blood from 
patients with ovarian cancers. 
Table 7.4 – 2: ImageStream setting HR assay. 
  
Table 8.1 - 1:  Summary of objectives and project outcomes 
Table 8.3 - 1:  Ovarian Cancer Clinical and Radiological Definitions of Disease Response 
Table 9.1 - 1: Optimisation of cell suspension fixation. 
Table 9.2 - 1:  Imagestream settings fro Rad51 foci HR assay. 
 
  
  
1 
 
Chapter 1: Introduction 
Cancer is a disease that is known to many but understood by few. We define 
cancer as an uncontrolled division of abnormal cells and with the understanding 
that there are more than 100 distinct types of cancer, each with multiple 
subtypes found within specific organs, the problem we face in treating this 
disease is overwhelming. There are now several lines of evidence which 
indicate that tumorigenesis is a multistep process and that these steps reflect 
genetic alterations that drive the progressive transformation of normal human 
cells into highly malignant derivatives (Hanahan 2000). This thesis aims to 
further develop our understanding of ovarian cancer and some of its unique 
molecular derangements aiming to exploit them with the use of targeted 
cytotoxic agents.  
The present chapter focuses on a literature review exploring the biology of 
epithelial ovarian cancer and how this may be exploited with the use of 
biomarkers of response to cytotoxic agents. The current classification system 
and current management strategies are described and this is presented 
alongside a proposed new classification system whereby groupings are based 
upon actual tumour biology rather than mere morphological appearance.  
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1.1. Ovarian Cancer 
1.1.1. Epidemiology 
Ovarian Cancer poses a significant challenge to both clinicians and 
researchers. Worldwide, there are more than 200,000 new cases each year, 
which accounts for around 4% of all cancers diagnosed in women. The risk of 
developing ovarian cancer by age 75 years varies, ranging from 0.5% to 1.6% 
(National Cancer Institute 2014Lawrenson 2009). Although standard treatment 
with a combination of debulking surgery and platinum based chemotherapy 
produces a good rate of response initially, almost all disease relapses and 
develops resistance to standard platinum chemotherapy treatments. Despite 
much research and the introduction of new chemotherapy agents such as 
taxanes, the overall mortality has changed little over the past 20 years with the 
5-year overall survival remaining low at 40%, Figure 1.1 - 1. 
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Figure 1.1 - 1: Ovarian cancer, age-standardised five-year relative survival rates, 
England and Wales 1971-1995, England 1996-2009; Cancer Research UK. 
 
The poor prognosis in ovarian cancer is complex and thought to be 
multifactorial. The insidious onset of non-specific symptoms, coupled with a lack 
of a reliable detection method for early stage disease, results in a late stage at 
presentation  at which time there are widespread metastases throughout the 
peritoneal cavity (Jemal 2009), Table 1.1 - 1. Aggressive surgical and medical 
treatment and a greater determination to treat recurrent disease is thought to be 
responsible for the small improvement in survival since the 1980s (Kitchener 
2008) but the high rate of recurrence and the frequent development of 
chemoresistance has prevented further improvements.  
3 
 
 
 
FIGO Stage 
 
Description 
% of 
Cases 
% 5-yr 
Survival 
Stage I  
Limited to ovaries/fallopian 
tubes 
IA:  Limited to one ovary/fallopian tube 
IB:  Both ovaries/fallopian tubes  
IC:  Stage IA/IB with capsule rupture,  
       malignant ascites/peritoneal washings 
29 92 
Stage II 
Involves ovaries/tubes 
extending to pelvic organs or 
primary peritoneal cancer 
IIA:  Extension onto the uterus and/or   
        fallopian tubes and/or ovaries. 
IIB:  Extension to other pelvic intraperitoneal  
        tissues 
4 55 
Stage III 
Abdominal and/or lymph 
node disease 
IIIA:  Positive lymph nodes or microscopic  
         extrapelvic peritoneal involvement  
IIIB:  Peritoneal metastasis <2 cm  
IIIC:  IIIB with extension to liver/spleen  
         surface 
45 22 
Stage IV  
Distant metastasis 
IVA:  Pleural effusion with positive cytology 
IVB:  Parenchymal metastases 
15 6 
 
Table 1.1 - 1: FIGO (International Federation of Gynaecology and Obstetrics) surgical 
staging of ovarian cancer (Prat 2013)  with five-year stage-specific relative survival 
rates, Cancer Research UK. 
 
1.1.2. Risk Factors 
Although ovarian cancer aetiology remains unclear, several risk factors have 
been identified, which can be broadly classified as hereditary or sporadic 
cancer.  
A hereditary predisposition occurs in 10 - 15% of cases and is caused by 
germline mutations in the tumour suppressor genes BRCA1 and BRCA2 or 
mutations in DNA mismatch repair (MMR) as seen in hereditary non-polyposis 
colorectal cancer (HNPCC) (Risch 2001, Gayther 2010). The lifetime risk of 
developing epithelial ovarian cancer (EOC) in women with a germline BRCA1/2 
mutation can be up to 66% and 27% respectively (Robles-Diaz 2004). Many 
different germline mutations in BRCA1 and BRCA2 genes have been described 
and tumorigenesis in individuals with germline BRCA mutations requires 
somatic inactivation of the remaining wild-type allele, suggesting that the BRCA 
genes are tumour suppressors (Smith, Easton et al. 1992, Collins, McManus et 
al. 1995). Biochemical, genetic and cytological studies have revealed multiple 
functions for BRCA1 and BRCA2. They have been shown to be involved in DNA 
damage repair, specifically homologous recombination (reviewed in (Scully and 
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Livingston 2000)), to function as transcriptional co-regulators through direct 
interaction with sequence-specific transcription factors and with components of 
the transcriptional machinery (reviewed in (Monteiro 2000)) and they may also 
regulate transcription of genes involved in other cellular functions (Harkin, Bean 
et al. 1999). It has been proposed that chromosomal instability, as a result of 
BRCA1/2 deficiency, may be the pathogenic basis for breast and ovarian 
cancer tumour formation (Welcsh and King 2001) and the influence of 
oestrogen may paradoxically facilitate cell growth rather than the expected 
apoptosis with loss of the wild-type allele in women with inherited BRCA 
mutations (Welcsh and King 2001). The expression of BRCA1/2 is upregulated 
during puberty and pregnancy, when oestrogen levels are dramatically 
increased, suggesting that oestrogen might stimulate expression of BRCA1 
and/or BRCA2 (Welcsh and King 2001). Ovarian cancers with BRCA1/2 
mutations have classical features in terms of histology, survival and 
chemosensitivity.  
Much remains unknown about sporadic ovarian cancer but advancing age 
confers the greatest risk with more than 85% of patients aged 50 years or older 
at diagnosis. Additional risk factors have been identified and are summarised in 
Table 1.1 - 2. Epidemiological studies have identified that factors that reduce 
ovulation (combined oral contraceptive pill use, breastfeeding and term 
pregnancies, hysterectomy and sterilisation) are protective against the 
development of ovarian cancer.   
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Risk Factors for Ovarian Cancer Development Protective Factors 
Increasing age 
White ethnicity 
Polycystic ovarian syndrome 
Family history 
Nulliparity 
Early menarche/Late menopause 
Hormone replacement therapy and Fertility drugs 
No contraceptive use 
Talcum powder  
Obesity (endometrioid, mucinous and low grade 
serous subtypes (Olsen, Nagle et al. 2013))  
Smoking (mucinous subtype (Jordan, Whiteman et al. 
2006)) 
Parity  
Combined oral contraceptive pill   
Breastfeeding  
Hysterectomy 
 
Table 1.1 -  2: Risk factors for ovarian cancer development (Fathalla 1971, Huncharek 
2003, Kurian 2005, Salehi 2008, Sueblinvong 2009, Lahmann 2010). 
 
1.1.3. Pathogenesis  
Ovarian cancer can develop from epithelium, stroma or germ cells. Epithelial 
ovarian cancer (EOC) is by far the commonest type in the adult population and 
this thesis will focus upon this subtype. 
Progress in the understanding of the biology and treatment of ovarian cancer is 
complicated by a lack of understanding of its origin. There are several theories 
for the site of origin and pathogenesis of ovarian cancer.  
Ovarian Surface Epithelium (OSE)  
Sir Spencer Wells proposed that ovarian cancer arises from OSE in 1872. OSE 
are mesothelial-like cells that share embryological origin with the Mullerian tract 
epithelium, which eventually gives rise to the tubal, endometrial and 
endocervical epithelium (Ahmed 2012). It has been hypothesised that EOC 
arise from the less differentiated OSE cells and subsequently differentiate into 
histological subtypes according to specific molecular perturbations (Ahmed 
2012). Fathalla proposed repeated ovulation, associated with inflammation, 
induces surface epithelial dysplasia (Fathalla 1971). Ovarian biopsies from 
women receiving ovulation stimulating fertility treatment have revealed a higher 
rate of dysplasia (Fathalla 1971). This theory is further supported by the finding 
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that pregnancy and oral contraceptive pill use, which prevent ovulation, protect 
against ovarian cancer development. 
Inclusion Cysts 
With age, invaginations develop in the OSE that may be incorporated into the 
ovarian stroma, forming inclusion cysts (IC) (Folkins 2009). The formation of ICs 
lined by OSE cells was suggested as the origin of EOC but this was later 
refuted (Dubeau 1999) and it was suggested that these cancers arise from 
secondary Mullerian tract structures. Dubeau’s argument was based on the fact 
that cells within ICs are indistinguishable from adjacent mesothelial cells lining 
the peritoneum, yet EOCs do not resemble mesothelial tumours (Ahmed 2012).  
Fallopian Tube  
Piek et al. first proposed the fallopian tube, with subsequent implantation on the 
peritoneum and ovary, as the origin of EOC in 2001 (Piek 2001, Piek 2007). 
Since then, evidence has accumulated to support this theory (Lee 2006, 
Medeiros 2006, Kindelberger 2007, Lee 2007, Herrington 2010, Przybycin 
2010). Initial evidence came from prophylactic salpingo oophorectomy 
specimens from BRCA patients, which showed occasional high grade serous 
carcinomas (HGSC) in the ovary but more commonly in the fimbrial tube 
(serous tubal intraepithelial carcinomas (TIC) (McCluggage 2011). Further 
studies systematically examined the tubes in patients with sporadic HGSC and 
found similar lesions in up to 60% of cases (Kindelberger 2007, Przybycin 
2010).  
A study examining fallopian tubes in a consecutive series of ovarian 
carcinomas, identified serous TIC in nearly 60% of HGSC but not in other 
morphological subtypes (Przybycin 2010). At the time of surgery, the fallopian 
tube often appears macroscopically normal even in the presence of extensive 
disseminated disease throughout the pelvis and abdomen. It is possible 
therefore that in these cases, the fallopian tubes are not involved in the disease 
process or that the abnormal cells are shed from the tube and there is 
something within the tube, which prevents implantation in that site.  
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Whilst these various theories account for many of the recognised risk factors for 
development of ovarian cancer, it is appreciated that tumorigenesis is a 
multifactorial process and a better understanding may be achieved through a 
combination of the above. It may also be possible that the heterogeneous 
nature of ovarian cancer with its distinct morphological subtypes have distinct 
and different pathogenic processes (Shih and Kurman 2004).  For instance, 
HGSC may originate in the fallopian tube mucosa with cancer cells being shed 
into the peritoneal cavity. They may implant into inclusion cysts causing 
development of cancerous ovarian masses or they may implant onto peritoneal 
surfaces, resulting in primary peritoneal cancer. Endometrioid and clear cell 
ovarian cancers may in fact originate within the endometrial cavity as there 
have been links to retrograde menstruation (Kurman 2011) and endometriosis 
(Worley 2013). Mucinous histological subtype may originate from the OSE and 
develop through a stepwise process. This theory of multiple aetiologies and 
sites of origin may explain the heterogeneous behaviour of ovarian cancer and 
the variable patterns of dissemination.  
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1.2. Current Classification System of Ovarian Cancer 
The WHO first categorized ovarian cancers in 1973 into distinct morphological 
categories based upon the cells from which they were derived; surface 
epithelial, germ and mesenchymal cells (Scully 1975). Ninety per cent of adult 
ovarian cancers epithelial in origin and sub classification of EOC into distinct 
histological types (high grade serous [68%], endometrioid [9%], clear [13%], 
mucinous [3%] and low grade serous [7%]) is well established (Kaku 2003). The 
clinical characteristics and natural behaviour of ovarian tumours vary according 
to histology and grade (Silverberg 2000, Itamochi 2002, Stany 2008) with 
poorer overall prognosis seen in higher grade tumours of all subtypes (Omura 
1991, Stany 2008). Surgical stage, extent of residual disease, patient 
performance status, grade and histological subtype have known prognostic 
significance. However, prognostication remains inaccurate (Agarwal and Kaye 
2005). Although differences in response to chemotherapy and  survival are 
recognised between different histological subtypes, no reliable predictors are 
available to indicate which patients will respond to chemotherapy and, 
therefore, in view of the obvious lack of any reliable selection criteria, currently 
all patients receive postoperative chemotherapy. In the provision of standard 
platinum based chemotherapy to all subtypes, it has been recognised that 
certain histological subtypes are not chemosensitive and alternative treatment 
strategies have been explored. Perhaps the best example of this is low grade 
serous ovarian cancer with 6% reported as being platinum sensitive 
(Gershenson, Sun et al. 2009). Alternative treatments including hormonal 
therapies (Gershenson, Sun et al. 2012) and MEK inhibitors (Farley, Brady et 
al. 2013) have therefore been explored with ongoing clinical trials in these 
areas.  Detailed understanding of the individual challenges within each 
histological subtype is however required if the introduction of new agents is to 
translate into better response and overall survival.  
More recently, following an understanding that ovarian cancer subtypes develop 
through disruption of distinct genetic and biological pathways, a new 
classification system categorising EOC into type I or II groups has been 
proposed, Table 1.1 – 3 (Shih and Kurman 2004). This simple reproducible 
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system is based upon clinicopathological behaviour and genetic mutations and 
indicates that the two tumour subtypes develop via different pathways (Shih 
2004, Vang 2009).   
Type I tumours are indolent and are thought to evolve in a stepwise manner 
from borderline tumours (Russell 2004). They are associated with distinct 
molecular changes that are rarely found in type II tumours and commonly 
involve KRAS, BRAF and p53 mutations (Singer, Oldt et al. 2003, Russell 2004, 
Singer, Stohr et al. 2005, Heinzelmann-Schwarz 2006). Endometrioid and clear 
cell ovarian carcinomas have been shown to be associated with micro-satellite 
instability (MSI) (Gras 2001) with hMLH1 promoter hypermethylation and loss of 
expression of hMSH2 (Geisler 2001). Mutations in the PI3K and Wnt signalling 
pathway have also been found in endometrioid and clear cell EOCs (Willner 
2007). Conversely, type II tumours are aggressive and rapidly progress to 
advanced disease. They have no recognisable precursor lesions and are 
chromosomally unstable with distinctly different mutational patterns compared 
to type I tumours. Mutations in p53 are present in more than 90% (Ahmed 2010, 
Kurman 2010) and mutations in KRAS/BRAF are rare (Singer, Oldt et al. 2003). 
Other features include Akt2 overexpression, p16 promoter methylation/mutation 
and mutation of the PI3K pathway (Wang 2005, Nakayama 2006).  
 
  
10 
 
 Description 
Typical Morphological 
Subtypes (frequency) 
Common Genetic 
Mutations 
 
Type I 
(25%) 
 
Slow growing, diagnosed 
at lower grades  
Identifiable precursor 
lesions 
Resistant to platinum 
chemotherapy 
Low grade serous and mucinous 
borderline (7%) 
Serous borderline (6%) 
Mucinous (3%) 
Low grade endometrioid (9-11%) 
Clear cell (12-13%) 
Malignant Brenner tumours 
KRAS / BRAF (4-67%) 
p53 (0-9%) 
MMR pathway (13-50%) 
PI3K pathway 
PTEN / PIK3CA(20%) 
ERBB2 
 
Type II  
(75%) 
Rapid growth with early 
metastasis. 
No defined precursor 
lesions. 
Sensitive to platinum 
chemo 
High grade serous carcinomas 
(68 - 71%) 
Undifferentiated carcinomas (1%) 
Malignant mixed mesodermal 
tumours 
High grade endometrioid (9-11%) 
BRCA 1/2 
p53 (50-98%) 
Akt2 (12-18%) 
p16 (10-17%) 
PIK3CA 
CCNE1 
 
Table 1.1 -  3: Ovarian cancer classification (Shih 2004) with frequencies (McCluggage 
2011) and common genetic mutations.  
 
Histological classification is used in clinical practice to define an individual’s 
cancer but neither histology nor classification into type I or II groupings has 
clinical use in terms of provision of prognostic information or guidance for 
provision of treatments. In the search for a clinically meaningful classification, 
recent work has subdivided HGSC using genomic (TCGA 2011), gene 
expression (Tothill 2008) and functional (TCGA 2011, Mukhopadhyay 2012) 
techniques. This has generated at least four distinct gene expression subgroups 
(Tothill 2008, Tan 2013) and at least two functional subgroups (Mukhopadhyay 
2012). The subgroups defined have distinct prognostic behaviour as well as 
differences in their sensitivity to conventional and novel chemotherapy agents. 
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1.3. The Reclassification of Ovarian Cancer?  
1.3.1. Why Should the Current Classification System be Updated? 
The current classification system based upon morphological features is of little 
clinical use as the histological subtype does not accurately predict disease 
behaviour, tumour spread, response to standard or novel therapies or reliably 
correlate with overall survival (Pieretti 2002, Bamias 2011). The observed 
clinical differences among ovarian tumour subtypes are likely to reflect different 
underlying molecular mechanisms associated with a variety of genetic 
mutations. Visible morphological differences may be accompanied by 
differences in the protein expression, which orchestrate cellular function and 
behaviour (Faratian 2011). However, there may be further genetic heterogeneity, 
which is responsible for changes in cell function, and therefore dictates tumour 
behaviour and response to therapy, which may not necessarily be reflected in 
changed morphology. In addition, poor tumour differentiation and non-uniformity 
can mean that it is not always possible to accurately assign a single histological 
subtype to a tumour. There is also significant inter-observer variability and a 
lack of reproducibility of subtype reporting (Cramer 1987, Shimizu 1998).  
Despite the heterogeneity, ovarian cancer is treated as a single disease using a 
combination of debulking surgery and platinum-based chemotherapy. The 
observed heterogeneity of the clinical behaviour of ovarian cancer and its 
response to standard treatment, alongside the growing data reporting molecular 
heterogeneity and the accompanying sensitivity to novel therapies, suggests 
that the reclassification of ovarian cancer is long overdue (Hennessy 2008). A 
classification system reflecting the tumour biology may also assist in the 
identification and development of biomarkers used for the prediction of 
response to therapy.  
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1.3.2. How Should Ovarian Cancer be Classified? 
There is much data describing gene expression in ovarian cancer (Fekete 
2011). The genes most commonly mutated in ovarian cancer include p53, 
KRAS, CTNNB1, CDKN2A, PTEN, PIK3CA and BRAF. Common mutations 
seen in tumour suppressor genes include BRCA1/2, RB1, ARH1, GATA1, 
RNASET2, LOT1, DCC and FHIT. Amplification or overexpression of the 
oncogenes CMYC, ERBB2, HRAS, CSF1R, ECCF1, EGFR, P13K/AKT2, 
PTEN/MMAC1, FGF3, MDM2, BCL2 and EGFR are also commonly reported 
(Bast 2009, Lawrenson 2009). Gene expression studies have been shown to be 
useful for distinguishing ovarian tumour subtypes (Vang 2009). However, gene 
expression does not always correlate with protein translation and cellular 
function (Gustafsson 2011) and meta-analysis of all available ovarian cancer 
gene profiling signatures has, to date, failed to identify clinically relevant gene 
sets (Fekete 2011) that have been reproducible in second data sets. It is 
therefore perhaps more meaningful to analyse disease-related molecular 
pathways, which have been shown to, or are hypothesised to, directly correlate 
with clinical sensitivity or prognosis. 
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1.4. DNA Damage Repair (DDR) Pathways 
Under physiological conditions, cells are constantly exposed to DNA damage 
caused by both endogenous and exogenous sources. In healthy cells, the DNA 
damage response (DDR) comprises of a number of cell cycle checkpoints and 
DNA repair pathways designed to signal DNA damage to repair and cell cycle 
arrest to allow time for repair and prevent damage being passed on to daughter 
cells. The repair pathway activated depends upon the type of damage and 
these pathways form a highly complex interacting mechanism for repair. There 
are six major pathways responsible for the repair of endogenous and 
exogenous DNA lesions: direct repair, mismatch repair (MMR), base excision 
repair (BER), nucleotide excision repair (NER) and double strand break (DSB) 
repair comprising homologous recombination (HR) and non-homologous end 
joining (NHEJ) (Hoeijmakers 2001, Bernstein 2002). Dysregulation of the DDR 
can lead to genomic instability that itself promotes cancer development but the 
exact disruptions, which in combination result in the development of cancer is 
not yet clear. Hanahan et al (2000) suggest that the huge number of cancer cell 
genotypes is a manifestation of six essential alterations in cell physiology that 
collectively dictate malignant growth: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis, 
and tissue invasion and metastasis. Each of these acquired capabilities 
represents the successful overriding of an anticancer defence mechanism 
(Hanahan 2000). 
In cancer, dysregulation of the DDR is common presenting both challenges and 
opportunities for tumour-specific cancer treatment.  Upregulated DNA repair 
pathways can cause resistance to DNA-damaging chemotherapy and 
radiotherapy and so inhibitors of these pathways have the potential to sensitize 
cells to these therapies (Curtin 2012). Loss of a DDR pathway can also lead to 
dependence on a compensatory pathway, which can then be targeted rendering 
subsequent DNA damage by cytotoxic agents irreparable and resulting in cell 
death. For this reason, dysfunctional DNA repair pathways have been shown to 
be important in many cancers, including ovarian cancer, and categorizing 
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tumours according to functional DDR pathways may result in clinically relevant 
groupings or provide biomarkers capable of predicting response and thereby 
enabling stratification of appropriate therapies.  
 
1.4.1. Direct Repair by O6-methylguanine-DNA Methyltransferase 
(MGMT) 
The simplest form of DNA repair is the direct reversal of the lesion. Use of 
cancer agents such as temozolomide, dacarbazine and nitrosoureas, alongside 
erroneous methylation, causes alkylation of the O6 position of guanine. 
Unrepaired O6-methylguanine is mutagenic as it results in mismatch of alkylated 
guanine with thymine instead of cytosine during replication (Saffhill 1985). 
Direct repair by O6-methylguanine-DNA methyltransferase (MGMT) removes 
the alkyl group. However, if this pathway is deficient, O6-methylguanine 
remains, resulting in persistent mismatching of bases during replication. The 
MMR pathway attempts to correct this but as the alkylated base is permanently 
bound with template DNA, repair is unsuccessful, triggering repeated cycles of 
excision and attempted repair and ultimately resulting in apoptosis. MGMT-
deficient cells are highly sensitive to alkylating agents. 
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1.4.2. Base Excision Repair (BER)  
BER is the main guardian against damage due to reactive oxygen species 
(ROS) including that resulting from cellular metabolism, methylation, 
deamination and hydroxylation (Hoeijmakers 2001). Dysregulation of ROS 
metabolism, leading to accumulation of DNA damaging agents, coupled with 
polymorphisms/ mutations that compromise BER function, is commonly seen in 
cancer (Curtin 2012). The most common base oxidations produced by ROS are 
8-oxoguanine (8-oxoG) and 5-hydroxycytosine, which mispair with adenine and 
thymine, respectively (Lindahl 1993, Van Loon 2010, Curtin 2012). 8-oxo-7,8-
dihydro-2’deoxyguanosine (8-OHdG) is repaired by the DNA glycosylase and 
BER enzyme OGG1 (Almeida 2007). If left unrepaired 8-OHdG, bound to 
adenine, is highly mutagenic and leads to G to T transversion mutations (David 
2007). The 8-OHdG – A mispair can be corrected by  BER that involves DNA 
synthesis and preferential insertion of the correct C base mediated by DNA 
polymerase β (Polß) (Krahn 2003).   
The BER pathway is subdivided into short patch (single nucleotide replacement) 
and long patch BER (two to 13 nucleotides are replaced), depending on the 
nature of the 5′ and 3′ ends and, possibly, ATP availability (De Vos 2012), and 
is the process that removes damaged DNA bases and repairs single-strand 
breaks that arise following removal of the break.  
In both pathways, the damaged base is removed by specific glycosylases 
forming an abasic site (or apurinic or apyrimidinic [AP] site), which is then 
hydrolysed by an AP endonuclease, such as APE1. The ‘nick’ is then repaired 
by short patch (the predominant mode) or long patch BER, Figure 1.4 - 1. In 
short patch repair, PARP-1 activation, resulting in production of PAR, leads to 
relaxation of the chromatin fibre and facilitates recruitment of proteins 
necessary for repair. PARP-1 mediated recruitment of XRCC1 is followed by 
nucleotide replacement by DNA polymerase-β (Pol β) and the gap is rejoined by 
ligase 3 (LIGIII). In long patch repair, XRCC1 recruits polynucleotide kinase 
(PNK), which converts the damaged DNA ends into 5’-phosphate and 3'-
hydroxyl moieties. Proliferating cell nuclear antigen (PCNA) and Pol δ or Pol ε 
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extend and fill the nucleotide gap. FEN1 cleaves the resulting flap and re-joining 
is completed by LIGI (Baute 2008, Kummar 2012).  
 
BER and Ovarian Cancer 
Oxidative damage is generally increased in tumours: increased metabolism, 
oncogenic signalling and mitochondrial dysfunction result in 100-fold more 8-
OxoG in cancer tissues than in normal tissues (Wiseman 1996). 
Chemotherapeutic agents achieve cellular cytotoxicity by inducing DNA 
damage. However, proficient BER in cancer cells results in therapeutic 
resistance and adversely impact patient outcomes. BER factors, therefore, are 
emerging as important prognostic factors as well as predictors of response to 
cytotoxic therapy in patients.  
Inhibition of BER (using methoxyamine) has been shown to sensitise cells to 
the alkylating agent temozolamide in ovarian cancer cell lines (Fishel 2007) and 
it has recently been shown that APE1 is overexpressed in 71.9% of ovarian 
cancers. Expression in this series has been shown to correlate with tumour 
type, optimal debulking, and overall survival (Al-Attar, Gossage et al. 2010). 
Additional studies have also demonstrated altered APE1 expression or 
cytoplasmic localisation of APE1 to be associated with platinum resistance or 
overall prognosis (Zhang, Wang et al. 2009, Sheng, Zhang et al. 2012).  
In a prospective cohort study of 310 ovarian cancer patients treated with 
platinum-based chemotherapy a lower survival rate and significant increased 
risk of death was observed in patients with XRCC1 399 Arg/Arg genotype 
(Cheng 2012).   
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Figure 1.4 - 1: Base excision repair pathway.Short-patch repair takes place after the 
excision of a damaged base. It involves PAR mediated recruitment of XRCC1 (scaffold 
protein), followed by DNA polβ and DNA ligase III which conducts the ligation of the 
DNA. Long-patch repair occurs after direct DNA breaks and involves recruitment of 
XRCC1 followed by polynucleotide kinase (PNK), which converts the damaged ends to 
5'-phosphate and 3'-hydroxyl moieties. Proliferating cell nuclear antigen (PCNA) and 
DNA polymerase δ/ε extend and fill the gap by 2–15 nucleotides, and FEN1 cleaves 
the resulting flap. The nick is then ligated by DNA ligase I.  
 
1.4.3. Nucleotide Excision Repair (NER) 
NER deals with the wide class of helix-distorting lesions that interfere with base 
pairing and generally obstruct transcription and normal replication (Hoeijmakers 
2001), for example, UV radiation induced thymidine dimers (T-T), and intra-
strand cross links, such as platinum-DNA adducts. There are two NER 
subpathways: global genome NER (GG-NER), which surveys the entire 
genome (both coding and non-coding genes) for distorting injury (Le Page 2000, 
Tang 2000) and transcription-coupled repair (TC-NER), Figure 1.4 - 2.  
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Figure 1.4 - 2: Nucleotide excision repair pathway. In GG-NER the protein complex 
XPC-hHR23B screens the genome (both coding and non-coding genes) for 
irregularities in the DNA structure such as bulky adducts (Le Page 2000, Tang 2000).  
TC-NER, exclusive to transcription, focuses on damage that blocks DNA polymerase II 
before CSB and CSA displace the stalled polymerase making DNA accessible for 
repair (Tornaletti 1999, Christmann 2003).. Upon recognition of the DNA lesion, (either 
by binding of XPC-hHR23B or DNA polymerase II stalling) a cascade of proteins are 
recruited. These proteins are the same for both TC-NER and GG-NER. XPB and XPD 
helicases (which are both components of the multi-unit transcription factor TFIIH) open 
the region incorporating the legion (Le Page 2000). The single-stranded-binding protein 
replication protein A (RPA) binds to the corresponding undamaged strand and 
stabilises it. In the rate-limiting step, the endonucleases XPG and ERCC1-XRF 
complex then cleave the open DNA strands and excise the damaged site. Resynthesis 
of the removed region is carried out by DNA polymerase δ/ε, ligase 3 and ERCC3 
(Hoeijmakers 2001). 
 
NER and Ovarian Cancer 
NER is a key pathway involved in mediating resistance to platinum. Multiple 
studies have shown high mRNA levels of some of the NER components in 
cisplatin-resistant ovarian cancer cells, mouse models and human tissue 
(Dabholkar 1994, Damia 1998, Dabholkar 2000), with greatest correlation seen 
between ERCC1 mRNA levels with cisplatin resistance (Ferry 2000, Li 2000). In 
vitro studies have demonstrated sensitivity to platinum in NER defective human 
ovarian cell lines, in particular those with reduced levels of ERCC1 and 
xeroderma pigmentosum complementation group F proteins. Cell lines with 
intrinsic cisplatin resistance have been shown to have increased sensitivity to 
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cisplatin after antisense RNA inhibition of ERCC1 (Selvakumaran 2003). In 
addition, cell lines that developed resistance in vitro after exposure to cisplatin 
chemotherapy were found to have increased expression of ERCC1 (Ferry 
2000). 
 
1.4.4. Mismatch Repair (MMR) 
Mismatch repair (MMR) is a highly conserved, strand-specific repair pathway, 
which follows a stepwise process. MMR is responsible for the recognition and 
repair of DNA damage caused by deamination, oxidation and replication errors 
and also targets DNA cross-links, dimers and alkylated bases. External agents, 
such as cisplatin, can cause such damage by inducing cross-links between 
adjacent guanine residues or nucleoside analogues.   
MMR is subdivided into two pathways according to the protein complexes that 
bind to the DNA lesion, Figure 1.4 - 3. The products of six genes (MLH1, MSH2, 
PMS1, PMS2, MSH6 and MSH3), originally identified for their involvement in 
Hereditary Non Polyposis Colorectal Cancer (HNPCC) syndrome, participate in 
MMR (Scartozzi 2003). When a mismatch is detected, MSH2 associates with 
either MSH6 or MSH3 to form MutSα and MutSß complexes respectively 
(Acharya 1996). These complexes assemble at the DNA mismatch site and 
recruit a third heterodimer, which comprises of MLH1 partnered with PMS2. The 
two protein complexes have overlapping specificities and functions, which 
ensure the majority of common replication errors are recognised and efficiently 
processed. Excision of the mismatch is performed by exonuclease 1 and 
proliferating cell nuclear antigen (PCNA) and it is followed by resynthesis DNA 
polymerase δ and religation of the DNA strand (Wu 2008, Boland 2010). 
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Figure 1.4 - 3: Mismatch repair pathway.The MutSα (MSH2/MSH6) heterodimer 
recognizes base-base mismatches and small insertion deletion loops (IDL). The MutSβ 
(MSH2/MSH3) heterodimer recognizes single nucleotide mismatches as well as longer 
IDLs (10-nucleotide loops). In association with the MutL heterodimer, MutH is activated 
which nicks the unmethylated strand containing the incorrect base. The cleaved strand 
then undergoes exonuclease activity, DNA resynthesis and ligation. 
 
MMR and Ovarian Cancer 
A significant proportion of carcinomas, including endometrial, ovarian, 
oesophageal, colorectal and head and neck cancers, develop through defective 
MMR (Gurin 1999, Hayashi 2003, Demokan 2006, Sinicrope 2012). Defects in 
MMR may be inherited, as in HNPCC (Watson 2001, Lynch 2009), or may 
occur through epigenetic silencing of an essential MMR gene (Suzuki 1999, 
Esteller 2000, Peltomaki 2003). HNPCC leads to increased risk of colon cancer 
(80% life time), endometrial cancer (40 - 69%) and ovarian cancer (12%) 
(Watson 2001). Mutations in MLH1 (50%), MSH2 (39%) and MSH6 (7%) 
account for the majority of reported germline variants (Peltomaki and Vasen 
2004, Anacleto 2005).  
When MMR is deficient, which has been reported in around 15% (0 - 39%) of 
ovarian tumours (Buller 2001, Helleman 2006), the cells bypass the intra-strand 
crosslinks and continue to proliferate in spite of the DNA damage and are 
therefore resistant to platinum agents as well as DNA methylating agents and 
thiopurines (Brown 1997, Vaisman 1998, Strathdee 1999, Helleman 2006). 
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Defects in the MMR pathway have been demonstrated to be significantly higher 
in tumours post-chemotherapy compared to untreated controls. These finding 
suggest resistance development by chemotherapy selection for subpopulations 
of intrinsically resistant cancer cells (Brown 1997, Scartozzi 2003, Cooke 2011). 
The presence of microsatellite instability (MSI) has been confirmed as a marker 
of MMR deficiency and takes into account mutations and epigenetic silencing of 
the functional pathway. Mutations in MLH/MSH account for 2% of all ovarian 
cancers. However, MSI has been reported in around 15% (0 - 39%) of ovarian 
tumours, mostly in endometrioid types (Buller 2001, Gras 2001, Zhang 2008). 
Two separate studies have raised the possibility that defective MMR may have 
prognostic significance (Fujita 1995, King 1995) and it is reasonable to 
hypothesise that MSI, indicating MMR deficiency in ovarian cancer, is a 
potential biomarker of platinum sensitivity. 
Cisplatin-resistant ovarian cell lines have been shown to be defective in MMR 
(Drummond 1996) and acquire an MSI phenotype when resistance develops 
(Anthoney 1996). Cell lines deficient in hMLH1 have previously been shown to 
be tolerant to DNA damage induced by alkylating agents (Koi 1994) and 
restoration of MMR in such cell lines can increase their sensitivity to cisplatin 
(Aebi 1996). In a study by Scartozzi et al (Scartozzi 2003), loss of hMLH1 was 
observed in over 50% of 34 stage III/IV ovarian cancers. Loss of hMLH1 has 
been shown to be significantly higher in ovarian tumours post chemotherapy 
compared to untreated tumours, suggesting that exposure to chemotherapy 
induces positive selection for MMR deficient tumour cells in vivo (Brown 1997). 
In a study by Watanabe et al. (Watanabe 2001), a change in microsatellite 
stability was seen after five to six cycles of cisplatin; post treatment biopsies 
showing MSI and down regulation of hMLH 1 expression. Similar results were 
seen in a study by Fink et al.(Fink 1998). Gifford et al (Gifford 2004) reported 
that 25% of the plasma DNA samples collected at relapse in advanced ovarian 
cancer patients enrolled in the SCOTROC1 study, were newly diagnosed to be 
positive for hMLH1 methylation, which correlated with poor overall survival.  
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1.4.5. Double Strand Break Repair (DSB) 
One of two pathways with overlapping components repairs DSB. HR involves 
alignment of a homologous chromatid to provide a template for error free repair 
and is limited to the S/G2 phase of the cell cycle when a sister chromatid is 
present (Lieber 2010). Non-homologous end joining (NHEJ) is the predominant 
method of repair in G0/G1 but functions in all stages of the cell cycle. NHEJ 
does not require a complementary template as it repairs the defect by direct 
ligation and is therefore error prone (Lieber 2008, Helleday 2010). Central to the 
DNA damage and repair responses are sensors, particularly the 
phosphatidylinositol 3-kinase-related protein kinase family, including DNA-
dependent protein kinase (DNA-PK), ataxia telangiectasia mutated (ATM) and 
ATM- and Rad3-related protein (ATR). ATM, ATR and DNA-PK. orchestrate the 
initiation of cell cycle checkpoints and DSB repair. These three proteins have 
many common substrates. However, they are generally thought to be involved 
in unique signalling pathways.  
Additionally, 53BP1 and BRCA1 directly influence DSB repair pathway choice 
by regulating 5’ end resection. In G1 the resection of the 5’ end is halted by the 
53BP1/Rif1 proteins allowing Ku to bind and NHEJ to predominate (Chapman 
2012, Chapman 2013). Synthesis of BRCA1 in S and G2 phases inhibits Rif1 
and allows 5’ end resection with subsequent inhibition of NHEJ and repair by 
HR (Chapman 2012, Chapman 2013).   
 
1.4.6. Non-Homologous End Joining (NHEJ)  
NHEJ repairs double strand breaks without the need for a homologous copy of 
the broken region of DNA, so is not restricted to a certain cell cycle phase. DNA 
sensors; DNA dependent protein kinase catalytic subunit (DNA-PKcs) and ATM 
play important roles in NHEJ by detecting DNA damage and signalling for repair 
responses (Drouet 2006). After DNA DSBs occur, NHEJ is initiated and the 
phosphorylated Ku70/Ku80/DNA-PKCS complex (DNA-PK) allows the alignment 
of the DNA strands, which are subsequently joined by the ligase IV/XRCC4 
complex (Martensson 2002), Figure 1.4 - 4.   
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Figure 1.4 - 4: Non-homologous end joining pathway. After phosphorylation of H2AX at 
DNA DSB sites, NHEJ is initiated by the binding of the Ku heterodimer (composed of 
Ku70 and Ku80). DNA-PKcs is then recruited and binds to the DNA end, activating its 
serine/threonine kinase activity. The Ku70/Ku80/DNA-PKcs complex, referred to as 
DNA-PK, holds the two DNA strands together in a synapse (Martensson 2002). 
Activation of DNA-PK by phosphorylation allows the alignment of the DNA strands, 
which are subsequently joined by the ligase IV/XRCC4 complex. This reaction is 
stimulated by XLF protein, which interacts with XRCC4 (Van Gent 2007) to catalyse the 
final end-joining reaction. 
 
The NHEJ Pathway and Ovarian Cancer 
NHEJ has been shown to be defective in 45% of EOC (McCormick 2015). The 
relationship between its functional status and that of HR appears to be complex 
and there are emerging theories, based upon ex vivo cultures of ovarian cancer, 
that NHEJ is in fact the predominant pathway of DNA DSB repair in ovarian 
cancer.  
1.4.7. Homologous Recombination Repair (HR)   
HR is an error free template-dependent repair pathway of complex DNA 
damage principally DNA DSB, stalled replication forks or collapsed 
forks (Doe 2002, Michel 2004, Shrivastav 2008). It is a process by which 
breaks are repaired through the use of homologous sequences of DNA in 
sister chromatid as a template for repair, occurring primarily during the 
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M phase of the cell cycle (Kennedy 2006).  A DSB is recognised by 
the MRN complex (formed from MRE11, Rad50 and NSB1) before 
phosphorylation of H2AX, NBS1, BRCA1 and FANCD2. RPA then binds 
unwind the DNA structure and Rad51 binds allowing invasion of the 
homologous sequence on the sister chromatid. This is used as a 
template for repair,  
 
Figure 1.4 -  5.   
 
 
Figure 1.4 -  5: Homologous recombination pathway (Cerbinskaite 2012). The MRN 
complex undergoes a series of conformational changes to attract, activate and 
increase affinity of ATM at the DSB site (Paull 2005, You 2005, Chistiakov 2008). ATM-
dependent phosphorylation of H2AX, NBS1, BRCA1 and FANCD2 occurs before 
replication protein A (RPA) binds to facilitate unwinding of the DNA secondary structure 
allowing access for the substrates of DNA repair (Sung 2006, Jacquemont 2007, Xing 
2008, Hartlerode 2009). BRCA2 mediates the loading of Rad51 onto the RPA coated 
single strand ends (Valerie 2003, Sy 2009, Zhang, Ma et al. 2009). After identification 
of the homologous sequence on the sister chromatid, Rad51 forms a nucleoprotein 
filament on the ssDNA and catalyses the invasion of the homologous sequence on the 
sister chromatid, which is then used as a template for accurately repairing the broken 
ends by DNA synthesis (Hoeijmakers 2001, Gudmundsdottir 2006). After replication 
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has extended past the region of the DSB, strand replication continues to the end of the 
chromosome (Hoeijmakers 2001, Khanna 2001, Bast 2010).  
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HR and Ovarian Cancer  
The tumour suppressor genes BRCA1 and BRCA2 are currently the only genes 
to be identified as highly penetrant ovarian cancer susceptibility genes (Gayther 
1999). BRCA1 and BRCA2 tumour suppressor genes have crucial functions in 
the HR pathway by promoting efficient and precise repair of DSB. Inactivation of 
BRCA1 or BRCA2 results in genetic instability.  Homozygous BRCA1 mutation 
is lethal in mice (Gowen 1996) and down regulation of BRCA1 leads to cell 
cycle arrest or apoptotic cell death (Bouwman 2010). BRCA2 functions are 
largely limited to DNA repair (Chistiakov 2008) controlling localisation and DNA 
binding of Rad51(Davies 2001).  
The vast majority of tumours from women with germline BRCA1/2 mutations 
show loss of heterozygosity of the wild type allele at the BRCA1/2 loci (Ramus 
2003) and are considered HR deficient (Venkitaraman 2004). Carriers of 
mutations in BRCA1 or BRCA2 have up to a 66% lifetime risk of ovarian cancer, 
section 1.1.2 (Robles-Diaz 2004). Ovarian cancers with germline or somatic 
BRCA1/2 mutation genes have unique features in terms of histology, survival 
and chemo sensitivity.  
Tumours with BRCA1 or BRCA2 mutations have been shown to be defective in 
HR (Moynahan 1999, Moynahan 2001) and this has fuelled the interest in the 
HR pathway in both breast and ovarian cancer.  
PolyADP-ribose polymerase 1 and 2 (PARP-1/2) enzymes have important roles 
in signalling single-strand DNA breaks as part of the base excision repair (BER) 
pathway (Dantzer 1999, Dantzer 2000) and represent a novel target in cancer 
therapy. Inhibition of PARP leads to an accumulation of unrepaired SSB that will 
convert to DSB and, unless repaired by HR, will lead to cell death (Schultz 
2003). Understanding of this phenomenon has led to the development of PARP 
inhibitors (PARPi) and HR defective cell lines (BRCA1/2 defective) have been 
shown to be 100 - 1000 fold more sensitive to PARPi than heterozygote or wild 
type cell lines (Bryant 2005, Farmer 2005). Additionally, PARP inhibitors have 
shown to be highly effective in the treatment of BRCA1/2 mutated solid tumours 
(Plummer, Jones et al. 2008, Fong 2009, Audeh 2010, Tutt 2010). 
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The function of the entire repair HR pathway can be affected if one or more 
genes are defective and a number of mutations, other than BRCA 1/2, in a 
variety of genes within the HR pathway have been reported (Cerbinskaite 
2012). Some of these mutations have also been shown to result in sensitivity to 
PARP inhibitors (McCabe, Turner et al. 2006). Mukhopadhyay et al describe a 
functional assay to identify HR deficient ovarian cancers based upon 
quantification of immunofluorescent Rad51 nuclear foci formation following 
induction of DNA damage (Mukhopadhyay 2010). Failure to induce Rad51 foci 
formation following DNA damage has been shown to be a reliable indicator of 
HR deficient ovarian cancers and correlates with ex vivo sensitivity to PARPi  as 
well as clinical sensitivity to platinum chemotherapy (Mukhopadhyay 2010, 
Mukhopadhyay 2012).  
Proteins involved in DSB repair pathways have also been implicated in 
chemoresponse to platinum (Martin et al. 2008). It is known that BRCA deficient 
ovarian cancers are platinum sensitive (Cass et al. 2003). In vitro, it has been 
seen that defects in the Fanconi-anaemia/BRCA pathway (FANCF inactivation 
by methylation) can enhance sensitivity to cisplatin in cell lines and that 
demethylation can induce platinum resistance (Taniguchi et al. 2003). BRCA1 
deficient mammary tumours have been shown to be highly sensitive to PARPi 
alone and in combination with platinum drugs (Rottenberg et al. 2008).  
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1.5. Other Pathways Important in Ovarian Cancer 
Dysregulation of proliferative signalling pathways is a characteristic of cancer 
cells. “Gain of function” mutations in the MAPK or PI3K/Akt/mTOR pathways 
are well described and known to be important in endometrioid and clear cell 
EOCs.  
The mitogen-activated protein kinase (MAPK) pathway is key to the 
transduction of external mitogenic signals to the nucleus after a mitogen binds 
to a cell membrane receptor kinase (Dong 2002). Oncogenic mutations in the 
pathway lead to activation of the pathway in the absence of a mitogenic signal 
leading to carcinogenesis (Smalley 2003). KRAS, BRAF and ERBB2 mutations 
are well documented in ovarian cancer and result in constitutive activation of the 
MAPK pathway. These are mutually exclusive mutations and are not specific to 
morphological subtypes with 66% of mucinous, 33% of low grade/borderline 
serous and 17% of endometrioid cancers having KRAS mutations, the majority 
being a single amino acid substitution (V12G) (Nakayama 2008). The KRAS 
variant has been shown to be a statistically significant predictor for platinum 
resistance (Ratner 2011). BRAF mutation (a single nucleotide substitution) 
leading to elevated kinase activity (Davies 2002) is seen in 33% of the low 
grade serous tumours (Shih 2004, Nakayama 2008, Geyer 2009). 
Overexpression of CMYC and ERBB2 is seen in 36 - 76% and 10 - 20% of 
advanced stage EOCs and is also associated with poor prognoses (Dimova 
2006, Nakayama 2006, Vang 2009).  
The PI3K/Akt/mTOR pathway transduces extra cellular signals associated with 
cellular growth, proliferation and apoptosis. Binding of extracellular signals, e.g. 
EGF to the receptor tyrosine kinases, results in translocation and activation of 
PI3K heterodimers (Chen and Guan 1994, Vanhaesebroeck 1999) resulting in 
phosphorylation of phosphatidylinositol-containing lipids (PIP). PIPs mediate 
recruitment of signalling proteins (Toker 1997) including Akt (a serine/threonine 
protein kinase) (Jiang 1999) which translocates to the nucleus and mediates the 
activation/ inhibition of various targets resulting in cellular survival and cell 
growth and proliferation. Amplification of the PI3K catalytic subunit and the lost 
function of PTEN are frequently detected in ovarian cancer cells (Yokomizo 
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1998, Meng 2006) with PIK3CA being increased in copy number in 40% of 
ovarian cancer cell lines and patient tumour samples, particularly  endometrioid 
and clear cell subtypes (Shayesteh 1999).  
The tumour suppressor gene PTEN (phosphatise and tensin homologue 
deleted from chromosome 10) is known to inhibit the PI3K/Akt pathway and 
therefore PTEN mutations result in activation of PI3K/Akt pathway and 
subsequent increased cell survival (Nagata 2004). Decreased PTEN expression 
has been shown to play a role in progression of ovarian disease (Schondorf 
2003).  
The most well described tumour suppressor gene TP53 is implicated in the 
development of several cancer types. It is involved in controlling cell cycle, 
apoptosis and maintaining the genome integrity. The TP53 gene located on the 
short arm of chromosome 17 (17p13.1) encodes p53 (Isobe 1986). If the TP53 
gene is damaged, tumour suppression is severely reduced and the cells will 
continue to divide uncontrollably.   
Following DNA damage, levels of the transcription factor p53 rapidly increase. 
p53 binds to the DNA, inducing expression of either p21 (Waf1/Cip1) or 
expression of bax, PIGs, IGF-BP3, Fas, FasL and DR5. The binding of p21 to 
CDK/cyclin complexes induces G1 arrest (Smith 2003) until the DNA damage is 
repaired. If the damage is irreparable, p53 induces the expression of apoptotic 
genes. Unsurprisingly, missense mutations resulting in overexpression of 
mutated p53 protein is seen in almost half of all cancers (Levine 1997). TP53 
mutation is almost invariably present in HGSC and p53 has been implicated in 
the regulation of BRCA1 function (Bouwman 2010) and in the transcriptional 
regulation of Rad51 (Arias-Lopez 2006). Because of its almost universal 
expression, it is not of substantial prognostic or predictive significance (Ahmed 
2010). 
Mutant TP53 has been shown to directly decrease tumour cell sensitivity to 
chemotherapeutic agents and promote the emergence of drug resistance in 
both in vivo and ex vivo studies (Lowe 1994, Righetti 1996, Blandino 1999, 
Knappskog 2012, Lai 2012). Examination of the p53 pathway and the 
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association of TP53 mutation with HGSC have singled out the p53 gene as a 
molecular target for novel cancer therapeutics. p53 gene replacement therapy 
within the cancer cells is one such approach that has not only become feasible 
but may also show benefit (Roth 1996, Nielsen 1997, Nielsen 1998, Buller, 
Runnebaum et al. 2002). Vaccine-induced p53-specific immune responses 
were previously reported to be associated with improved response to secondary 
chemotherapy in patients with small cell lung cancer (Antonia 2006). The effect 
of p53 vaccination is now being explored in ovarian cancer patients (Leffers 
2012). 
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1.6. Current Treatment Strategies in Ovarian Cancer 
1.6.1. Ovarian Cancer Surgery  
Surgery plays a pivotal role in the management of ovarian cancer and has 
evolved since the first report of an inverse relationship between survival and the 
size of residual disease following surgery in 1975 (Griffiths 1975). The 
significance of optimal resection (to less than one cm residual tumour) is well 
established in both retrospective and prospective randomised controlled trials 
(RCTs) and maximal cytoreduction has been shown to be one of the most 
powerful determinants of survival among patients with stage III/IV EOC (Griffiths 
1975, Hoskins 1994, Bristow 2002) with an improvement in survival of 5.5% 
with every 10% increment in cytoreduction (Bristow 2002).  
Two management strategies with variable orders of treatment are used for 
advanced stage disease: primary debulking surgery followed by six cycles of 
adjuvant chemotherapy (platinum +/- taxol) or three cycles of neoadjuvant 
chemotherapy (NACT), at which time response to treatment is assessed and, if 
appropriate, interval debulking surgery (IDS) is followed by a further three 
cycles. Surgery is undertaken at a time when optimal cytoreduction is thought to 
be achievable. Two major clinical trials, the European Organisation for 
Research and Treatment of Cancer (EORTC) 55971 (Vergote 2010) and 
Chemotherapy or Upfront Surgery (CHORUS) (Kehoe 2015) aimed to compare 
the clinical outcomes of these two management options. EORTC has not shown 
any difference in survival between the two groups but subgroup analysis 
showed survival was significantly associated with optimal resection of the 
tumour whether undertaken as primary or interval surgery (Vergote 2010). Two 
recent Cochrane Reviews reported similar survival benefit from optimal 
cytoreduction (Elattar 2011, Al Rawahi 2013).  
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The Biological Benefits of Surgery 
Many theoretical explanations for the benefits of cytoreductive surgery have 
been proposed including; 1) excision of poorly vascularised tumour; 2) 
enhancement of the immune system; 3) improved cell kill with residual tumour 
being better perfused and in the growth phase; 4) small volume of tumour 
leading to better efficacy of chemotherapy and 5) reduced resistance to 
chemotherapy due to the reduced bulk of tumour and removal of chemo-
resistant clonogenic cells (Covens 2000).  
Surgical ‘Resectability’ and Tumour Biology 
The ability to completely resect EOC may not necessarily be merely a reflection 
of the ability of the surgeon but may, in part, be a reflection of the biological 
aggressiveness of the disease. A retrospective review of the Gynaecologic 
Oncology Group (GOG) data showed that survival in women who had their 
large volume extra-pelvic disease cytoreduced to optimal (less than one cm) 
was poorer compared to women presenting with de novo optimal volume (less 
than one cm) extra-pelvic disease (Hoskins 1992). Similarly, Hacker et al. 
reported poorer prognosis in women with >10 cm metastatic disease compared 
to women with small volume initial tumour load (<10 cm), despite both groups 
being optimally cytoreduced (Hacker 1983). 
1.6.2. Tumour Sampling for Histological and Molecular Subtyping 
Tumour sampling is infrequent during standard treatment strategies and 
currently limited to histological review at initial diagnosis. Therefore, treatment 
strategies are often largely independent of the actual tumour biology and 
cellular characteristics.  
Tumour sampling prior to surgery is commonly only done when there is 
diagnostic doubt or when disease is extensive, suggesting that NACT with IDS 
may be preferred. In these circumstances, typically a single biopsy is taken from 
one region, most commonly the omentum, which may or may not be 
representative of the primary tumour in the pelvis. Even at relapse, biopsies are 
infrequent but if taken, would again typically be limited to a single image guided 
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biopsy. Laparoscopy is being used in some units as an aid to pre-operative 
diagnosis and staging but does not form part of routine practice and its ability to 
predict optimal cytoreduction is not yet clear (Fagotti 2008).  
It is not yet clear if solid tumour biopsy is superior to ascitic cell sampling in 
terms of biomarker assessment. Both sampling techniques are however 
invasive procedures and alternative less invasive sampling techniques should 
be considered if we are to move towards biomarker stratification of therapy.  
1.6.3. Chemotherapy 
Ovarian cancer, irrespective of histological subtype, stage or surgical outcome, 
is currently treated with a combination of cytoreductive surgery and platinum 
chemotherapy, with or without taxanes.  
There has been much research to investigate which patients should receive 
chemotherapy, the optimum regimen and optimum order of treatment, Table 1.6 
- 1.  Attempts to improve the standard two drug chemotherapy by adding a third 
agent failed to affect PFS or OS but did result in increased side-effects (Du Bois 
2006, Pfisterer 2006, Bookman 2009, Hoskins 2010).  
 
Trial Description Reference 
GOG 111 Paclitaxel and cisplatin combined produced a higher response 
rate and a longer PFS in comparison to the standard 
cyclophosphamide and cisplatin regimen 
(McGuire 1996) 
OV10 (Piccart 2000) 
GOG132 Single agent cisplatin vs. paclitaxel/cisplatin combination with 
no benefit to the paclitaxel/cisplatin regimen 
(Muggia 2000) 
GOG158 14% reduction in risk of disease progression following 
paclitaxel and carboplatin 
(Bookman 2003) 
ICON3 Paclitaxel/carboplatin vs. a control arm of single-agent 
carboplatin or the three drug combination (cyclophosphamide, 
doxorubicin and cisplatin) with no survival benefit seen with 
the addition of taxol.  
(ICON Collaborators 
2002) 
 
Table 1.6 - 1: Randomised Controlled Trials (RCT) for chemotherapy treatment for 
ovarian cancer.  
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1.6.4. Platinum 
Mechanism of Action 
Cisplatin and carboplatin are transported into the cell by a copper transporter 
(CTR1). Once inside the cell, it is activated through a series of aquation 
reactions, whereby one of the chloride ligands is displaced by water. Aquated 
platinum readily binds DNA, with a preference for purine bases, (Jamieson 1999) 
forming monoadducts. Intra- and inter-strand DNA crosslinks are subsequently 
formed, causing conformational DNA changes, impairing replication and DNA 
synthesis (Siddik 2003). Platinum-induced DNA lesions attract DNA binding 
proteins that either signal for apoptosis or initiate DNA MMR, which can lead to 
continued cell viability and result in platinum resistance (Tapia 2012).  
Platinum Resistance  
Approximately 80% of ovarian cancers are sensitive to platinum therapy at 
presentation but the vast majority of patients will develop resistance and 
ultimately succumb to their disease as a result of ineffective second line 
therapies in the presence of chemo resistance (Thigpen 1993). Intrinsic and 
acquired resistance results from the numerous genetic and epigenetic changes 
occurring in cancer cells, which may include alterations in proliferation signalling 
pathways, for example P13K/Akt/mTOR or MAPK pathways, section 1.5.1, 
suppression of tumour suppressor genes, for example PTEN, section 1.5.3, 
changes to drug import/export, for example CTR1/ATP7 copper transporters in 
platinum resistance; and changes in DNA damage response.  
Definitions 
GOG adopted the definition of chemosensitivity based upon clinical criteria from 
a retrospective case series. Following initial treatment when patients were re-
challenged with platinum, those with a longer interval from the last dose of 
platinum had better response and overall outcome (Ledermann 2010). This 
clinical observation set the basis for the current classification of platinum 
resistance, Figure 1.6 - 1, (Tapia 2012) and allowed the commonly used 
stratification criteria in clinical trials of recurrent EOC. Platinum resistant disease 
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is defined as disease that recurs within 6 months of completion of 
chemotherapy, with platinum sensitive disease defined as recurrence beyond 
12 months, although there is variability in this definition. Refractory disease 
demonstrates no response to chemotherapy with either static or progressive 
disease seen up to the date of their post chemotherapy treatment evaluation.  
 
Figure 1.6 - 1: Platinum-resistance definition by the Gynaecologic Oncology Group 
(GOG). Platinum sensitivity is classified as resistant, partially sensitive or sensitive, 
according to the time relapsed since finishing first-line treatment. Probability of re-
treatment response is shown for each group of patients (Tapia 2012).  
 
Treatment options are limited at relapse and the toxicities of conventional first 
and second line chemotherapies and the frequent development of chemo-
resistance limits their use (Guppy 2005, Markman 2009). The current treatment 
for platinum-resistant EOC consists of chemotherapy agents whose mechanism 
of action is different from that of platinum (Harter 2006). Selection of second line 
agent is currently largely based upon likely tolerance by patients rather than 
tailored according to the biology of the disease. 
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1.6.5. Second Line Agents 
Treatment of recurrent disease is considered palliative and is initiated with the 
goals of controlling disease-related symptoms, limiting treatment-related 
toxicity, maintaining or improving quality of life, delaying time to progression and 
prolonging survival (Herzog 2004). Numerous second line agents are available, 
Table 1.6 - 2. Typically, one, or a maximum of two, agents are given at one time 
due to potent side effects and the typical frailty of patients. There is little 
guidance available to assist in the appropriate selection of an effective second 
line agent and the decision is frequently based upon the likely patient tolerability 
as well as evidence from limited clinical trials.  
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Cytotoxic 
Agent 
Mechanism of Action Licenced Indication 
Common / Significant  
Side-effects 
Platinum  
 
Alkylating agents which irreversibly bind to DNA bases, resulting in DNA fragmentation as 
well as formation of DNA cross-links preventing DNA synthesis or transcription. 
 First line  
 Recurrent platinum 
sensitive disease  
 Myelosuppression  
 Renal impairment 
 Peripheral neuropathy 
Paclitaxel  
 
Binds to the β subunit of tubulin arresting microtubule function, preventing intracellular 
transportation. Additionally induces apoptosis by binding to Bcl-2 arresting its anti-
apoptotic function (Gaitanis 2010). 
 First line with platinum  
 Recurrent disease  
 Myelosuppression 
 Peripheral neurotoxicity 
 Fatigue/Myalgia 
Gemcitabine 
 
A nucleoside analogue activated intracellularly to dFdCTP by deoxycytidine kinase. 
Incorporation of dFdCTP into DNA results in inhibition of DNA synthesis and induction of 
apoptosis.  
 Monotherapy in pre-
treated patients. 
 Myelosuppression 
 Hepatic impairment 
 
Doxorubicin 
 
Antineoplastic anthracycline antibiotic with antimitotic and cytotoxic activity. Doxorubicin 
forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase 
II activity preventing DNA religation (Weiss 1992). 
 Paclitaxel and 
platinum refractory 
disease 
 Fatigue 
 Mucositis/stomatitis 
  
Bevacizumab 
 
A recombinant monoclonal antibody that binds to VEGF preventing interaction with Flt-1 
and KDR receptors. This prevents blood vessel proliferation and tumour metastasis 
(Velcheti 2006). 
 Suboptimal 
cytoreduction and 
recurrent disease 
 Hypertension  
 Fatigue 
 GI perforation / fistula 
Topotecan 
 
A synthetic camptothecan derivative that binds to the topoisomerase I-DNA complex 
interfering with the replication fork at SSB, leading to replication arrest and DNA DSB 
(Dennis 1997, Kollmannsberger 1999).  
 Paclitaxel and 
platinum refractory 
disease 
 Myelosuppression 
 
Etoposide 
 
A semisynthetic derivative of podophyllotoxin. Inhibits DNA topoisomerase II, thereby 
inhibiting DNA re-ligation causing critical errors in DNA synthesis and subsequent 
apoptosis.  
 Recurrent ovarian 
cancer  
 Myelosuppression 
 Fatigue 
Tamoxifen 
 
Tamoxifen selectively binds to oestrogen receptors (ER) resulting in up/own regulation of 
oestrogen dependent genes  resulting in reduced DNA polymerase activity and impaired 
thymidine utilization (Jordan 2006).  
 Oestrogen receptor 
positive cancers 
 Headaches 
 Hot flushes 
 Fatigue 
Table 1.6 - 2: Second line chemotherapy agents in the treatment of ovarian cancer.
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1.7. Targeted Therapies for Ovarian Cancer?  
Despite the growing understanding of the molecular complexity and 
heterogeneous nature of ovarian cancer, the disease continues to be treated as 
a single entity. The majority of patients are treated with surgery and 
chemotherapy but the timing of this, alongside the highly variable treatment of 
recurrent disease makes incorporation of disease biology into clinical decision 
making highly complex. Additionally, in spite of the availability of multiple 
second line therapies, their effect upon overall survival is relatively modest. The 
inability to predict their effect for each individual, coupled with their side-effects, 
limits their use.  
Novel biological agents, aim to target tumour cells and /or the tumour 
microenvironment by exploiting specific molecular abnormalities within tumour-
specific oncogenic pathways. A number of agents are currently being 
investigated including PARP, mTOR, MEK, EGFR and HER2 inhibitors 
(Mazzoletti 2010, Gui 2012, Vergote 2012, Anglesio 2013, Farley 2013, 
Naumann 2013). These agents aim to cause selective cancer cell cytotoxicity 
by inhibiting key cellular pathways making them more susceptible to 
chemotherapy agents.  Adverse systemic effects are hence reduced. When 
used in combination, these novel agents provide an opportunity to potentiate 
action and counteract resistance of current cytotoxic therapies (Drew 2009). 
However, of more importance to this project is their use as monotherapies in 
tumours with defective DNA repair pathways. 
1.7.1. Angiogenesis Inhibitor: Bevacizumab 
Angiogenesis, the process of new blood vessel growth, has an essential role in 
tumour formation, growth, metastasises and repair (Hollingsworth 1995) and is 
under the control of a complex interaction between angiogenic factors, including 
vascular endothelial growth factor (VEGF) and inhibitors. In ovarian cancer, 
increased levels of VEGF are associated with poor prognosis and have been 
confirmed in multivariate analysis as an independent prognostic indicator of 
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survival (Hollingsworth 1995, Hartenbach 1997, Alvarez 1999, Shen 2000, Xu 
2000, Sonmezer 2004, Duncan 2008).  
Bevacizumab, a recombinant humanised monoclonal antibody to the VEGF 
ligand, has shown single-agent activity in phase 2 EOC trials (Burger 2007, 
Cannistra 2007) and two phase 3 trials (GOG 0218 and ICON7) have 
demonstrated extended PFS of up to 4 months following standard 
chemotherapy for stage III/IV disease (Burger 2011, Perren 2011). Furthermore, 
addition of bevacizumab to chemotherapy in platinum sensitive (OCEANS study) 
(Aghajanian 2012) and platinum resistant (AURELIA study) (Pujade-Lauraine 
2012) recurrent disease has been shown to improve PFS. Bevacizumab is 
currently licensed in combination with carboplatin and paclitaxel for first line 
treatment of suboptimally cytoreduced FIGO stage 3/4 EOC and in combination 
with carboplatin and gemcitabine for the treatment of first recurrence platinum-
sensitive cancer (Aghajanian 2012). Benefit in the treatment of platinum 
resistant disease has not been seen in a phase 3 trial but this may be due to the 
limitations of the trial design. Several markers that have been explored, include 
the measurement of angiogenesis, the measurement of secreted factors and/or 
cytokines such as VEGF, interleukin (IL)-8 and IK-6 and circulating endothelial 
cells (Campos 2009).   
1.7.2. PARP Inhibitors  
PARP and the Development of PARP Inhibitors 
The PARP inhibitors represent one of the most exciting recent developments in 
cancer therapy. Poly (ADP-ribose) polymerase (PARP) is a family of 17 proteins 
involved in a number of cellular processes involving mainly DNA repair and 
programmed cell death. All members of the PARP family have different cellular 
functions with only PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2, 
(PARP-5a, PARP-5b) having confirmed PARP activity. The other members of 
the family are mono ADP ribosylators or have unknown function. PARP-1 is 
however the founding member and has been the most extensively studied. The 
gene encoding PARP-1 protein is ADPRT- 1 gene located on 1q41-q42 (Auer 
1989). PARP is activated by binding to a DNA break (De Murcia 1994), resulting 
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in a cascade of intracellular signals and culminating in either DNA repair as part 
of the BER pathway or apoptosis (Dantzer 1999, Dantzer 2000). Inhibition of 
PARP leads to accumulation of SSB that convert to DSB during replication 
(Schultz 2003, Gottipati 2010), Figure 1.7 - 1. In isolation, this is insufficient to 
cause cell death as DSB can be repaired by the HR DNA repair pathway. 
However, if the HR pathway is defective, as in BRCA1 or BRCA2 deficient 
cancer cells, then cell death results (Bryant 2005, Farmer 2005). This 
phenomenon, whereby two non-lethal genetic mutations that are innocuous if 
present in isolation, but,  result in cell death when present in combination, is 
termed synthetic lethality (Dobzhansky 1946, Helleday 2008). Cancer therapy 
aims to exploit this phenomenon by exposing tumour cells known to be deficient 
in one DNA repair pathway to an agent that targets its synthetically lethal 
partner pathway, thereby causing selective tumour cell death (Helleday 2008). 
As non-cancer cells are likely to be competent in both DNA repair pathways, 
non-cancer cells remain viable thereby reducing systemic side-effects.  
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Figure 1.7 - 1: Synthetic lethality in HR defective tumours with PARP inhibition. The 
mechanism of PARP inhibitors is based on inhibition of PARP-1-dependent BER that 
leads to persistent DNA single strand breaks. Those breaks are subsequently 
converted into DSB due to collision of progressing replication fork with SSB. In normal 
cells, these DSBs would be repaired by HR thereby PARPi have no overall cytotoxic 
effect. However in cancer cells defective in BRCA1/2 and therefore defective in HR, 
DSBs cannot be repaired which leads to DNA fragmentation and cell death with the 
defect in HR and the inhibition of BER being synthetically lethal in combination. 
 
The first generation of PARPi were the 3-substituted benzamides (Purnell 
1980), which decreased DNA repair capacity, thereby enhancing the cytotoxic 
effect of DNA methylating agents in murine leukaemia cells (Durkacz 1980). 
Several generations of PARPi have since been developed and were designed 
to improve on the potency and specificity for PARP (Iwashita, Mihara et al. 
2004, Curtin 2005, Jagtap, Baloglu et al. 2005, Loh 2005, Wells 2006, Ferraris 
2010) Since the development of first generation PARP inhibitors, several 
compounds i.e., isoquilnolines, methyl-quinazolin and phenanthridinones (Suto 
1991, Banasik 1992, Griffin 1995) have been explored to develop PARPi which 
have been used as potent radio and chemosensitizers (Tentori, Leonetti et al. 
2003, Veuger 2003, Calabrese 2004).  
Interest in PARPi was initially concentrated to those breast and ovarian cancer 
patients with germline mutations in BRCA1 and BRCA2, following 
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demonstration of sensitivity to PARPi in BRCA defective cell lines and xenograft 
models (Bryant 2005, Farmer 2005, Plummer 2007, Drew 2011). There was an 
observed 100-1000 fold increase in sensitivity to PARPi compared to 
heterozygous or BRCA wild-type in hamster cell lines (Bryant 2005, Farmer 
2005) and a 5-7 fold increase in human cell lines (Drew 2011). 
PARPi sensitivity has also been demonstrated in cell lines harbouring mutations 
in the genes encoding various other components of the HR pathway (namely 
ATM, Rad51, Rad54, RPA1, NBS1, ATR, CHK1, CHK2 and FANC group), 
consistent with the hypothesis that these therapies, at least in part, work by 
exploiting the concept of synthetic lethality (McCabe, Turner et al. 2006). In 
2011, the Cancer Genome Atlas Research Network reported defective HR DNA 
repair in up to 50% of HGSCs providing confidence that PARPi could be 
effectively utilised in this condition (Cancer Genome ResearchNetwork 2011). 
This hypothesis has been supported by the double-blind phase II trial in patients 
with platinum-sensitive relapsed EOC, which demonstrated a significant 
increase in PFS in individuals treated with olaparib monotherapy in comparison 
to placebo (Ledermann 2012).      
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Clinical Trials  
Several generations of PARPi have been developed (Ferraris 2010). PARPi 
(rucaparib) first entered clinical trials in 2003. They were used to potentiate the 
effect of radio- and chemo-therapies and showed a beneficial effect in several 
cancers (Plummer 2005). Clinical trials initially concentrated on assessing the 
effect of PARP inhibition in hereditary breast and ovarian cancers but their use 
has since been explored in sporadic EOC and platinum resistant EOC. Ongoing 
and completed clinical trials for rucaparib and olaparib are summarised in Table 
1.7 - 1. The situation is however not universally positive with negative studies 
reported in heavily pre-treated sporadic triple negative cancer (Gelmon 2010) 
and no evidence of activity in combination with temozolomide (Isakoff 2010). To 
understand why some studies have succeeded, and others failed, biomarkers 
capable of predicting sensitivity, or resistance, are required (Turner 2011).  
PARP inhibitors only target HR-defective tumour cells, therefore, their 
associated side-effects, including myelosuppression and nausea, are relatively 
mild (Plummer 2007). Long-term effects of PARPi treatment are awaited from 
clinical trials. 
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Drug Study Population Drug Regimen Phase Outcome Reference 
Olaparib   BRCA1/2 breast/ovarian ca  
 Triple negative breast ca 
 Sporadic ovarian cancer 
100 mg bd to 600 mg bd) I Dose escalation with Grade 1/2 toxicities: nausea (32%), fatigue (30%), 
vomiting (20%). 5% anaemia, 3% Grade 4 thrombocytopenia. 12/19 BRCA 
carriers had radiological/ biochemical response or disease stabilization.  
(Fong 2009) 
 Advanced stage pre-treated 
EOC with BRCA1/2 mutations 
40 mg od to 600 mg bd. 
Dose expansion cohort: 
200 mg bd 
I Dose- escalation and single-stage expansion of a phase I trial. 20/50 
achieved complete/partial response (RECIST) or biochemical response and 
3/50 achieved disease stabilisation. Overall clinical benefit in 46% of BRCA 
patients.  
(Fong 2010) 
 BRCA1/2 ovarian cancer 
 Recurrent sporadic EOC 
400 mg bd or 100 mg bd  II Objective tumour response rate was 33% (400 mg bd) with a median PFS 
of 5.8 months. Complete/partial response (RECIST) or stable disease in 
57.6% of patients (400 mg) vs. 16.7% (100 mg). 
(Audeh 2010) 
 Triple negative breast cancer 
 Sporadic ovarian cancer 
400 mg bd II 25/63 ovarian cancer patients had clinical response (28 of which were 
BRCA1/2 mutant).  
(Gelmon 2011) 
 Platinum sensitive relapsed 
HGSC pre-treated with 2+ 
platinum agents 
400 mg bd vs. placebo II Double-blind RCT with an increase in PFS with olaparib (median PFS 8.4 
months) monotherapy in comparison to placebo (median PFS 4.8 months). 
No significant difference was seen for OS.    
(Ledermann 2012).    
 BRCA1/2 relapsed ovarian 
cancer 
400 mg bd vs. doxorubicin 
50 mg/m
2
 
II  (NCT00628251) 
Rucaparib  Advanced solid malignancies Dose escalation with (100 
mg/m
2
) temozolomide (TZ) 
and 12 mg/m
2
 PARPi with 
200 mg/m
2
 TZ 
I PARP inhibition was seen in all 33 patients with advanced solid 
malignancies. No toxicity attributable to Rucaparib alone was observed.  
(Plummer, Jones et 
al. 2008) 
 Chemo naïve metastatic 
melanoma 
12 mg/m
2
 PARPi with oral 
TZ 200 mg/m
2
 
II 46 patients with metastatic melanoma had a response rate of 17.4% with a 
median time to progression of 3.5 months and median OS of 9.9 months.  
(Plummer 2013) 
 BRCA1/2 breast  
 BRCA1/2 ovarian cancer 
 II Ongoing. Dose escalation followed by open-label multicentre study (NCT00664781) 
 
Table 1.7 – 1: Clinical trials of olaparib and rucaparib PARP inhibitors. 
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Rationale for HR Functional Assay 
BRCA mutant ovarian cancers represent only 10 - 15% of all ovarian cancers 
and it is clear from molecular studies, as well as clinical trials, that the potential 
scope of PARPi should not be limited to familial cancers.  
The tumour suppressor genes BRCA1 and BRCA2 are currently the only genes 
to be identified as highly penetrant ovarian cancer susceptibility genes (Gayther 
1999). The vast majority of tumours from women with germline BRCA1/2 
mutations show loss of heterozygosity of the wild type allele at the BRCA1/2 loci 
(Ramus 2003) and are considered HR deficient (Venkitaraman 2004).  
Ovarian cancers with germline mutations in BRCA1/2 genes represent 15% of 
all EOC and have classical features in terms of histology, survival and 
chemosensitivity. The term ‘BRCAlike’ is used to describe tumours without 
germline BRCA mutations, but which have a similar phenotype (Turner 2004). 
The loss of function of other components in the HR pathway, resulting in an 
overall pathway function defect, has been demonstrated to account for these 
similarities (Turner 2004). A number of mutations in a variety of genes within the 
HR pathway have been reported (Cerbinskaite 2012). Testing for each of these 
individual genetic mutations may be impractical and their cumulative effect on 
overall function of the pathway remains unknown. Pennington et al 
demonstrated that 31% of ovarian carcinomas had a deleterious germline (24%) 
and/or somatic (9%) mutation in one or more of the 13 homologous 
recombination genes: BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, 
FAM175A, MRE11A, NBN, PALB2, Rad51C, and Rad51D (Pennington 2014).  
An assay to test the end function of the pathway, irrespective of mutation of its 
individual components ,has been developed and demonstrates that in actual 
fact up to 50% of sporadic EOC are HR defective (Mukhopadhyay 2010). 
Therefore relying upon BRCA mutations in isolation, or even genomic 
sequencing of all HR genes, may underestimate patients with defective HR and 
who would therefore respond to PARPi by 20 - 35%. Additionally, the overall 
effect upon function of isolated mutations in single genes within the HR pathway 
is unknown and epigenetic silencing, endogenous repressors or mutations / 
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dysregulation of other components of HR may interact and change functional 
status.  
The Development of the Rad51 Assay to Determine Functional 
Homologous Recombination Repair Status 
The Rad51 assay was developed in Newcastle University and adapted by 
Mukhopadhyay et al for use in ovarian cancer primary cultures generated from 
malignant ascites (Mukhopadhyay 2010).   
The assay aims to assess the ability of a live cell population to identify DNA 
damage, which is specifically repaired by homologous recombination (DSB, 
stalled/collapsed replication forks). There are a series of proteins and factors, 
which take part in the HR repair of the DNA and the assay combines an 
assessment of the cell’s ability to recognise and quantify DNA damage with the 
cells ability to complete the cascade of complex protein interactions required for 
repair using HR.  
A key component in DNA repair is the histone protein H2AX, which becomes 
rapidly phosphorylated to form large numbers of γH2AX at DSB, creating a 
focus where proteins involved in DNA repair and chromatin remodelling 
accumulate (Mukhopadhyay 2010). This amplification makes it possible to 
detect DSBs with an antibody to γH2AX, with the number of DSBs estimated 
from the number of foci (Bonner, Redon et al. 2008, {Paull, 2000 #698)}. Rad51 
is a crucial downstream protein involved in HR repair, which is relocalised within 
the nucleus in response to DNA damage to form distinct foci that can be 
visualized by immunofluorescent microscopy and are thought to represent 
assemblies of proteins at these sites of HR repair(Mukhopadhyay 2010). 
Therefore, it was hypothesised that quantification of Rad51 could serve as a 
marker of HR function to distinguish between HR-competent and HR-defective 
cells (Lee, Roques et al. 2009). 
The HR Rad51 assay protocol is described in detail in section 3.6. Briefly, 
primary cell cultures generated from malignant ascites, or solid tumour, growing 
exponentially in an adherent monolayer are seeded onto sterile coverslips and 
double strand (DSB) DNA damage induced. After assessment of several 
methodologies to induce DNA damage (irradiation, hydroxyurea, PARPi), 
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induction with 2 Gy irradiation and incubated with 10 μM PARP inhibitor to 
maintain DSB was selected on account of its safety and consistency. Cells are 
fixed after 24 hours and following permeablisation and washing and blocking 
steps, described in detail in Section 3.6, immunofluorent labelled antibodies are 
used to identify nuclear foci of γH2AX and Rad51.  
Image-J technology, previously validated against manual foci counting by two 
independent reviewers, is used to calculate the mean foci count per cell and 
counts compared to untreated controls, without DNA DSB induction. Foci 
counting, not quantification of actual protein levels,  is important as it indicates 
that the protein is functioning within the pathway and prevents high levels of 
non-functional protein resulting from genetic or epigenetic alterations resulting 
in false positive results.  Further experiments demonstrated consistent co-
localisation of γH2AX and Rad51 within the nucleus.  
In initial experiments the actual Rad51 counts obtained were highly variable 
indicating a range of baseline Rad51 foci activity and the comparison to 
untreated controls was introduced to control for this. Additionally, despite 
standardisation of induction of DNA DSB levels of γH2AX were also variable 
and a standard of a two fold increase in γH2AX foci was adopted as a measure 
of induction of sufficient DNA damage in order to enable assessment of 
pathway function.   
Initial experiments included Rad51 assays alongside cytoxicity to PARP 
inhibitors in paired cell lines (mutations in key proteins in the HR pathway with 
WT)  as well as 25 primary cultures generated from ovarian cancer patients 
(Mukhopadhyay 2010).  There was an increase in γH2AX foci in all cultures 
confirming induction of DNA damage. Rad51 foci increased following treatment 
by ∼2-fold compared with controls in 9 of 25 primary cultures, which were 
therefore deemed to be HR competent. In the remaining 16 cultures, there was 
no increase or even a decrease in Rad51 foci in response to DNA damage and 
therefore, they were deemed to be HR deficient. There was good correlation in 
Rad51 foci counting between two reviewers and good agreement in prediction 
of HR status. The cultures predicted to be HR competent on the basis of Rad51 
focus formation remained viable in both cytotoxicity and cell proliferation assays 
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with PARP inhibitor, further supporting the utility of the assay. The definitions for 
competent HR function was therefore adopted as more than a twofold rise in the 
mean Rad51 foci count/cell following induction of DNA damage defined as at 
least a two fold increase in γH2AX foci formation. 
 
  γH2AX 
  
>2 fold <2 fold 
R
a
d
 5
1
 
>2 fold Competent Invalid 
<2 fold Defective Invalid 
 
1.8. Rationale for this Project 
Despite a growing appreciation of the molecular differences between, and within, 
the histological subtypes of ovarian cancer, it is essential that we understand 
what effect these mutations have upon the biology of the tumour. Although 
some mutations have been shown to be associated with prognostic differences, 
no reliable biomarkers, capable of predicting actual response to therapy, have 
translated into clinical practice.  
This project aims to further explore the potential of HR functional status in 
predicting disease response and gain an understanding of its clinical application 
in terms of tumour sampling and its ability to accurately predict disease 
behaviour.   
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Chapter 2. Hypothesis and Aims 
This project seeks to develop and exploit the concept of synthetic lethality 
further. Firstly, by developing a greater understanding of HR function in ovarian 
cancer and by exploring more clinically relevant tests for HR status. Secondly, 
by exploring whether other cytotoxic agents can also be used in a synthetically 
lethal manner; and finally, by considering how to sample ovarian tumours so 
that the biological assessment of the chosen sample is representative and 
correlates with clinical outcome.  
  
 50 
 
2.1. Primary Cultures 
Hypotheses   
 Epithelial cells can be cultured from malignant ascites obtained during 
surgery for ovarian cancer and the functional homologous recombination 
assay can be performed which predicts sensitivity to cytotoxic agents. 
 Ex vivo culture has no effect upon cell phenotype in terms of antigen 
expression or EMT phenotype. 
Aims 
 To characterise PCO cultures derived from ascitic samples in terms of 
antigen expression, growth potential and morphology in order to further 
understand the strengths and weaknesses of this model.  
 To understand the extent of epithelial mesenchymal transition (EMT) 
within ovarian cancer and the effect of ex vivo culture upon this.  
 To explore the presence of subpopulations of cells within ascites, their 
antigen expression, growth and HR status.  
 To determine the homologous recombination (HR) DNA repair status of 
PCO cultures with corresponding ex vivo sensitivity to rucaparib and 
cisplatin and to compare with in vivo platinum sensitivity and clinical 
outcome.  
 To explore the ability to simplify the currently complex HR assay in order 
to transform it into a reliable, reproducible and clinically applicable 
process, enabling rapid, large volume turnover in clinical trials and 
routine practice and to explore alternative assays for HR function based 
on expression signatures at RNA level.  
 Assess the utility of ex vivo proliferation assays in predicting clinical 
response to platinum chemotherapy.  
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2.2. Solid Tumour Culture and Heterogeneity 
Hypotheses   
 Epithelial cells can be cultured from solid tumour obtained during surgery 
for ovarian cancer and the functional homologous recombination assay 
can be performed, which can predict sensitivity to cytotoxic agents. 
 Within ovarian cancer, subpopulations exist. Sampling tumour from 
different anatomical sites will demonstrate heterogeneity in morphology, 
antigen expression, DNA repair function and response to cytotoxic 
agents. 
Aims 
 Explore the feasibility of culturing ovarian cancer solid tumour from 
various metastatic sites within the abdomen.  
 Explore spatial intra-tumoural heterogeneity (ITH) within an individual’s 
cancer by characterising PCO subcultures in terms of antigen expression, 
growth potential and morphology alongside functional HR status and 
sensitivity to PARP inhibitors and platinum.  
 Investigate intra-tumoural heterogeneity as a prognostic marker 
alongside other recognised prognostic markers (histological subtype and 
surgical cytoreduction).  
 Investigate temporal changes in HR status using longitudinally collected 
samples of ovarian cancer.  
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2.3. Sapacitabine 
Hypotheses 
 CNDAC (the metabolically active component of sapacitabine is cytotoxic 
in HR defective cell lines and PCO (primary culture ovary) cultures. 
 Alternative DNA repair mechanisms also play important roles in the 
prediction of sensitivity to CNDAC in cell lines and PCO cultures.  
Aims 
 Assess the cytotoxic effect of CNDAC and its effect upon cell 
survival/proliferation of cell lines with mutations in the homologous 
recombination DNA repair pathway.  
 Determine the HR status of PCO samples derived from ascitic cultures, 
with corresponding sensitivity to CNDAC,  rucaparib and cisplatin.  
 Establish if defects in other DNA repair pathways are determinants of 
sensitivity to CNDAC.  
 Establish a functional assay to test base excision repair status and 
assess its potential use as a biomarker for stratification of CNDAC 
therapy. 
 Explore the effect of variable CNDAC uptake (by ENT receptor), 
activation (by dCK) and deactivation (by CDA) upon ex vivo sensitivity to 
CNDAC.  
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2.4. Circulating Tumour Cells 
Hypotheses 
 CTCs can be reliably detected and quantified within whole blood from 
ovarian cancer patients.  
 CTC number predicts PFS/OS with greater numbers seen in higher stage 
disease  
 HR status can be performed using ImageStream on cell lines, PCO 
cultures and on CTC.  
 Ascites can be processed using ImageStream to identify and 
characterise tumour cells and the HR assay can be applied to such cells  
Aims 
 Develop a method for sample preparation of whole blood to positively 
identify ovarian cancer cells from blood cells, using cell lines and healthy 
volunteer blood.  
 Develop a method for data handling and analysis of such samples.  
 Develop a method for the accurate identification, quantification and 
characterisation of CTCs from whole blood taken from ovarian cancer 
patients 
 Correlate enumeration of CTCs with stage of disease/PFS/OS 
 Develop a method for application of the HR functional assay based upon 
γH2AX and Rad51 foci formation to cell lines, PCO cultures, and CTC 
using ImageStream. 
 Explore the alternative approach of using ImageStream technology to 
directly characterise and functionally assess the cellular component of 
malignant ascites. 
  
 49 
 
Chapter 3. Materials and Methods 
3.1. General Equipment 
Equipment Manufacturer 
Agilent 2100 Bioanalyser Agilent Technologies, USA 
Agilent RNA Bioanalyser Agilent Technologies, USA 
Balance model Ohaus Discovery Balance DV215CD  Ohaus, UK 
BD Falcon round bottom polystyrene 14 ml tubes BD Biosciences, UK 
ColCount™ colonies counter Oxford Optronix Ltd., UK 
Coulter Counter model Z1  Beckman Coulter Ltd., UK 
Cytospin (Shandon) Thermo Scientific, UK 
Digital pH meter model pH302  Hanna Instruments, UK 
EasySep™ big easy magnet Stemcell Technologies, UK 
Fuji LAS-3000 Luminescent Image Analyser Raytek Ltd. 
Haemocytometer (Improved Neubauer) Weber Scientific, UK 
ImageStream Mark-II Amnis Corporation, USA 
Immunoblot manifold 
Department of engineering, Newcastle 
University, UK 
Leica DMR Immunofluorescent microscope  Leica microscopes, Germany 
Incubator MCO-20AIC  Sanyo E&E Europe BV, Medical Division, UK 
Lambda 2 Spectrophotometer Perkin Elmer, USA 
Micro-balance Mettler Toledo 
NanoDrop ND-1000 UV spectrophotometer Fisher Scientific, UK 
Orbital shaker IKA-Vibrax-VKR Sigma Aldrich 
Platform shaker  IKA Vibrax, Germany 
Qiagen RNA easy Mini kit  Qiagen, UK 
Refrigerated centrifuge MSE Falcon 6/300 
Refrigerated microcentrifuge Eppendorf centrifuge 5417R 
Spectramax 250 microplate reader Molecular Devices 
Sterile cell culture flasks 25 cm
2
, 75 cm
2
  Corning Incorporated, USA 
Stuart Vortex mixer Scientific Laboratory Supplies, UK 
Vacusafe Comfort IBS Integra aspiration system BD Biosciences, UK 
Water bath   Gallenkamp, UK 
X-ray irradiator XSTRAHL RS320  Gulmay Medical Ltd., UK 
VisCam® software VWR International Ltd., UK 
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3.2. Chemicals and Reagents 
Reagent Order No. Manufacturer 
10H PAR antibody (1.5 mg/ml) 
 
Dr Alex Burke 
4-15% Mini-PROTEAN® TX™ gels  456-1085 Bio-Rad Laboratories, USA 
Acetic acid A6283-2.5L Sigma Aldrich Company Ltd., UK 
Albumin bovine serum (BSA)  A9647 Sigma Aldrich Company Ltd., UK 
Amersham ECL detection fluid RPN2232 GE Healthcare Life Sciences, UK 
Amersham Hybond ECL nitrocellulose 
membrane 
RPN303D GE Healthcare Life Sciences, UK 
Anti-CD56 V450 (clone H130) mouse 
monoclonal antibody  
560367 BD Biosciences, USA 
Anti-CDA rabbit polyclonal antibody Ab82347 Abcam, UK 
Anti-D2-40 mouse monoclonal antibody  IS072 Dako, France 
Anti-dCK rabbit polyclonal antibody  Ab96599 Abcam, UK 
Anti-ENT antibody (rabbit polyclonal anti-
human ENT1) 
Ab48607 Abcam, UK 
Anti-EpCAM (CD326) Alexa Fluor® 488 
mouse monoclonal antibody 
324310 Biolegend, UK 
Anti-MOC-31 monoclonal  mouse antibody  M3525 (01) Dako, France 
Anti-mouse Alexa Fluor®546 goat  IgG 
(H+L) monoclonal antibody 
A-11030 Life Technologies Ltd, UK 
Anti-mouse goat monoclonal HRP antibody P0447 Dako, France 
Anti-MUC16 (CA125) [X75] mouse 
monoclonal antibody   
AB1107 Abcam, UK 
Anti-pancytokeratin (clone C-11) PE mouse 
monoclonal antibody 
10478 Cayman Chemical, USA 
Anti-pancytokeratin FITC (clone C11), 
mouse monoclonal antibody 
CBL234F Upstate Millipore Corp., USA 
Anti-phospho-histone H2AX (Ser 139), 
mouse monoclonal antibody, clone JBW301 
05-636 Upstate, Millipore Corp, USA 
Anti-rabbit Alexa Fluor®488 goat IgG (H+L) 
monoclonal antibody  
A-11034 Life Technologies Ltd, UK 
Anti-rabbit goat monoclonal HRP antibody A0545-1ml Sigma Aldrich Company Ltd., UK 
Anti-rabbit PE-Cy5.5 goat IgG (H+L) 
monoclonal antibody 
L42018 Invitrogen, USA 
Anti-Rad51 (Ab-1) rabbit polyclonal 
antibody  
PC130 Calbiochem,  USA 
Anti-vimentin (clone EPR3776) rabbit 
monoclonal antibody 
ab92547 Abcam, UK 
APEX™ Alexa Fluor® 594 antibody 
labelling kit 
A10474 Invitrogen, USA 
AutoMACS rinsing solution 130-091-222 Miltenyi Biotec, Germany 
Cal-lyse™ lysing solution GAS-0105-100 Invitrogen, USA 
Chromatography filter paper 3030917 Whatman 
Cisplatin 400-040-M250 Enzo Life Sciences 
CNDAC 
 
Cyclacel, UK 
Collagense/Dispase 11097113001 Roche Diagnostics, Ltd., UK 
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Crystal violet  C6158-50G Sigma Aldrich Company Ltd., UK 
Cyto-Chex® BCT blood collection tubes 213361 Streck, ISA 
DC™ Protein Assay 500-0111 Bio-Rad Laboratories, USA 
Dextran 31390 Sigma Aldrich Company Ltd., UK 
Digitonin D141 Sigma Aldrich Company Ltd., UK 
Dipyridamole D9766  D9766-1G Sigma Aldrich Company Ltd., UK 
DMSO D8418-50ML Sigma Aldrich Company Ltd., UK 
DRAQ 5 DR50200 Biostatus, UK 
Dried non-fat milk powder 
 
Marvel Premier Int Foods Ltd., UK 
Dynabeads® CD45 1153D Invitrogen, USA 
DynaMag 12321D Invitrogen, USA 
EasySep™ Human CD45 Depletion Kit 18259 Stemcell Technologies, UK 
EDTA E9884 Sigma Aldrich Company Ltd., UK 
EGTA E3889 Sigma Aldrich Company Ltd., UK 
Ethanol 10107 BDH Ltd., UK 
FACS Clean  340345 Beckman coulter 
FACSFlow™ 342003 BD Biosciences, USA 
FcR Blocking Reagent, human 130-059-901 Miltenyi Biotec, Germany 
Foetal bovine serum (FBS) 10106-169 Gibco, Scotland 
Gen Elute Mammalian Genomic DNA 
Miniprep kit  
G1N350 Sigma Aldrich Company Ltd., UK 
Goat serum  X090710 Dako, France 
HEPES H3784 Sigma Aldrich Company Ltd., UK 
HT 8-oxo-dG ELISA kit II 4380-096-K Trevigen, USA 
Hydrochloric acid H1756 Sigma Aldrich Company Ltd., UK 
Hygromycin B (50 mg/ml) 10687-010 Invitrogen, USA 
Isopranolol  10224BQ BDH Ltd., UK 
Lysing Solution, Whole Blood Lysing 
Solution  
010S-100 Invitrogen, USA 
MACS BSA Stock Solution 130-091-376 Miltenyi Biotec, Germany 
MACS CD45 microbeads 130-045-801 Miltenyi Biotec, Germany 
MACS® CD45 Microbead 130-045-801 Miltenyi Biotec, Germany 
MEGM BulletKit (CC-3151 & CC-4136) CC-3150 Lonza, Switzerland 
Methanol  M/4056/017 Fisher Scientific Int Ltd., UK 
Methoxyamine 226904-1G Sigma Aldrich Company Ltd., UK 
MiniMACS™ separator 130-042-102 Miltenyi Biotec, Germany 
Mini-PROTEAN Tetra cell System  165-8004 Bio-Rad Laboratories, USA 
Mini-PROTEAN TGX Gel (4-15%) 456-1085 Bio-Rad Laboratories, USA 
Nicotinamide adenine dinucleotide (NAD+) N1511 Sigma Aldrich Company Ltd., UK 
Nylon net filter (180 μm pore) NY8H09000 Millipore, UK 
Oligonucleotide (CGGAATTCCG) 
 
Invitrogen, USA 
PAR polymer 202-043-C001 Enzo Life Sciences 
Parafilm PM996 Pechiney plastic packaging, USA 
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Penicillin/Streptomycin (10,000 μg/ml)  P4333 Sigma Aldrich Company Ltd., UK 
Phosflow Lyse/Fix buffer 558049 BD Biosciences, USA 
Phosflow Perm/Wash I 557885 BD Biosciences, USA 
Ponceau S solution P7170-1L Sigma Aldrich Company Ltd., UK 
Propidium iodide (PI) P4170 Sigma Aldrich Company Ltd., UK 
RNA Bioanalyser 6000 Nano kit 5067-1511 Agilent technologies, USA 
RNA easy Mini kit  74106 Qiagen 
RNAse R5503-1G Sigma Aldrich Company Ltd., UK 
RoboSep buffer 20104 Stemcell Technologies, UK 
RosetteSep™ Human CD45 Depletion 
Cocktail,  
15122 Stemcell Technologies, UK 
RPMI 1640  with L-glutamine R8758 Sigma Aldrich Company Ltd., UK 
Rucaparib, AG014699 
 
Clovis, USA 
S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) N2255-25MG Sigma Aldrich Company Ltd., UK 
Spectra™ multicolour broad range protein 
ladder  
26634 Life Technologies Ltd, UK 
Speed Beads 4000400 Amnis, USA 
Sulforhodamine B (SRB) 230162-5G Sigma Aldrich Company Ltd., UK 
TransFix® vacuum collection tubes TVT-10-50 Cytomark 
Trichloroacetic acid (TCA) T4885 Sigma Aldrich Company Ltd., UK 
Tris T6066 Sigma Aldrich Company Ltd., UK 
Trypan blue 0.4%  T8154 Sigma Aldrich Company Ltd., UK 
Trypsin-EDTA  2.5% (10x) T4174 Sigma Aldrich Company Ltd., UK 
Tween 20 P1379 Sigma Aldrich Company Ltd., UK 
Vacutainer® collection tubes containing 
K3EDTA 
366450 BD Biosciences, USA 
Vectashield mounting medium with DAPI H-1200 Vector, USA 
Virkon®  1.3E+11 Antec International Ltd., UK 
WST-1 5015944001 Roche Diagnostics, Ltd., UK 
β-Mercaptoethanol M6250-10ml Sigma Aldrich Company Ltd., UK 
 
 
Stock solutions of rucaparib (10 mM), CNDAC (10 mM), methoxyamine (1 M), 
NBMPR (10 mM), and dipyridamole (10 mM) were dissolved in DMSO, 
aliquoted and stored at -80 °C. All experiments were corrected for 1% DMSO in 
final concentration. Cisplatin (2 mM) was dissolved in PBS and stored as above.  
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3.3. General Laboratory Practice 
All experiments were performed to university standards, complying with the 
Control of Substances Hazardous to Health Regulations 2002 (COSHH) and 
Biological COSHH (BioCOSHH). Routinely used chemicals, reagents and 
equipment are detailed in the tables below. Preparations of specific reagents for 
investigations are described in the relevant sections below.  
3.4. Cell Culture  
3.4.1. Cell lines  
Experiments were carried out using cells lines described in Table 3.4 - 1. All 
media were stored at 4 °C and warmed to 37 °C prior to use. All cells were 
handled separately with their own reagents and underwent regular mycoplasma 
testing (MycoAlert Mycoplasma detection kit; Lonza). Early passages (<35) of 
cell lines were grown in at 37 °C, 5% CO2, 95% humidified air, maintained at 
exponential growth. Passage was performed using an aseptic technique in a 
containment level II laminar flow microbiological cabinet. Medium was aspirated 
and cells washed with PBS before incubation with 5 ml 0.25% trypsin-EDTA for 
at 37°C until detachment. The cell suspension was centrifuged at 50 g for 5 
minutes, the supernatant discarded and the cell pellet re-suspended in 10 ml 
medium before 10 l of the solution was loaded onto a Neubauer 
Haemocytometer. Cells were seeded into flasks / culture dishes as required. 
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Cell line 
ATCC 
number 
Description Media 
Doubling Time 
(hours) 
Source 
OVCAR3 ATCC® HTB-
161 
Human ovarian adenocarcinoma derived from ascites after 
combination chemotherapy with cyclophosphamide, 
adriamycin, and cisplatin (Hamilton 1983). 
RPMI 1640 medium with 25 mM 
HEPES modification, mom L-glutamine, 
10% heat inactivated fetal calf serum 
(FCS), penicillin (100 U/ml) and 
streptomycin (100 up/ml), referred to as 
10% RPMI  
 ATTC© 
A2780  Human ovarian adenocarcinoma derived from tumour from 
an untreated patient. p53 and MMR-proficient, (Anthoney 
1996) 
10% RPMI  ATTC© 
CP70-B1 
CP70-A2 
 A2780 derivatives. MMR-defective (hMLH1 promoter 
hypermethylation) (Strathdee 1999). CP70-B1 cells have 
functional MMR (chromosome 3 transfer). CP70-A2 cells 
carry a transferred chromosome 3 with mutant hMLH1 
(Plumb 2006), both CP70 derivatives carry a dominant-
negative p53 mutation (Brown 1993, Lu, Errington et al. 
2001).   
10% RPMI 
 
 R Brown (Beatson 
Laboratories, UK) 
UWB1-
289 
ATCC®CRL-
2945 
Human ovarian serous carcinoma derived from a patient with 
breast cancer age 42 and ovarian cancer age 54. Germline 
BRCA1 mutation within exon 11 and a deletion of the wild-
type allele (DelloRusso 2007). 
50% Mammary Epithelial Cell Growth 
Medium™ and 50% RPMI with 20 mM 
L-glutamine, 10% FCS, penicillin (100 
U/ml) and streptomycin (100 μg/ml). 
53 ATTC© 
UWB1-
289 BR-1 
ATCC®CRL-
2946 
Derivative of UWB1-289 transfected with a pcDNA3 plasmid 
carrying wild-type BRCA1. Transfected cells were selected 
with addition of G418. 
50% MEGM and 50% RPMI + 200 
μg/ml G418 
45 ATTC© 
VC8  Chinese hamster lung fibroblasts derived from V79. Biallelic 
nonsense mutation in BRCA2 (Wiegant 2006). 
10% RPMI  39 
M. Zdzienicka (University 
of Leiden, Netherlands) VC8 BR-2  Derivative of VC8 transfected with bacterial artificial 
chromosome (BAC) containing wild type murine BRCA 2. 
10% RPMI  25 
VC8 PIR 
clone 1c 
 PARPi-resistant derivative of VC8 derived by mutagenesis 
with ethyl methane sulphonate (EMS) followed by selection 
in 4-amino-1,8-naphthalimide (ANI, PARPi).  
10% RPMI 23 T. Helleday (Oxford 
University, UK) 
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L1210  ATCC®CRL-
219 
Murine leukaemia lymphocyte cell line established from a 
tumour developed following skin paintings with 0.2% 
methylcholanthrene in ether. 
Internal control PAR assay 
Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 20 mM L-
glutamine, 10% FCS, penicillin (100 
U/ml) and streptomycin (100 μg/ml) 
 ATTC© 
V3  DNA-PKCS deficient Chinese hamster ovary cells defective in 
non-homologous end-joining (NHEJ) DNA repair (Whitmore 
1989)  
DMEM supplemented with 20 mM L-
glutamine, 10% FCS, penicillin (100 
U/ml) and streptomycin (100 μg/ml) 
48 
P Jeggo (University of 
Sussex, United Kingdom) V3-YAC  Derived from V3 Chinese hamster ovary cells, transfected 
with a yeast artificial chromosome (YAC) carrying the human 
DNA-PKCS gene, competent in NHEJ. 
DMEM, as above, with addition of 200 
μg/ml G418.  
38 
AA8 ATCC® CRL-
1859  
 
Derivative of the CHO-K1 cell line. 21 chromosome line, 
heterozygous at the aprt locus (Thompson, Fong et al. 1980). 
10% RPMI 16 ATTC© 
EM9 ATCC® CRL-
1861 
BER deficient with XRCC1 mutation derived from AA8 
(Thompson, Rubin et al. 1980, Thompson, Brookman et al. 
1982). Defective in SSB repair with a 10-fold higher baseline 
frequency of sister chromatid exchange relative to AA8 and a 
2-fold greater sensitivity to irradiation.  
10% RPMI 18 ATTC© 
UV5 ATCC® CRL-
1865 
AA8 derived UV sensitive cell line defective in NER. CXPD 
mutation resulting in an amino acid substitution within 
excision repair complementation group 2 (Thompson, Rubin 
et al. 1980, Thompson, Brookman et al. 1982, Weber 1994). 
10% RPMI 53 ATTC© 
MCF7 ATCC® HTB-
22 
Derived from a patient with breast adenoma and pleural 
effusion carry nonmutated BRCA1/2 (Elstrodt 2006). 
10% RPMI 38 ATTC© 
Capan-1 ATCC® HTB-
79 
Human pancreatic cancer cells with mutated BRCA2 
(6174delT) in one allele and loss of the other allele (Goggins 
1996). 
DMEM:Hams F12 1:1 supplemented 
with 2 mM glutamine and 15% FCS 
77 ATTC© 
MX-1 ATCC®  Derived from a primary ductal breast carcinoma of a 40yr old 
patient with BRCA1 truncating mutation at codon 999 and 2 
nonsynomous SNPs in BRCA2 (BRCA2 16864A>C, 
Asn289His, and BRCA2 221847A>G, Asn991Asp) . 
DMEM:Hams F12 1:1 supplemented 
with 2 mM glutamine and 10% FCS 
27 ATTC© 
Table 3.4 - 1: Cell lines.
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3.4.2. Primary Ovarian Ascitic Cancer Cells (PCO) 
Ethical approval was granted (12/NW/0202) and specimens were registered in 
accordance with the Human Tissue Act. Following written consent (see 
Appendix 5), ascitic fluid and solid tumour was collected from patients at the 
Northern Gynaecological Oncology Centre (NGOC), Gateshead, UK. Ascites 
was aspirated directly from the patient into a sterile suction bottle, either at the 
time of surgery for ovarian cancer or following a therapeutic ward paracentesis. 
Solid tumour, collected at the time of surgery, was placed into a sterile 
universal, containing culture medium (RPMI 1640 medium supplemented with 
20% FCS, 20 mM L-Glutamine and 1% penicillin and streptomycin) pre-warmed 
to 37 °C. Samples were transported from the hospital to the lab immediately, in 
compliance with UK Category B regulations UN3373. 
Samples were given a unique identifier, ‘PCO’, followed by a serial number to 
maintain anonymity. Multiple derivative samples were generated from each 
PCO sample collected and used in multiple assays, Figure 3.4 - 1. For all 
patient samples collected detailed clinical data was recorded including 
treatments undertaken and where appropriate, PFS/OS, see Appendix 6 for a 
summary. 
 
Figure 3.4 - 1: PCO collection flow chart for sample analysis.  
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Ascitic Culture 
20 ml of ascites was added to 20 ml of medium (RPMI 1640 medium 
supplemented with 20% FCS, 20 mM L-glutamine and 1% penicillin and 
streptomycin) in T75 flasks. Medium was replaced on day 5 to 7. Ascites fluid is 
often contaminated with red blood cells, mucin or fatty tissue but these 
contaminants do not adhere and are therefore removed during media changes. 
Aspirated media/ascitic fluid from the PCO samples was collated from a number 
of matched samples and reseeded into a T175 flask. The resulting adherent 
monolayer cultures were labelled ‘PCO x-2’ to denote their secondary nature. 
Ascitic cultures were collected and maintained by Dr Angelika Kaufmann and 
me. Michelle Dixon and Aiste McCormick also contributed to maintenance. Cell 
lines and established PCO cultures were frozen at early passage by re-
suspending cell pellets in 1 ml of freezing medium (RPMI medium, 10% FCS 
and 10% dimethyl sulphoxide [DMSO]) and slowly freezing to –120 °C. Frozen 
samples were rapidly defrosted, centrifuged to remove freezing media and re-
suspended in pre-warmed medium before transferring into 25 cm3 culture flasks 
and incubated at 37 °C.  
Ascites Cytocentrifugation and Coverslip Culture  
Cytospinning is a form of cell centrifugation and was explored as a method of 
increasing the speed of analysis of PCO ascitic samples to enable more rapid 
characterisation and determination of HR status.  
A 10% RCLB solution (Ammonium chloride, Stemcell, UK) was added to ascites 
(1:4, v/v) and incubated on a rocker at 37 °C for 5 minutes. The lysate was 
centrifuged at 300 G for 5 minutes before washing the cell pellet with PBS and 
re-suspended in 10 ml of media. 200 μl of the ascitic /media solution was 
cytospun using the Shandon cytospin2 centrifuge at 450 RPM for 5 minutes 
before air drying, fixing with methanol and storing at -20 °C for later analysis. 
 
Ascitic fluid samples were cultured directly onto sterilised coverslips to reduce 
the time taken to characterise and perform functional assays on culture cells. 
Two ml ascitic fluid was added to sterilised coverslips with media (1:1, v:v) in 6-
well plates and incubated at 37 °C for 48 hours to allow cell adherence. Cells 
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were then either fixed with methanol for characterisation studies or DNA DSB 
induced for the HR assay.  
Solid Tumour Culture: Final Assay Protocol  
Ascitic fluid and solid tumour were collected from each patient. A solid tumour 
sample from the bulk of the disease in the ovary was taken in every case with 
additional biopsies from multiple other intra-abdominal sites collected where 
possible, Appendix 7. Ascites was aspirated into sterile bottles and solid tumour 
(approximately 1 cm3) placed into sterile containers with warmed media.  
Once in the laboratory, solid tumour was dissected into 3 mm3 pieces and 
collagenase/dispase solution (1 mg/1 ml in full medium) added to immerse the 
sample. The sample was incubated for 2 hours at 37C on an orbital shaker at 2 
g before centrifuging at 400 g for 5 minutes, PBS washing and re-suspending in 
full medium. Samples were transferred into T25 flasks for 30 minutes to allow 
fibroblast seeding. Fibroblasts were disposed of and the epithelial cell 
suspension transferred to a T25 flask for on-going culture.  
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3.5. Cytotoxicity and Proliferation Assays 
3.5.1. Colony Formation Assays 
Principles of the Assay 
Colony formation assay is a technique for studying the effect of cytotoxic agents 
on the survival and proliferation of proliferating cells by assessing the ability of 
cells to form colonies. Colony formation assays were performed to study the 
effect of cisplatin, rucaparib and CNDAC on cell survival in cell lines. 
Assay protocol  
Each cell line was plated at low density estimated to give colony numbers 
between 30 and 200 into a 6 well plate for 24 hours to allow attachment. Media 
was replaced with media containing a cytotoxic agent at increasing drug 
concentrations in 1% DMSO with controls treated with 1% DMSO. After 24 
hours, incubation media was replaced with drug-free media and incubated at 37 
°C for 14 days. Media was aspirated, plates were PBS washed, then fixed with 
2 ml of Carnoy’s fixative (acetic acid: methanol 1:3 v/v) for 5 minutes at room 
temperature, followed by addition of 5 ml 1% crystal violet (in PBS w/v) to stain 
colonies before washing with water and drying. Colonies were manually 
counted and percentage survival calculated using the formula:  
 
Cloning efficiency (CE) %  =  Colonies counted / cells seeded x 100 
    
Survival %    =  CE treated cells / CE control       x 100 
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3.5.2. Growth Assay (Sulforhodamine B [SRB])  
Principles of the Assay  
SRB assay is a used to determine cell density of adherent cells based upon the 
measurement of cellular protein. SRB is an aminoxanthene water-soluble dye 
that binds to basic amino acids of cellular proteins under acidic conditions 
producing a colour change quantified using a spectrophotometer. The amount 
of dye extracted from the stained cells is directly proportional to the cell mass 
(Vichai 2006).The advantages of the SRB assay include practicality and 
flexibility. This method has limitations in that an increase in cell size in response 
to a drug could be interpreted as an increase in cell number, and therefore is 
only accurate as long as the cell size remains constant (Skehan 1990).SRB 
assays were used to determine the effect of cisplatin, rucaparib and CNDAC on 
cell proliferation in cells lines and PCO cultures.  
Cell Growth and Doubling Times  
Cells were seeded at concentrations of 500, 1000 and 2000 cells/well in 100 µl 
medium with six replicate wells for each cell concentration in 96 well plates.  
After 24 hours for attachment, cells were fixed at 24 hour intervals for 10 days 
with 20 μl of 50% trichloroacetic acid (TCA) per well, and stored at 4 °C. Plates 
were then washed three times with distilled water and dried. 100 μl of 0.4% 
SRB solution (in 1% acetic acid) was added to each well for 30 minutes at room 
temperature, after which the unbound SRB dye was removed by washing 4 
times with 1% acetic acid. A blank control was created after adding SRB to a 
well containing full medium but no cells. The protein-bound dye was dissolved 
in 100 μl of 10 mM Tris (pH 10.5) solution for optical density determination at 
570 nm using a Spectra Max 250 microplate reader. Doubling time was 
calculated using Graphpad PRISM (version 5) software. 
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3.5.3. Growth Inhibition Assays 
SRB 
Cells were seeded into 96 well plates at a concentration of 1000 cells/ well in 
100 µl medium with 6 replicate wells per concentration. After 24 hours for 
adherence media was replaced with media containing increasing concentrations 
of cytotoxic agent with an untreated control, all corrected for 1% DMSO. Cells 
were incubated for 3 doubling times (cell lines) or 10 days (PCO cultures) 
before fixing and staining, using the protocol above.  
The mean optical density for each drug treatment were obtained and expressed 
as a percentage of the related untreated or treated control. Growth inhibitory 
GI50 values (the concentration that results in 50% growth inhibition) and 
percentage survival at each drug concentration were calculated using a point to 
point curve on Graphpad Prism software. Final data represented the mean of 
three experimental repeats, each experiment containing six replicates, with 
SEM.  
 
WST-1 Assay 
Principles of the Assay 
Viable cellular enzymes cleave tetrazolium salts to formazan resulting in a 
colour change (Berridge 2005). Increasing numbers of viable cells results in an 
increase in the overall activity of mitochondrial dehydrogenases in the sample 
leading to an increase in the amount of formazan dye formed which is quantified 
by a multi well spectrophotometer. The WST-1 assay was used to assess the 
effects of cytotoxic agents on cell proliferation in parallel to the SRB assay in 
cell lines and PCO cultures.  
Assay Protocol 
Cells were prepared as for an SRB assay. Following incubation with increasing 
doses of cytotoxic agent 10 μl of WST-1 cell proliferation reagent was added to 
each well. A blank control was created after adding WST-1 reagent to a well 
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containing full medium but no cells. The plates were returned to the incubator 
and the absorbance was read at 450 nm after 15 minutes. Data analysis was 
performed as in the SRB assay. 
 
Cell Counting Assay 
Assay Protocol 
PCO cultures were seeded in triplicate into six well plates at a concentration of 
2x105/ml for 24 hours. Media was replaced with media containing increasing 
concentrations of cytotoxic agent, with an untreated control with equivalent 
0.1% DMSO. After 10 days media was aspirated, cells were PBS washed and 
trypsinised. 100 μl of the cell suspension was added to 990 μl of FACS rinse 
and the cell concentration determined by Coulter counter. A mean of three 
measurements per sample was used and normalised to untreated controls.  
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3.6. Homologous Recombination Repair Functional Assay  
3.6.1. Principles of the Assay 
There are three principles of the immunofluorescent HR assay:  
1. Induction of DNA DSB damage 
2. Quantification of DNA damage by γH2AX foci 
3. Quantification of Rad51 foci as a marker of DNA repair by HR. 
 
DSB as well as stalled/collapsed replication forks are the substrates for HR 
DNA repair and therefore induction and quantification of DNA damage and 
quantification of proteins used by the HR pathway provides the basis for this 
assay,  
 
Figure 1.4 -  5. H2AX becomes phosphorylated to form foci of γH2AX at the site 
of DNA DSB and the number of foci has been shown to correlate with the 
number of DSBs (Rogakou 1998, Sedelnikova 2002). There is a variable 
background γH2AX signal expressed mostly in S-phase associated with DNA 
replication (Celeste 2003) and this is controlled for when quantifying DNA 
damage. 
Rad51 is the central protein required for HR and is re-localised within the 
nucleus in response to DSB DNA damage to form distinct foci. Rad51 unwinds 
duplex DNA and forms helical nucleoprotein filaments at the site of a DNA 
break (Thacker, 2005). Rad51- coated nucleoprotein filament carries out the 
search for homology and strand invasion in HR (Sung 1994, Baumann 1996, 
Lundin 2003). Quantification of Rad51 in response to DNA damage serves as a 
marker of HR function allowing distinction between competent and defective 
cells,  
 
Figure 1.4 -  5. Both γH2AX and Rad51 were localised by binding of specific 
antibodies followed by fluorescently tagged secondary antibodies and 
immunofluorescence microscopy. DAPI, a fluorescent DNA stain was used to 
identify nuclei. 
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3.6.2. Assay Protocol 
Cells were cultured on glass coverslips at a concentration of 5 x 105 cells/well.  
After adherence DNA DSB were induced with 2 Gy ionising irradiation 
(Irradiator XSTRAHL RS320, Gulmay Medical Ltd., UK) at a dose rate of 2.4 
Gy/min, 310 kV, 10 mA.  Standard operating procedure for using the irradiator 
in NICR (D3300 X-ray system) was followed. Incubation for 24 hours with media 
containing 10 μM rucaparib (a potent inhibitor of PARP-1/2 Ki <5 nM/L) in 1% 
DMSO prevented repair of SSB and DSB induced by irradiation thereby 
creating stalled/collapsed replication forks. 
All experiments were performed alongside untreated controls with equivalent 
1% DMSO. Coverslips were washed with PBS and fixed with ice-cold methanol 
(-20 °C) for 20 minutes. Cells were rehydrated with two PBS washes and 
transferred to 90 mm petri dishes covered with parafilm. Cells were blocked for 
1 hour at room temperature in KCM buffer (120 mM KCl, 20 mM NaCl, 10 mM 
Tris-HCl, 1 mM EDTA, pH 8.0), 0.1% Triton X-100, 2% bovine serum albumin, 
and 10% milk powder to reduce non-specific binding. Cells were incubated 
overnight at 4 °C with primary anti-γH2AX histone IgG mouse monoclonal 
antibody or primary anti-Rad51 IgG rabbit polyclonal antibody at a concentration 
of 1:100 in blocking buffer. After three 15 minute washes with KCM buffer with 
0.1% Triton, cells were incubated with the corresponding secondary antibody,  
Alexa Fluor® 546-conjugated goat anti-mouse IgG antibody or Alexa Fluor® 
488-conjugated goat anti-rabbit antibody, for 1 hour at room temperature in the 
dark. After washing, coverslips were mounted on glass slides with 4 μl 
Vectashield DAPI mounting media and foci images with the Leica DMR 
fluorescent microscope, Table 3.6 - 1.  
Stain 
Filter 
colour 
Excitation 
(nM) 
Emission 
(nM) 
Gamma Gain 
Exposure 
(m seconds) 
Rad51 Green 495 519 0.35 16 3500 
γH2AX Red 556 573 0.35 16 3500 
DAPI Blue   0.35 4 300 
 
Table 3.6 -  1: Microscope settings for immunofluorescent HR assay. 
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3.6.3. Immunofluorescence Microscopy: Focus Counting 
Image J counting software (Abramoff 2004, Znojek 2011) was used to count 
γH2AX and Rad51 foci in at least 50 cells across three microscope fields. 
Overlapping cells and cells with fragmented nuclear outline on DAPI staining 
were excluded to avoid over/under estimation of foci counts.  The mean number 
of foci/cell in treated cells was normalised to untreated controls and results 
expressed as the fold increase from untreated controls.   Image J software has 
previously been validated when compared to manual counting by several 
independent reviewers (Mukhopadhyay 2010).  Cells were classed as HR 
competent if there was more than a 2-fold increase in Rad51 foci after DNA 
damage, confirmed by a 2-fold increases in γH2AX, and HR defective if less 
than a 2-fold increase in Rad51 foci count was seen.  
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3.7. 8-hydroxy-2’-deoxyguanosine: A functional BER assay 
Principles of the Assay 
8-hydroxy-2’-deoxyguanosine (8-OHdG) is produced during oxidative DNA 
damage with the main attack site by oxidative radicals at the N7-C8 bond 
(Chiou 2003). Cells competent in BER remove the 8-oxo-dG and have low 
residual levels, whilst cell lines defective in BER fail to remove 8-oxo-dG and 
have high residual levels. Trevigen’s competitive ELISA kit quantifies baseline, 
unstimulated, 8-OHdG in DNA using colorimetric detection. The assay uses an 
8-OHdG pre-coated 96 strip well plate to which samples are added followed by 
an anti-8-OHdG monoclonal mouse antibody. The 8-OHdG monoclonal 
antibody binds competitively to 8-OHdG immobilized on pre-coated wells and in 
the sample. Antibody bound to 8-OHdG in the sample is washed away while 
antibody bound to 8-OHdG attached to the well is retained. The remaining 8-
OHdG is quantified using colorimetric detection with HRP conjugate and 
colorimetric substrate. Colour formation is inversely proportional to 8-OHdG 
present in sample. High 8-OHdG levels indicate defective BER whilst low levels 
indicate competent repair.  
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Assay Protocol 
Cell pellets were prepared from PCO cultures when 80% confluent and stored 
at -80 °C.  DNA extraction was performed using the Sigma-Aldrich Gen Elute 
Mammalian Genomic DNA Miniprep kit as per manufacturer’s instructions. DNA 
concentration and purity was checked by Nano drop 1000 UV 
Spectrophotometer. DNA with 260/280 OD ratio of 1.6 to 1.9 were considered 
adequate quality and stored at -20 °C until further use. 
DNA at a concentration of more than 50 μg/ml was required for use in functional 
assays. DNA was concentrated by adding 300 μl 100% ethanol and 13 μl 
sodium acetate (pH 5.5) at -20°C for 30 minutes. Samples were centrifuged at 
120 g for 15 minutes before washing with 70% ethanol and resuspending in 
elution buffer. DNA was re-quantified as above.   
Equivalent DNA from PCO samples alongside positive and negative controls 
(AA8 and BER cell lines) were prepared to quantify baseline 8-OHdG. 1X 
cations were added to each sample followed by 2 μl DNAse I per 50 μg DNA 
and incubated at 37 °C for 1 hour. 2 μl alkaline phosphatase per 50 μg DNA 
was added and incubated at 37 °C for 1 further hour. DNA samples were ready 
for the ELISA. Standards were prepared as per manufacturers instruction by 
adding 3 μ l of 200 nM 8-OHdG solution to 297 μl of assay diluent. Serial 
dilutions were prepared from this. Samples and standards (25 μl) were added to 
the 96 well plate with 25 μl 1:250 8-OHdG monoclonal solution and incubated at 
25°C for 1 hour. Plates were washed 4 times with 0.1% (v/v) Tween PBS before 
adding 50 μl of goat 1:500 anti-mouse IgG-HRP conjugate to each well and 
incubating for 1 hour at 25 °C. After washing 4 times with 0.1% Tween PBS 50 
μl TACS-sapphire™ was added and the plate incubated in the dark for 5 
minutes. 50 μl 0.2 M HCl was added to each well to stop the reaction and the 
plate read at 450 nm using Spectramax 250 microplate reader.  
Data Interpretation 
Data analysis was performed using the Trevigen online worksheet: 
http://www.trevigen.com/docs/1309882151.4380_096_k_8_ohdg_calculation_w
orksheet.xls. Briefly, the mean absorbance of each 8-OHdG standard and blank 
was calculated. Following subtraction of the blank reading, the log of 8-OHdG 
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standard concentrations (nM) was plotted against the relative absorbance. The 
standard curve is a second order polynomial function represented by the 
equation: y = a+ bx + cx2, where y is the relative absorbance, x is the log of 8-
OHdG concentration in nM and a, b and c are coefficients. The 8-OHdG sample 
concentrations were calculated by interpolation from the standard curve.  
 
3.8. RNA Genome Expression Arrays  
Principles of the Assay 
The relative expression of particular genes involved in DNA DSB repair was 
determined in selected PCO, stratified by HR or BER functional status.  
RNA was extracted, quality checked then processed by the Oxford genomics 
centre (Oxford, UK) using Illumina Genome Studio and HumanHT 12v4.0 R1 
15002873 array, as per manufacturer’s instructions. 
Assay Protocol 
Reagents and RNA were kept on ice throughout the experiments and 
contamination minimized by using RNAZap solution for cleaning all surfaces, 
and RNase/DNase-free pipette tips and tubes. RNA was extracted from frozen 
cell pellets using the Qiagen RN easy Mini kit as per manufacturer’s 
instructions. Briefly, cells were lysed and homogenised, then RNA was bound to 
an RNeasy silica gel membrane in spin-column format, after which 
contaminants were removed by washing in provided buffers. RNA was eluted in 
30 μl nuclease-free distilled water (dH2O).  
RNA concentration and purity was checked by Agilent RNA bioanalyser and 
RNA 6000 Nano Lab chip kit (Agilent technologies, USA) as per manufacturer’s 
instructions. Briefly, 2 μl samples of concentrated RNA extract are treated for 2 
minutes at 70 °C before adding 1 μl aliquots to the Agilent RNA chip. A 6-peak 
RNA nano ladder is included in the chip for control.  Data analysis was done 
using the 2100 Expert software. Good quality RNA was verified by the presence 
of a sharp distinction at the small side of both the 18 S and 28 S ribosomal RNA 
bands and peaks. Any smearing or shouldering to the rRNA bands or peaks 
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was indicative of RNA degradation. A RNA integrity number (RIN) of >8.0 was 
considered satisfactory.  
The HumanHT-12 v4 Expression BeadChip consist of oligonucleotides 
immobilised to beads held in mircowells on the surface of an array substrate 
and provides genome-wide transcriptional coverage of well-characterized 
genes, gene candidates, and splice variants, with high-throughput processing of 
12 samples per BeadChip. Each array on the HumanHT-12 v4 Expression 
BeadChip targets more than 47,000 probes derived from the National Centre for 
Biotechnology Information Reference Sequence (NCBI) RefSeq Release 38 
(2009). Labelled cRNA are detected by hybridisation to 50-mer probes on the 
Beadchip. After washing and staining steps using the Direct Hybridization 
Assay, beadchips are scanned on the HiScan or iScan systems. Illumina 
Genome Studio Gene expression software is used to extract relative gene 
expression across samples, clustering them into differential groups. The 
comparative Ct (ΔΔCt) method was used to assess the expression level of 
components of each pathway relative to endogenous controls normalized to the 
reference panel. The fold change differences in expression of each gene 
between sample categories (HRC and HRD; BER competent and BER 
defective) was calculated. The HR genes analysed are describes in Table 3.8 - 
1. The BER genes analysed are described in Table 3.8 – 2. 
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Gene Description 
APE1 The damaged base is removed by specific glycosylases forming an abasic site (or apurinic or 
apyrimidinic [AP] site), which is then hydrolysed by an AP endonuclease, such as APE1. 
XRCC1 XRCC1, a scaffold protein, is recruited to the site of DNA damage followed by DNA polβ and DNA 
ligase III that conducts the ligation of the DNA. Pol β 
LIGIII 
PNK PNK converts damaged DNA ends to 5'-phosphate and 3'-hydroxyl moieties. PCNA and DNA 
polymerase δ/ε extend and fill the gap, and FEN1 cleaves the resulting flap. The nick is then ligated 
by DNA ligase I. 
PCNA 
FEN1 
LIGI 
PARP Following DNA damage, activated PARP-1 binds to SSB releasing PAR. This leads to the relaxation 
of chromatin facilitating access and the recruitment of the proteins necessary for repair (Althaus 
1993, Dantzer 2000, Schreiber 2006). 
 
Table 3.8 – 2: BER genes analysed in RNA genome analysis. 
 
 
Gene Description 
ATM The phosphoinositide-3-kinase-like protein kinases, ATM and ATR signal in response to DNA 
damage by phosphorylating BRCA1 (Cortez 1999), NBS1 (Gatei 2000), Rad51 (Baskaran 1997), 
p53 (Siliciano 1997) and the checkpoint kinases Chk2 and Chk1 (Abraham 2001) resulting in cell 
cycle arrest, activation of  DNA repair pathways or triggering apoptosis (Zhou 2000, McGowan 
2004). 
ATR 
Rad50 
NSB1 
BRCA1 The BRCA genes regulate the HR machinery by binding to Rad51 recombinase (Pellegrini 2002). 
BRCA2 BRCA2 functions are largely limited to DNA repair and recombination. BRCA2 protein controls the 
availability, localization, DNA binding activity and nucleofilament stabilization of Rad51 (Yu 2003, 
Esashi 2007, Thorslund 2007, Ayoub 2009) (Carreira 2009, Shivji 2009). BRCA2 stimulates Rad51-
dependent strand exchange (Pellegrini 2002). Jensen et al. (2010) described that BRCA2 acts by 
targeting Rad51 to the ssDNA, enabling displacement of the replication protein- 
Rad51 Rad51 family consists of several proteins, which preferentially bind to single stranded DNA, and 
form complexes with each other. Rad51, Rad52, Rad54 are components of the Rad52 epistasis 
group (Petrini 1997, Baumann 1998, Takata 2000). Rad51 unwinds duplex DNA and forms helical 
nucleoprotein filaments at the site of a DNA break (Thacker 2005). Rad51- coated nucleoprotein 
filament carries out the search for homology and strand invasion in HR (Sung 1994, Baumann 1996, 
Lundin 2003). 
Rad52 Rad52 can recruit Rad51 to ssDNA, perhaps loading Rad51 on to the DNA and facilitating 
nucleoprotein filament formation (Sung 1997, New 1998, Van Dyck 1999, Wray 2008). 
Rad54 Rad54 is also important in HR repair promoting branch migration (Bugreev 2006); loss of Rad54 
leads to recombinational deficiencies and DSB repair defects (Essers and de Wit 1997, Mazin 2003, 
Chi 2006). 
XRCC2 XRCC2 and XRCC3, members of the Rad51 family, maintain chromosomal stability during 
homologous recombination (Liu 1998, Forget 2004, Liu 2005, Krupa 2009) (Tambini 2010) and have 
been implicated to maintain a balance between short and long tract gene conversions between the 
sister chromatids (Nagaraju 2009). 
XRCC3 
FANC ATM-dependent phosphorylation of H2AX, NBS1, BRCA1 and FANCD2 occurs before replication 
protein A (RPA) binds to facilitate unwinding of the DNA secondary structure allowing access for the 
substrates of DNA repair (Sung 2006, Jacquemont 2007, Xing 2008, Hartlerode 2009). 
RPA 
PARP Following DNA damage, activated PARP-1 binds to SSB releasing PAR. This leads to the relaxation 
of chromatin facilitating access and the recruitment of the proteins necessary for repair (Althaus 
1993, Dantzer 2000, Schreiber 2006). 
 
Table 3.8 – 1: HR genes analysed in RNA genome analysis. 
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3.9. PARP Assay 
Principles of the Assay 
Poly(ADP-ribose) (PAR) is quantified following maximal stimulation of a defined 
quantity of permeabilised cells during a 6-minute reaction. Excess NAD+, a 
substrate for the PARP enzyme, alongside oligonucleotides that mimic DSB 
thereby activating PARP are added. The reaction is stopped by adding 
rucaparib and placing the samples on ice. Cells are blotted on to a membrane 
that is treated with anti- PAR primary antibody followed by secondary antibody 
conjugated with HRP. A chemiluminescence agent is added and following 
image capture with a sensitive camera, PARP activity is expressed as 
‘luminescent arbitrary units’. This assay has been previously validated in our 
laboratory (Plummer 2005) to GCLP standard and used as a pharmacodynamic 
endpoint for clinical trials (Plummer, Jones et al. 2008). 
Assay Protocol 
PCO cell pellets and one 106 cell aliquot of L1210 (quality control) were 
defrosted, washed twice in ice cold PBS and permeabilised with digitonin (0.15 
mg/ml) at room temperature for 5 minutes.  Nine volumes of ice-cold isotonic 
buffer (7 mM HEPES, 26 mM KCl2, 0.1 mM Dextran, 0.4 mM EGTA, 0.5 mM 
MgCl2, 45 mM sucrose dissolved in distilled water, pH 7.8) was added and the 
samples placed on ice. A 10 μl cell suspension was mixed 1:1 (v/v) with trypan 
blue and permeabilised cells counted. The cell suspension was diluted with 
isotonic buffer to a density of 6 x 105 cells/ ml. Duplicate PCO samples (1000 
cells) were exposed to oligonucleotide at 200 μg/mL in the presence of excess 
NAD+ (7 mM) in reaction buffer (100 mM Tris–HCl, 120 mM MgCl2, pH 7.8) for 
6 minutes at 27 °C alongside unreacted cells.  
500 μl of the PARP reaction mixture was loaded in duplicate alongside 
corresponding unreacted samples and PAR standards (0 – 25 pmol) into a 48-
well manifold containing a nitro cellulose Hybond-N membrane and drawn 
through using a vacuum pump. 400 μl 10% trichloroacetic acid / 2% sodium 
pyrophosphate followed by 800 μl 70% ethanol were drawn through the 
membrane as a fixative. The membrane was PBS washed 3 times and blocked 
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(5% milk powder in 0.0005% Tween-20 PBS) for 1 hour. Mouse monoclonal 
anti-PAR 10H antibody (1:1000) was added at for 1 hour, followed by polyclonal 
goat anti-mouse IgG anti-PAR horseradish peroxidase–conjugated antibody 
(1:1000). Secondary antibody was followed by Amersham ECL detection fluid 
and chemiluminescence recorded by Fujifilm LAS 3000 imager then analysed 
using Aida Image Analyser software (version 3.28.001,). Three blank areas 
were defined on the image and the relative luminescence of each sample in 
‘luminescent arbitrary units (LAU / mm2)’ calculated.  
Data Analysis 
A standard curve was constructed by non-linear regression of the PAR standard 
values using Graph Pad Prism 6. The resulting equation relating PAR to 
chemiluminescence (R2 ≥ 0.9) was used to calculate the amount PAR present 
in each well. Results were expressed as picomoles of ADP-ribose monomer 
incorporated per 106 permeabilised cells. Results were normalised to PAR in 
internal controls (L1210 cell line) to account for inter-assay variability. PAR 
activity in stimulated cells was expressed as the percentage of the activity in 
untreated control cells.  
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3.10. Western Blotting  
Principles of the Assay 
Western blotting separates and identifies specific proteins extracted from cells 
by electrophoretically separating proteins by molecular weight. Protein samples 
are denatured using SDS (sodium dodecyl sulfate) and heating, as 3D structure 
may prevent antibody binding and slow transition through the gel. Denatured 
protein samples are then run through a polyacrylamide gel under electric 
current. Larger proteins migrate the least whilst smaller proteins move further in 
the same time period. Resulting protein bands are transferred onto 
nitrocellulose membranes by blotting using an electric current to move 
negatively charged proteins from the gel, to the membrane. The membrane is 
placed in blocking buffer to prevent non-specific binding of antibodies to the 
membrane and the target protein is then positively identifying using a specific 
primary antibody to the protein of interest followed by a secondary –HRP 
conjugated antibody directed at the primary antibody. Once primary and 
secondary antibodies are hybridised, antibodies can be visualised using ECL 
(enhanced chemiluminescence), which reacts with HRP to emit 
chemiluminescence that can be detected and visualised by CCD (charge 
coupled device) camera. Detected protein size can be estimated by the 
inclusion of and comparison with a predetermined molecular weight marker.  
The number of antibody molecules which can bind to each protein (and hence 
the amount of label detected) is proportional to the amount of protein present, 
therefore protein expression levels can be compared between samples. 
Assay Protocol  
Culture medium was removed and cells PBS washed. Cells were lysed with 
addition of 300 μl of SDS lysis buffer (SDS sample buffer with 10% β-
Mercaptoethanol) and stored at -80 °C for later analysis. Protein concentration 
was quantified using a colorimetric Bio-Rad DC™ protein assay as per 
manufacturer’s instructions. Briefly, alkaline copper tartrate solution is added to 
protein solution followed by Folin reagent. The reaction between protein and 
copper in an alkaline medium, and the subsequent reduction of Folin reagent by 
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the copper-treated protein results in colour formation (predominantly due to 
tyrosine and tryptophan residues)read at 405 - 750 nm absorbance. 
Protein concentration was estimated from the corrected mean absorbance 
values by the spectrophotometer software (SOFTmax Pro 3.0, molecular 
Devices Corporation), via comparison to a bovine serum albumin (BSA) 
standard curve which was also prepared each time the assay was performed. 
Samples were diluted to 20 mg/ml protein before lysates were denatured at 100 
°C for 5 minutes. Gels were assembled and resolved in a Mini-PROTEAN Tetra 
cell. Lysates were loaded into 4-15% Mini-PROTEAN® TGX™ gels alongside 
multicolour broad range protein ladder (4 kDa to 250 kDa). Proteins were 
separated by electrophoresis at 200 mVolts for 1 hour in buffer (77.9% glycine, 
16.6% tris-base, 5.48% SDS) before protein transfer to Hybond ECL 
membrane. Gels were placed in transfer cassettes with the membrane 
sandwiched between 3 mm Whatman chromatography papers and transfer 
sponges, all soaked in transfer buffer (78.7% glycine, 21.2% tris-base). 
Electrophoresis for transfer was undertaken in the tetra cell filled with transfer 
buffer at 100 mVolts and ice pack for 1 hour. Membranes were blocked in 5% 
non-fat milk powder solution for 1 hour at RT after which membranes were 
incubated in primary antibody in TBST with 1% milk at 4 ˚C overnight. 
Membranes were washed for 15 minutes with TBST (Tris-buffered-saline 
solution containing 0.05% tween) and horseradish peroxidase-conjugated 
secondary antibodies were applied in TBST with 1% milk for 60 min at RT. 
Membranes were washed with TBST before detection of bound antibodies 
using ECL detection solution. Chemiluminescence was imaged using the Fuji-
imager (Lass3000).  
Membranes were washed with TBST and incubated with Ponceau S solution 
(0.1% Ponceau S [w/v] and 5.0% acetic Acid [w/v]) for 5 minutes before repeat 
imaging for total protein quantification using the Fuji-imager. All immune-blotting 
experiments were carried out in triplicate.  
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3.11. Clinical Definitions 
Surgical staging was assessed in accordance with International Federation of 
Gynaecologists and Obstetricians (FIGO) classification. Complete debulking 
was defined as no visible disease; optimal debulking was defined as ≤ 1 cm 
(diameter) residual disease, and suboptimal debulking was > 1 cm (diameter) 
residual disease.  
Disease progression was determined based on CA125 marker levels and 
imaging results according to Gynaecologic Cancer Inter Group (GCIG) 
modification of Response Evaluation Criteria in Solid Tumours (RECIST) 
guidelines modified for ovarian cancer (Therasse 2000, Rustin 2004, Rustin 
2011), or on clinical examination. Progression-free survival (PFS) was defined 
as the interval between histological diagnosis and first progression, death due 
to disease or last follow-up. Death due to a non-disease related cause was not 
considered an event in the calculation of PFS. Overall survival (OS) was 
defined as the interval between histological diagnosis and the date of death due 
to disease, or last follow-up (active follow-up for 5 years, passive thereafter). 
 
3.12. Statistical Analysis 
Microsoft Excel 2010 and Graph Pad PRISM version 6 software were used for 
simple statistical analyses.  
Cytoxicity Assays 
In the colony formation assays, each experimental point was set up in triplicate 
and each assay was repeated identically and independently three times. The 
final data were expressed as a percentage of the survival that took place in 
control wells where cells were not exposed to any drugs. IC50 values were 
determined for each experiment. To evaluate the differences across various 
experimental conditions students t-test was used to evaluate differences 
between individual pairs of experimental conditions. 
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Proliferation Assays 
For cell proliferation assays, each experimental point was set up with six 
replicates and data expressed as the mean and standard error of the mean 
(SEM). GI50 values were calculated using a point to point graph of percentage 
growth inhibition with increasing drug concentration. Differences in survival 
between treated cells were determined by One-Way ANOVA, Two-Way ANOVA 
or paired t-test as appropriate.  
Survival  
Progression free (PFS) and overall survival (OS) was evaluated with Kaplan-
Meier survival analyses. Univariate analysis of differences between the various 
cohorts of each experiment was performed using the log rank test (Mantel Cox).  
Correlation 
The Spearman test was applied for analyses of correlations.  
For all statistical analyses, significant differences were set as p < 0.05.  
Receiver Operating Characteristic (ROC) Curve 
A ROC curve, using the area under the curve (AUC), is used to assess the 
ability of a numerical score to accurately predict a binomial outcome. This is 
done by assessing the cut off value that discriminates the two groups by 
tabulating sensitivity and specificity of the test at various cut off values. A table 
of sensitivity and specificity for each value is created and is used to draw a 
graph of 100%-Specificity% vs. Sensitivity%. The area under a ROC curve 
quantifies the overall ability of the test to discriminate between the two 
outcomes. An area of 1 represents a perfect test; an area of 0.5 represents a 
worthless test. A p value tests the null hypothesis that the area under the curve 
really equals 0.05.   
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Chapter 4. Assessment of the Primary Ovarian Cancer  
(PCO) Culture Model and Exploration of  
Biological Markers of Clinical Survival 
4.1. Introduction: Primary Culture  
Established cell lines provide an invaluable tool for studying biological functions 
at the molecular and cellular level. Existing human ovarian cancer cell lines 
possess the advantage of high proliferative capacity, clonogenicity and 
extended life span in culture. However, most have acquired significant genetic 
alterations from their cells of origin, including deletion or upregulation of 
regulatory cell cycle genes supporting immortality. Additionally, there is 
evidence to suggest that many cell lines contain significant misidentification, 
duplication and loss of integrity (Korch 2012).   
Primary cells isolated from patients are often considerably different from cell 
lines of similar origin. The ability to culture freshly isolated OSE (ovarian surface 
epithelium) and EOC (epithelial ovarian cancer) cells from patients provides an 
important experimental system that resembles the patient situation more closely 
(Dunfield 2002, Mukhopadhyay 2010).  
Ascitic fluid is an abundant resource in ovarian cancer patients, is relatively 
easy to obtain and culturing the suspended cells is technically straightforward. 
Ascitic cultures have been shown to generate epithelial cell rich populations and 
have been used in this study to further explore the application of functional 
assays in the stratification of therapy in ovarian cancer. In this study, this 
method has been considered the benchmark technique for biological testing of 
primary material against which exploratory techniques are tested.  
The use of cultures derived from patient ascites has arisen due to the ongoing 
search for cancer biomarkers, capable of predicting response to conventional 
and novel (e.g. PARPi) therapy. In ovarian cancer, a number of potential 
biomarkers have been tested including BRCA status. This alone has failed to be 
shown to be predictive. In one phase 2 trial of olaparib many ovarian cancer 
patients showed response to olaparib therapy despite no BRCA mutation and 
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there was also a low overall response in BRCA patients with response in only 
7/17 patients (Gelmon 2011) . These difficulties in identifying a single biomarker 
have forced clinicians and academics to reassess the current approach. It 
appears that a functional assay, developed by Newcastle University, 
distinguishing ovarian cancer into groups based upon a competent or defective 
HR DNA repair pathway shows greatest promise (Mukhopadhyay 2010, TCGA 
2011, Mukhopadhyay, Plummer et al. 2012).  
Work in this Chapter aims to develop our understanding of the ascitic primary 
culture model as well as explore alternative approaches to the complex 
functional HR assay previously described, with the goal of incorporating HR 
function as a biomarker into large scale clinical trials.    
4.2. Aims 
 To characterise PCO cultures derived from ascitic samples in terms of 
antigen expression, growth potential and morphology in order to further 
understand the strengths and weaknesses of this model.  
 To understand the extent of epithelial mesenchymal transition (EMT) 
within ovarian cancer and the effect of ex vivo culture upon this.  
 To explore the presence of subpopulations of cells within ascites, their 
antigen expression, growth and HR status.  
 To determine the homologous recombination (HR) DNA repair status of 
PCO cultures with corresponding ex vivo sensitivity to rucaparib and 
cisplatin and to compare with in vivo platinum sensitivity and clinical 
outcome.  
 To explore the ability to simplify the currently complex HR assay in order 
to transform it into a reliable, reproducible and clinically applicable 
process, enabling rapid, large volume turnover in clinical trials and 
routine practice and to explore alternative assays for HR function based 
on expression signatures at RNA level. 
 Assess the utility of ex vivo proliferation assays in predicting clinical 
response to platinum chemotherapy.  
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4.3. Methods 
4.3.1. Characterisation 
Ascitic fluid is composed of multiple cellular components. A characterisation 
panel consisting of culture morphology, immunofluorescent antigen detection, 
cross-referenced with standard pathological examination of matched tumour 
FFPE was developed to confirm exclusive growth of cancer cells. 
4.3.2. Morphology 
Brightfield microscopy images of cultures were captured using VisCam® 
software. Comparison to three reference images allowed classification into 
cobblestone, mesenchymal or spindle morphologies. A cobblestone monolayer 
is typical of epithelial-like cells and describes polygonal cells with regular 
dimensions, which grow attached to the culture substrate in discrete patches. 
Mesenchymal morphology describes bipolar or multipolar cells with elongated 
shapes. Spindle morphology is most typical of fibroblast-like cells, which are 
elongated regular shaped cells with indistinct cell boundaries typically growing 
in the same orientation.  In controversial cases, final assignment to a 
morphological category was validated by two further reviewers,  
Figure 4.3 -  1.  
 
Cobblestone Mesenchymal Spindle 
   
 
Figure 4.3 -  1: PCO culture morphology reference images. Brightfield microscopy (x10) 
demonstrating cobblestone, mesenchymal and spindle cell morphology. 
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4.3.3. Immunofluorescence Characterisation Panel 
Standard techniques for immunofluorescence were used to detect epithelial, 
ovarian and mesenchymal antigens, Table 4.3 - 1. Briefly, cells were cultured 
on glass coverslips before methanol fixation. After PBS wash, coverslips were 
incubated with primary antibody solution for 1 hour followed by the appropriate 
secondary antibody. Coverslips were mounted onto glass slides with 4 μl DAPI 
mounting media and images captured using a Leica DMR fluorescent 
microscope and RT SE6 Slider Camera Spot advanced software version 3.408, 
Table 4.3 -2.  Antigen expression was scored as absent, patchy or strong using 
reference images obtained from positive and negative cell line controls. In 
controversial cases, final assessment of antigen expression was validated by 
two further reviewers.   
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Antigen Species Conc Secondary Antibody 
CK Cytokeratins are intermediate filaments, produced by epithelial 
cells, which make up the majority of the cytoskeleton. Epithelial 
in origin if > 95% of cells express 
Mouse monoclonal FITC 
conjugated, Clone C11, (Upstate 
Millipore ,USA) 
1:100 N/A 
EpCAM Cell surface glycosylated protein is expressed in normal 
epithelial cells as well as carcinomas. EpCAM functions as a 
calcium independent cell adhesion molecule and is believed to 
be involved in carcinogenesis by its ability to induce genes 
involved in cellular metabolism and proliferation (Strand 1989, 
Munz 2004, Rao 2005).  
Mouse monoclonal Alexa Fluor® 
488–conjugated, (Biolegend, UK)  
1:100 NA 
CA125 The ovarian tumour marker CA125 is expressed in 
approximately 80% of epithelial ovarian cancers (Rosen 2005), 
It is expressed on human MUC16, a cell surface bound mucin 
that is also shed by proteolytic cleavage. MUC16 facilitates the 
binding of ovarian tumour cells to mesothelial cells lining the 
peritoneal cavity. 
Mouse monoclonal, (Abcam, 
USA)  
1:100 1:1000 Alexa Fluor® 546 goat 
anti-mouse (Invitrogen, USA)  
MOC-31 Epithelial transmembrane glycoprotein 2 (EGP-2, also known 
as ESA, GA733-2, KSA) is present on most normal and 
malignant epithelia (Souhami 1991, Hecht 2006) enabling 
discrimination from mesothelial derived tumours with a 
specificity of 87-100% and specificity of 89% (Ruitenbeek 
1994, Morgan 1999, Hecht 2006, Kundu 2011)  
Mouse monoclonal, (Dako, 
France)  
1:100 1:1000 Alexa Fluor® 596 goat 
anti-mouse (Invitrogen, USA)  
Vimentin Marker commonly used to detect epithelial-mesenchymal 
transition (EMT). It is a protein that, in humans, is encoded by 
the VIM gene. Vimentin is a type III intermediate filament 
protein that is expressed in mesenchymal cells. 
Rabbit monoclonal, clone 
EPR3776, (Abcam, USA) 
1:100 1:1000 Alexa Fluor® 488 goat 
anti-rabbit (Invitrogen, USA)  
D2-40 Anti-D2-40 identifies an O-linked sialoglycoprotein present on 
germ cell tumours but not epithelial cells (Marks 1999). 
Mouse monoclonal, (Dako, 
France) 
1:100 1:1000 Alexa Fluor® 596 goat 
anti-mouse (Invitrogen, USA)  
 
Table 4.3 -  1: Antibodies for the PCO immunofluorescent characterisation panel.
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Stain 
Filter 
Colour 
Excitation 
(nM) 
Emission 
(nM) 
Gamma Gain 
Exposure 
(m seconds) 
DAPI Blue 358 461 1.00 2   500 
CK Green 494 521 1.00 4/8 5000 
EpCAM Green 495 521 1.00 4/8 8000 
CA125 Red 556 573 1.00 8 8000 
MOC-31 Red 556 573 1.00 8 8000 
Vimentin Red 495 519 1.00 2 2000 
D240 Red 556 573 1.00 8 8000 
 
Table 4.3 -  2: Immunofluorescence microscope settings for PCO culture 
characterisation using antigen panel. 
 
Morphology and the immunofluorescent characterisation panel aimed to 
assess the degree of epithelial mesenchymal transition (EMT) within the 
cultures and several subsequent experiments were designed to explore the 
effect of prolonged ex vivo culture upon morphology and antigen expression, 
Section 4.7.5. EMT, described in detail in Section 4.7.2, is a biological 
process that allows epithelial cells to undergo multiple biochemical changes, 
which ultimately lead to increased stability of the acquired mesenchymal 
phenotype.  The completion of an EMT is signalled by the degradation of 
underlying basement membrane and the formation of a mesenchymal cell 
with enhanced migratory capacity, invasiveness, greater resistance to 
apoptosis and increased production of extracellular matrix components 
(Kalluri 2003, Polyak 2009). Sustained activation of EMT leads to 
progressive epigenetic alterations n cells, inducing heritable effects that 
maintain the mesenchymal state even after EMT-initiating signals are no 
longer present (Dumont, Wilson et al. 2008). The phenotype of each PCO 
culture was investigated as part of the characterisation assessment in order 
to explore the possible effect of ex vivo culture upon phenotype.  
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4.3.4. Formal Histopathology 
Formal cytological and histological examination of ascites and solid tumour was 
used to further characterise cultures, assigning each specimen to an ovarian 
histological subtype according to universal World Health Organisation criteria 
(Tavassoli 2003). This was performed by NGOC pathologists blinded to the 
other characterisation studies.  
When all characteristics were in keeping with epithelial ovarian origin, samples 
were used in subsequent experiments. Where results were inconsistent with 
epithelial origin, cultures were discarded.  
4.3.5. Surface Antigen Characterisation Timeline 
In order to assess the potential effects of time, ex vivo culture and passage on 
antigen expression, ascites was cultured directly onto glass coverslips and fixed 
at various time points, without passage. Immunofluorescent detection of antigen 
expression was assessed and compared to parallel PCO cultures following 
repeated passage. Ascitic samples were cytocentrifuged directly onto coverslips 
for immediate processing to assess antigen expression at time zero.  
4.3.6. Reducing Analysis Time of PCO Cultures (Characterisation 
and HR Assay) 
Ascitic cellular fluid was centrifuged directly onto glass slides or cultured onto 
coverslips and then used directly for immunofluorescent microscopy.  
4.3.7. Cytocentrifugation  
Ascitic samples were incubated with 10% ammonium chloride red cell lysis 
buffer (RCLB) solution (1:4 v/v) at 37 °C for 5 minutes. (For HR analysis, DSB 
were induced by incubation with 10 µM rucaparib for 24 hours, alongside 
untreated control). Following centrifugation (300 g for 5 minutes) and PBS 
washing, cells were re-suspended in 10 ml of media. 200 μl of the ascitic/media 
solution was centrifuged (Shandon Cytospin 2 centrifuge) at 45 g for 5 minutes 
before fixation with methanol. 
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4.3.8. Coverslip Cultures 
Ascitic fluid was added to coverslips with media (1:1 v/v) in 6-well plates and 
incubated at 37 °C for 48 hours to allow adherence. Cells were then either fixed 
with methanol for characterisation or DNA DSB induced for the HR assay. 
4.3.9. PCO culture, HR Functional Assay, Cell Proliferation, PARP 
Assays and Gene Expression Methods 
The method for PCO ascitic culture, HR functional assay, proliferation assays 
(SRB, WST-1), cell counting assay, PARP activity assay and RNA analysis are 
described in detail in Chapter 3 Methods.    
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4.4. Results:  
4.5. PCO Collection 
Patients enrolled in this study belonged to a defined geographical area covered 
by the North of England Cancer Network and were registered with the NGOC at 
Queen Elizabeth Hospital, Gateshead. Demographic and surgicopathological 
data were collected from the hospital and pathology databases. The histological 
diagnosis of ovarian cancer was confirmed by independent pathologists and 
surgical stage, grade and cell type were classified according to WHO and FIGO 
standards (Prat 2013).  
Between 2011 and 2014, 84 ascitic samples were collected at the time of 
surgery (n=69, 82%) or drainage of symptomatic ascites (n=15, 18%). Of the 69 
samples collected intra-operatively, 55 (80%) were collected during primary 
surgery and 14 (20%) during interval surgery following chemotherapy. 
Successful culture was achieved in 72 cases (86%). Three cultures were 
discarded due to failed epithelial characterisation, another three became 
infected and 5 samples excluded due to non-ovarian cancer pathology, leaving 
61 cultures that were used in further experiments.  
4.6. Clinical Characteristics 
The mean age at diagnosis of the PCO patients was 63 years (41-85). The 
majority of patients were diagnosed at advanced stage (FIGO stage IIIC/IV 
n=55), with HGSC being the predominant subtype (n=47). A summary of patient 
characteristics is given in Table 4.6 – 1 with further detail in Appendix 6.  
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Demographic 
Median (range) / 
n (%) 
Age at presentation (years) 63 (41 – 85) 
Serum CA125 at presentation (U/l) 1252 (6 – 10000) 
Histology                              High grade serous carcinoma (HGSC) 
Clear cell 
Endometrioid 
Other 
47 (77.0) 
2 (3.3) 
1 (1.6) 
11 (18.0) 
Time of collection                   Primary surgery (pre-chemotherapy) 
Interval surgery (post- chemotherapy) 
43 (70.5) 
18 (29.5) 
Surgical outcome                                                 Optimal/Complete 
Suboptimal 
No debulking surgery 
47 (77.0) 
7 (11.5) 
7 (11.5) 
FIGO Stage                                                                           Stage I 
Stage II 
Stage III 
Stage IV 
No staging 
2 (3.3) 
2 (3.3) 
46 (75.4) 
9 (14.8) 
2 (3.3) 
 
Table 4.6 -  1: Summary of PCO patient demographics. See Appendix 6 for detailed 
individual PCO patient data.  
 
4.7. Characterisation  
4.7.1. Original Characterisation Protocol and its Limitations 
The original protocol for PCO culture characterisation was limited to 
cobblestone morphology and more than 95% expression of a single antigen, 
cytokeratin (CK). More than 20 cytokeratins have been identified, of which 
subtypes 8, 18, and 19 are the most abundant in simple epithelial cells (Barak 
2004). However, ascitic mesothelial cells have also been reported to express 
cytokeratins (5, 7, 8, 14, 17, 18, and 19) and therefore CK should not be used in 
isolation. This was further confounded when PCO 160 was shown to express 
CK but formal histology confirmed an ovarian dysgerminoma.  
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4.7.2. Expanded Characterisation Panel  
The characterisation panel was expanded to include further epithelial markers, 
an ovarian marker, mesenchymal markers and germ cell markers. Selection of 
antigens, alongside details of the antibodies used, is described in detail in Table 
4.3 – 1. A summary of the characterisation profile from all PCO cultures is 
shown in Figure 4.7 -  1. All PCO included for further analysis expressed 
cytokeratins and the majority expressed an epithelial marker (EpCAM or 
MOC31) or the ovarian marker CA125. This work was conducted by myself with 
contributions by Michelle Dixon, Angelika Kaufmann and Aiste McCormick.  
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B  C  D        A 
E  F  G  H  
Figure 4.7 -  1: PCO immunofluorescent characterisation panel A: Summary of PCO antigen expression, n=61 shown as % expression of each 
antigen across all cultures; B: Brightfield - cobblestone monolayer. Immunofluorescent images; C: FITC-anti-CK; D: Alexa Fluor 596 anti-CA125; E: 
Alexa Fluor 488 anti-EpCAM; F: Alexa Fluor 596 anti-MOC 31; G: Alexa Fluor 488 anti-Vimentin; H: Alexa Fluor 596 anti-D240 (PCO 160 – 
dysgerminoma).
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4.7.3. CA125 Expression: Immunofluorescence vs. 
Immunohistochemistry  
In a subset of PCO samples (n=32), immunofluorescent (IF) assessment of 
CA125 expression using ascites cultures was compared with 
immunohistochemical (IHC) detection using matched FFPE tissue, Figure 4.7 -  
2. Concordance of results from the two assessments was seen in 18 (56.3%) 
cases; 15 of which had positive expression of CA125 and 3 with no expression. 
Of the 14 (43.8%) discordant cases, CA125 expression was detected by IF but 
not IHC. Several CA125 antibodies had been tested, alongside positive cell line 
controls and discordance is therefore thought to represent true differences in 
expression between the samples tested. There was no relationship between 
serum CA125 level tested and CA125 detection using immunofluorescence of 
PCO cultured cells, (t-test, p = 0.2701) or IHC on FFPE (p=0.2693), Figure 4.7 - 
3.  
 
A 
 
B 
 
 
Figure 4.7 -  2: Concordant CA125 expression in PCO 158. A: Immunofluorescent 
detection of CA125. PCO 158 cells were seeded at 8 x 106 on sterile glass coverslips 
and following fixation/permeabilisation with methanol and PBS washing, incubated with 
1:100 anti-CA125 antibody for 1 hour. After PBS washing, slides were incubated with 
an Alexafluor 596  seondary antibody and image captured with immunoflourescent 
microscopy.B: Immunohistochemical detection of CA125 using matched FFPE 
(performed by pathology Queen Elizabeth Hospital, Gateshead).   
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Figure 4.7 – 3. Relationship between Serum CA125 (U/L) and CA125 protein 
expression, detected by immunohistochemistry (A) and serum CA125 with CA125 
detected byimmunofluorescence on corresponding PCO culture (B). Briefly, PCO cells 
were seeded at 8 x 106 on sterile glass coverslips and following 
fixation/permeabilisation with methanol and PBS washing, incubated with 1:100 anti-
CA125 antibody for 1 hour. After PBS washing, slides were incubated with an 
Alexafluor 596  seondary antibody and image captured with immunoflourescent 
microscopy. Immunohistochemical detection of CA125 was performed by the pathology 
department at Queen Elizabeth Hospital, Gateshead.   
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4.7.4. Epithelial Mesenchymal Transition (EMT) and PCO Phenotype 
EMT, first described in 1982 (Hay 1995), is a biological process that allows 
epithelial cells to undergo multiple biochemical changes enabling them to 
assume a mesenchymal phenotype with enhanced migratory capacity, 
invasiveness, greater resistance to apoptosis and increased production of 
extracellular matrix components (Kalluri 2003, Polyak 2009). Induction of EMT 
has been associated with poor clinical outcome in multiple tumour types 
(Sabbah 2008) and has also been implicated in two of the most important 
processes responsible for cancer-related mortality: progression to distant 
metastases and acquisition of cellular resistance (Polyak 2009). The phenotype 
of each PCO culture was investigated as part of the characterisation 
assessment in order to explore the possible effect of ex vivo culture upon 
phenotype.  
All PCO cultures were shown to co-express vimentin and CK, 
Figure 4.7 -  4, suggesting a mixed epithelial-mesenchymal phenotype. Only 
25% and 31% of cultures diffusely expressed the epithelial markers EpCAM and 
MOC31 respectively, Figure 4.7 -  1, and it was unclear if this lower than 
anticipated level of expression of cell surface epithelial markers reflected in vivo 
expression or whether a process of EMT was induced during ex vivo culture. A 
series of experiments were subsequently designed to explore the effect of 
prolonged culture upon antigen expression.  
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Figure 4.7 -  4: Cytokeratin and vimentin co-expression in PCO 163. PCO 163 cells 
were seeded at 8 x 106 on sterile glass coverslips and following 
fixation/permeabilisation with methanol and PBS washing, incubated with 1:100 
primary antibody for 1 hour. After PBS washing, slides were incubated with a 
secondary antibody with fluorochrome and image captured with immunoflourescent 
microscopy.FITC-conjugated Cytokeratin (green), Alexaflour 596-vimentin (red), DAPI 
nuclear stain (blue). 
 
 
 
 
4.7.5. Stability of Characterisation Phenotype with Time and 
Passage 
Firstly, three separate ascitic cultures were plated directly onto sterilised 
coverslips and fixed at various timepoints as indicated in Table 4.7 – 1. An 
ascitic sample was also cytospun onto a coverslip and fixed immediately for a 
time 0 control. As the majority of PCO cultures are characterised at passage 1 
or 2, a parallel sample was characterised following passage to assess the 
potential effect of harvesting by trypsin and re-plating upon expression of 
markers.  
There appears to be little change with time in the expression of epithelial, 
mesenchymal and ovarian antigens, suggesting that ex vivo culture alone does 
not alter phenotype or induce EMT. However, when the same cultures were re-
characterised after undergoing passage with trypsin and re-plating, there was 
reduced detection of surface antigens (* in Table 4.7 - 1). Loss of EpCAM, 
CA125 and MOC-31 expression suggests that cell surface antigens may be 
affected by the mechanical/biochemical stresses of passage or that the process 
of passage results in selection of sub-populations. When PCO cultures, 
following passage with trypsin, were re-characterised 7 days later, without 
further passage, they did not regain their epithelial phenotype. Seven days 
however may be insufficient time for cells to re-express cell surface markers 
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after ‘stripping’ with trypsin. The short life span of PCO cultures prevented 
further assessment of this.  
 
 PCO 226 
 Antigen 
Time from Collection  Passage 
 0 hrs  24 hrs  48 hrs  72 hrs  1 wk  2 wks  3 wks P1 
 CK  +  +  +  +  +  +  +  + 
 EpCAM  +  +  +  +  +  +  +  -  * 
 CA125  +  +  +  +  patchy  patchy  patchy  patchy 
 MOC31  +  +  +  +  +  +  +  patchy 
 D240  -  -  -  -  -  -  -  - 
 Vimentin  +  +  +  +  +  +  +  + 
 PCO 232 
 Antigen 
Time from Collection  Passage 
 0 hrs  24 hrs  48 hrs  72 hrs  1 wk  2 wks  3 wks P1 
 CK  +  +  +  +  +  +  +  + 
 EpCAM  -  -  -  -  -  -  -  - 
 CA125  +  patchy  patchy  patchy  patchy  patchy  patchy  -  * 
 MOC31  patchy  patchy  patchy  patchy  patchy  patchy  patchy  patchy 
 D240  -  -  -  -  -  -  -  - 
 Vimentin  +  +  +  +  +  +  +  + 
 PCO 233 
 Antigen 
Time from Collection  Passage 
 0 hrs  24 hrs  48 hrs  72 hrs  1 wk  2 wks  3 wks P1 
 CK  +  +  +  +  +  +  +  + 
 EpCAM  patchy  patchy  patchy  patchy  patchy  patchy  patchy  -  * 
 CA125  patchy  patchy  patchy  patchy  patchy  patchy  patchy  -  * 
 MOC31  -  -  -  -  -  -  -  - 
 D240  -  -  -  -  -  -  -  - 
 Vimentin  +  +  +  +  +  +  +  + 
 
Table 4.7 -  1: Immunofluorescent characterisation timeline. Antigen expression was 
assessed at time 0, 24, 48, 72 hrs, 1, 2, 3 wks by fixed immunofluorecence. Antigen 
detection was assessed as positive (+), negative (-), or patchy in comparison to 
positive and negative cell line reference images. Highlighted in grey: parallel results for 
immunofluorescent assessment of antigen detection following routine passage.* = loss 
of cell surface antigen following passage with trypsin.  
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4.7.6. Morphology  
52 PCO cultures underwent formal morphological classification. 42 (80.8%) had 
a cobblestone morphology and 10 (19.2%) were mesenchymal. None of the 
cultures were classified as spindle cell. There was no relationship between 
histological subtype and morphological appearance with no significant 
difference seen in the proportion of cultures of cobblestone or mesenchymal 
morphology within each histological subtype, Table 4.7 - 2. A significantly 
greater proportion of PCO with cobblestone morphology were HRD but this may 
be a reflection of the higher proportion of unclassified PCO cultures within the 
mesenchymal morphological group.  
Additionally, there was no significant difference in the expression of 
characterisation antigens between the morphological subgroups, with the 
exception of MOC31. This was expressed in 8/23 (34.7%) of cultures classified 
as cobblestone in comparison to 7/10 (70%) of mesenchymal cultures, (Chi2, 
p<0.0001). Numbers within the mesenchymal group were however small 
(n=10).   
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Cobblestone 
(n=43) 
Mesenchymal 
(n=17) 
Chi
2
 
p 
PCO                                 PCO 
PCO-2 
2 (97.7) 
1 (2.3) 
10 (58.8) 
7 (41.2) 
0.0019 * 
0.0001 * 
Histology           
HGSC 
Mucinous 
Clear cell 
Endometrioid 
Other 
 
35 (81.2) 
1 (2.3)  
1 (2.3) 
1 (2.3) 
5 (11.6) 
 
14 (82.4) 
0 (0) 
0 (0) 
1 (5.9) 
2 (11.8) 
0.8759 
- 
- 
0.1573 
0.8960 
HR status 
Competent 
Defective 
Unclassified 
 
22 (51.2) 
18 (41.9) 
3 (7.0) 
 
7 (41.2) 
4 (23.5) 
6 (35.3) 
0.2971 
0.0267 * 
0.0001 * 
CK                            n=60#                 43 /43(100) 17/17 (100) - 
EpCAM n=49# 7/35 (20) 4/14 (28.6) 0.1985  . 
CA125    n=54# 25/40 (62.5) 9/14 (64.3) 0.9293  . 
MOC31 n=39# 8/23 (34.7) 7/10 (70) 0.0006  * 
D240    n=34# 1/27 (3.7) 0/7 (0) - 
Vimentin n=49# 36/36 (100) 13/13 (100) - 
 
Table 4.7 -  2: Histological subtype, characterisation antigen expression, HR DNA 
Repair Status in PCO Cultures (n=61) stratified by Morphological Subtype.  
PCO-2 cultures are described in full in section 4.9. HR status of PCO and PCO-2 
cultures are described in sections 4.10 and 4.9.3. 
# total number of cultures tested for selected antigen 
 
4.8. PCO Culture Growth 
The median PCO growth rate is markedly slower than many cell lines and is 
highly variable with a median doubling time (DT) of 133 hours, range of 35–487 
hours, Figure 4.8 -  1. The typically prolonged doubling time may be a 
consequence of ex vivo culture itself. Malignant cells within ascites are held in 
suspension before they are deposited upon peritoneal surfaces, where they 
proliferate. Despite provision of fluid and heat with cell cultures being grown at 
37 °C, 5% CO2, 95% humidified air, an excess of  L-glutamine and growth 
factors (fetal calf serum), the peri-tumoural microenvironment is lacking and this 
may result in the prolonged doubling time seen.  
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Figure 4.8 -  1: PCO growth.A: Growth curve for PCO 180 showing lag, exponential 
and plateau growth phases. B: Doubling time (hours) for all PCO cultures. Histogram of 
the doubling time for each PCO. Red line represents the median doubling time of all 
cultures.Briefly, cells were seeded at 500, 1000 and 2000 cells/well with six replicate 
wells for each cell concentration and were fixed at 24 hour intervals for 10 days with 
TCA. After washing cells were stained with 0.4% SRB solution. Protein-bound dye was 
dissolved in 10 mM Tris solution and optical density determination by 
spectrophotometry.  
 
4.8.1. Growth and HR Status 
The growth rate of PCO cultures, stratified according to homologous 
recombination (HR) status (see section 4.10 for full details on HR status), 
shows no significant difference in the mean DT of HR competent (HRC) and HR 
defective (HRD) cultures. The median DT of HRC cultures was 127.7 hours 
(range 35.0–486.7) n=29, in comparison to 135.0 hours (83.0–312.4), n=21, for 
HRD cultures, t test p=0.7935, Figure 4.8 -  2. 
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Figure 4.8 -  2: Growth rate PCO cultures by HR status results. Dot plot of doubling 
time (hours), determined by SRB proliferation assay, of PCO cultures stratified into 
HRC and HRD cultures. Median of group shown with red vertical line with 
corresponding range. 
4.9. PCO-2 Cultures 
PCO cultures are a limited resource. Most cultures senesce after five passages, 
indicating that the ovarian cancer stem cell population is unlikely to be present. 
‘PCO-2’ is the monolayer cell culture formed from the aspirated media/ascites 
mix following initial seeding of the standard PCO culture. As the cells present in 
ascites are in suspension in situ, it was hypothesised that the stem cell 
population may in fact remain in suspension longer whilst other cellular 
populations attach to the plastic of the culture flasks. A subset of cultures with 
matched PCO and PCO-2 cultures (n=22) underwent antigen characterisation 
assessment and HR assessment to further explore this, Table 4.9 - 1, Table 4.9 
- 2.  PCO-2 experiments were conducted by myself and Aiste McCormick. 
4.9.1. PCO vs. PCO-2 Antigen Characterisation  
Concordance in the expression of markers between PCO and PCO-2 cultures 
was seen in 86.2% of cases, Table 4.9 - 1. Discordance in the remaining 13.8% 
was seen in the cell surface antigens (EpCAM, MOC31 and CA125). This may 
therefore represent loss of antigen detection due to the mechanical and 
biochemical effects of passage with trypsin, as discussed in Section 4.7.5. 
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Alternatively, the discrepancies may be a reflection of failed assays or genuine 
heterogeneity in expression between subpopulations of cells cultures.  
When all PCO and all PCO-2 cultures were grouped together, no significant 
difference was seen in the detection of the epithelial or mesenchymal markers. 
A statistically significant higher percentage of PCO cultures expressed CA125 
in comparison to PCO-2 samples, p=0.035, Table 4.9 - 2.  
 
PCO 
CK EpCAM MOC31 CA125 D240 Vimentin 
PCO 
PCO-
2 
PCO 
PCO-
2 
PCO-
2 
PCO-
2 
PCO 
PCO-
2 
PCO 
PCO-
2 
PCO 
PCO-
2 
170 + + -  -  + - -  +  
171 + + -  -  + + -  +  
174 + + -  -  + + -  +  
175 + + -  +  + P -  +  
177 + + P P +  + + -  +  
180 + + - - - + + + - - + + 
182 + + + P +  + + -  +  
197 + + - + -  -  - - + + 
209 + + - - - - + - - - + + 
211 + + - - - - P P - - + + 
213 + + - + - - - - - - + + 
222 + + + + + + P P - - + + 
224 + + - - - P P P - - + + 
225 + + - - - - - - - - + + 
226 + + - - + - - P - - + + 
227 + + - - - + P - - - + + 
229 + + - - - - - - - - + + 
230 + + - - - - - P - - + + 
233 + + - - - - - - - - + + 
234 + + + - - - - - - - + + 
238 + - + - - - P P - - + + 
239 + + - - - - - - - - + + 
 
Table 4.9 -  1: Immunofluorescent antigen characterisation of matched PCO and PCO-
2 cultures. Antigen detection was assessed using fixed immunofluorescence as 
positive (+), negative (-), or patchy in comparison to positive and negative cell line 
reference images.. Grey denotes discordance between matched samples. 
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Antigen 
PCO 
Expression 
n (%) 
PCO-2 
Expression 
n (%) 
Chi
2
 
p 
Epithelial CK                n=83        61/61 (100) 22/22 (100) - 
EpCAM n=59 13/51 (25.5) 6/18 (33.3) 0.2935  . 
MOC31 n=60 14/45 (31.1) 5/15 (33.3) 0.8026  . 
Ovarian CA125 n=76 39/55 (70.9) 10/21 (47.6) 0.0350  * 
Germ cell D240 n=62 0/46 (0) 0/16 (0) - 
Mesenchymal Vimentin    n=63 47/47 (100) 16/16 (100) - 
 
Table 4.9 -  2: Summary of antigen expression of PCO and PCO-2 cultures. 
 
4.9.2. PCO vs. PCO-2 Growth 
Although PCO-2 took longer to establish from time of collection in comparison 
to standard PCO cultures of ascites from the same patient, there was no 
significant difference in SRB determined doubling time (DT) between PCO and 
PCO-2 cultures, one-way ANOVA p=0.9812,  
Figure 4.9 -  1.  
 
Figure 4.9 -  1: Doubling time for PCO vs. PCO-2 cultures. Cells were seeded at 1000 
cells/well and fixed at 24 hour intervals for 10 days. Cell proliferation was determined 
by SRB assay and doubling time (DT) calculated. Median DT is shown with the red 
line, with corresponding range.  
D o u b lin g  T im e
D o u b lin g  tim e  (h o u rs )
0
2
0
0
4
0
0
6
0
0
8
0
0
1
0
0
0
P C O
(n = 5 2 )
P C O -2
(n = 3 4 )
M e d ia n  1 2 7 .1  (5 0 .3 -8 7 4 .9 )
M e d ia n  1 3 2 .7  (3 5 .0 -4 8 6 .7 )
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4.9.3. PCO vs. PCO-2 HR Status 
No significant differences were detected in the phenotype of the PCO vs. PCO-
2 populations. A number of PCO-2 samples were assessed for HR function 
alongside their paired PCO, Table 4.9 - 3. 
 
PCO HR Status PCO HR Status PCO-2 
229 HRC HRD 
230 HRC HRD 
233 HRC HRD 
234 HRC HRD 
238 HRD HRD 
239 HRC HRD 
 
Table 4.9 -  3: Functional HR status (determined by Rad51 foci assay) of paired PCO 
and PCO-2 cultures. Discordance between PCO and their corresponding PCO-2 
cultures is seen in 5/6 patient samples.  
 
Considerable discordance is seen between PCO and PCO-2 cultures with 5/6 
patient samples showing HRC in their PCO culture but HRD being shown in the 
corresponding PCO-2 culture. This may reflect genuine heterogeneity between 
different cell populations. However, in this small cohort, all PCO-2 cultures were 
HRD. There are two possible explanations. Firstly, the group of cells that remain 
in suspension for longer (PCO-2) represent a genuine different subpopulation to 
PCO cells, which differ in their ability to repair DNA damage. Alternatively, as 
the PCO-2 cells remain in suspension for longer with fewer media changes, the 
cells may undergo senescence and therefore are unable to fully repair DSB, 
reflecting their dying status rather than a genuine pathway dysfunction.   
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4.10. Homologous Recombination DNA Repair Status of PCO 
Cultures 
These studies were conducted by myself and Michelle Dixon.In total, 56 PCO 
cultures have been classified according to HR functional status. In all 56 
cultures, DNA DSB damage was confirmed by a greater than 2 fold increase in 
γH2AX. Of the 56 cultures, 34 (60.7%) had a greater than 2 fold increase in 
Rad51 foci formation and were therefore classified as HR competent (HRC) and 
22 (39.3%) were HR defective (HRD),  
Figure 4.10 -  1. This predominance of HRC tumours may be a reflection of the 
cohort tested, with 22 (36.6%) being sampled following administration of 
chemotherapy (15/22 HRC, 7/22 HRD).  
A 
 
B 
 
Figure 4.10 -  1: HR assay. Immunofluorescence detection of nuclear γH2AX (A) and 
Rad51 (B) in PCO 164. DAPI nuclear stain is used to make a nuclear mask enabling 
quantification of intra-nuclear foci using ImageJ technology.  
 
When subdivided according to histological subtype, there were in general, no 
significant differences in the proportion of each subtype being HRC, Table 4.10 
- 1. The predominance of HRC tumours within the ‘mixed/other’ group should be 
interpreted with care, owing to the small number within this group and the mix of 
actual histologies included. This group included 3 mixed endometrioid/clear cell 
(2 HRC), 1 HGSC/clear cell (HRC), 2 low grade serous carcinomas (1 HRC), 1 
ovarian carcinosarcoma (HRC) and 1 enteric type mucinous tumour arising from 
within a teratoma (HRC).   
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Histological Subtype 
HRC 
n (%) 
HRD 
n (%) 
HGSC                                             n=43 24 (54.5) 20 (45.5) 
Mucinous                                          n=2 1 (50.0) 1 (50.0) 
Clear cell                                           n=2 2 (100) 0 (0) 
Endometrioid                                    n=1 1 (100) 0 (0) 
Mixed / Other ovarian                       n=8 6 (75.0) 2 (25.0) 
All                                                    n=56 34 (60.7) 22 (39.3) 
 
Table 4.10 -  1: Functional HR status of PCO cultures by histological subtype. HR 
status was determined by quantification of nuclear Rad51 foci following induction of 
DNA DSB with 2 Gy irradiation and incubation with 10 μM rucaparib. HRC was defined 
as more than a 2 fold increase in Rad51 foci formation, in comparison to untreated 
controls.  
 
4.11. Sensitivity to Cytotoxic Agents  
Numerous established assays exist for sensitivity testing of cytotoxic agents. 
Colony formation studies are considered the gold standard but rely upon the 
ability of the culture to form discrete, quantifiable colonies. However, PCO 
cultures do not proliferate well at low density and fail to form countable colonies 
precluding this assay. Several assays were tested as alternatives, including the 
cell proliferation assays SRB and WST-1; as well as cell counting, using a panel 
of cell lines before adopting SRB as the preferred single method for PCO 
assessment.  
Discrepancies in results from sensitivity assays using different techniques are 
well described. The Cancer Cell Line Encyclopaedia (CCLE) (Barretina 2012) 
and Cancer Genome Project (CGP) (Garnett 2012) provide gene-expression 
profiles and drug-sensitivity assays with 471 overlapping cell lines. Analysis 
shows low correlation between the two data sets (Weinstein 2013). The gene-
expression profiles showed good concordance, whereas the sensitivity to 
agents did not, which is likely to reflect the two different readouts (cellular ATP 
vs. dehydrogenase activity) of cytotoxicity used.  
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4.11.1. Selection of Methodology: SRB vs. WST-1 vs. Colony 
Formation vs. Cell Counting 
A series of experiments comparing the selected assays were conducted in two 
sets of cell lines (VC8, VC8 BRCA2, VC8 PIR; UWB1-289, UWB1-289 BRCA1), 
paired for BRCA mutation with WT, (see section 6.5.1 for full experimental 
details) and in PCO samples, Figure 4.11 -  1.  SRB assay determines cell 
density based upon the measurement of cellular protein, with a directly 
proportional relationship between protein measurement and cell mass (Vichai 
2006). WST-1 is a tetrazolium salt that is reduced to a coloured formazan by the 
action of mitochondrial dehydrogenase activity, which is proportional to cell 
number (Berridge 2005), see Chapter 3 for details of assay protocols. 
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Figure 4.11 -  1: Comparison of growth inhibition by rucaparib using SRB, WST-1 
proliferation assays and cell counting in PCO 170. PCO 170 cells were treated with 
rucaparib at various concentrations, as indicated, for 10 days and cell number 
estimated by SRB or WST-1 assays or cell counting. Data are the mean values if 6 
repeats, error bars represent SD.   
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Review of the comparative assessments of the proliferation assays (SRB and 
WST-1) with cytotoxicity assays (colony formation), using cell lines paired for 
BRCA mutation with WT (VC8/VC8-BRCA2/VC8-PIR, UWB1-289/UWB1-289-
BRCA1) and PCO samples, confirmed that a single methodology was essential 
in order to ensure results obtained from sequentially acquired PCO samples 
were directly comparable. SRB was selected as the methodology of choice due 
to its simplicity, reproducibility and concordance with colony formation assays, 
Table 4.11 - 1. Good correlation was observed between SRB and colony 
formation assays, r = 0.9856 (p=0.0021). Correlation between WST-1 and 
colony formation assay was poor, Pearsons correlation r = -0.0729 (p = 0.9072).  
 
Cell Line 
GI50 µM  
SRB 
GI50 µM 
WST-1 
LC50 µM 
Colony formation 
 Mean (SD) 
VC8 9.5 (1.7) 0.0003 (0.000006) 0.6 (0.3) 
VC8 BR2 907.3 (150.1) 67.2 (77.2) 384.4 (143.5) 
VC8 PIR 8.5 (1.5) 143.7 (246.3) 11.8 (4.9) 
UWB1-289 0.2 (0.3) 0.4 (0.3) 0.5 (0.1) 
UWB1-289 BR1 8.2 (0.7) 2429 (4194) 68.9 (9.5) 
 
Table 4.11 -  1: Comparing cytotoxicity to rucaparib in a cell line panel by colony 
formation assay and proliferation assays. Colony formation: cells were treated with 
cytotoxic agent at various concentrations, as indicated, for 24 hours and survival was 
determined with colony formation assay. Data are the mean values (SD) from three 
independent experiments, with triplicate values for each concentration (colony 
formation) and six replicates for SRB and WST-1 assays. 
4.11.2. SRB Assay to Evaluate Effect of Cytotoxic Agents on PCO 
Cultures 
Having optimised the methodology for assessment of cytotoxicity, the sensitivity 
of each PCO culture to rucaparib and cisplatin was determined using SRB 
proliferation assays and correlated with HR functional status, Figure 4.11 -  2, 
Figure 4.11 -  3. It was not feasible to determine the doubling time (DT) of each 
PCO prior to SRB assay due to their limited life span. The median DT for PCO 
was 132 hours and a standard incubation time of 10 days was adopted. 
Concentration-response curves were generated but in many cases it was not 
possible to accurately calculate a GI50 because of insufficient suppression of 
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growth at the highest concentrations used. For this reason, data are given as % 
control cell growth at a single drug concentration.  
A 
H R  s ta tu s  a n d  fo ld  in c re a s e  R a d 5 1  fo c i c o u n t f ro m  c o n tro l
P C O  c u ltu re s
F
o
ld
 i
n
c
r
e
a
s
e
 f
r
o
m
 c
o
n
tr
o
l
1
3
8
1
3
9
1
4
2
1
5
4
1
5
7
1
6
2
1
6
3
1
6
8
1
6
9
1
7
0
1
7
1
1
7
4
1
7
5
1
7
7
1
8
0
1
8
2
1
8
4
1
8
7
1
9
2
1
9
4
1
9
9
2
0
1
2
0
2
2
0
5
2
0
9
2
2
1
2
2
4
2
2
5
2
2
9
2
3
0
2
3
1
2
3
3
2
3
4
2
3
9
1
4
3
1
4
4
1
5
6
1
5
8
1
7
9
1
8
3
1
9
0
1
9
1
1
9
7
2
0
0
2
1
0
2
1
1
2
1
3
2
1
7
2
1
8
2
1
9
2
2
2
2
2
3
2
2
6
2
2
7
2
2
8
2
3
8
0
5
1 0
1 5 H R C
H R D
 
B 
H R  s ta tu s  a n d  %  s u rv iv a l R u c a p a r ib  a t  1 0 0  M
P C O  c u ltu re s
C
e
ll
 g
r
o
w
th
: 
%
 c
o
n
tr
o
l
1
3
8
1
3
9
1
4
2
1
5
4
1
5
7
1
6
2
1
6
3
1
6
8
1
6
9
1
7
0
1
7
1
1
7
4
1
7
5
1
7
7
1
8
0
1
8
2
1
8
4
1
8
7
1
9
2
1
9
4
1
9
9
2
0
1
2
0
2
2
0
5
2
0
9
2
2
1
2
2
4
2
2
5
2
2
9
2
3
0
2
3
1
2
3
3
2
3
4
2
3
9
1
4
3
1
4
4
1
5
6
1
5
8
1
7
9
1
8
3
1
9
0
1
9
1
1
9
7
2
0
0
2
1
0
2
1
1
2
1
3
2
1
7
2
1
8
2
1
9
2
2
2
2
2
3
2
2
6
2
2
7
2
2
8
2
3
8
0
5 0
1 0 0
H R C
H R D
 
C 
 
H R  s ta tu s  a n d  %  s u rv iv a l C is p la t in  a t  1 0  M
P C O  c u ltu re s
C
e
ll
 g
r
o
w
th
: 
%
 c
o
n
tr
o
l
1
3
8
1
3
9
1
4
2
1
5
4
1
5
7
1
6
2
1
6
3
1
6
8
1
6
9
1
7
0
1
7
1
1
7
4
1
7
5
1
7
7
1
8
0
1
8
2
1
8
4
1
8
7
1
9
2
1
9
4
1
9
9
2
0
1
2
0
2
2
0
5
2
0
9
2
2
1
2
2
4
2
2
5
2
2
9
2
3
0
2
3
1
2
3
3
2
3
4
2
3
9
1
4
3
1
4
4
1
5
6
1
5
8
1
7
9
1
8
3
1
9
0
1
9
1
1
9
7
2
0
0
2
1
0
2
1
1
2
1
3
2
1
7
2
1
8
2
1
9
2
2
2
2
2
3
2
2
6
2
2
7
2
2
8
2
3
8
0
5 0
1 0 0
H R C
H R D
 
Figure 4.11 -  2: Rad51 foci count and growth inhibition by rucaparib and cisplatin. 
Each PCO underwent the HR Rad51 assay to characterise cultures into HRC (60.7%) 
and HRD (39.3%) categories. Briefly, cells were treated with 2 Gy irradiation and 10 μM 
rucaparib beofre quntifying nucelar γH2AX and Rad51. Results are expressed as fold 
change from equivalent counts in untreated controls. Each culture was also treated 
with rucaparib (B) or cisplatin (C) at various concentrations for 10 days before 
determining growth inhibition by SRB assay. Results are expressed as % survival at 
100 µM rucaparib or 10 µM cisplatin, compared to untreated controls. Red bars = HR 
competent, Blue bars = HR defective cultures. See Appendix 6 for detailed patient 
demographics and assay outcomes.     
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Figure 4.11 -  3: Sensitivity to cisplatin and rucaparib stratified by HR status. 
Data from Figure 4.11 -  2 using SRB cell proliferation assay were grouped into HRC 
and HRD cultures and analysed for significance. T-test was used to compare the mean 
% survival at a given concentration of cytotoxic agent (see Y axis) between the HRD 
and HRC groupings.  
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4.11.3. Sensitivity to Rucaparib and Cisplatin by HR Status  
When grouping all cultures into their functional HR groups, there are statistically 
significant differences between the mean GI50 and percentage survival of drug 
of each group, Table 4.11 - 2, Figure 4.11 -  4, suggesting HR stratification to 
reliably predict sensitivity.  
However, assessing the response in each individual patient reveals large 
overlap of responses within the two groups. HRD cultures can be resistant to 
both rucaparib and cisplatin, whilst HRC cultures can be sensitive to one or both 
agents. 2/22 (9.1%) HRD PCOs have more than 50% cell survival at 100 μM of 
rucaparib indicating resistance. 17/34 (50%) HRC PCOs are sensitive to 
rucaparib with less than 50% cell survival at 100 μM rucaparib. The PPV and 
NPV for HR function in the prediction of sensitivity to rucaparib was 91.7% and 
36.4%. PPV and NPV for cisplatin sensitivity was 73.0% and 27.8%.  
 
 
 
HRC 
n=34 
HRD 
n=22 
t test 
p 
Rucaparib 
Mean % survival at 100 μM rucaparib (SEM) 52.3 (4.2) 39.9 (1.8) 0.0275  * 
Mean GI50 (SEM) 69.0 (6.8) 35.1 (7.4) 0.0017  * 
Cisplatin 
Mean % survival at 10 μM cisplatin (SEM) 66.9 (4.2) 46.6 (3.8) 0.0014  * 
Mean GI50 (SEM) 9.2 (0.3) 5.5 (0.8) 0.0001  * 
 
Table 4.11 -  2: Comparison of growth inhibition, determined by SRB assay, by 
rucaparib and cisplatin stratified by HR functional status. Briefly, PCO cell cultures 
were seeded at density of 1000 cells/well, with six replicates per condition, and 
exposed to increasing concentrations of rucaparib or cisplatin for 10 days, corrected for 
1% DMSO. After fixation with TCA,bound protein was quanitified using 0.4% SRB 
solutiono by spectrophotometry.   
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Figure 4.11 -  4: Growth inhibition by rucaparib (A) and cisplatin (B) in PCO cultures by 
HR functional status.Cells were treated with rucaparib or cisplatin at various 
concentrations, as indicated for 10 days and cell proliferation determined by SRB 
assay. Results are the mean of 6 repeats at each concentration. Error bars represent 
SD.  
 
 
4.11.4. Sensitivity Rucaparib vs. Cisplatin 
Work in this thesis adds to a small published dataset (Mukhopadhyay 2010, 
Mukhopadhyay 2012) demonstrating that HRD PCOs are more sensitive to 
rucaparib ex vivo in comparison to HRC cultures. This study confirms published 
data and additionally, has extended cytotoxic assessment to cisplatin ex vivo.  
In this dataset 16/54 (29.6%) PCOs were resistant to both rucaparib and 
cisplatin, Figure 4.11 - 5. 13/16 (81.3%) of these cultures were HRC. Of the 21 
cultures sensitive to both agents, 18/21 (85.7%) were HRD, Fishers exact test, 
p<0.0001.  
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A 
Resistant 
 
B 
Sensitive 
 
Figure 4.11 -  5: Resistance to rucaparib and cisplatin.The percentage of PCO cultures 
resistant to rucaparib and/or cisplatin is shown numerically within Venn diagram (A) 
and the percentage of PCO cultures sensitive to rucaparib and/or cisplatin are shown 
Venn diagram (B). 
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4.12. Clinical Application of HR Assay 
The HR assay is currently complex, lengthy and user dependent. Simplification 
of the assay protocol may also facilitate its application into clinical trials and 
routine clinical practice. Additionally, although cultures are typically developed 
within 14 days from collection, further analysis for the Rad51 assay with 
concurrent testing for sensitivity to cytotoxic agents using SRB assays can take 
a further 14 days. This leaves a very small window for experiments before 
planning chemotherapy. Alternative methodologies were explored in an attempt 
to reduce the time taken from sample collection until assignment of HR status.  
4.12.1. Cytocentrifugation and Coverslip Culture 
These studies were conducted with Anna Grundy and Laura Woodhouse (MRes 
2012).  
In parallel to standard PCO culture, nine ascitic samples were 1) cytospun 
directly onto coverslips and 2) cultured directly onto coverslips. Each PCO 
culture, cytospun and coverslip culture sample underwent characterisation 
(morphology assessment and immunofluorescent assessment of CK and 
CA125), as well as assessment of the feasibility of performing HR assays, see 
section 3.4.2 for assay details.   
Characterisation 
Cytocentrifugation: Contamination of slides with cellular debris and frequent 
cellular damage prevented accurate assessment of characterisation antigens. 
Assessment was possible in only 5/9 of the PCO tested. Concordance with 
parallel conventional IF characterisation was poor, with discordance in 90% of 
cases.     
Coverslip Culture: The morphological appearance of cells cultured on coverslips 
was similar to parallel flask cultures. Characterisation of coverslip cultures 
showed 100% staining for CK and CA125. Concordance with parallel 
conventional IF characterisation was high with agreement in 80%. Discordance 
was seen, with loss of CA125 membrane antigen expression, in 2 cultures at 
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passage 1 (following passage with trypsin), Table 4.12 - 1. It is possible this 
represents chemical/mechanical loss of the cell surface antigen, as previously 
described, section 4.7.5. 
 PCO 
PCO Conventional 
Culture 
Coverslip Culture Cytospun 
162 
CK + + - 
CA125 + + - 
163 
CK + + - 
CA125 + + + 
164 
CK + + - 
CA125 - + Patchy 
167 
CK + + - 
CA125 - + Patchy 
168 
CK + + - 
CA125 + + Patchy 
 
Table 4.12 -  1: PCO culture antigen characterisation. Characterisation of cultures, 
using three culture techniques, from five PCO patients were compared for expression 
of CK and CA125. Conventional culture: a 50:50  (v:v) ascites: media mix was cultured 
in T75 flasks. Cells were trypsinised and replated prior for antigen characterisation at 
passage 1. Coverslip culture: a 50:50 ascites: media mix was cultured directly onto 
sterilised glass coverslips. Cytospinning: Fresh ascites was cytospun directly onto 
glass coverslips for immediate characterisation, without culture.  
 
Homologous Recombination Repair Assay 
Cytocentrifugation: Nuclear γH2AX foci were visible but Rad51 detection was 
poor and fold increase in γH2AX foci inadequate. HR status could not be 
determined.  
Coverslip Cultures: The HR assay was successfully performed on 5/5 cultures 
with 100% concordance with parallel traditional HR assays, Figure 4.12 -  1. 
However, the γH2AX and Rad51 fold increase was typically much lower. This 
may be a reflection of the earlier passage at which the HR assay was 
performed or that the cells had failed to replicate. 
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Figure 4.12 -  1: PCO HR status: comparison of HR results following traditional culture 
technique vs. direct culture onto coverslips. Rad51 fold increase in 5 PCOs comparing 
standard technique with and coverslip cultures (+/- SEM). 100% concordance between 
functional status was seen.  
 
Time for Assay Result 
Culturing directly onto coverslips reduced the time taken to determine the HR 
status from a mean of 11.6 days (SD 2.5) to 5.3 (1.6) days. 
4.12.2. PARP Activity as a Surrogate Assay for HR Function  
These assays were performed with Dr Miranda Patterson and James Murray.  
Although PCO cultures provide an exceptionally useful model for the study of 
cancer cell biology, it may be favourable to generate a more clinically applicable 
HR assay. A single surrogate marker for HR function would reduce the need for 
complex multistep assays requiring live cultured tissues.  
Poly (ADP-ribose) (PAR) polymerase 1 (PARP1) is activated (forming PAR) by 
DNA SSB, DSB and stalled replication forks to facilitate DNA repair within 
several pathways including BER, NHEJ and HR. PARP is expressed variably in 
all nucleated human cells excluding neutrophils (Schreiber 2002) with variable 
expression between tissues. Pilot studies measuring PARP-1 activity in PBMCs 
from healthy volunteers and metastatic melanoma patients before and during 
temozolomide therapy and in tumour biopsies revealed large inter-individual 
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differences in PARP activity in both healthy volunteers and cancer patients 
(Plummer 2005). 
PARP-1 has been shown to be hyperactivated in BRCA2-defective cells and 
additionally PARP activity has been shown to revert to near normal levels in 
PARPi–resistant BRCA2-defective cells (Gottipati 2010). On the basis of this 
and other clinical studies PARP activity assay has been proposed as a 
surrogate marker for HRD (Plummer 2005, Zaremba 2009). PARP activity was 
assessed in PCO cell pellets, already characterized by HR status with 
sensitivity data to both rucaparib and cisplatin. 24 cryofrozen PCO samples 
were assessed for stimulated PARP activity (9 HRD, 15 HRC). 
HRD PCO cultures had significantly less PARP activity than HRC cultures, with 
a mean PAR formation of 24.0 (SEM 3.6) pmol/106 cells and 41.9 (4.8) 
respectively, Mann Whitney test p = 0.0248, Figure 4.12 -  2. The ability of the 
PAR level detected to predict sensitivity to rucaparib and cisplatin was explored 
using correlation of PAR level with % survival at 10 μM cisplatin and 100 μM 
rucaparib, Figure 4.12 -  3, but no significant relationship was detected.  
HR and PARP are both involved in the repair of DNA strand breaks and 
replication lesions and may act in a complementary fashion, so that if one 
pathway is lost, the other needs to be upregulated to compensate for the loss. 
However, in the study by Gottipati et al. (2010), increased PARP activity found 
in HR defective cells was not explained by accumulation of DNA lesions known 
to trigger PARP activity (i.e., DNA strand breaks or damaged replication forks). 
PARP is involved in multiple DNA repair pathways and the low PARP activity 
seen in the group of HRD tumours in this study may actually reflect alternative 
dysfunctional pathways. Interpretation of PARP activity in a larger group of 
samples characterised for other pathway function may clarify this relationship.   
PARP activity therefore serves as a poor biomarker for predicting sensitivity to 
cytotoxic agents. It is known that PARP-1 and PARP-2 expression varies widely 
across all nucleated human cells excluding neutrophils (Schreiber 2002, Csete 
2009). Large inter-individual differences in PARP activity has also been 
reported in healthy volunteer and cancer patients before and during therapy. 
This may at least in part explain the variable levels in this study.   
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     C 
 
    D 
 
Figure 4.12 -  2: Stimulated PARP activity in PCO. PAR is quantified following maximal stimulation of permeabilised cells during a 6-minute reaction 
with excess NAD+ and oligonucleotides. Cells are blotted on to an immunoblot membrane and treated with anti- PAR primary antibody followed by 
secondary antibody conjugated with HRP. A chemiluminescence agent is added and PARP activity is expressed as ‘luminescent arbitrary units’. A: 
Immunoblot; Dots 1-6 (red) show results for 25, 10, 5, 1, 0.2, 0 pmol PAR standards. PCO duplicates (blue), alongside corresponding unreacted 
samples. Dots 49, 50, 51 (green) show background blank measurements. B: A standard curve constructed by non-linear regression of PAR standard 
values and the resulting equation relating PAR to chemiluminescence (R2 ≥ 0.9) used to calculate the amount PAR present in each well.; C: Results 
expressed as picomoles of ADP-ribose monomer incorporated per 106 permeabilised cells and PAR activity in stimulated cells expressed as the 
percentage mean (SD) PAR pmol/106 cells of activity in untreated control cells. HRC (red), HRD (blue) D: PARP activity stratified by HR function 
demonstrating association between HRC and high PARP activity.  
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0.9414 
Figure 4.12 -  3: Correlation of PAR level and % survival 10 μM cisplatin (A) and 100 
μM rucaparib (B).  
 
4.12.3. HR Gene Expression as a Surrogate for HR Function 
DNA micro-arrays have become an established tool to study gene expression 
patterns in ovarian cancers for both diagnostic and prognostic markers (Hibbs 
2004, Spentzos 2004). This approach carries the advantage of high throughput 
analysis and also the use of RNA which can be extracted easily from clinical 
material including FFPE tissues. 
Gene expression profiling using FFPE samples comparing (Jazaeri 2002) 
profiles from BRCA1/2 mutated cancers with sporadic EOC showed a BRCA-
like profile in many of the sporadic EOC (named BRCA linked). In another 
micro-array dataset which included 61 patients with EOCs (sporadic/ BRCA 
mutant) Konstantinopoulos et al. (2010) developed a BRCA-like profile. The 
BRCAness profile in sporadic EOC was shown to correlate with responsiveness 
to platinum and PARP inhibitors (in cell lines) and was predictive of a subset of 
sporadic EOCs with improved outcome. Additionally, Pennington et al (2014) 
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have demonstrated that 31% of 390 ovarian cancers tested had at least one 
loss-of-function germline or somatic homologous recombination mutation and 
that this correlated with in vivo platinum sensitivity and overall survival. The 
ongoing ARIEL 2, a phase 2 trial of rucaparib therapy for women with relapsed 
HGSC or endometrioid ovarian cancer, aims to identify a molecular signature of 
HRD and this will be evaluated further in ARIEL 2 (NCT01891344) and in 
ARIEL 3 (NCT01968213) which aims to assess rucaparib as maintenance 
therapy. Abkevich et al studied the association between HR defected and 
genomic patterns of loss of heterozygosity (LOH) and found that an HRD score 
(defined as the number of regions within HR pathway components where LOH 
had occurred) was capable of detecting HR defects regardless of aetiology or 
mechanism (Abkevich 2012).  
In order to identify potential biomarkers of the HR pathway, which would be 
suitable for clinical use, RNA expression of key components of the pathway 
were examined and correlated with HR function. Using RNA extracted from the 
PCO ascitic cultures characterised for HR function (Rad51 assay) and 
assessed for sensitivity to rucaparib and cisplatin, the relative expression of 
genes involved in DNA DSB repair was determined by the Oxford genomics 
centre (Oxford, UK) using Illumina Genome Studio and HumanHT 12v4.0 R1 
15002873 array, as per manufacturer’s instructions, see Chapter 3. 24 PCO 
samples, 14 of which were HRC and 10 of which were HRD were tested. All 
patients had RNA extracted from the same ascitic fluid primary culture as used 
in the Rad51 assay and PARP inhibitor cytotoxicity assay. The relative 
expression of each component of the HR DNA repair pathway was calculated 
and differences between the HRD and HRC group expression calculated.  
 
Stratification by HR function  
The 10 HRD samples were compared as a group with 14 HRC samples to study 
whether a panel of genes could be identified to differentiate the two groups, 
Figure 4.12 -  4. More than 47000 probes were used to assess fold change in 
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expression and each PCO sample appeared to be dysregulated in some 
component of the HR pathway. 14 key components of the HR pathway were 
assessed and compared between the two functional groups with significance 
detected in three components with 2 components upregulated (ATM, MRE11) 
and one down regulated (Rad51) in the HRC group in comparison to HRD. 
Statistical significance was seen between the expression of ATM, MRE11 and 
Rad51 in HRC compared to HRD groups, Figure 4.12 -  5. ATM, which is 
involved in several DNA repair pathways and in the detection of DSB, is 
significantly upregulated in HRC in comparison to HRD. MRE11 forms part of 
the MRN complex, which is involved in the detection and binding of DSB and it 
may therefore be that cells are HRD because they cannot identify, bind and 
initiate the HR pathway as efficiently as HRC cultures. Interestingly, significantly 
higher Rad51 expression was seen in HRD cultures in comparison to HRC 
cultures although I had hypothesised that Rad51 may be higher in HRC 
cultures. The HR assay is not based upon absolute levels of Rad51 to 
determine functional status but a change in level in response to DNA damage. 
This higher baseline level in the RNA sampled may therefore represent 
dysfunctional Rad51 present in the nucleus but not the functional Rad51 
needed for HR. 
Although no correlation between RNA expression of these markers with 
sensitivity to rucaparib or cisplatin was seen, further evaluation of these 
components for use as a surrogate biomarker for HR status is required. 
BRCA2 was down regulated in 6/10 HRD samples and 6/14 HRC samples, but 
not to a statistically significant degree. BRCA1 was upregulated in 5/10 HRD 
and 6/14 HRC samples with copy fold changes in excess of 200 universally 
across the three probes used.  
Future work will aim to explore unsupervised hierarchical clustering upon an 
expanded panel of samples.  
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Figure 4.12 -  4: RNA expression of key components of the HR DNA repair pathway for 24 PCO samples. HRD PCO samples (denoted in blue) are 
shown on the left and HRC PCO samples on the right. Downregulation of RNA for each gene of interest in marked in the rows by red with significant 
upregulation (>200 fold change) shown in green.  
PROBE_ID SYMBOL 143 158 190 191 210 211 213 219 226 227 187 142 157 169 170 174 175 177 182 184 192 202 209 224 SEARCH_KEY ILMN_GENE
HR STATUS DEF DEF DEF DEF DEF DEF DEF DEF DEF DEF COMP COMP COMP COMP COMP COMP COMP COMP COMP COMP COMP COMP COMP COMP
ILMN_1713630 ATM -16.20846 -20.176 -12.84836 -11.49141 -5.742648 -13.28789 -9.801975 -3.228968 -2.056082 -5.655308 -10.94918 -8.839348 -9.018829 -7.261518 12.10423 2.498819 -19.12911 -18.59771 -18.65437 -4.136273 -13.07505 -10.01394 6.661379 -12.28766 NM_000051.3 ATM
ILMN_2370825 ATM 404.0371 347.0973 133.8201 300.724 511.7194 454.0731 369.8382 508.4669 468.0821 450.5182 485.8292 410.163 303.4397 446.1061 608.4989 442.5184 414.903 358.5688 540.4095 605.0289 216.3266 548.3122 379.2445 480.8474 NM_000051.3 ATM
ILMN_1779214 ATM 364.1045 517.4083 181.2755 296.2152 538.6665 386.824 453.872 449.7072 381.4586 389.0792 538.5323 410.0215 297.9734 467.9624 855.4619 569.7107 512.6835 427.338 534.1614 652.1263 260.8386 578.0817 435.5921 374.2001 NM_000051.3 ATM
ILMN_1716231 ATM 7.809299 -6.814474 -5.083456 -2.112921 11.976 -3.898418 8.693777 7.356684 3.250225 0.8241983 8.894722 2.436414 12.74283 -2.672285 17.77222 3.859221 -1.547083 -1.66437 -1.824357 0.08947874 -6.168601 -10.78865 -2.834106 4.288241 NM_138292.3 ATM
ILMN_2277201 ATR 4.079968 13.66779 -10.53975 -2.279081 11.19568 0.723635 -1.651765 -11.75178 -4.911851 -0.3690689 -6.695678 5.435325 -10.07945 10.68898 -0.8583184 -2.70555 -4.104887 5.823266 2.660997 -7.157846 -6.293251 -1.070501 11.06017 4.759901 NM_001184.2 ATR
ILMN_1660342 ATR -16.09195 -16.21752 -3.896492 -25.77199 -13.77062 -22.88853 -12.26793 -20.39309 -7.831137 -16.79352 -12.04817 -8.176921 -7.53889 -4.87832 -14.16431 -24.35883 -9.027575 -14.53287 -7.327774 -16.76665 -9.439044 6.884889 -21.14888 -16.34603 NM_001184.2 ATR
ILMN_1810385 ATR 16.58816 62.78116 12.00026 35.539 33.79847 36.85277 69.23827 30.072 -3.072364 17.92166 50.2422 13.9277 44.36462 63.57623 58.43261 64.30002 58.4824 30.14116 50.28194 58.20673 32.40369 57.10649 67.7361 32.23521 NM_001184.2 ATR
ILMN_2376771 ATR 9.109874 27.65783 7.49747 11.123 14.94702 16.70328 12.18947 18.07521 -8.23085 2.560361 21.83323 19.27847 54.68998 32.09208 8.112411 16.58816 6.485281 33.51632 18.84089 26.85566 20.28166 26.02123 29.32808 14.58879 NM_001184.2 ATR
ILMN_2311089 BRCA1 51.16379 36.61445 166.9714 279.8017 26.46712 131.1208 159.629 9.348722 10.32923 264.2051 151.9676 118.2036 102.7735 89.19927 10.20145 273.7585 122.2872 189.0804 77.83929 48.64391 50.87378 133.2586 119.4447 44.38351 NM_007304.2 BRCA1
ILMN_1738027 BRCA1 86.62818 62.80723 281.7982 403.8167 72.64795 246.2086 352.2682 23.1109 20.6481 360.1515 259.8784 150.331 196.7555 128.6001 49.35919 447.688 210.7039 299.8925 118.1398 84.61773 130.2138 210.6044 199.3285 79.66733 NM_007301.2 BRCA1
ILMN_1666652 BRCA1 43.14746 51.40815 43.17533 37.79308 53.16131 45.78283 36.81658 41.016 49.16716 60.70359 54.20085 55.34061 46.68485 34.83811 55.55183 33.74536 30.82522 62.95033 26.75381 49.2518 27.72092 41.13319 39.01644 35.24897 NM_007306.2 BRCA1
ILMN_1771065 BRCA1 67.11613 28.68555 76.41686 74.48272 56.25835 78.76285 51.02493 57.15689 92.98721 89.75253 51.81628 64.61904 64.51543 53.35278 49.99949 77.99491 58.07809 55.44242 27.28679 66.92319 53.08088 57.96724 69.41319 42.99944 NM_007295.2 BRCA1
ILMN_1677794 BRCA2 -3.93308 -5.241463 -5.088156 -4.97215 0.640877 10.10251 42.91273 -0.7685792 -11.96606 0.2182563 11.3427 -7.472057 8.606776 -5.432899 0.3502572 24.41572 7.954782 19.90457 -2.354892 -7.543347 -4.853921 15.1702 -6.058078 -13.31219 NM_000059.1 BRCA2
ILMN_1799224 FANCA 28.01375 2.054548 26.97709 34.48122 16.65421 39.38312 20.69934 30.8213 36.7732 36.62489 22.53315 57.27476 50.13609 21.73999 29.79693 21.23748 22.96673 40.26795 14.22908 22.17863 35.09032 30.94111 26.15141 41.05052 NM_000135.2 FANCA
ILMN_1769758 FANCA 0.9239479 19.58075 23.20579 -6.373938 6.102721 3.760617 31.97113 17.14719 -2.064278 5.873023 8.802949 8.817059 10.31704 13.11709 1.916054 21.95505 8.090856 4.452212 49.85747 -6.98869 1.283804 7.591918 19.67349 3.671796 NM_001018112.1 FANCA
ILMN_1682747 FANCA 1.601668 -3.810309 4.758424 18.5586 -8.224247 5.493771 37.32028 2.953667 0.2321665 3.866567 10.64526 6.622058 2.059307 -1.122352 3.55733 -1.300824 4.348334 35.50324 1.906197 -2.430683 3.377376 2.802481 2.672903 -0.1003781 NM_001018112.1 FANCA
ILMN_1726756 FANCB 4.925931 49.15212 44.87112 144.9498 29.1714 77.85735 74.26141 40.07652 -3.17956 91.5701 83.85864 87.66771 79.30841 15.86372 37.18451 183.2164 112.2046 143.1901 75.22813 46.62956 42.14937 81.44099 64.43993 22.94468 NM_001018113.1 FANCB
ILMN_1698252 FANCB 46.94723 130.1798 101.0724 233.6936 127.6757 426.9807 315.8657 141.3642 60.2979 203.1758 172.3983 123.9248 191.4886 113.4144 90.86283 247.665 221.1075 301.6512 177.9665 185.721 121.6132 197.72 161.1712 124.8022 NM_001018113.1 FANCB
ILMN_1683112 FANCC 2.166301 -9.945371 7.320209 24.75574 7.276146 28.13638 71.47564 11.76279 13.03035 31.25033 12.53307 32.15759 10.05931 4.000021 -0.9779444 43.50102 8.750628 24.52455 17.91885 10.35187 45.80806 26.96418 14.58008 8.269217 NM_000136.2 FANCC
ILMN_2235137 FANCD2 179.6713 155.9985 419.6043 371.5026 121.0857 501.2227 713.4563 274.7752 33.56076 476.972 316.8522 319.3924 287.2077 262.619 104.8616 495.2321 300.341 389.8582 186.6204 240.2165 436.8642 333.6218 295.2543 216.2439 NM_001018115.1 FANCD2
ILMN_1657634 FANCD2 -10.64923 -3.435461 17.75829 -1.411813 -19.14526 70.08607 50.06385 21.01673 -19.27741 24.08491 -3.789656 4.610622 -0.2306443 -0.1756898 -1.825254 -0.87907 -11.09946 7.999865 -2.169135 -6.499821 7.675657 4.686993 -5.66051 -7.903827 NM_033084.3 FANCD2
ILMN_1712122 FANCD2 -2.970124 2.544606 42.64164 46.35108 0.6084241 42.74695 107.231 21.57 -6.249458 22.7435 27.42577 22.42068 18.93308 8.269217 -5.292853 25.65843 19.19923 39.13492 -4.821208 17.66931 47.41558 17.53071 4.087009 3.245071 NM_001018115.1 FANCD2
ILMN_2043452 FANCE 124.462 96.3123 217.683 399.9905 142.952 251.2066 188.4864 154.8375 114.2264 209.7586 167.5315 206.3897 265.7662 115.4421 92.06023 298.0425 243.4243 569.0911 184.3229 167.3443 245.9294 250.4777 129.027 87.24194 NM_021922.2 FANCE
ILMN_1682724 FANCF -17.37206 0.6335506 5.36414 -4.033645 1.356531 -5.032208 3.021417 -1.537133 -9.889712 9.581355 8.010229 14.70493 7.763339 7.792455 -2.412018 14.76994 19.05179 32.60504 4.986661 2.79331 2.082206 -3.365647 2.610328 -7.264358 NM_022725.2 FANCF
ILMN_1758728 FANCG 168.5432 135.7819 476.1943 1055.961 128.783 507.1436 431.0581 295.2869 108.4029 319.5628 312.3313 517.8503 370.3058 190.841 81.53729 748.6462 423.8431 673.239 249.0978 253.7623 615.5146 424.6003 272.647 234.2106 NM_004629.1 FANCG
ILMN_1655642 FANCI 75.77596 132.9258 197.72 380.6356 84.50811 318.3111 414.3842 166.6191 19.26005 320.8572 238.4278 274.1317 268.46 193.9294 75.27999 528.9709 267.3491 358.1055 155.7411 160.7793 136.2099 277.1494 196.8014 130.2984 NM_018193.1 FANCI
ILMN_2188909 FANCL -4.547523 -4.154737 -14.94517 5.792452 -11.65007 -2.668253 2.005923 5.439537 -16.67073 -14.774 -5.199243 -3.852045 0.8155673 5.243841 2.246155 0.6596784 -6.886708 0.02320441 -4.125425 -6.247816 -14.02523 -4.647019 -2.940693 -18.78169 NM_018062.2 FANCL
ILMN_1754045 FANCL 219.6664 305.1885 209.7866 547.3874 205.081 364.3044 274.2741 363.5753 177.2913 377.8425 370.8578 317.9106 356.3297 277.6909 260.3598 439.411 385.222 427.0877 255.4588 296.045 444.6254 332.4118 390.4234 310.9799 NM_018062.2 FANCL
ILMN_1811995 FANCM -16.10699 -4.536084 -4.604692 -4.799142 -18.50746 -14.30717 -3.106746 -5.594966 -5.70724 -10.00377 -5.428276 -24.37162 -10.60256 2.025946 -7.465542 -9.831143 -13.78537 1.496745 -10.61607 -9.813713 -9.695395 -9.708503 -12.25849 -15.30563 NM_020937.1 FANCM
ILMN_1686871 PARP1 1274.036 1434.725 2129.233 2407.645 1552.114 2559.502 2374.579 1688.436 783.9633 1984.024 2206.183 2497.311 1860.862 1432.706 792.9666 2366.07 2147.153 2490.22 1625.332 1816.025 2933.982 2144.765 2674.374 1533.808 NM_001618.2 PARP1
ILMN_1721411 PARP10 34.78125 51.53519 46.18204 51.25769 76.27304 134.0006 46.7281 84.61773 43.60463 -0.2459161 21.75436 54.46056 27.3012 30.68843 22.80993 12.39307 43.44387 12.51429 68.35304 40.6769 236.7015 71.08185 54.91572 16.03047 NM_032789.1 PARP10
ILMN_2262044 PARP10 380.8903 155.7002 342.2902 439.411 317.5634 487.7328 361.6324 709.8436 253.6896 144.658 253.6896 322.3332 203.9519 366.8387 203.3224 259.2487 229.0322 143.8849 394.9313 221.4719 938.0045 328.4681 469.3763 234.0706 NM_032789.1 PARP10
ILMN_1724722 PARP10 -12.76499 -5.132348 2.267896 13.37827 -15.40597 -5.77291 -8.961834 16.34155 10.40292 -12.89627 -5.446508 -13.90342 -1.582707 4.51946 -18.58308 -9.923936 -4.901851 -1.844391 -2.890149 -9.334124 -0.06868815 -0.07128691 -17.63269 -9.49312 XM_937629.1 PARP10
ILMN_1710844 PARP10 112.6617 110.6908 102.1662 135.9471 97.20454 205.5654 94.58484 163.4263 129.6083 141.1937 86.08296 102.5668 99.72658 125.1776 65.0787 44.86428 90.64549 105.633 113.4685 116.4687 384.0918 116.1956 121.6633 71.16582 XM_937629.1 PARP10
ILMN_2129877 PARP11 60.41655 81.12275 7.489007 37.71383 64.68293 24.5759 25.31789 55.83678 45.27221 43.93537 85.20109 58.58143 45.14434 21.27076 54.73777 40.01856 64.35223 59.99875 73.40966 90.94112 27.15392 40.24715 70.64545 68.01575 NM_020367.3 PARP11
ILMN_1718558 PARP12 668.1191 373.7173 670.1763 830.6989 551.1233 1173.951 596.7644 999.0295 852.7212 429.0555 352.8715 538.4106 524.2217 697.2126 354.6703 506.3737 536.0356 370.3058 897.0582 491.1176 1635.302 1076.472 995.6802 401.968 NM_022750.2 PARP12
ILMN_1691731 PARP14 377.1869 243.7861 319.9311 317.0037 365.3338 692.9581 239.2918 1301.817 191.1482 264.6773 346.364 232.5051 195.832 447.2358 220.2567 285.4521 298.6705 169.3488 648.8748 335.2651 1466.282 392.7738 792.4954 274.8981 NM_017554.1 PARP14
ILMN_1776778 PARP15 -14.65346 -8.449115 -0.3965563 -7.478885 -1.634558 -11.75333 0.05167795 -15.63487 -10.46991 -7.495828 -1.52909 -13.25032 -11.9784 -7.240621 -11.3526 -12.25997 -10.4754 -9.650719 -9.365726 -4.714425 -8.075027 -6.004756 -7.916588 -2.974333 NM_152615.1 PARP15
ILMN_1812080 PARP16 20.31752 60.81814 36.18818 46.43767 40.07652 39.55922 97.38561 39.22884 76.91669 72.23705 55.32563 42.5027 55.12665 44.45078 56.25835 44.18777 58.31726 42.34159 89.06181 50.37818 28.80417 29.65461 47.74036 79.44642 NM_017851.4 PARP16
ILMN_1757995 PARP2 385.0136 376.4261 388.419 478.4494 239.5683 573.3431 726.2099 257.9162 354.4835 436.2542 366.7574 440.4101 428.6856 339.5807 298.3386 585.863 398.7978 486.2426 386.6014 283.5873 753.2136 444.5096 307.1738 315.8087 NM_005484.2 PARP2
ILMN_2354237 PARP2 101.9585 101.6524 217.7379 223.3336 64.63461 179.784 235.6228 70.031 108.4792 172.5094 117.1861 153.3538 171.7194 103.1735 76.23618 214.998 121.7303 165.7528 99.17316 137.1603 379.2445 167.7133 113.7155 123.7564 NM_001042618.1 PARP2
ILMN_1703411 PARP3 29.26495 8.370529 11.31679 30.79965 6.324096 11.17948 0.279938 12.01461 40.57242 31.40495 29.40281 24.14754 24.40842 20.41884 17.85139 22.57769 29.89859 21.28123 0.9960657 17.1922 9.348722 13.69568 30.92778 -4.015318 NM_001003935.1 PARP3
ILMN_2397954 PARP3 2093.206 840.5041 379.7164 1477.528 1636.626 1230.851 1015.446 1891.917 1492.173 1249.707 1459.921 1678.812 1139.191 1611.194 1701.527 1673.946 1265.397 1210.567 1272.773 1661.395 637.707 915.3014 1784.812 1987.213 NM_005485.3 PARP3
ILMN_1796682 PARP3 429.3369 250.2149 87.7526 308.6039 382.9507 235.83 193.0538 321.373 367.0389 269.7444 309.6394 381.0051 202.6295 335.9593 310.5677 244.0621 246.7179 238.4278 240.6696 388.0974 126.1531 196.6085 382.143 371.4338 NM_001003931.1 PARP3
ILMN_1776464 PARP4 2135.561 1839.853 2497.311 2035.526 2319.128 2521.699 2140.537 2980.472 2824.909 2166.173 2529.228 2430.824 2167.028 1961.303 1713.935 2192.779 1505.168 1653.626 1709.898 2245.323 1746.073 2040.32 2659.358 2183.949 NM_006437.2 PARP4
ILMN_1813620 PARP6 59.87925 45.44374 90.53114 72.14812 51.51782 90.76958 41.23518 68.32859 53.23433 52.99805 45.42955 63.14521 85.99459 55.38223 58.65481 51.24901 39.82384 58.08959 45.78971 52.60984 66.97959 60.81814 80.57362 69.09812 NM_020214.1 PARP6
ILMN_1771832 PARP6 160.1254 147.2687 187.1809 156.3935 139.802 203.2347 127.5822 191.011 235.683 160.0177 140.6009 125.0449 145.1255 124.2538 124.4076 86.57357 121.0674 145.8073 179.1919 138.6982 208.4776 204.7545 175.5414 73.62627 NM_020213.1 PARP6
ILMN_1662256 PARP6 5.579383 -4.76013 -4.008076 -0.3439875 -5.813511 -12.98878 2.92935 -7.619428 -10.78626 -2.047949 -2.502154 1.838212 -3.93839 -3.471883 10.31704 -3.848729 -0.9545626 -4.034875 -2.211263 7.608224 -4.90506 -0.9164979 4.640332 -5.437513 NM_020213.1 PARP6
ILMN_1752791 PARP8 -6.132291 0.3735557 11.2719 16.57944 19.66604 3.856809 7.984205 -6.604836 14.15747 -1.940083 4.778837 0.5650901 4.36557 -7.676579 9.190999 -13.04532 -2.57093 -0.1770039 -1.823154 8.439711 0.3150602 -2.713881 -1.280506 0.2731456 XM_943884.1 PARP8
ILMN_1810299 PARP8 -5.185313 0.01420046 3.676488 -4.742458 -2.864934 -7.942566 4.57114 2.599401 -10.14202 -5.498398 -5.973943 -12.35844 -4.647972 -8.383871 2.047778 0.1840699 -6.716969 -8.320704 1.639302 -3.596399 -6.414392 -6.91369 -0.4980806 -13.70637 XM_943891.1 PARP8
ILMN_1669117 PARP8 -9.099865 -2.916746 -21.21624 -11.6132 0.008711426 -16.12109 -8.16481 -11.06365 -15.24413 -15.54502 0.4340788 -19.04468 -14.46684 -13.95853 -12.11056 -0.7323129 -6.268991 -2.33248 -10.19789 -9.960147 -15.49928 -5.060191 -11.16439 -3.257055 XM_943889.1 PARP8
ILMN_1806651 PARP8 542.1426 450.5182 741.2888 445.1376 620.7933 511.1123 449.8076 540.9141 665.3322 461.9704 409.0436 578.8828 505.3276 750.251 536.8187 588.1393 585.7159 545.0004 521.7348 428.1033 876.252 382.8651 353.756 431.158 NM_024615.2 PARP8
ILMN_2053527 PARP9 396.1858 423.0021 291.4695 351.4614 216.9018 517.2164 245.3049 806.5927 111.0693 316.178 456.8744 233.4892 302.6021 560.3231 157.0805 315.656 291.4695 132.272 505.8026 253.6331 531.8171 425.0814 863.1497 208.7374 NM_031458.1 PARP9
ILMN_1731224 PARP9 663.2814 794.6964 493.1464 806.371 493.4396 909.873 366.6247 1676.288 306.1367 472.9612 738.1271 396.5666 453.4887 815.6827 241.9788 410.163 511.7194 295.8722 723.1746 517.4083 1517.689 698.544 1487.543 500.0013 NM_031458.1 PARP9
ILMN_1755023 RAD50 176.5881 394.0911 172.1204 244.1173 234.3454 352.6654 244.9294 196.7555 204.5845 218.7493 271.8175 218.15 300.9061 210.3069 218.3728 152.1767 219.5389 281.7982 240.2846 294.338 215.2488 234.2907 324.1026 121.9252 NM_005732.2 RAD50
ILMN_1708789 RAD50 -12.21346 -14.81208 -19.89178 -8.267653 -7.635687 5.525312 -18.40544 -18.26267 -24.37162 -16.47545 -11.6318 -21.82034 -20.51138 -10.13298 -17.1945 -21.09986 -23.8524 -14.93287 -7.882333 -8.014898 -14.76158 -13.65505 -22.112 -12.04321 NM_005732.2 RAD50
ILMN_1795609 RAD51 -4.594101 2.285023 7.54671 23.82409 -10.09123 13.60724 -4.700007 -0.9189432 1.709469 11.74225 -0.5291443 5.52422 10.68312 5.471033 -3.227576 11.31462 -2.505136 10.29892 -2.934549 14.59918 1.050964 6.088331 12.58396 1.372895 NM_133487.1 RAD51
ILMN_2363027 RAD51 214.5776 279.6746 335.2651 205.0255 232.8867 597.3262 582.9297 214.6633 514.6483 279.8017 214.9494 221.0504 288.1609 198.8406 144.7003 251.723 180.4737 140.6683 186.6758 223.2228 214.2681 261.3714 142.2847 192.7267 NM_133487.1 RAD51
ILMN_2257432 RAD51 113.6257 61.19771 250.629 290.3181 74.39206 146.5986 194.0957 97.32966 89.12152 191.1482 109.0324 138.8584 139.346 101.3718 76.1573 204.4851 140.6683 214.3782 87.93769 80.09756 133.5759 174.8722 114.4921 178.6445 NM_002875.2 RAD51
ILMN_1670353 RAD51AP1 293.1254 293.6477 518.1398 1287.733 220.2567 700.4219 961.799 536.9295 63.99352 779.4056 697.9521 560.8017 576.8193 331.0405 155.9672 1170.761 719.8737 870.3471 433.0553 411.1389 1026.065 661.2267 643.4348 518.1398 NM_006479.2 RAD51AP1
ILMN_1830985 RAD51AP2 -10.22338 -4.121432 -1.90926 -8.365785 -9.377777 -9.018829 -9.166408 -13.46777 -6.853818 -8.152133 -3.480449 -8.829082 -3.455684 0.09558988 -1.145743 1.180731 6.611318 10.68898 -11.07508 -0.9387748 6.817635 -12.07384 8.970359 -9.106819 Hs.515802 RAD51AP2
ILMN_2238928 RAD51C 371.1346 267.4905 583.8455 846.9445 268.8706 295.3735 463.1514 334.14 181.9269 777.8318 484.6705 518.5927 443.1913 478.2118 326.9864 660.3853 502.576 637.3607 316.3054 362.6536 505.8026 439.3098 481.1037 345.7767 NM_058216.1 RAD51C
ILMN_1667644 RAD51C -14.55153 -20.48207 -16.82803 -17.16851 -20.73443 -19.50943 6.589756 -20.59434 -10.89528 -13.57209 -24.31843 -13.54691 -19.37395 -14.92727 -22.84375 -13.17622 -7.205653 -16.41944 -17.65019 -26.67332 -11.81441 -12.50947 6.125223 -15.0241 NM_002876.2 RAD51C
ILMN_1695386 RAD51C 475.5262 333.9683 713.2286 1040.088 286.7478 443.998 572.5854 460.909 270.0201 966.4843 603.5863 531.1437 435.968 563.5534 456.2535 772.3358 523.8883 564.4167 392.5936 508.9819 591.6015 434.5 583.4453 549.3346 NM_002876.2 RAD51C
ILMN_1760635 RAD51C 381.9456 326.7864 702.1894 1007.205 179.6981 275.7184 419.238 417.4958 178.7892 781.2534 408.192 454.3065 395.7339 447.774 363.0149 579.2773 469.5049 524.931 305.4932 354.0241 475.8076 404.5481 445.2462 373.7173 NM_058216.1 RAD51C
ILMN_1802392 RAD51L1 -0.2342187 2.660997 -7.018138 -14.5052 -4.338575 -11.17419 -13.03547 7.226482 -9.168349 5.764211 19.78918 -2.088514 -12.74363 -17.73098 0.8987922 -5.034459 -7.286561 -20.9933 0.4548174 7.064575 7.372947 -6.124195 15.25847 8.68342 NM_133509.2 RAD51L1
ILMN_1801262 RAD51L1 -10.37287 -11.30359 19.00092 4.355921 -6.120648 -1.898392 9.693084 -0.9636371 20.24553 -6.848073 -0.7620904 4.574938 -5.404643 0.3979749 6.344601 13.57031 -7.032794 1.720653 6.79011 -11.49856 0.244928 2.321918 5.972262 -10.44617 NM_133510.2 RAD51L1
ILMN_1727831 RAD51L1 39.66032 56.27106 35.63946 54.57924 45.73581 37.543 47.71311 49.93537 15.1702 35.60649 91.03457 40.86807 20.28461 37.11707 49.44695 41.82219 50.56204 32.64636 49.3983 50.57949 29.44723 32.6741 57.95813 54.03013 NM_002877.4 RAD51L1
ILMN_2370907 RAD51L3 54.64086 49.14391 50.50821 134.5475 47.08409 81.5799 45.16069 27.35626 37.15868 110.0557 58.44439 54.27799 81.53729 45.85735 34.34831 74.99988 80.44553 109.1894 46.21056 48.18342 21.42002 82.23052 49.62233 79.93037 NM_002878.2 RAD51L3
ILMN_2273921 RAD51L3 3.027309 -11.7454 -4.691676 5.795645 6.9059 1.211603 -8.937379 -9.2349 -2.974333 4.170034 -3.91695 -7.503894 -1.071782 9.332094 -2.129834 -6.947268 -1.308356 -0.5350295 -5.604526 -7.230454 -2.217978 -7.029795 -1.626247 2.101618 NM_002878.2 RAD51L3
ILMN_2370910 RAD51L3 25.18272 31.80971 25.82727 86.6043 6.653216 34.88238 42.11996 31.79952 7.146621 80.4286 27.05375 26.04375 34.84762 30.19617 29.8277 47.23817 26.56422 58.25132 21.66948 16.35228 10.45821 33.47168 28.57506 31.42581 NM_002878.2 RAD51L3
ILMN_1731051 RAD52 -13.63343 29.96481 4.322254 -5.805526 4.782311 2.552072 18.78155 3.516829 5.291224 -6.477865 8.41838 -16.64733 7.329353 -12.63217 -6.666139 8.380435 -0.843291 -0.2156494 -6.725646 -2.071811 -0.6260901 11.54167 11.95926 -1.921296 NM_134423.1 RAD52
ILMN_1781345 RAD52 8.180799 -3.365647 23.4746 9.103351 -8.975156 15.90147 -11.53334 1.017295 3.060865 1.155152 4.202458 -12.2276 6.343276 -0.6442134 9.61494 -14.15317 -0.6904978 -6.083917 3.299098 -1.693913 7.482685 9.944949 7.28119 19.93578 NM_134422.1 RAD52
ILMN_1669745 RAD54B -7.646547 -7.032794 -17.81551 -16.25163 -13.50765 -8.226047 -9.965244 -1.796477 -22.42806 -9.08385 -2.303022 -24.03796 -7.160113 -3.715949 -12.47783 -13.32518 -19.89679 -10.19101 -13.27359 -7.286561 -7.400716 -14.09575 -14.97491 -14.46868 NM_012415.2 RAD54B
ILMN_1722127 RAD54B 106.8737 68.54154 269.4291 150.5157 81.56023 85.53775 119.2551 139.2434 134.9872 62.6465 107.7796 110.0557 132.016 85.7764 100.6892 162.6278 152.8467 190.5705 91.82646 97.14352 190.2188 123.9248 108.1007 94.14458 NM_012415.2 RAD54B
ILMN_1658027 RAD54L 81.53729 47.61658 283.5873 300.9971 58.06945 294.2062 340.6468 100.6212 24.49226 203.5986 112.8052 171.2966 161.8538 65.88805 34.6223 247.7256 131.0129 260.1468 78.59128 81.13715 226.9627 146.4955 119.8874 118.3713 NM_003579.2 RAD54L
ILMN_3244803 RAD54L2 252.395 170.7728 426.9807 241.5395 338.892 512.6835 505.3276 290.0019 309.6394 270.7621 184.0976 248.9474 289.3526 251.7798 234.0706 165.2256 221.4719 256.1949 308.0186 238.725 188.4244 325.9146 209.3447 221.7532 NM_015106.2 RAD54L2
ILMN_1751743 XRCC1 133.7844 68.96929 164.2215 314.2337 162.8211 248.8235 227.3484 267.8009 186.1024 159.1192 129.297 240.3372 172.271 216.7986 114.5154 273.2015 155.9067 207.809 137.39 180.072 251.5953 201.2492 165.3084 168.1587 NM_006297.1 XRCC1
ILMN_2204909 XRCC2 1907.596 3484.561 3321.322 1681.841 3254.675 3970.213 3539.96 1435.73 3327.416 2369.654 1814.851 2208.202 2550.222 2139.602 2317.919 1743.557 1766.374 1014.652 1956.358 1506.542 2415.302 3196.087 2069.524 2139.602 NM_005431.1 XRCC2
ILMN_1651569 XRCC2 36.01908 22.02056 51.69333 61.30371 54.45124 45.95456 38.1927 41.17136 98.20934 70.66402 47.23005 42.32492 67.93492 41.74457 28.98569 50.1914 40.68171 77.51304 57.91013 40.83216 43.17533 38.8008 42.30631 55.63398 NM_005431.1 XRCC2
ILMN_1696266 XRCC3 61.2906 55.34992 238.9722 219.7837 25.06923 144.156 115.3793 99.17316 61.51579 87.54275 52.96701 115.5197 108.2997 59.31707 39.20341 90.82065 75.43411 114.5154 55.30733 47.73441 232.2723 71.2391 95.90694 73.29884 NM_005432.2 XRCC3
ILMN_2049642 RPA1 1026.86 1253.439 2055.44 1870.631 1329.87 1420.156 1200.79 1016.829 1224.13 1605.757 1052.526 1518.319 1788.16 1098.592 1210.976 1398.591 1620.393 1803.063 1315.717 1288.268 1666.604 1948.894 1637.379 1199.716 NM_002945.2 RPA1
ILMN_1795719 RPA1 407.9517 441.4777 751.7821 788.2227 347.5617 449.3922 481.6778 407.8265 396.9601 471.1344 442.7214 648.727 518.1398 443.0654 302.3791 477.6501 485.5795 790.2976 402.1254 479.0107 944.8186 580.1551 553.8436 579.0951 NM_002945.2 RPA1
ILMN_1753582 RPA2 924.5509 999.0295 1302.815 1969.816 1092.479 1640.79 1261.3 1243.373 1306.776 1285.206 981.7574 1251.499 1289.252 1521.815 679.4088 1553.396 1233.73 2020.647 1071.144 974.0256 2338.726 1827.821 1160.281 832.8535 NM_002946.3 RPA2
ILMN_1716895 RPA3 1141.323 1055.567 1398.979 1962.863 891.4655 1480.216 1695.562 1356.107 529.3173 2374.579 2333.104 1240.737 1158.498 1494.573 1261.739 2214.8 1430.228 1657.419 1190.668 1216.933 1133.482 1672.573 1716.017 1410.248 NM_002947.3 RPA3
ILMN_1798880 RPA4 8.758545 -5.561729 41.76402 15.84576 19.10637 35.03696 9.487024 7.677464 31.43016 10.85876 11.80233 -4.567155 -5.285791 21.36677 -8.592299 1.826629 -0.8338277 -9.348234 21.97547 -7.903827 12.95216 30.10264 1.652397 -9.136872 NM_013347.1 RPA4
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 Figure 4.12 -  5: RNA expression of key components of the HR DNA repair pathway in 
PCO grouped by HR status, n=24. The mean and SD are plotted with HRC cultures 
shown in red and HRD shown in blue.  
 
PARP1 mRNA as a Surrogate for HRD 
There was no statistically significant difference in PARP1 mRNA levels between 
the HRC and HRD groups tested with only a modest increase in the HRC 
group. This trend was however consistent with the PARP activity, section 
4.12.2. In this group of samples however, there was a significant correlation 
between PARP1 expression and sensitivity to rucaparib, r2=0.2213, p=0.0102, 
Figure 4.12 -  6. 
 
Figure 4.12 -  6: Correlation between PARP-1 RNA expression and sensitivity to 
rucaparib (% survival at 100 µM). 
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4.13. Alternative HR analysis 
A cut-off of a 2-fold increase in Rad51 foci in comparison to control was 
assigned during development of the HR assay based upon Rad51 counts in cell 
lines with known HR function (Mukhopadhyay 2010, Drew 2011). This cut off 
enabled reliable discrimination between PCOs that were sensitive or resistant to 
rucaparib. The actual focus count as well as the fold increase from control was 
highly variable, Figure 4.13 -  1, and in order to explore if simplification of the 
HR assay may be possible, the ability of isolated foci counts to predict HR 
function was assessed. 
  
 
  
Figure 4.13 -  1: Fold increase in Rad51 focus formation from control with subsequent 
HR classification. DNA DSB induction and repair following 2 Gy IR and 24 hour 
exposure to rucaparib in PCO cultures. A 2-fold increase in γH2AX foci from baseline 
(not shown) indicated induction of DNA DSB. A 2-fold or greater increase in 
quantification of Rad51 nuclear foci following DNA DSB compared to untreated controls 
indicated functional HR competence (red bars). Less than 2-fold increase indicated 
defective HR function (blue bars). Data are expressed as the percentage of untreated 
control.  
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4.13.1. Correlation of Focus Count With Rucaparib Sensitivity  
Although using HR status to stratify patients into two groups will enrich the 
population of patients who will respond to platinum or rucaparib, this approach 
may still result in a proportion of patients who will undergo treatment from which 
they will not benefit and a proportion of patients who may not be given 
treatment who would have responded. One possible reason for this may be 
incorrect assignment to the functional groups. It is unclear if there is a 
relationship between the actual foci count and sensitivity to cytotoxic agents and 
correlation between Rad51 foci counts with percentage survival at 100 μM 
rucaparib/10 μM cisplatin was assessed. The correlation between mean Rad51 
focus count of control, after induction of DNA damage  following IR and 
rucaparib, and fold increase with the % survival to rucaparib was calculated, 
Figure 4.13 – 2. There was a statistically significant positive correlation between 
the mean Rad51 focus count following induction of DNA damage (IR and 
rucaparib) and percentage survival at 100 μM rucaparib. A positive correlation 
between higher fold increase in Rad51 foci formation with higher percentage 
survival at 100 μM rucaparib. This reinforces the relationship between 
quantification of Rad51 foci indicating HR pathway function and its association 
with resistance to rucaparib. 
 
4.13.2. Correlation of Focus Count With Cisplatin Sensitivity  
The same analysis was repeated with percentage survival at 10 μM cisplatin, 
Figure 4.13 -  3. Similar results were obtained demonstrating that there is a 
positive correlation between Rad51 count, (following DSB and fold increase) 
with percentage survival at 10 μM cisplatin. As above, there is a negative 
relationship between Rad51 focus count at baseline and percentage survival.  
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Figure 4.13 -  2: Correlation of γH2AX and Rad51 foci counts with % survival at 100 μM 
rucaparib. Following 2 Gy irradiation and incubation with 10 μM rucaprib for 24 hours 
the nuclear foci of γH2AX and Rad51 were counted using Image-J technology 
(described in section 3.6.3). Counts were expressed as mean foci count per cell and 
compared to untreated control cells. Each PCO culture was treated with rucaparib at 
various concentrations for 10 days before determining growth inhibition by SRB assay. 
Results are expressed as % survival at 100 µM rucaparib compared to untreated 
controls. 
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Figure 4.13 -  3: Correlation of γH2AX and Rad51 foci counts with % survival at 10 μM 
cisplatin. Following 2 Gy irradiation and incubation with 10 μM rucaprib for 24 hours the 
nuclear foci of γH2AX and Rad51 were counted using Image-J technology (described 
in section 3.6.3). Counts were expressed as mean foci count per cell and compared to 
untreated control cells. Each PCO culture was treated with cisplatin at various 
concentrations for 10 days before determining growth inhibition by SRB assay. Results 
are expressed as % survival at 10 µM cisplatin compared to untreated controls.
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4.13.3. Rad51 Alone as a Predictor of HR Function  
This alternative analysis utilising single measurements from the HR assay, 
thereby potentially enabling a simplified protocol, suggests that there is 
correlation between sensitivity to cytotoxic agents and the mean Rad51 foci 
count. To further assess this relationship and to determine if the Rad51 count in 
isolation could be used to reliably predict HR functional status, ROC analysis 
was performed to assess the predictability of HR status, Figure 4.13 -  4.   
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Figure 4.13 -  4: ROC curve of ability of Rad51 foci count to predict HR function. 
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The above analyses reinforces that fold increase, as currently used in the HR 
assay, is the most reliable way to ascertain HR functional status but also 
suggests that the baseline Rad51 foci count also shows a predictive relationship 
with HR function, Figure 4.13 -  4. This may offer one possible way in which the 
HR assay could be modified in order for it to be more easily incorporated into a 
research trial or the routine clinical setting.  
4.14. Clinical Correlations 
Survival data was calculated using the date of diagnosis, defined as the date of 
histological/cytological confirmation of EOC. For overall survival (OS), patients 
who died at follow-up (any cause) were uncensored, whereas patients alive at 
follow-up were censored (Bergmann 2007). For progression free survival (PFS) 
patients who died of cancer or who were alive with objective tumour progression 
were considered as uncensored, whereas patients who died of other reasons or 
alive without tumour progression at follow up were considered as censored. 
4.14.1. HR Status as a Predictor of Survival  
It is well known that BRCA deficient cancers have distinct clinicopathological 
features and patients typically have improved OS and PFS compared to non 
BRCA related sporadic EOCs (Pharoah 1999, Chetrit 2008). This is at least in 
part, likely to be due to increased sensitivity to platinum based chemotherapy 
(Foulkes 2006, Konstantinopoulos 2010). HR deficient tumours from our group 
have previously been shown to have better PFS than HRC tumours 
(Mukhopadhyay 2012) and assessment of PFS and OS has been repeated in 
this larger dataset.  
Univariate analyses for OS and PFS were generated by Kaplan-Meier Survival 
curves and differences in survival experience between HR competent and HR 
deficient patients were assessed for statistical significance using log rank 
(Mantel- Cox) test, Figure 4.14 -  6. Patients with HRC cultures (n=35) had a 
median progression free survival (PFS) of 11 months (95% CI 0.4 – 1.6) in 
comparison to 13 months (0.6 – 2.3) for patients with HRD cultures (n=22), log-
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rank (Mantel-Cox) test p=0.0574. Median OS of HRC cultures was 27 months 
(0.6 – 2.4) in comparison to 23 months (0.4 – 1.8) in HRD cultures, p=0.3868. 
These small none statistically significant differences were not explained by the 
differences in patient demographics, histology or surgical outcome, Table 4.14 - 
1. 
 
 
A B 
  
Figure 4.14 -  6: Kaplan-meier survival curves for patients stratified by HR function of 
ascitic PCO cultures. (A) Progression free survival (PFS) and (B) Overall survival (OS). 
Univariate analyses for OS and PFS were generated by Kaplan–Meier survival curves 
and log-rank (Mantel–Cox) tests used for statistical significance. 
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Demographic 
HRC (35) HRD (22) 
p 
Median (range) / n (%) 
Age at presentation (years) 65 (41 – 85) 63 (41-85) 0.8291 
Serum CA125 at presentation (U/l) 1252 (6-10000) 1000 (6-10000) 0.765 
Histology                                             
HGSC 
Non-HGSC 
 
25 (71.4) 
10 (28.6) 
 
19 (86.4) 
3 (13.6) 
 
0.2313 
Time of ascitic sample collection 
Primary surgery /  pre-chemotherapy 
Interval surgery / post- chemotherapy 
 
25 (71.4) 
10 (28.6) 
 
16 (72.7) 
6 (27.3) 
 
0.8676 
Surgical outcome  
                                        Complete / 
Optimal 
Suboptimal 
No debulking surgery 
 
25 (71.4) 
5 (14.3) 
5 (14.3) 
 
18 (81.8) 
2 (9.1) 
2 (9.1) 
 
0.3788 
FIGO Stage     
                                                 Stage I 
Stage II 
Stage III 
Stage IV 
 
1 (4.5) 
1 (4.5) 
29 (82.9) 
4 (11.4) 
 
1 (4.5) 
1 (4.5) 
16 (72.7) 
4 (18.2) 
 
0.4233 
 
Table 4.14 -  1: Patient demographic data stratified by HR status. See appendix 6 for 
detailed raw data for indivudal patients. 
 
4.14.2. Clinical vs. Ex Vivo Sensitivity to Platinum  
Almost all of the patients from this study received platinum-based 
chemotherapy during their treatment. Response to chemotherapy was 
determined by serial clinical examinations, serum CA125 levels and computed 
tomography (CT) scans at predefined intervals and at completion of 
chemotherapy unless new onset symptoms warranted urgent evaluation. 
Comparison was made with pre- treatment imaging and tumour markers. 
Tumour response was defined as radiological evidence of complete/ partial 
response by RECIST criteria or a CA125 response defined as more than 50% 
decline sustained for at least 4 weeks (Therasse 2000). Tumour progression 
/recurrence were defined as presence of progressive disease on CT scan, rising 
CA125 levels or clinical evidence. Clinically, patients who have 6 months or 
more of disease free survival following treatment with platinum are defined as 
having platinum sensitive disease (PFS ≤6 months). Platinum-refractory or 
resistant disease is defined by disease recurrence prior to cessation of therapy 
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(refractory) or within 6 months after cessation (resistant). By stratifying patients 
according to their clinical sensitivity to platinum, assessment of the ability of ex 
vivo culture proliferation assays as biomarkers of actual clinical outcome could 
be made. An ROC area of 0.5530 indicates poor ability of ex vivo culture 
sensitivity to predict clinical sensitivity to platinum, p=0.4962, Figure 4.14 -  7. 
Patients who had received NACT prior to ascitic sampling or who had residual 
tumour following surgery (suboptimal cytoreduction) were excluded from 
analysis as rapid progression is more likely with residual bulky disease. 
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0.3998 – 0.7062 
0.4962 
   
Figure 4.14 -  7: Ex vivo PCO culture sensitivity to cisplatin as a predictor of clinical 
sensitivity to platinum based chemotherapy. Analysis was limited to patients whose 
cultures were collected at primary surgery, with optimal / complete cytoreduction and 
who went on to receive 6 cycles of platinum based chemotherapy. Ex vivo sensitivity 
was determined by SRB proliferation assay and results expressed as % survival from 
control after 10 days incubation with 10 µM cisplatin.   
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4.14.3. Growth as a Predictor of Time to Relapse (PFS)  
The variability of clinical tumour progression, relapse and response to treatment 
is well recognised but there are currently no reliable pathological or clinical 
factors that are capable of predicting the disease course or time to next relapse. 
All PCO cultures were handled in the same way and the only explanation for the 
variable growth rates seen is a biological difference in the cells themselves. The 
ability of the ex vivo doubling time to predict PFS and OS was therefore 
explored.    
Positive correlation is seen between the ex vivo growth rate of PCO cultures 
and time to relapse (progression free survival), p=0.0459, Figure 4.14 -  8. Ex 
vivo growth rate may be one indirect indicator of prognosis.  
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Figure 4.14 -  8: Correlation of PCO culture doubling time with PFS and OS.  
There is a statistically significant positive correlation between DT and PFS, p=0.04.  
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An arbitrary cut-off of a 2-fold increase in Rad51 foci in comparison to control 
was assigned during development of the HR assay (Mukhopadhyay 2010, Drew 
2011). This cut off enabled reliable discrimination between PCOs that were 
sensitive or resistant to rucaparib in initial assays and therefore formed the 
basis of the definition for HRC and HRD cultures. The actual foci count as well 
as the fold increase from control is highly variable, Figure 4.11 -  2A.  
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4.15. Summary 
 The antigen panel tested indicate that ovarian tumours undergo epithelial 
mesenchymal transition and that this is not exclusively a phenomenon 
seen during ex-vivo culture. 
 Ex vivo PCO sensitivity to cisplatin and rucaparib is associated with HR 
function with greater association in rucaparib (likely owing to cisplatin’s 
multiple modes of action and resistance).  
 HRD PCO cultures had significantly less PARP activity than HRC 
cultures, but this failed to correlate with sensitivity to cisplatin or 
rucaparib.  
 Differential gene signatures that correlate with HR functional are 
promising but require further investigation. Paradoxically Rad51 was 
downregulated in HRC cultures and gene signatures require further 
evaluation. 
 HR function of primary ovarian cancer cultures determined by Rad51 foci 
quantification is reliable but fold change is the most reliable way to 
assess function.  
 Application of the HR status to prediction of overall clinical outcome is 
complex and should be interpreted alongside other clinical variables 
including surgical outcome, treatment provided and other patient 
morbidity 
 Use of HR status is likely to enrich a population of patients which are 
likely to respond to PARPi and should be incorporated into future clinical 
trials 
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4.16. Discussion 
As the appreciation of the need for novel therapeutics in ovarian cancer grows 
with the recognition that stratification of therapy based upon tumour biomarkers 
is favourable, the need for a realistic ex vivo ovarian cancer cell model becomes 
paramount for the pre-clinical testing of cytotoxic agents.  
Several methods for the culture of primary ovarian cancer cells isolated from 
ascites have been described (Hirte 1992). These methods however require 
complex multi-step procedures. Dunfield et al and Shepherd et al describe a 
more simple and reliable culture method  involving mixing ascites directly with 
medium which results in epithelial cell culture (Dunfield 2002, Shepherd 2006). 
This technique has been adapted and used throughout this thesis and has been 
utilised and adapted by other groups for successful establishment of cultures 
from malignant ascites (Ince 2015).   
This primary culture model has many advantages including the relative ease of 
obtaining primary material and a straightforward technique resulting in 
generation of an epithelial rich cell population. This project however has also 
highlighted some limitations and we must acknowledge the complexities of 
characterisation and the possible effects of ex vivo culture upon surface antigen 
detection, see section 4.7.4, 4.7.5.  Some histological subtypes are 
underrepresented using this technique and the added appreciation of possible 
intra-tumoural heterogeneity with subpopulations of cells with different biological 
function also forces us to reassess the ability of PCO cultures from ascites to 
represent the entire tumour and therefore accurately predict disease behaviour.  
The increased morphological and antigen expression differences are likely to be 
accompanied by differences in other protein expression which orchestrate 
cellular function and behaviour, and therefore, the appearance of the cell 
(Faratian 2011). However, there may also be further genetic heterogeneity, not 
responsible for cellular appearance, which is responsible for cellular function, 
which therefore determines tumour behaviour and response to therapy. The 
relationship between morphological and molecular heterogeneity and prognosis 
is not yet known. 
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Although there are several possible explanations for the discrepancy seen 
between CA125 expression using IHC and IF microscopy of matched samples 
from PCO patients (section 4.7.3.), this may provide the first evidence of intra-
tumoural heterogeneity. It is possible that the ascitic cell population cultured 
genuinely express CA125 whilst the solid tumour tissue examined by IHC 
represents a different subpopulation of cells with different underlying molecular 
mechanisms associated with a variety of genetic mutations. Other explanation 
for discordant CA125 expression may be sampling error, as not all FFPE 
samples are uniform tumour deposits and may include other non-tumour tissues 
such as stroma or vascular tissue. Alternatively, the fixation and antigen 
retrieval protocol for FFPE tissues may result in reduced exposure of the 
epitope and/or affinity of Ab for the antigen.  
Although concordance in antigen expression was seen in 86.2% cases between 
PCO and PCO-2 cultures analysed a statistically significant higher percentage 
of PCO cultures expressed CA125 in comparison to PCO-2 samples. PCO-2 
cultures result in monolayers with the same morphological and 
immunofluorescent features as the original PCO cultures and behave similarly 
in terms of their growth patterns. The small degree of discordance in antigen 
expression between PCO and the corresponding PCO-2 again, raising the 
possibility of two distinct subpopulations. PCO-2 cultures also senesced after 
several passages with little to indicate that they contain stem cells responsible 
for the continued exponential growth seen clinically in vitro. These cultures do 
however provide an additional resource for further experiments.  
The series of expanded characterisation experiments for PCOs has increased 
our understanding of the effect of culture on primary cells. We can now 
appreciate that culture on plastic alone does not induce significant changes in 
antigen expression but the mechanical and chemical effects of passage are 
more likely to be responsible for loss of cell surface antigens, (Sections 4.7.4 
and 4.7.5). As the majority of PCO cultures undergo characterisation 
assessment between passage 1 and 3, this may at least in part explain the 
lower than anticipated detection of surface epithelial and ovarian markers. The 
almost universal expression of vimentin in all subcultures, even at time zero, 
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suggests that EMT is a process that takes place in vivo. The extent of EMT 
within a tumour may be variable with a spectrum of phenotypes ranging from 
pure epithelial to pure mesenchymal with a population of cells with mixed 
phenotypes of varying degrees (Kalluri 2009). The universal expression of 
vimentin in ascites may be a reflection of the prolonged lag time thought to exist 
between the development of ovarian cancer and clinical presentation.   
Characterisation of cultures should therefore ideally be performed at time 0, 
prior to passage. If the characterisation panel could be performed upon all cells 
simultaneously with a tumour specific marker, i.e. p53 in HGSC, this would 
enable more robust characterisation. Ideally, the actual cells that had 
undergone characterisation could then be cultured and used in subsequent 
experiments.   
The data suggests that HR function remains important in determining sensitivity 
to PARPi and platinum agents irrespective of the underlying genetic 
mechanisms for dysfunction. Its PPV and NPV of 91.7 and 36.4 (Rucaparib); 
and PPV of 73.0 and NPV of 27.8 (cisplatin) although not ideal to provide robust 
guidance for the stratification of therapy are, as far as we are aware, the highest 
in the literature. Stratification of therapy based upon HR status of ascites would 
be likely however to enrich the population and result in higher levels of 
response in comparison to universal provision of therapy.  
There is a pressing need to identify unifying biomarkers of HR deficiency that 
detect the resulting functional defect in HR irrespective of all of the diverse 
mechanisms involved in the pathway each with their own detectable variable 
mutations. Such a marker of ‘BRCAness’ may predict the benefit from PARPi in 
ovarian cancer and potentially multiple other cancer types, regardless of the 
underlying molecular mechanism (Turner 2011). 
Despite several methodological approaches to the identification of HR defective 
tumours using mutational screening, gene expression profiling, loss of 
heterozygosity (LOH) assays, telomeric allelic imbalances and large scale 
transition scores, the limitations that result in a relatively low positive predictive 
value for these biomarkers remain (Watkins 2014). These gene signatures, 
however, have not yet achieved widespread use. This may be partly because of 
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concerns of reproducibility. Additionally, tumours whose genome has 
undergone one or more events that restore HR function are likely to be 
misclassified as HRD as a result of prior repair deficiency and its genomic 
scarring. In a way analogous to microsatellite instability in mismatch repair 
deficient cancers, there is likely to be a genomic mutational pattern that predicts 
for underlying HR deficiency (Turner 2011). Proposals have been made to 
integrate a genomic scar-based biomarker with a marker of resistance in an 
attempt to improve the performance of any companion diagnostic for PARP 
inhibitors but as yet this has not been tested in clinical samples (Watkins 2014). 
Several unsupervised multi-strategy approaches and statistical methods have 
been developed to identify informative genes from a high throughput genomic 
data and identify differentially expressed genes (Li 2008, Liu 2010) and may 
represent a superior method of analysis in future studies. Of particular interest 
is a DNA repair pathway–focused score developed by Kang et al (Kang 2012) 
using the TCGA dataset. This was analysed strategically assessing the repair 
pathways predominantly involved in repair of platinum-induced DNA damage  
they identified a high risk gene signature, reproducible in validation datasets, 
and correlated with survival (Kang 2012).  
Gene expression arrays are the most appealing of the surrogate assays for HR 
function due to their high throughput analysis and ease of application to 
historical datasets. The differential expression of several genes in this small 
dataset between HRD and HRC cultures, with upregulation of ATM and MRE 
and down regulation of Rad51, is promising but should not be over interpreted. 
It is unlikely that one marker in isolation is capable of predicting function of the 
entire pathway and therefore expansion of this dataset combining regression 
analysis of all relevant components is required. Interestingly significantly higher 
Rad51 expression was seen in HRD cultures in comparison to HRC cultures, 
(section 4.11.3). Based upon the HR pathway, we had hypothesised that Rad51 
may have been higher in HRC cultures. The HR assay is not based upon 
absolute levels of Rad51 to determine functional status, but a change in level in 
response to DNA damage. This higher baseline level in the RNA sampled may 
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therefore represent dysfunctional Rad51 present in the nucleus but not the 
functional Rad51 needed for HR which forms foci.  
 
Assay Advantages Disadvantages 
Rad51 functional 
assay 
Identifies HRD irrespective of 
cause at time of treatment decision 
Needs viable tissue, complex and 
lengthy 
HR gene mutation Rapid, can be done on FFPE 
material.  
Does not identify epigenetic 
silencing and mutations in HR 
genes not yet identified 
Gene expression 
profiling 
Rapid, can be done on FFPE 
material.  
Unreliable, conflicting data in 
literature 
Loss of 
heterozygosity 
(LOH) 
Identifies HRD irrespective of 
cause. Can be done on FFPE 
material 
Genomic scarring, will not identify 
revertants or where HR has been 
restored by other means (e.g. loss 
of 53BP1) 
 
The literature suggests a correlation between chemo sensitivity to platinum and 
PARP inhibitors. BRCA deficient EOCs have been shown to have increased 
platinum sensitivity (Taniguchi 2003). In clinical studies, response to the oral 
PARP inhibitor olaparib seems to correlate with platinum free interval, platinum 
sensitive cancers showing a greater clinical benefit rate (Fong 2010). 
Interestingly 14/54 (26%) PCO cultures showed sensitivity to rucaparib ex vivo 
that were resistant to cisplatin ex vivo (see section 4.13.4). Similar complexities 
have been encountered in clinical studies where resistance to PARP inhibitor 
was seen in platinum sensitive patients or PARP sensitivity seen in platinum 
resistant patients (Fong 2010), and indicates that other mechanisms may be 
responsible as well.  
In this data set ex vivo growth rate may serve as an indicator of prognosis with 
shorter PFS seen in patients with more rapid doubling times (see section 
4.12.3). It is likely that growth rate is just one of many biological properties that 
may serve as a prognostic marker. As knowledge of these individual markers 
grows, it may be possible to combine them creating a scoring system that 
includes clinical, pathological and biological information that may guide 
response to treatment and prognosis facilitating clinical counselling and 
provision of adjuvant treatments.  
The preclinical testing of rucaparib in PCO cultures in this study, with sensitivity 
seen in approximately 50% of cultures (section 4.11.2) creates optimism for its 
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use in the clinical setting in both platinum naïve and platinum resistant disease. 
This however will only translate into prolonged survival if ex vivo cultures are 
genuinely representative of the tumour. The inability of cisplatin sensitivity ex 
vivo to accurately predict clinical sensitivity to platinum chemotherapy is likely to 
be multifactorial. Perhaps the adherent monolayers of cells cultured represent 
just one subpopulation and are not representative of the residual microscopic 
tumour following surgery. Additionally, the standardised SRB protocol used, 
which did not take into account the doubling time of individual cultures, may 
have overestimated sensitivity in rapidly growing cultures and underestimated 
sensitivity in slow growing cultures. Finally, this analysis has not taken into 
account histological subtype, the residual volume of tumour at the end of 
surgery, and combination chemotherapy treatments actually given, which have 
previously been identified as being important in the prediction of overall clinical 
outcome (Von Heideman 2014). 
Exploration of the use of more clinically applicable assays as surrogates for the 
functional HR assay is essential if HR functional status is to be used to guide 
therapy for patients in routine practice. The functional assay utilising cultures 
cells is not reproducible outside of the research setting. The finding of greater 
PARP activity in HRC cultures in comparison to HRD cultures (section 4.13.2) is 
promising that this rapid and resource-friendly assay may be used clinically. 
This PARP activity in HRC cultures may actually be a marker of a functional 
BER pathway and this may explain the lack of correlation seen between PAR 
level and % survival in sensitivity studies to cisplatin and rucaparib. The 
difference seen in PARP activity between the two experiments is likely to reflect 
simple inter-assay variability. Extreme culture conditions i.e., freeze and thaw 
can alter PARP activity as well, although it has been shown that there is no 
deterioration of PARP activity in frozen samples up to 15 weeks (Plummer 
2005). 
Irrespective of these points, the current cell culture model remains a valuable 
resource, which far exceeds cell line models in its ability to replicate in vivo 
tumour biology. It serves as a valuable resource for ex vivo testing and to 
survey tumour molecular aberrations, which may serve as druggable targets. 
 141 
 
Future work may focus upon ongoing development of the culture model 
whereby characterisation and molecular analysis of HR function could be 
performed simultaneously in a rapid, reproducible and clinically relevant 
manner.  
As we continue to evaluate various techniques during the search for accurate 
and reliable biomarkers, the importance of the actual sample taken to provide 
the biological information should not be forgotten. Gene mutation analysis 
undertaken by Pennington et al (2014) revealed improved survival in cases with 
somatic mutations in HR genes but this did not reach statistical significance. 
They hypothesised that somatic mutations would be less stable over time due to 
clonal selection and would have less impact on overall survival than germline 
mutations but they based their analysis upon single tumour biopsies only and 
may in fact not identified all of the mutations present in the bulk of the tumour.  
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Chapter 5. Inter- and Intra-tumoural Heterogeneity 
5.1. Introduction 
In many malignancies the extent of tumour heterogeneity is an emerging theme 
that is incompletely understood. How molecular heterogeneity affects tumour 
evolution and clinical progression is unknown and additionally the interaction 
with unique environmental factors that influence heterogeneity is also yet to be 
characterised.  
Heterogeneity in cancer is driven by two principle factors: the introduction of 
genetic (or epigenetic) alterations mediated, for example, by genomic instability, 
and the evolutionary selection thereof (Alizadeh 2001). Not all of the somatic 
mutations that occur have a phenotypic or functional effect and are therefore 
termed passenger mutations, Figure 5.1 – 1. Furthermore selection pressure for 
particular phenotypic alterations can favour the outgrowth of cells with 
passenger genetic alterations associated with that phenotype. It may be more 
clinically relevant to examine the functional effects of heterogeneity rather than 
just relying on genomic variation. 
 
 
Figure 5.1 -1: Somatic evolution (Alizadeh 2001). In tumour evolution, driver alterations 
result in formation of the initial clone. As further driver alterations occur, clones branch 
off forming subclones.  
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A significant proportion of ovarian cancer patients present with large volume 
ascites. However, limiting sampling to ascites under represents the broad range 
of histological subtypes as the majority of patients with ascites have HGSC. 
Additionally, patients undergoing interval debulking surgery after chemotherapy 
often do not have ascites. Cultures derived from solid tumour, particularly in the 
absence of ascites, enables exploration of the broad range of histological 
subtypes ensuring that inter-tumoural functional heterogeneity between all 
histological subgroups is explored. Additionally, solid tumour culture from 
multiple anatomical sites allows investigation of the intra-tumoural heterogeneity 
(ITH) at a functional as well as morphological level.  
Throughout this chapter, the term inter-tumour heterogeneity is used to describe 
differences seen in tumours from different patients and the term intra-tumour 
heterogeneity (ITH) is used to describe differences seen in tumours from 
different locations within the same patient.  
5.1.1. Heterogeneity in Ovarian Cancer: What is Already Known? 
Ovarian cancer is recognised as a heterogeneous disease and there is much 
evidence emerging regarding inter-tumour heterogeneity in terms of genetic 
mutations and defective intracellular pathways between the different histological 
subtypes.  More recent work has taken this further and subdivided high grade 
serous cancer using genomic (TCGA 2011) gene expression (Tothill 2008) and 
functional (TCGA 2011, Mukhopadhyay 2012) techniques. This has generated 
at least four distinct gene expression subgroups (Tothill 2008, Tan 2013) and at 
least two functional subgroups (Mukhopadhyay 2012). The subgroups have 
distinct prognostic behaviour as well as differences in their sensitivity to 
conventional and novel chemotherapies.  
To date, ovarian cancer is treated as a homogenous disease with platinum-
based chemotherapy but effective delivery of novel cytotoxics and the correct 
selection of patients will require the use of accurate biomarkers capable of 
predicting response. Ovarian cancer frequently presents at a disseminated 
stage with multiple sites of disease within the peritoneal cavity and elsewhere. 
Unless tumours are homogeneous, it is likely that biopsies from a single site of 
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a tumour may not be representative of the rest of the tumour and therefore such 
biopsies will be unable to predict response accurately. In particular, most 
biopsies used for clinical diagnosis are taken from the omentum under 
radiological guidance and it is rare for disease on the diaphragm or nodal 
disease to be sampled. Given that there are possible biological differences 
between disease which disseminates within the peritoneal cavity through direct 
spread,  compared to disease that disseminates by a classical process using 
lymphatic or haematogenous spread (Lengyel 2010), it can be hypothesised 
that there will therefore be a systematic bias in reporting of biopsies. This will 
have an impact as biopsies start to be used to direct therapy both in clinical 
trials and in clinical practice. The question of spatial heterogeneity and its 
potential effect upon clinical response to therapy has not been addressed in any 
prospective study. 
There is general consensus that whilst most ovarian cancers are monoclonal in 
origin with a high degree of genomic parsimony there exists significant 
heterogeneity within microsatellites and SNPs (single nucleotide polymorphism) 
(Khalique 2007), copy number and driver mutation status (Bashashati 2013) 
from anatomically distinct regions (Le Page 2006). This does not however 
appear to translate into a significant degree of heterogeneity in terms of gene 
expression (Jochumsen 2007). The significance of this is uncertain. Other 
possible mechanisms of heterogeneity, including epigenetic changes in 
methylation, known to be important in determining functional status of the 
tumour, have not yet been studied. 
Evidence for the presence of intra-tumour heterogeneity within EOC is growing. 
Gene expression studies have indicated different biological profiles in the 
cancer cells derived from ascites and solid tumour from the same patient in 
terms of metastasis, invasion and angiogenesis (Le Page 2006). Genetic 
analysis has provided evidence to suggest that although tumours arise from a 
single cell, subsequent mutations result in subpopulations with diverse 
molecular characteristics (Nowell 1976, Khalique 2007). The translational 
significance of this phenomenon was demonstrated in the robust study 
undertaken by McAlpine et al, where variable response to chemotherapeutic 
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agents was seen between synchronous samples in 22.4% of the tumours 
examined (McAlpine 2008). However, this finding is not universally described. 
Indeed, in the work undertaken by Jochumsen et al, minimal genetic intra-
tumour heterogeneity was reported (Jochumsen 2007). In this latter study, only 
three regions of each tumour were examined in a sample size of nine, 
suggesting that the lack of heterogeneity identified could simply be a 
manifestation of sampling error. Additionally, this discrepancy could be 
explained by different opinions amongst authors as to what constitutes a 
significant quantity of intra-tumour heterogeneity. In fact, Jochumsen et al did 
not report the existence of no variation, simply that they believed the disparity to 
be ‘minimal’. Additionally, phenotypic differences (e.g. antigen status) and 
functionality (HR status) may vary more than genotypic. Sequence analysis may 
not pick up epigenetic changes that would affect expression and neither 
genotypic nor expression analysis will pick up changes in protein levels through 
changes in stability or post translational modification that affects function. 
Bashashati et al have recently described extensive intra-tumoural mutational 
diversity in a small panel of HGSC, with TP53 being the only somatic mutation 
present in all samples and only 51.5% concordance in the presence of other 
driver mutations across all samples from each patient (Bashashati 2013). This 
builds upon previous work by Khalique et al, who suggested that ovarian cancer 
develops by a non linear clonal evolutionary process (Khalique 2009). More 
recently, Scharz et al have demonstrated heterogeneity in genomic clonal 
expansion both spatially and temporally across multiple samples in 14 HGSC 
patients (Schwarz 2015). Multiple sampling of primary and metastatic sites in 
breast, pancreas, and renal carcinoma has catalogued genetic divergence and 
shown that metastases from the same site can show organ-specific 
phylogenetic branches (Shah 2009, Campbell and McLaren 2010, Navin 2010, 
Navin 2011, Gerlinger 2012).Taken together, these findings suggest a model in 
which early divergence gives rise to clones with different driver mutation 
phenotypes, the only common feature being mutation of TP53.   
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5.1.2. Reported Solid Culture Methodologies  
Normal ovarian epithelium can be cultured by scraping surface cells off the 
ovary and culturing as epithelial sheets (Auersperg 1984, Auersperg 2001) 
(Edmondson 2002). However, EOCs do not maintain this structural integrity and 
few studies have managed to effectively culture EOC. 
Several methods for the culture of malignant tissue have been described and 
include tissue homogenisation using collagenase with a reported success rates 
of  51% with normal ovary, 45% with benign ovarian tumour material, 66% for 
malignant tumour and 56% for ascites (Lounis 1994). Mechanical digestion 
using a Medimachine has also been described and enables rapid processing of 
solid tumour to a homogenous cell lysate within 15-30 minutes without the need 
for collagenase digestion (Rodriguez-Casuriaga 2009). 
Explant culture of tissue sections has been described for ex vivo culture, which 
maintains cellular architecture, thus mimicking the in vivo environment (Vaira 
2010). This has been achieved in a heterogeneous group of tumours, with the 
use of organotypic inserts consisting of Teflon membranes with 0.4 μm pores, 
which enabled 3D growth for up to 5 days (Vaira 2010). Gene expression 
profiling and immunofluorescent staining were performed on these tissue 
sections but application to the current functional HR assay is limited as the 
current protocol is limited to monolayer cell cultures. Additionally, this 
methodology is time and resource consuming and highly complex.  
More realistic preclinical cancer models are thought to be provided by 
transplantable, patient-derived cancer tissue xenograft (PDX) lines based on 
the grafting of fresh cancer tissue specimens subcutaneously, orthotopically or 
under the kidney capsules of immunodeficient mice (Choi 2014). In one such 
model by Strauss et al (Strauss 2011), solid ovarian tumour was incubated in 
collagenase/dispase and trypsin before implantation into mammary fat pads of 
immunodeficient mice. Once growth was established, xenograft tumours were 
excised and cells cultured as monolayers. This method is time consuming, 
costly and technically difficult and although this method may preserve the 
tumour microenvironment, cultivation in mice at a different anatomical location 
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may not accurately represent original ovarian tumour behaviour. We aimed to 
develop a method for the culture of solid tumour, which would allow functional 
testing to be expanded from HGSC ovarian cancer to the other histological 
subtypes.  
Gene expression studies have indicated different biological profiles in the 
cancer cells derived from ascites and solid tumour from the same patient in 
terms of metastasis, invasion and angiogenesis(Le Page 2006). 
Several methods have also been described to enrich the epithelial cell 
populations without fibroblast contamination. This includes the use of serum 
free media devoid of calcium and growth factors needed for fibroblast growth 
(Hammond 1984); filters with a pore size to separate cellular components; 
special collagen or extra-cellular matrix (ECM) coated plates and flasks 
(Crickard 1983); frequent passaging to eliminate fibroblast growth; use of flow-
cytometry to segregate cell populations (Chan 2007); and magnetic bead 
separation of cells tagged to specific binding antibodies.  
 
5.2. Aims 
 Explore the feasibility of culturing ovarian cancer solid tumour from various 
metastatic sites within the abdomen.  
 Explore spatial intra-tumoural heterogeneity (ITH) within an individual’s 
cancer by characterising PCO subcultures in terms of antigen expression, 
growth potential, morphology, with functional HR status and sensitivity to 
PARP inhibitors and platinum.  
 Investigate intra-tumoural heterogeneity itself as a prognostic marker 
alongside other recognised prognostic markers (histological subtype and 
surgical cytoreduction).  
 Investigate temporal changes in HR status using longitudinally collected 
samples of ovarian cancer.  
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5.3. Methods 
5.3.1. Characterisation of Solid Tumours 
All solid subcultures were characterised in terms of morphology, 
immunofluorescent detection of antigen expression and HR function at passage 
1 as previously described, Section 4.3.1. All subcultures were assessed for 
growth and sensitivity to cisplatin and rucaparib using standard SRB growth 
inhibition assays, sections 3.5.2, 3.5.3.  
 
5.4. Results 
5.4.1. Culture Method Optimisation 
These studies were conducted with Laura Woodhouse, MRes 2012.            
Solid tumour culture methodology was optimised using solid tumour samples 
from six HGSC patients. Single 1 cm3 samples were obtained from the ovarian 
tumour and, with each sample, one variable was altered to allow measurable 
protocol optimisation, Table 5.4 - 1. This was assessed by satisfactory epithelial 
cell growth and confirmed by examination of morphology and cytokeratin 
staining. 
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Method Variable Results 
Sample dissection Whole No culture from undiced tumour 
Diced (3M) Small explant cultures from small solid 
tumour pieces 
Dissociation from 
connective tissue 
Trypsin (0.25%) 
30 minutes 
1 hour  
Minimal dissociation of tumour and poor 
culture/ high cell death 
No culture  
Collagenase/Dispase 
20 hours 
2 hours 
Poor culture/ high cell death 
More rapid formation of explant 
transforming into monolayer cultures from 
small diced tumour pieces 
Selective seeding to 
exclude fibroblast 
No selective seeding Mixed morphology within culture with rapid 
overgrowth of fibroblasts within 24 hours   
Agitation to prevent any 
seeding for 24 hours*   
No culture 
24 hour selective fibroblast 
seeding~  
All cell types seeded in first flask with 
overgrowth of fibroblasts within 24 hours 
30 minute fibroblast seeding~ Optimal separation of fibroblast and 
epithelial monolayer cultures 
Table 5.4 -  1: Optimisation of Solid Culture Methodology. Dissociation: solid tumour 
sample was incubated with trypsin or collagenase/dispase for variable times on a 
rocker, as indicated. Dissociated cells alongside residual solid pieces were collected by 
centrifugation before PBS washing and plating in culture flasks. Selective fibroblast 
seeding was incorporated under the assumption that fibroblasts would adhere faster to 
the hydrophilic surface of the first culture flask and leave an epithelial cell suspension 
for seeding in the second flask.  
 
To confirm exclusion of fibroblasts using selective seeding, excluded cells were 
grown to confluence and compared to the epithelial component of the same 
culture in terms of morphology and CK staining. Epithelial cells grow in a 
cobblestone monolayer whereas fibroblasts are typically bipolar or multipolar 
with an elongated shape and grow in a mesenchymal morphological pattern, 
Figure 5.4 -  1. 
The final solid tumour culture method, described in section 3.4.2, used diced 
tumour, which was dissociated from connective tissue by 2 hour incubation with 
collagenase/dispase. Selective seeding of the resulting cell suspension 
excluded fibroblasts before seeding the cell suspension in T75 flasks for further 
characterisation and use in further experiments.  
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A 
 
B 
 
C 
 
D 
 
Figure 5.4 -  1: Fibroblast exclusion using selective seeding. A/B: epithelial component; 
A: cobblestone monolayer; B: CK expression; C/D: fibroblast component, C: 
mesenchymal morphology; D: No CK expression. 
5.5. PCO Solid Culture Case Series 
5.5.1. Culture Success 
Of the 30 patients with malignant disease from whom solid tumour was 
sampled, successful culture was achieved in 25 (83%) patients. 3/5 of the 
patients with unsuccessful cultures had samples taken at the time of interval 
surgery when chemotherapy had been given in the preceding month. Lack of 
culture may therefore be a consequence of the cytotoxic effect of 
chemotherapy.  
From the 25 patients included, 98 individual samples were collected of which 68 
(69.4%) were successfully grown and used in further experiments. 14 (14.3%) 
cultures were lost to infection and a further 16 (16.3%) cultures had no growth 
or were classified as non-epithelial with suboptimal CK expression. Additionally, 
three cultures were attempted from patients with benign disease but no growth 
resulted.  
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5.5.2. Patient Demographics 
Demographics of the 25 patients from whom ascites and at least one sample of 
solid tumour tissue was taken are summarised in Table 5.5 - 1 and in detail in 
Appendix 7. Solid tumour was sampled from pelvic tumour only in 13 patients 
and from pelvic and intra-abdominal deposits in the remaining 12 patients. 
Demographic Median (range) / n (%) 
Patient age (years) 63 (43 - 83) 
FIGO Stage                              
Stage 2 
Stage 3 
Stage 4 
 
1 (4) 
19 (76) 
5 (20) 
Serum CA125 at presentation (U/l) 600 (57 - 9740) 
Histology 
High grade serous carcinoma 
Clear cell 
Endometrioid 
Other 
 
19 (76) 
(8) 
1 (4) 
3 (12) 
Surgery 
Primary 
IDS 
 
16 (64) 
9 (36)  
Surgical outcome 
Optimal/Complete 
Suboptimal 
 
22 
2 
Progression free survival (PFS) (months) 11 (3 - 26) 
Overall survival (OS) (months) 13 (4 - 36) 
 
Table 5.5 -  1: Solid tumour patient demographics. See Appendix 7 for detailed data for 
indivudual patients. . 
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5.5.3. Characterisation  
Morphology 
Within 24 hours of seeding, adherent cells could be visualised. Cultures initially 
retained cell-cell adhesions and displayed explant morphology before adopting the 
typical cobblestone monolayer seen with primary cultures,  
Figure 5.5 -  1. 
A 
 
B 
 
C 
 
D 
 
 
Figure 5.5 -  1: Solid PCO cultures. A: Solid tumour in culture; B: Explant; C/D: 
Development of cobblestone monolayer .   
 
Morphology of each solid subculture was recorded with 15/45 (33.3%) cultures 
classified as cobblestone, 29 (64.4%) as mesenchymal and 1 (2.2%) as having 
spindle morphology. There was no relationship between histological subtype 
and morphology and no significant difference seen in the proportion of cultures 
of each morphology within histological groups, Table 5.5 – 2, Figure 5.5 - 2.  
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Histology 
Cobblestone 
(n=15) 
Mesenchymal 
(n=29) 
Spindle 
(n=1) 
Chi
2
 
p 
 
HGSC 
Clear cell 
Endometrioid 
Other ovarian 
Non-ovarian 
 
12 
0 
2 
1 
0 
 
22 
4 
0 
2 
1 
 
0 
0 
0 
1 
0 
 
0.0863 
- 
- 
0.7556 
- 
 
Table 5.5 – 2: Solid tumour subculture morphological classification by histological 
subtype. 
 
Immunofluorescent Antigen Expression 
All subcultures were assessed in terms of expression of the six characterisation 
antigens, Chapter 3. Both inter- and intra-tumour heterogeneity was seen, with 
differences seen between cultures from the same histological subgroup. 
Heterogeneity was also seen between cultures taken from different anatomical 
sites from the same patient, Figure 5.5 - 3. The majority of the cultures showed 
expression of epithelial as well as mesenchymal markers. Vimentin expression 
was universal throughout all subcultures, Figure 5.5 -  2. There was no 
relationship between histology and antigen expression.  
 
Figure 5.5 -  2: Summary of Characterisation Antigen Detection. All subcultures from 25 
patients are combined and antigen status expressed as a % of cultures tested. All 
cultures used in further experiments were diffusely CK positive. Only 30% of cultures 
showed expression of EpCAM and MOC31, which may reflect loss of antigen during 
passage, section 4.7.5. All cultures were diffusely positive for Vimentin, which 
paralleled ascitic cultures.  
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Figure 5.5 -  3: PCO 179. Solid tumour biopsies taken from five intra-abdominal sites 
cultured, alongside ascites culture (A). (B) Intra-tumoural heterogeneity of antigen 
detection of EpCAM and CA125 using immunofluorescent microscopy. (C) Variable 
proliferation following 10-day exposure to rucaparib, assess using SRB assay.  
  
 155 
 
Heterogeneity of expression was seen universally amongst all antigen groups 
(epithelial, mesenchymal and ovarian). This heterogeneity was not reflected in 
the histological classification of the tumours, with only 2/16 (12.5%) patients 
with heterogeneous antigen expression being classified as having mixed 
histological subtypes on formal pathology. Inter- and intra-tumoural 
heterogeneity exists for each of the characterisation antigens tested. For future 
studies, use of the ImageStream characterisation protocol, see Chapter 7, to 
numerically quantify antigen expression may give a more robust analysis of 
heterogeneity. 
5.5.4. Growth  
Once each culture was seen to have established into an adherent monolayer, a 
standard SRB growth assay was performed to determine doubling time (DT), 
Chapter 3 Methods. The median DT for all cultures (ascitic and solid tumour 
cultures combined) was 126 hours, range 55 – 303. The DT for solid cultures 
(120 hours, 82 – 279) was faster than for ascitic cultures (159 hours, 55 - 303, p 
= 0.0142). All solid tumour and ascites samples were obtained from the patient 
at the same time, with no differences in culture preparation or handling, and 
therefore the differences observed can be assumed to reflect differences in the 
subpopulations themselves. Inter- and intra-tumour DTs were highly variable. 
When comparing all subcultures from each PCO patient, there was no 
significant difference in growth between patients (ANOVA, p = 0.1425) but there 
was a significant difference between the SD of each group of subcultures 
(Brown-Forsythe, p = 0.0098), indicating that intra-tumour heterogeneity was 
greater than inter-tumour heterogeneity in terms of growth, Figure 5.5 -  4. 
There was no correlation between ascites doubling time and solid tumour 
subculture doubling time, r2 = 0.007 (95% CI -0.26 – 0.41), p=0.6361. All 
cultures underwent assessment of HR functional status, see section 3.6. There 
was no difference between the median DT of HRC (126 hours, range 55 - 303) 
and HRD tumours (128 hours, 81 - 233), p = 0.2543, Figure 5.5 -  5. 
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Figure 5.5 -  4: PCO Subculture Doubling Time  
The doubling times (hours) for each ascites sample (x axis) is plotted against the 
doubling time of each of the solid subcultures (y axis). Where there is more than one 
solid tumour subculture per PCO patient, subcultures are shown in the same colour.  
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Figure 5.5 -  5: Growth Comparison. A: HRC vs HRD; B: Ascites vs solid cultures 
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5.5.5. Functional HR Status  
When considered individually, 32/68 (47.1%) ascitic and solid subcultures 
tested were HRC and 36 (52.9%) were HRD, Table 5.5 - 3. HR function was 
homogeneous in all subcultures from an individual patient in 13/25 PCOs. Of 
these homogeneous PCOs, 5 were universally HRD and 8 universally HRC.   
 
When considering a single biopsy from the ovary only and comparing the HR 
function of this culture to that of the paired ascitic culture, concordance was 
seen in 19/25 (76%) cases. This decreased to 3/12 (25%) when sampling was 
from two or more spatially distinct areas of solid tumour. Sampling a single solid 
area, even in conjunction with ascites, will therefore miss ITH in approximately 
51% of cases.   
 
  
 158 
 
PCO 
Sample 
location 
HR 
status 
Heterogeneous 
/ Homogeneous 
Rucaparib (µM) Cisplatin (µM) 
% 
survival 
at 100 μM 
GI50 
 
% 
survival 
at 10 μM 
GI50 
 
155 Ascites HRD Homogeneous 21.5 0.1   
Ovary HRD     
156 Ascites HRD Homogeneous 33.7 11.1 34.8 1.9 
Ovary HRD     
157 Ascites HRC Homogeneous 99.6 >100   
Ovary HRC     
158 Ascites HRD Homogeneous 38.3 13.4   
Ovary HRD     
162 Ascites HRC Homogeneous 33.6 3.3   
Ovary HRC     
163 Ascites HRC Heterogeneous 30.2 40.3   
Omentum HRC     
Uterus HRD     
167 Ascites HRC Heterogeneous 76.3 >100 36.6 4.6 
Ovary HRD     
168 Ascites HRC Homogeneous 46.7 >100 71.1 >10 
Ovary HRC     
174 Ascites HRC Heterogeneous 58.6 >100 75.6 >10 
Left ovary HRC 62.2 >100 72.7 >10 
Right ovary HRD 38.0 15.4 32.9 2.3 
175 Ascites HRC Heterogeneous 45.0 45.5 53.8 >10 
Left ovary HRD 36.4 40.5 37.3 1.5 
Right ovary HRD 62.2 >100 50.6 6.7 
179 Ascites HRD Heterogeneous 42.1 14.6 61.7 >10 
Left ovary  HRD 18.5 11.2 27.2 1.7 
Omentum HRD 16.4 7.4 32.3 6.3 
Right ovarian 
deposit  
HRD 
76.6 >100 47.5 4.5 
Right ovary HRC 97.0 >100 29.5 3.1 
Right tube HRD 15.6 5.8 23.4 2.4 
180 Ascites HRC Homogeneous >100 >100 >100 >10 
Left ovary  HRC 63.6 >100 67.2 >10 
Right ovary HRC 86.9 >100 >100 >10 
181 Ascites HRC Homogeneous 71.3 >100 79.1 >10 
Ovary HRC 81.8 >100 91.5 >10 
183 Ascites HRD Homogeneous 33.7 10.9 41.0 >10 
Ovary HRD 52.0 >100 42.7 7.8 
184 Ascites HRC Heterogeneous 25.8 60.3 60.2 >10 
Ovary HRD 13.1 8.1 49.4 >10 
185 Ascites HRC Heterogeneous   86.4 >10 
Left tube  HRD 30.2 0.2 34.5 5.9 
Right tube HRD 24.4 28.8 25.2 5.2 
Omentum HRC 36.7 6.6 57.9 >10 
186 Ascites HRC Homogeneous   79.1 >10 
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Omentum 1  HRC 66.9 >100 68.9 >10 
Omentum 2 HRC 76.2 >100 72.5 >10 
Pelvic 
peritoneum 
HRC 
74.2 
>100 69.9 >10 
192 Ascites HRC Heterogeneous >100 >100 98.0 >10 
Ovary HRD 35.7 3.0 33.6 1.8 
Omentum HRD 36.2 1.7 54.1 2.9 
200 Ascites HRC Heterogeneous 34.5 0.4 46.2 1.4 
Ovary HRD 46.6 4.6 44.8 6.7 
Omentum HRC >100 >100 >100 >10 
201 Ascites HRC Heterogeneous 63.1 >100 96.7 >10 
Ovary HRC 25.7 23.2 96.7 >10 
209 Ascites HRC Homogeneous 55.3 >100 76.7 >10 
Ovary HRC 54.9 >100 75.3 >10 
217 Ascites HRD Heterogeneous 36.2 47.1 32.4 0.9 
Ovary HRC 57.1 >100 65.9 >10 
223 Ascites HRD Heterogeneous 37.1 1.3 67.5 >10 
Left ovary  HRD 33.9 11.5 18.5 1.4 
Left tube HRD 35.4 26.6 32.3 4.4 
Omentum HRC 59.3 >100 76.6 >10 
226 Ascites HRD Homogeneous 42.1 14.6 31.9 2.3 
Ovary  HRD 25.0 0.5 23.4 2.4 
Omentum HRD 20.1 0.2 18.5 1.4 
Bowel 
mesentery  
HRD 16.6 0.1 15.6 0.9 
228 Ascites HRD Heterogeneous 33.7 10.9 27.3 2.8 
Left ovary  HRD 16.3 5.1 64.3 >10 
Right ovary HRD 40.1 35.0 34.0 2.8 
Omentum HRC 43.9 26.4 48.8 3.4 
 
Table 5.5 – 3: PCO solid tumour samples with HR status and corresponding 
sensitivities to rucaparib and cisplatin, determined using SRB cell proliferation assay. 
Briefly PCO subcultures from ascites and solid tumour were seeded at density at 1000 
cells/well with six replicates per condition and exposed to increasing concentrations of 
rucaparib or cisplatin for 10 days, corrected fro 1% DMSO.After fixation, bound cellular 
protien wasstained using 0.4% SRB and quanitifed by spectrophotometry.  
 
5.5.6. Sensitivity to Cisplatin and Rucaparib 
Sensitivity to cisplatin and rucaparib was assessed for 59/68 subcultures using 
a standard SRB proliferation assay, Chapter 3 Methods, Table 5.5 - 3. There 
was 84.7% concordance between HR status and rucaparib sensitivity and 
75.5% concordance between HR status and platinum sensitivity between 
cultures. When subcultures are grouped together according to HR function, 
HRD cultures were sensitive to both cisplatin and rucaparib with mean GI50 of 
4.02 µM (CI 3.2 - 5.1) and 9.73 µM (CI 6.7 - 15.9) respectively, compared to 
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HRC cultures with mean GI50 of >10 µM and >100 µM, (p < 0.0001), Figure 5.5 
-  6, Table 5.5 - 3.  
A 
  
B  
 
Figure 5.5 -  6: Growth Inhibition  
A routine SRB assay was used to determine cytotoxicity to rucaparib and cisplatin 
stratified by HR function. A total of 59 subcultures were generated and treated with (A) 
rucaparib or (B) cisplatin. Those cultures deemed HR defective had greater sensitivity 
to both agents (p <0.0001). 
 
5.6. Heterogeneity as a Prognostic Marker 
Of the 25 patients from whom solid tumour was sampled, 13 patients were 
found to have homogenous HR status in all subcultures (ascites and solid) 
tested. The remaining 12 demonstrated discordance in at least one subculture 
and therefore classified as heterogeneous.  
The median PFS of homogenous cultures was 11 (3 - 19) months in 
comparison to 14 (6 - 26) months for patients with heterogeneous subcultures, 
(p = 0.0504), Figure 5.6 -  1, Table 5.6 - 1. Median OS for the heterogeneous 
patients was 272.5 (7 - 1117) months compared to 13 (4 - 36) months for the 
homogeneous patients. There were no statistically significant differences in 
event free survival between the heterogeneous and homogenous groups in 
survival at 6 months, 1 year or 2 years, Table 5.6 – 1,  p = 0.0801 at 1 year.  
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Median PFS 
(months) 
Median OS 
(months) 
Event free survival n(%) 
6 months 1 year 2 years 
Heterogeneous  
(n=12) 
14    (6 - 26) 272.5 (7 - 1117) 11 (91.7) 3 (25.0) 0 (0) 
Homogeneous 
(n=13)  
Homogeneous HRD 
Homogeneous HRC 
11 (3 - 19)  
 
10 (3 - 19)  
11 (6 - 18) 
13 (4 - 36)  
 
13 (4 - 21)  
36 (9 - 36) 
10 (76.9) 
 
4 (30.7) 
6 (46.2) 
5 (38.5) 
 
3 (23.1) 
2 (15.4) 
2 (15.4) 
 
1 (7.7) 
1 (7.7) 
 
Table 5.6 - 1: Intra-tumoural heterogeneity of HR status and survival (PFS and OS). 
Each PCO was classified as heterogeneous if subcultures from the donor patient 
varied in their HR functional status and homogeneous if all subcutlures from the same 
donor PCO patient were concordant.  
 
A 
 
B 
 
Figure 5.6 -  1: Kaplan Meier: heterogeneous HR cultures vs homogeneous HR 
cultures.  
 
The differences seen between the heterogeneous and homogeneous are not 
due to differences in surgical outcome with no significant differences between 
the proportions of patients with complete, optimal or suboptimal cytoreduction in 
the two functional groupings, Figure 5.6 -  2. 
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Figure 5.6 -  2: Cytoreductive surgical outcome by homogenous and heterogeneous 
functional groupings. There was no statistical relationship between heterogeneity and 
surgical cytoreductive outcome with no statistical difference between the proportion of 
patients with heterogeneous or homogeneous tumours within each group.  
 
 
Heterogeneity of HR function may itself be a prognostic marker but this should 
be considered alongside other recognised prognostic markers. Future clinical 
trials should be designed and analysed with this in mind, taking into account HR 
as ascites, histology and surgical cytoreductive success alongside patient 
factors.  
Further exploration of prognostic markers, see Table 5.6 – 2, reveals greater 
complexity. PCO patients are ordered by progression free survival, 
heterogeneity and HR function. There is no clear grouping to reveal a single 
prognostic marker and this suggests that many factors should be taken into 
account to predict prognosis, perhaps including heterogeniety, HR function, 
histological subtype and cytoreductive surgical outcome. 
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PCO 
Age 
(yrs) 
CA1
25 
(U/L) 
Histological 
subtype 
FIGO 
Stag
e 
Surgery 
NACT 
Post-op 
chemotherapy 
PFS OS 
Homogeneous/ 
Heterogeneous 
HRC /  
HRD 
Primary / 
IDS 
Debulking 
outcome 
(months) 
192 66 2425 Clear cell 3C Primary Optimal NA 3 carbotaxol 4 7 Heterogeneous   
181 72 176 HGSC 3C IDS Optimal  3 carbotaxol 3 carbotaxol 5 7 Homogeneous HRC 
175 66 250 Clear cell 3B Primary Optimal NA 5 carbotaxol 5 8 Heterogeneous   
156 49 1320 HGSC 4 IDS Optimal 4 carbotaxol 1 carbotaxol 5 8 Homogeneous HRD 
200 59 602 HGSC 3C IDS Optimal 4 carbotaxol 2 carbotaxol >6 >6 Heterogeneous   
223 43 2074 HGSC 3C Primary Optimal NA 3 carbotaxol >6 >6 Heterogeneous   
228 59 2349 HGSC 4 Primary Optimal NA 6 carbotaxol >6 >6 Heterogeneous   
226 83 1964 Low grade serous 3C Primary Optimal NA Tamoxifen >6 >6 Homogeneous HRD 
167 63 600 Neuroendocrine 3C Primary Optimal NA Cisplatin, etoposide 6 >7 Heterogeneous   
209 52 419 HGSC 3C IDS* Optimal 4 carbotaxol 2 carbotaxol >7 >7 Homogeneous HRC 
217 81 2738 HGSC 3C No surgery 3 carbotaxol 6 carbotaxol >7 >7 Heterogeneous   
180 50 521 HGSC 3C IDS Optimal 3 carbotaxol 3 carbotaxol 8 >9 Homogeneous HRC 
179 66 57 HGSC 4 IDS Optimal 4 carbotaxol 2 carbotaxol 8 >14 Heterogeneous   
185 58 500 HGSC 4 IDS Complete 4 carbotaxol 2 carbotaxol >9 >9 Heterogeneous   
186 47 74 HGSC 3C Primary Complete NA 6 carbotaxol >9 >9 Homogeneous HRC 
157 58 500 HGSC 3C Primary Suboptimal NA 6 carbotaxol, tamoxifen 10 12 Homogeneous HRC 
201 55 678 HGSC 3C Primary** Optimal NA 
6 carbotaxol, tamoxifen, 
rucaparib 
11 36 
Heterogeneous   
183 82 6388 HGSC 2C Primary Complete NA 4 carboplatin >13 >13 Homogeneous HRD 
163 77 500 HGSC 3C Primary Optimal NA 5 carbotaxol 13 >20 Heterogeneous   
168 66 1500 HGSC 3C Primary Complete NA 6 carbotaxol 14 >15 Homogeneous HRC 
155 55 117 Adenocarcinoma  3C Primary Optimal NA FOLFOX 15 18 Homogeneous HRD 
174 45 552 Endometrioid 3A Primary Complete NA 
6 carboplatin, 2 
paclitaxol, 4 docetaxol 
>16 >16 
Heterogeneous   
184 73 9740 HGSC 4 IDS Suboptimal 4 carbotaxol 2 carbotaxol >16 >16 Heterogeneous   
162 68 186 HGSC 3C Primary Optimal NA 6 carbotaxol >21 >21 Homogeneous HRC 
158 68 780 HGSC 3C Primary Optimal NA 6 carboplatin >22 >22 Homogeneous HRD 
Table 5.6 - 3: PCO patient demograpghics with heterogeneity of HR function ordered by progression free and overall survival.   
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5.7. HR of Ascites as a Prognostic Marker  
Sampling multiple areas of tumour in every patient may not be feasible 
routinely. By hypothesising that cells from all intra-peritoneal areas are released 
into ascites, we can hypothesise that, collectively, ascitic cells are 
representative of the entire tumour and therefore functional status of ascitic 
cultures should correlate with clinical response to therapy and overall outcome.  
Stratifying patients into HRC and HRD groups reveals separation of the PFS 
survival curves at 30 months, Figure 5.7 -  1. The median PFS for HRD tumours 
was 12 months compared to 11 months in the HRC group, (log-rank, p = 
0.0750). This disease- free benefit is lost with continued follow-up with no 
significant difference in overall PFS or OS. This may be a reflection of the 
changing biological function of the tumour with time with possible emergence of 
resistance in HRD to HRC followed by overgrowth of a new HRC population or 
growth of a pre-existing HRC population already present in a heterogeneous 
tumour.  
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C 
  
Figure 5.7 -  1: Kaplan-Meier survival curves for PFS/OS by HR status (A), histological subtype (B)and outcome of cytoreductive surgery (C)  
A, Overall median PFS in the HRD and HRC groups being (12 vs. 11 months, log-rank, p = 0.1545). Median OS was 21 months in HRD group 
compared with 23 months in HRC group (log-rank, p = 0.7879). 
B. Median PFS was 11 months in HGSC, 32 in mucinous disease, 9 in clear cell, 55 for endometrioid cancer and 6 months for mixed tumours (p = 
0.0128). OS was 23 (HGSC), 30.5 (Mucinous), 13 (clear cell), 60 (endometrioid) and 10 for mixed tumours (p = 0.0668). When grouped into HGSC 
(n=79) and non-HGSC (n=23), HGSC had a median survival of 11 months compared to 10 months for non-HGSC (p = 0.0781).The OS for HGSC was 
23 months compared to 19 months for non-HGSC (p = 0.4426).   
C. Stratifying patients into surgical outcome (complete, optimal or suboptimal cytoreduction) shows median PFS of 26, 10, 11 months respectively (p 
= 0.0011), OS was 38, 15 and 15 months (p = 0.0024).
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5.8. Histology as a Prognostic Marker 
Combining data from all PCO ascitic cultures with HR status (n=109) collected 
from 2007 – 2011 (Mukhopadhyay 2010) with that in this thesis (2011 – 2014), 
demonstrates the relative incidence of HRC and HRD tumours within each 
histological subtype, Figure 5.7 -  1, Table 5.8 - 1. No relationship can be seen 
between histological subtype and HR status, with approximately 50% of each 
subtype being HRC. Although differences can be seen between the PFS and 
OS of patients subdivided according to histological subtype, numbers within 
some of the less common subtypes are small. Histological subtype may be a 
contributory factor to PFS due to the different stages of presentation and the 
cytoreductive rate achieved with surgery.  
Histological Subtype 
HR Competent 
n (%) 
HR Defective 
n (%) 
Chi
2
 
P 
HGSC n = 81 43 (53.1) 38 (46.9) 0.5485  . 
Mucinous n = 4 2 (50.0) 2 (50.0) - 
Clear cell n = 2 2 (100) 0 (0) - 
Endometrioid n = 4 2 (50.0) 2 (50.0) - 
Mixed n = 11 7 (63.6) 4 (36.4) 0.0051  * 
Other n = 7 4 (57.1) 3 (42.9) 0.1615  . 
 
Table 5.8 – 1:  Incidence of HRC and HRD by Histological Subtype. HR status was 
determined by quantification of nuclear Rad51 foci following induction of DNA DSB with 
2 Gy irradiation and incubation with 10 μM rucaparib. HRC was defined as more than a 
2 fold increase in Rad51 foci formation, in comparison to untreated controls.  
5.9. Surgical Cytoreduction as a Prognostic Marker 
Patients underwent primary cytoreductive surgery or NACT followed by interval 
surgery (IDS). All surgeries were carried out at NGOC by accredited 
Gynaecologic Oncology consultants. Complete or optimal cytoreduction 
(residual disease of less than 1 cm in its largest diameter) has been shown to 
be the best predictor of PFS and OS (Gadducci 2005, Wimberger, Lehmann et 
al. 2007). This data shows significant differences in PFS and OS in patients with 
complete/optimal cytoreduction at the time of initial surgery. There was an 
excess of HRC in both the completely cytoreduced and the suboptimally 
cytoreduced groups and therefore it is unlikely that HR status affects 
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cytoreduction or is responsible for the improved survival in the complete/optimal 
cytoreduced groups, Table 5.9 - 1.  
 
HRC 
n (%) 
HRD 
n (%) 
Chi
2
 
p 
Complete 14 (60.9) 9 (39.1) 0.0278  * 
Optimal 34 (54.0) 29 (46.0) 0.4237  . 
Suboptimal 8 (61.5) 5 (38.5) 0.0161  * 
 
Table 5.9 – 1: The Distribution of Cytoreductive Surgical Outcome within the 
Homogeneous and Heterogeneous Tumour Groups. Complete cytoreduction is defined 
as no visible macroscopic tumour at the end of the procedure, optimal as visible 
disease <1cm in greatest diameter and suboptimal cytoreduction as >1cm residual 
disease. 
 
5.10. Longitudinal Sequential Samples 
The majority of patients with ovarian cancer recur despite optimal surgery and 
aggressive chemotherapy. It is unclear if intratumoural heterogeneity exists 
following chemotherapy. During the study period, five patients had samples 
collected at two time points, Figure 5.10 -  1. 
In this small mixed series, it can be seen that in one patient (PCO 177/222), the 
HR status of the PCO culture generated from her ascites preoperatively 
appears to have converted from HRC to HRD, following 2 lines of 
chemotherapy. In another patient (PCO 219/234), the PCO culture from ascites 
appears to have converted from HRD preoperatively to HRC after  4 cycles of 
carboplatin chemotherapy. These apparent changes in the HR status of ascites 
may be a result of sampling, inaccurate HR assays but may also reflect the 
heterogenous nature of the entire tumour volume with ‘shedding’ of different 
dominant populations into ascites at any one time.   
Recurrent disease may represent a regrowth of tumour, which is biologically 
identical to the original cancer or provision of chemotherapy may induce growth 
of new subpopulations, biologically distinct to the original tumour. In 
heterogeneous tumours, recurrence may represent overgrowth of 
subpopulations that are resistant to the chemotherapy given. Irrespective of the 
cellular origin of active disease at any one time point, it seems likely that the 
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growing populations of cells will continue to acquire new mutations that may 
accumulate to modify tumour behaviour and response to therapy. Therefore, it 
should not be presumed that a tumour, which was clinically responsive to first 
line chemotherapy at presentation, should remain responsive at the time of 
relapse and perhaps serial tumour sampling, with accurate molecular profiling at 
several time points throughout the course of a patients disease course, should 
be considered.  
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Figure 5.10 -  1: Longitudinal sampling 
  
 
Key 
 
A: HR functional status (Rad51 assay) from cultured ascites 
B: Graphical representation of volume of disease burdon based 
upon clinical status 
C: Surgical treatment 
D: Chemotherapy regimen 
E: Radiological assessment of disease status 
F: Biochemical measurement of serum CA125 (U/L) 
 
 
PCO 25: Presented with abdominal distension and ascites (ward 
paracentesis). NACT (3 carboplatin and 2 taxol). Repeat ascitic sample 
at IDS – optimal debulking. Post-op 3 carboplatin chemotherapy. 
Clinical recurrence (PFS 10 months), treated with 3 docetaxol.  OS 14 
months. 
A 
 
B 
 
 
C 
D 
E 
 
F 
B 
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PCO 169: Presented with abdominal distension and ascites (ward 
paracentesis). NACT (3 carboplatin and taxol). Repeat ascitic sample at 
IDS – optimal debulking. Post-operative 3 carboplatin and taxol. PFS 9 
months, OS 11 months.  
 
 
PCO 170: Presented with abdominal distension and ascites (ward 
paracentesis). NACT (4 carboplatin and taxol). Repeat ascitic sample 
at IDS –sub optimal debulking with more than 1 cm residual disease. 
Post-op 2 carboplatin and taxol chemotherapy. Bevacizumab 
(suboptimal debulk), given as 6 cycles then maintenance therapy. 
Climbing CA125 suggesting possible development of recurrent disease. 
OS 27 months. 
A 
 
B 
 
 
C 
D 
E 
 
F 
B 
A 
 
B 
 
 
C 
D 
E 
 
F 
B 
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PCO 177: BRCA 1 carrier. Presented with abdominal distension and 
ascites (ward paracentesis). NACT (4 carboplatin and taxol). IDS – 
optimal debulking. Post-op chemotherapy completed with 2 carboplatin 
and taxol. Clinical recurrence 6 months before re-challenging with 6 
further carboplatin. Ascites resampled at 23 months (9 months following 
diagnosis of recurrence) were HR defective. PFS 13 months, OS 23 
months.  
 
 
PCO 219: Presented with abdominal distension and weight loss (ward 
paracentesis). NACT (4 carboplatin). IDS – optimal debulking. HR 
function of ascitic culture changed from defective to competent. Post-op 
chemotherapy completed with 2 carboplatin and taxol. Clinical 
recurrence at 4 months treated with Tamoxifen. Alive and well at 13 
months. 
A 
 
B 
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A 
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5.11. Discussion 
5.12.1. Heterogeneity 
Inter-tumour Heterogeneity 
The classification of EOC into histological types is well established and we 
understand that the observed clinical differences among tumour subtypes are 
likely to reflect different underlying molecular mechanisms associated with a 
variety of genetic mutations. The differences seen in survival between the PCO 
patients with different histological subtypes are small. These differences are 
independent of HR function (with equal proportions of HRC and HRD within 
each subtype) and independent of cytoreductive surgery outcome (with equal 
proportions of optimal cytoreduction in each histological subgroup). Histological 
subtype may therefore be only a crude marker of some underlying biological 
differences that contribute to response to chemotherapy and overall prognosis.  
When assessed in isolation, there is not a statistically significant difference seen 
in PFS and OS in HRC and HRD groups. The separation of the PFS curves at 
about 30 months, following treatment between the two functional groups, does 
however suggest that HR function of ascitic cultures is important in reflecting 
tumour response to treatment in at least the short term, section 5.7. The initial 
survival benefit seen in patients with HRD tumours is however lost with time and 
it may be over ambitious to expect a single measure of the tumour, taken at a 
single time point to predict overall outcome. We understand that the 
management of recurrent disease is highly variable and only some patients may 
go on to receive secondary and tertiary treatments for recurrent disease with 
variable cytotoxic agents and or surgical strategies used. Additionally, as time 
goes on, the biology of the tumour may change. None of these factors were 
taken into account during the simplistic analysis of the data shown in this 
chapter.  
In reality, it is likely that there are several prognostic markers as well as 
biomarkers of disease response and it may be needed in future clinical practice 
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to develop an algorithm to combine these markers in order to guide clinical 
practice accurately. The understanding of intra-tumoural heterogeneity further 
complicates our ability to accurately combine biomarkers with response to 
cytotoxic agents.  
Intra-tumour Heterogeneity 
In this study, we provide evidence that a large proportion of ovarian cancer 
patients have heterogeneous tumours in terms of antigen expression, cellular 
growth and HR function, with 12/25 (48%) tumours demonstrating heterogeneity 
in HR status when two or more samples are taken. This may in fact be an 
underestimation of intra-tumoural heterogeneity and increased sampling may 
reveal a higher proportion of heterogeneity in future studies. Functional intra-
tumoural heterogeneity was not predictable by assessment of morphology, 
antigen expression or growth, reinforcing the importance of a novel functional 
assay to characterise tumour deposits. Antigen expression may just be a 
marker of the particular site of disease sampled and have no relevance to the 
underlying biology. The correlation of DNA damage repair status and correlation 
with cytotoxic sensitivity seen in this study is important as it not only 
demonstrates the clinical relevance of the approach of functional analysis, 
section 5.5.6, but also suggests that heterogeneity may have clinical relevance.  
The new appreciation of intra-tumoural heterogeneity of HR pathway function 
may help to explain some of the results in this project, for instance discordance 
between expression of CA125 using IHC in FFPE tissue and CA125 expression 
on cultures assessed by IF. It may also explain why some patients with HRD 
ascitic cultures have short PFS and OS despite optimal cytoreduction (with 
possible residual microscopic HRC disease). However, it may also mean that 
the HR result from ascites is not representative of the entire tumour and that a 
more complex analysis may be required in order to assess the overall impact of 
HR function in the clinical setting.     
 175 
 
The apparent changes in the HR function in ascitic cultures obtained  from the 
same patient at different time intervals in their treatment may be a reflection of 
the changing biology of the tumour with time or may reflect shedding of different 
cell subpopulations into ascites at different times, depending upon the 
predominant proliferating area of tumour. The HR function of ascitic culture from 
PCO 219 appears to have changed from HRD to HRC in just four months, 
which is unlikely (but not impossible) to be sufficient time for genomic changes 
to result in a change in a whole pathway. A more likely explanation is sampling 
of a different subpopulation. The variable growth and regression of different 
areas of tumours simultaneously is widely appreciated and often causes 
difficulties in clinical practice in judging if tumours have responded or 
progressed over time with chemotherapy treatment. The fact that PCO 177 
(section 5.11) expectantly changed from HRC to HRD over 23 months may 
therefore not necessarily reflect a series of revertant mutations resulting in a 
change in HR function but instead may reflect overgrowth and shedding of cells 
from a new area of tumour, which was previously small or dormant. Given that 
dysfunction of DNA damage repair pathways are also key driver events (Curtin 
2012), it is perhaps unsurprising to see variable DNA repair status in different 
areas of the same tumour representing these different, early divergent clones, 
Figure 5.12 -  1.  
 
Figure 5.12 -  1: Tumour Evolution and Intra-tumour Heterogeneity 
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Despite clear differences in response to cisplatin and rucaparib ex vivo between 
the HRD and HRC groups (section 4.13), this did not translate to differences in 
PFS and OS. The impact of ITH upon PFS and OS is difficult to interpret in this 
small cohort and is additionally complicated by the many variable clinical factors, 
many of which have not been taken into account during this analysis. These 
data suggest that that tumours demonstrating heterogeneity at presentation are 
more likely to respond to treatment resulting in better PFS and OS. This was 
unexpected as it was hypothesised that ITH would lead to a greater chance of 
selecting a drug-resistant sub-population or the genomic instability it reflects 
would have a greater likelihood of acquiring mutations associated with 
resistance/progression. Interestingly the homogeneous HRD group had the 
worst outcome, which but it is unclear if this is a consequence of the small 
sample size or a true reflection of underlying biology. Further investigation in a 
larger cohort is essential. 
ITH may therefore reflect underlying tumour genomic instability. Homogenous 
tumour may have acquired driver mutations at an early stage in tumour 
evolution and is therefore more genetically stable, resulting in less response to 
chemotherapy. In the series of 14 patients, with 135 samples by Schwarz et al 
greater heterogeneity in terms of genomic clonal expansion correlated with 
poorer PFS and OS (Schwarz 2015). This cohort of patients was however 
clinically not comparable to the dataset in this series, with 99% of patients being 
treated with NACT and almost all samples taken at IDS following chemotherapy. 
Comparisons to the disease’s molecular profile at presentation were based 
upon a single diagnostic biopsy and did not take into account spatial intra-
tumour al heterogeneity that existed before treatment commenced. 
We have previously demonstrated a very strong correlation between HR status 
and ex vivo sensitivity to the PARP inhibitor rucaparib, using cells cultured from 
just one compartment, namely ascites (Mukhopadhyay 2010), with responses 
seen in approximately 50% of cases (Mukhopadhyay 2012). However, in clinical 
practice, response rates in non-germline BRCA 1 and 2 patients are only 24% 
(Gelmon 2011). This may be a result of underlying heterogeneity at 
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presentation and subsequent clonal selection pressure as a result of initial 
chemotherapy. 
The demonstration in this study that the results of predictive biomarkers will be 
affected by intra tumour heterogeneity has ramifications for future translational 
research and biomarker directed therapy. There are several hypotheses that 
must be considered. The functional status of the ascitic culture may be a 
reflection of the status of the bulk of the tumour from which tumour cells are 
shed into the abdominal cavity. Following surgery, the patient’s response to 
subsequent chemotherapy may be more likely to be dependent upon the 
functional status of the subpopulations of tumour, which has not been excised 
rather than that of the bulk of the tumour, which has been excised. If the 
functional status of the residual tumour is different from that of the excised 
tumour, then the biomarker may be falsely rejected as inaccurate when, in fact, 
this is a reflection of sampling error. It is therefore crucial that future studies 
include multiple biopsies to allow assessment of ITH and that protocols that 
require sequential biopsies, taken before and after treatment, attempt to collect 
these biopsies from the same tumour site to minimise the risk of selecting non-
paired clones. 
Further work is required to extend this work. In particular, multi-site longitudinal 
tissue sampling, integrating functional, genomic and clinical data, has the 
potential to reveal the composition of subclones and track tumour evolution to 
address the true effect of heterogeneity upon response to therapy and to begin 
to define the breadth of genetic diversity. Correlation of molecular heterogeneity 
with disease location (intra peritoneal versus extra peritoneal) would additionally 
provide insight into the biology of the metastatic process in ovarian cancer and 
such studies may provide further evidence for drug-resistance mechanisms 
informing combinatorial, adaptive, and tumour immune therapies placed within 
the context of tumour evolution..  
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5.12.2. Other Factors Which May Impact Upon Survival 
The one factor, which is repeatedly reported in the literature and also found in 
this case series as predictive of outcome is the success of cytoreductive 
surgery. Complete > optimal > suboptimal cytoreduction has been shown in this 
data set to be predictive of greater PFS and OS, which is independent of HR 
function and histological subtype, section 5.7, 5.8, 5.9.  
In vitro sensitivity to cytotoxic agents provides an indication of tumour sensitivity 
but even culturing primary patient samples has limitations and may therefore 
not be entirely predictive of overall clinical response. The process of culture 
may select out certain subpopulations and the limited life span of primary 
cultures and slow growth seen suggests that vital environmental support may 
be lacking. Future work may explore alternative methodologies to incorporate 
growth of the tumour’s stroma in an attempt to prolong culture lifespan.  
The ability of ex vivo culture sensitivity to cisplatin to predict clinical sensitivity 
was described in Chapter 4 and the AUC (ROC curve) of 0.5530 (95% CI 
0.3998 – 0.7062) demonstrated poor test accuracy, Figure 4.13 – 7. The 
inability of in vitro cisplatin sensitivity alone to accurately predict clinical 
response may in part be a reflection of the variation in surgical management. 
Unexpected prolonged PFS was seen in women with HRC tumours with in vitro 
resistance to cisplatin and this may be a reflection of the high rate of 
optimal/complete surgical debulking in this cohort. Complete or optimal 
cytoreduction (residual disease of less than 1 cm in its largest diameter) 
remains the best predictor of PFS and OS, Figure 5.7 - 1. It is likely however, 
that overlooking intra-tumoural heterogeneity by sampling and testing only one 
area of tumour may significantly distort our interpretation of response to 
cytotoxic agents when tested clinically.  
  
 179 
 
5.12.3. Evidence of the Fallopian Tube as the Origin of Ovarian 
Cancer 
There is substantial evidence to indicate that HGSC actually arises from the 
fallopian tube. Within this case series of solid tumour culture, four cultures were 
successfully created from macroscopically normal tubes. Although numbers are 
small and therefore no firm conclusions should be drawn, this, alongside the 
concordance in expression of antigens between the tube and ascitic cultures, 
suggests that the tube is the likely site of origin. Interestingly, one of the tube 
cultures was found to be HRD potentially raising the possibility that HRD is an 
early event in carcinogenesis (providing the genomic instability that is an 
enabling characteristic of cancer) and these cells were pre-malignant. This 
possibility warrants further investigation in BRCA carriers undergoing 
prophylactic surgery to remove ovaries and fallopian tubes. Tumour cells may 
originate in the tube but are quickly shed into the peritoneal cavity, either 
depositing on the ovary resulting in formation of an ovarian mass or depositing 
on other peritoneal surfaces creating ascites. The inability of cells to seed in the 
fallopian tube may be a result of the unique, and not yet understood, functional 
ability of the tube epithelium. Comparisons between the antigen expression and 
functional HR status of each subculture can, in some circumstances, be 
suggestive of the mode of spread and evolution of the tumour, Figure 5.12 -  1.  
5.12.4. The Tumour Microenvironment 
In contrast to the prolonged and resilient growth of ovarian cancer in vivo, the 
life span of ex vivo cultures is typically short suggesting that there is something 
uniquely present within the tumour microenvironment required for growth.  
It is now known that tumours are complex ‘organs’ consisting of malignant and 
many non-malignant cell types including cancer associated fibroblasts (CAFs), 
tumour associated macrophages (TAMs) and vasculature endothelial cells; all 
of  which contribute to tumour cell survival, proliferation, angiogenesis, 
metastasis and drug resistance (Rebucci 2013).  It is likely that there is a bi-
directional interaction between the cancer cells and stroma and there is 
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significant evidence supporting the role of peri-tumoural tissues in tumour 
maintenance and the role of the stroma in the acquisition of resistance  (Orimo 
2006, Patocs 2007). It is also becoming increasingly apparent that the stroma 
can modify the aggressiveness of tumour cells and that tumour cells re-program 
the stroma to generate a nurturing environment that is crucial for tumour 
survival, progression and metastasis (Schauer 2011). This may in fact be an 
explanation for the poor PFS/OS seen in some patients with HRD cultures. At 
least some of the intra-tumoural heterogeneity seen in this series may be 
related to stromal interaction with the tumour.  
During the culture of primary tumour, attention has focused upon the reliable 
isolation of malignant cells separate from the other cell types present in ascites 
or solid tumour. It is unclear what role, if any, that the stroma plays in 
maintaining and promoting cancerous, cellular growth or in determining tumour 
behaviour and ITH. Standard primary cell-culture systems, as used in this study, 
and cell-line xenografts have advanced our understanding of tumour behaviour. 
However, these methods have inherent limitations in evaluating the role of the 
tumour microenvironment. Modification of the culture method to include either 
growth of the actual tumour stroma or provision of an artificial stroma may 
create an optimal growth environment to maintain prolonged survival in culture. 
If culture of stromal cells is possible, it may be of interest to test stromal cultures 
for their HR function and to assess resistance to cytotoxics with and without 
concomitant culture with stroma to explore its effects. If the stroma has an 
impact upon intra-tumoural heterogeneity of HR function that we have found in 
ovarian cancer then it may be of interest to compare HR function at defined 
intra-abdominal sites between patients. Ex vivo tissue slices seem to be the 
most promising of techniques (Schmeichel 2003, Guyot 2007). The advantage 
of this approach is the ability to both maintain organ and cellular architecture, 
while also preserving the integrity of the tumour–stroma interaction 
(Umachandran 2006).  
The difference seen in the median DT of solid tumour in comparison to ascitic 
cultures may be a reflection of differences in the cellular components of the 
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cultures. Solid tumour in vivo has a markedly different environment in 
comparison to malignant cells within ascites and perhaps the malignant 
component of solid tumour is more vigorous due to better nourishment through 
the vascular supply. This may result in a more robust primary culture with a 
greater growth rate. Quantification of Ki-67, an established marker of cell 
proliferation, and correlation with SRB determined growth rate may clarify if the 
ex vivo growth rate is a true reflection of the tumour’s proliferation rate. 
5.12. Conclusions 
ITH exists in ovarian cancer in terms of function of the HR DNA repair pathway. 
This results in a variable response to cytotoxic agents between cultures taken 
from different areas of tumour from within the abdominal cavity and offers one 
possible explanation for clinical resistance to chemotherapy seen in tumours 
with HRD cells within the culture from ascitic fluid. Thus ITH is not predictable 
from morphological appearances or from antigen detection. It is now clear that a 
single biopsy, from any site, is insufficient if chemotherapy agents are to be 
stratified based upon tumour biology.  
A change in the approach to tumour sampling, classification of tumours and 
quantification of response to therapy is needed if novel chemotherapies are to 
result in improvement in PFS and OS.  
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Chapter 6. Sapacitabine as a Therapeutic Agent in the  
Treatment of Ovarian Cancer 
6.1. Introduction  
The ideal agent for the treatment of ovarian cancer would be orally bioavailable, 
non-toxic, highly targeted and paired with a reliable biomarker capable of 
accurately predicting the response to therapy. Pairing targeted cytotoxic agents 
with biomarkers is particularly important in ovarian cancer. Patient frailty and the 
high frequency of comorbidities prevent polypharmacy and provision of 
successive ineffective therapies is unlikely to translate into a survival benefit. A 
biomarker would enable accurate stratification of therapy to those patients who 
are likely to benefit preventing overtreatment and increasing overall response 
rates 
6.1.1. Nucleoside Analogues: Alternative Targeted Agents  
Nucleoside analogues are a major class of antimetabolite cytotoxic agents and 
were among the first chemotherapeutic agents to be introduced for the 
treatment of cancer. The anticancer nucleosides include several analogues of 
pyridimine and purine that compete with physiological nucleosides and interact 
with a large number of intracellular targets to induce cytotoxicity. These agents 
can exert their cytotoxic activity by being incorporated into and altering DNA 
and RNA macromolecules themselves, by interfering with various enzymes 
involved in synthesis of nucleic acids or by modifying the metabolism of 
physiological nucleosides (Galmarini, Mackey et al. 2002).   
Nucleoside analogues have been in clinical use for almost 50 years and have 
become cornerstones of treatment of cancer and viral infections. Following the 
discovery of fluracil in the 1950s, cytarabine was approved for the treatment of 
acute myeloid leukaemia (AML) by the FDA in 1969 and since this time 
numerous nucleoside analogues have been evaluated in patients for the 
treatment of cancers (Jordheim 2013).  
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6.2. Sapacitabine 
6.2.1. Structure 
Sapacitabine is an oral cytosine nucleoside analogue and is the pro-drug of 2’-
C-cyano-2’deoxy-1-β-D-arabino-pentofuranosyl-cytosine (CNDAC). 
Sapacitabine has been explored as an alternative agent for the treatment of 
ovarian cancer (Shapiro 2012). The structure of CNDAC is very similar to that of 
the other nucleoside analogues but it functions in a different way and therefore 
arguably should not be included in this class of drug, Figure 6.2 -  1. The 
incorporation of an additional N4-palmitoyl group (Kaneko 1997, Hanaoka 1999) 
results in protection of the amino group of CNDAC (reduced inactivation by 
deamination (Liu 2012)), resulting in better diffusion into the gastrointestinal 
cells, thereby enabling oral administration (Serova 2007).  
 
  
Figure 6.2 -  1: Structure of Sapacitabine, CNDAC, Gemcitabine and Ara-C (Serova 
2007). 
 
6.2.2. Function and Mechanism of Action  
Sapacitabine is primarily metabolised by plasma, gut and liver amidases into 
the active metabolite CNDAC, which subsequently enters the cell via the human 
equilibrative nucleoside transporter (hENT) (Serova 2007). It has a novel 
mechanism of action by becoming incorporated in the DNA chain and interfering 
with DNA synthesis by inducing DNA damage. 
 184 
 
CNDAC is phosphorylated by deoxycytidine kinase (dCK) to form CNDAC 
triphosphate, which accumulates in a concentration-dependent manner (Azuma, 
Huang et al. 2001) and competes with dCTP for incorporation into DNA 
(Azuma, Huang et al. 2001) by DNA polymerase α (Hayakawa 1998, Hanaoka 
1999, Azuma, Huang et al. 2001, Serova 2007). Rather than cause chain 
termination, like the other nucleoside analogues, resulting in S-phase 
arrest/collapsed replication forks (Plunkett, Huang et al. 1995) CNDAC causes 
G2 arrest in a number of cell lines (Liu 2005) through activation of the G2 
checkpoint through the canonical Chk1-Cdc25C-Cdk1/CyclinB1 signal pathway 
following induction of DNA damage (Liu 2012)..  
Ligation of the 3’-hydroxyl of the analogue by incorporation of subsequent 
deoxynucleotides initiates β-elimination (Liu 2010). In DNA, this process 
cleaves the phosphodiester linkage 3’ to the analogue as the CNDAC 
nucleotide is rearranged to form 2’-C-cyano-2’,3’-didehydro-2’,3’-
dideoxycytidine (CNddC) (Liu 2010), Figure 6.2 -  2. CNddC nucleoside is 
unique and lacks the 3’hydroxyl group and is subsequently not a substrate for 
repair by ligation, nor can it be extended without processing to remove the 
chain-terminating analogue (Liu 2012). This functionally prevents repair until 
CNddC is removed.  The presence of CNddC at the 3’ terminus acts as a DNA 
chain terminator forcing the formation of a single-strand DNA breaks or nicks 
during first S-phase which are repaired to only a small extent by the TC-NER 
pathway (Hayakawa 1998, Hanaoka 1999, Azuma, Huang et al. 2001, Wang 
2008). 
CNDAC has been demonstrated to have potent anti-tumour activity in a number 
of preclinical trials across multiple tumour types. The antiproliferative effects of 
CNDAC in terms of IC50 values were more potent than those observed with ara-
C (Matsuda, Nakajima et al. 1991, Tanaka 1992). In two separate studies, 
broad spectrum activity has been demonstrated across a panel of tumour cell 
lines (Hanaoka 1999, Serova 2007).  
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Figure 6.2 -  2: Incorporation of CNDAC into DNA, β-elimination Resulting in CNddC. 
Adapted from (Azuma, Huang et al. 2001) 
 
During subsequent replication, unrepaired SSB are converted to DSB in second 
S-phase and, if not repaired, lead to cell death phase (Hanaoka 1999, Azuma, 
Huang et al. 2001, Liu 2010). Repair of replication-associated DSB or collapsed 
replication forks is primarily dependent upon the HR pathway, Figure 6.2 -  3.  
 
 
 
Figure 6.2 -  3: S-Phase stalled replication forks 
SSB are formed after incorporation of CNDAC into DNA that are converted to stalled 
replication forks or DSB when cells enter the second S phase during replication. DNA 
DSB require repair by homologous recombination (HR) repair. 
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6.2.3. Sapacitabine and DNA Repair Pathways 
The repair mechanisms of CNDAC-induced DNA damage are largely unknown.  
Sapacitabine and Homologous Recombination Repair 
An understanding of the DNA pathways involved in CNDAC-induced damage is 
important for the identification of reliable biomarkers to facilitate treatment 
stratification. Several studies have suggested HR (section 1.4.7) as the major 
pathway for repair of sapacitabine induced DNA damage (Hayakawa 1998, 
Hanaoka 1999, Azuma, Huang et al. 2001, Wang 2008, Frame 2010, Liu 2010, 
Frame, Armour et al. 2012).  
Inactivation or inhibition of ATM, BRCA2, Rad51 and XRCC3, key components 
of the HR pathway, has been shown to sensitise cells to sapacitabine (Liu 
2010). Depletion of BRCA1 or BRCA2 by siRNA has also been shown to 
increase sensitivity to CNDAC as well as to platinum and PARPi agents but not 
to other nucleoside analogues (Frame, Armour et al. 2012). Similarly, BRCA2 
mutation enhances CNDAC sensitivity (50x) but does not enhance gemcitabine 
sensitivity (Frame 2010). Further studies have demonstrated increased levels of 
components in the HR pathway in response to exposure to CNDAC (Liu 2010) 
suggesting pathway activation following exposure-related damage. CNDAC has 
also been shown to have additive or synergistic effects in combination with 
cisplatin and PARPi (Frame, Armour et al. 2012) indicating that it may have 
several roles in the management of ovarian cancer.  
Sapacitabine and Non-homologous End Joining (NHEJ) 
Evidence suggests that NHEJ (section 1.4.6) is not involved in CNDAC 
cytotoxicity. Cell line models defective in components of the NHEJ pathway are 
not more sensitive to CNDAC than their matched wild type cell lines and the 
DNA-PK inhibitor, NU7441, does not sensitise cells to CNDAC, indicating that 
the NHEJ pathway is unlikely to be critical for repair of CNDAC induced SSB 
(Liu 2010).  
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Sapacitabine and Nucleotide Excision Repair 
NER (section 1.4.3) is the predominate pathway repairing platinum-DNA 
adducts, the predominant chemotherapy agent of choice in ovarian cancer. 
Lack of components of the transcription-coupled nucleotide excision repair (TC-
NER) pathway has been shown to render cells  3- to 5-fold  more sensitive to 
CNDAC-induced cytotoxicity, and it is thought that the single-strand nick caused 
by CNDAC is recognized and, in part, repaired by the TC-NER pathway (Wang 
2008). However, the overall removal rate of the analogue from DNA is a 
relatively slow process and it is thought that single-strand nicks are in fact 
converted to DSB during mitotic processes prior to initiation of TC-NER repair 
(Liu 2010). This was supported by biochemical evidence of activation of H2AX 
phosphorylation and the physical indicators of DSB formation demonstrated by 
both pulsed-field gel electrophoresis (PFGE) and neutral comet assays 
following pulsed treatment with CNDAC (Liu 2010). 
Sapacitabine and Base Excision Repair 
The incorporation of CNDAC into DNA with subsequent collapse of the 
replication fork also results in damaged DNA bases and SSB, which may 
require repair by BER, section 1.4.2, at least until they are converted into DSB 
during replication. However, reports to date suggest it is not important in 
CNDAC cytotoxicity (Wang 2008). 
Sapacitabine in Clinical Trials 
Two multicentre Phase I clinical trials of CS-682 (an earlier orally bioavailable 
compound to sapacitabine) in patients with solid tumours demonstrated disease 
stabilisation in 11/47 patients with neutropenia limiting further dose escalation 
(Delaunoit 2006, Green, Choudhary et al. 2010), Table 6.2 - 1. The 
recommended Phase II does was 40 mg/m2. In the second trial, a range of CS-
682 doses from 1.5 to 120 mg/m2 were given in 4 weeks cycles (Delaunoit 
2006). Six of the 40 patients included experienced stable disease with few non-
haematological side effects and the recommended Phase II dose was 30 
mg/m2. The pharmacokinetic investigations incorporated into these trials 
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demonstrated oral administration of CS-682 resulted in blood concentrations 
similar to those of the cytosine nucleoside analogues, cytarabine and 
gemcitabine, although metabolic clearance by deamination occurred at a lesser 
rate (Liu 2012). Administered orally at the maximum tolerated dose of 40 mg/m2 
on the daily times 5 days schedule, the peak plasma concentration of 4.1 ± 1.2 
ng/ml (approximately 8 nM) was observed at 2.0 h (Gilbert 2006). 
In clinical trials sapacitabine has been shown to be efficacious in the treatment 
of several haematological malignancies in clinical trials and is currently in 
“SEAMLESS”, a Phase 3 trial for the first line treatment of acute myeloid 
leukaemia (AML) in elderly patients, Table 6.2 - 1. Additionally, a trial evaluating 
its use in various solid tumour malignancies showed measureable tumour 
shrinkage in 2/7 (28%) patients with ovarian malignancy (Shapiro 2012). TAS-
109, a formulation of the parent nucleoside, was studied in solid tumours using 
2 different schedules (Sankhala 2008). Myelosuppression was the dose-limiting 
toxicity but stable disease was observed in several patients within each dose 
schedule.  
These studies, and those described in Table 6.2 - 1, demonstrate that the 
metabolic pathways observed in models systems are active in human and that 
several schedules of CS-682/sapacitabine administered orally generate plasma 
concentrations of CNDAC that have been shown to reduce clonogenicity  of cell 
lines and primary AML cell in vitro (Liu 2010).  
Importantly, initial clinical trials demonstrated response in patients who had not 
responded to treatment with cytarabine or decitabine (Liu 2012).  Cross-
resistance among these drugs was not apparent, providing rationale for 
combination strategies. 
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Study Study Population Trial Registration Phase Outcome Reference 
Safety and pharmacology study 
to treat advanced leukaemias 
or myelodysplastic syndromes 
63 patients  NCT00380653 
 
I  
 
Complete remissions were achieved in 6 patients. Median survival was 
252 days. 41% of patients received sapacitabine for 4+ cycles. The 30 
day mortality rate from all causes was 5%. 
(Kantarjian 
2010, Garcia-
Manero 2012)  
Oral sapacitabine for the 
treatment of AML in elderly 
patients 
105 patients aged 70 
years or older 
treatment naive or at 
first relapse 
NCT00590187 II Randomisation to 3 schedules: (A) 200 mg bd 7 days, (B) 300 mg bd 7 
days, (C) 400 mg bd 3 days. 1-year OS was 35% in (A), 10% in (B), and 
30% in (C). 14/105 died <30 days and 27 died <60 days. Grade 3-4 
adverse events: anaemia, neutropenia, and thrombocytopenia. Grade 5 
events: pneumonia and sepsis.  
(Kantarjian 
2009, Kantarjian 
2012)  
A randomized phase 2 study in 
patients with advanced 
cutaneous T-cell lymphoma 
16 patients after 
failure of ≥1 systemic 
therapies 
NCT00476554 
 
II 
 
Partial remissions were observed in three patients. 
 
JH Chiao 
Cyclacel 
Study of sapacitabine in AML 
 
Open label trial of 
patients with newly 
diagnosed AML 
NCT01211457 
 
I/II 
Recruiting 
Sapacitabine in alternating cycles with decitabine. 30‐day mortality from 
all causes was 4.5% and 60‐day mortality was 9.5%. The overall response 
rate was 34.8%.  
(Ravandi 2011) 
A phase 2 trial for relapsed 
CLL/SLL with 11q22-23 deletion 
40 patients with 
relapsed CLL / SLL  
NCT01253460 
 
II 
Recruiting 
Oral sapacitabine once daily (days 1-3 of 28) with IV cyclophosphamide 
and IV rituximab. The primary outcome is overall response.  
WG Wierda. MD 
Anderson 
A phase 1 study of sapacitabine 
and seliciclib for solid tumours 
124 patients with 
incurable solid 
malignancy  
NCT00999401 
 
I 
 
Stable disease and tumour shrinkage was seen in 20 patients (5 NSCLC, 4 
colorectal, 1 breast, 2/7 ovarian, 2 bladder, 2 GIST, 1 renal, 3 unknown 
primary, 1 SCLC and 1 parotid tumour).  
(Shapiro 2012) 
SEAMLESS: First line treatment 
of AML in elderly patients 
 
485 patients >70 
years 
NCT01303796 
 
III 
Recruiting 
Multicentre, randomised, open-label trial comparing two drug regimens; 
sapacitabine sequentially with decitabine vs. decitabine alone. The 
primary outcome measure is overall survival.  
H Kantarjian 
MD Anderson  
A Phase 2 study in patients with 
previously treated NSCLC 
 NCT00885963 
 
II 
 
Open label multicentre trial for patients who have progressed after 
treatment with one or more platinum regimens. The primary outcome 
measure is rate of response and stable disease.  
P Bonomi  
Rush Uni Med 
Centre  
Table 6.2 - 1:  CNDAC in Clinical Trials 
AML: Acute myeloid leukaemia; CLL: Chronic lymphocytic leukaemia; SLL: Small lymphocytic lymphoma; NSCLC: Non-small cell lung cancer
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Resistance to Sapacitabine 
The clinical efficacy of nucleoside drugs depends on a complex interplay of 
transporters mediating cellular entry, efflux mechanisms that remove drugs from 
intracellular compartments and cellular metabolism to active metabolites. 
Nucleoside transporters (NTs) mediate the uptake of physiologic nucleosides as 
well as anticancer and antiviral nucleoside drugs (Baldwin 1999) and the 
interaction between nucleoside drugs and intracellular enzymes (e.g. kinases, 
deaminases and nucleotidases) may regulate the rate and extent of metabolism 
of nucleoside drugs to cytotoxic derivatives (Damaraju 2003). 
CNDAC is a hydrophilic nucleoside analogue that enters the cell via 
transmembrane equilative nucleoside transporters, ENT1 and ENT2. The 
abundance and tissue distribution of nucleoside transport proteins contributes to 
cellular specificity and sensitivity to nucleoside analogies (Mackey, Baldwin et 
al. 1998). The poor clinical response of patients to treatment with the nucleoside 
analogues cytarabine and gemcitabine has, through independent clinical 
research, been correlated with reduced levels or absence of ENT1 (Mackey, 
Yao et al. 1999, Galmarini 2002, Farrell 2009). In the same study, pancreatic 
cancer patients with high levels of ENT1 expression had a greater median 
overall survival following treatment with gemcitabine compared to that for  
patients with low or no ENT1 expression (Farrell 2009).  
ENTs can be pharmacologically inhibited. Nitrobenzyl mercaptopurine 
ribonucleoside (NBMPR) is a potent inhibitor of ENT1 (IC50 of 0.4–8 nM) and a 
weak inhibitor of ENT2 (IC50 of 2.8 μM) (Ward 2000, SenGupta 2002). 
Dipyridamole (DP) inhibits both ENT 1 and 2 (with IC50 of 5 and 356 nM, 
respectively) (Pastor-Anglada 2005) and has been used for many years to 
prevent strokes and other vascular diseases due to its antiplatelet and 
vasodilating activities. NBMPR and DP reduce sensitivity to gemcitabine by 39- 
and 1,800-fold respectively by reducing the cellular uptake of gemcitabine 
(Mackey, Mani et al. 1998) and both agents have been used in this study to 
investigate the role of ENT in the sensitivity to CNDAC.  
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CNDAC activation is by deoxycytidine kinase (dCK) whilst deactivation occurs 
through deamination by cytidine deaminase (CDA) (Abbruzzese 1991, Owens 
1992, Plunkett, Huang et al. 1995) generating the inactive uracil derivative 
CNDAU, Figure 6.2 - 4. It has previously been shown that cell lines with lower 
mRNA expression of hENT1 and deoxycytidine kinase (dCK) are more resistant 
to CNDAC than cell lines with higher expression (Serova 2007). Such cells were 
not cross resistant to sapacitabine, suggesting other mechanisms of resistance. 
Other enzymes such as cytidine deaminase (CDA) have recently been shown to 
play a role in sapacitabine resistance (Fleming 2007).  
 
Figure 6.2 - 4: CNDAC metabolism.  
CNDAC enters the cell via ENT1 before activation into CNDAC triphosphate by dCK. 
CNDAC triphosphate is then incorporated into the DNA Deactivation by β elimination. 
CDA deactivates CNDAC by deamination to CNDAU.  
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DNA Repair as a Mechanism of Resistance 
The incidence of HRD tumours in ovarian cancer is approximately 50% and we 
would therefore anticipate that 50% of ovarian cancer patients would potentially 
respond to CNDAC. Testing CNDAC in primary cultures provides a more 
realistic model to explore the potential use of CNDAC in clinical practice.   
 
6.3. Aims 
 Assess the cytotoxic effect of CNDAC and the effect upon proliferation of 
cell lines with known mutations leading to homologous recombination 
dysfunction  
 Determine the HR status of PCO samples derived from ascitic cultures 
with corresponding sensitivity to CNDAC, alongside rucaparib and 
cisplatin  
 Establish if defects in other DNA repair pathways are determinants of 
sensitivity to CNDAC  
 Establish a functional assay to test base excision repair status and 
assess its potential use as a biomarker for stratification of CNDAC 
therapy 
 Explore the effect of variable CNDAC uptake (by ENT receptor), 
activation (by dCK) and deactivation (by CDA) upon ex vivo sensitivity to 
CNDAC  
 
6.4. Methods 
Methods for PCO and cell line culture alongside cell line descriptions and 
chemical reagents are described in Chapter 3. Detailed methods for colony 
formation assays, SRB proliferation assay, cell counting assay, the Homologous 
Recombination (HR) functional assay, PARP activity assay, and RNA analysis 
are also described in Chapter 3.    
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6.4.1. Cell ines 
A panel of cell lines paired for defective BRCA1 or BRCA2 function with WT 
(VC8, VC8-BR2, VC8 PIR; UWB1-289 and UWB1-289-BR1) were used in initial 
experiments to assess the effect of HR status upon sensitivity to CNDAC. See 
Table 3.4 – 1, Chapter 3 for details of cell lines. 
 
6.4.2. Growth Inhibition of BER Proficient and Deficient Cells by 
CNDAC With and Without Nucleoside Transport Inhibitors 
Paired cell lines (AA8 –BER competent, and EM9 – BER defective with XRCC1 
mutation; Chapter 3 methods) were seeded at a concentration of 1000 cells in 
100 µl medium per well in 96 well plates. After 24 hours for adherence, media 
was aspirated and replaced with media containing increasing concentrations of 
CNDAC (0, 1, 3, 10, 30, 100 µM). NBMPR (0, 0.1, 1, 10 µM), DP (0, 300 nm, 3 
μM, 30 μM) or methoxyamine (0, 1 mM, 5 mM, 20 mM)  were added and cell 
density assessed after three doubling times (AA8: 48 hours; EM9: 54 hours), 
Table 6.4 - 1. All experiments were corrected for 1% DMSO and density 
normalised to CNDAC-free controls. The potentiation factor (PF), a measure of 
the increase in growth inhibition in the presence of BER or nucleoside transport 
inhibitor, was also calculated as stated below. 
 
PF50  =          GI50 CNDAC 
GI50 CNDAC + inhibitor 
  
 194 
 
 
Inhibition agent Mode of action Hypothesis 
Methoxyamine 
An alkoxyamine derivative that binds to the AP 
site after glycosylase-mediated removal of a 
damaged base. The MX-adducted AP site is 
resistant to AP endonuclease cleavage and to 
polymerase β (members of the BER pathway) 
(Fortini 1993, Horton 2002).  
Addition of methoxyamine 
sensitises BER competent 
cell lines (AA8) to CNDAC 
but does not increase 
sensitivity in BER deficient 
cell lines (EM9).  
Dipyridamole 
 
Inhibitor of equilibrative nucleoside transporters, 
ENT 1 and ENT 2.  
If CNDAC is transported 
into cells via ENT1 and/or 
ENT2 inhibition by DP will 
result in resistance.  
S-(4-Nitrobenzyl)-
6-thioinosine 
(NBMPR) 
Inhibitor of equilibrative nucleoside transporters , 
particularly adenosine transporters (ENT1) 
If CNDAC is transported by 
ENT1 but not ENT2  
NBMPR will result in 
resistance to CNDAC 
 
Table 6.4 – 1: Agents for the inhibition of BER or transporter protein, their mode of 
action and hypothesis for effect with simultaneous treatment with sapacitabine 
 
6.4.3. Development of an Assay of BER Function 
Principles of the Assay 
Oxidative DNA damage results in production of 8-hydroxy-2’-deoxyguanosine 
(8-OHdG), without a functional BER pathway, these adducts will accumulate in 
DNA. The Trevigen ELISA kit is a competitive immunoassay for 8-OHdG 
quantification in DNA samples.  
Extracted DNA yield from PCO cultures is low and therefore the optimum 
concentration of DNA required for the assay was assessed using the matched 
BER cells lines, AA8 and EM9. 1.2 μg/25 μl DNA was an achievable DNA 
concentration from PCO cultures and allowed clear differentiation of 8-OHdG 
levels from AA8 and EM9 cell lines, data not shown.  
Assay Protocol 
Equivalent amounts of PCO DNA alongside controls (AA8 and EM9 cell line 
DNA) were prepared. 2 μl DNAse I per 50 μg DNA was added and incubated at 
37 °C for 1 hour. 2 μl alkaline phosphatase per 50 μg DNA was added and 
incubated at 37 °C for 1 further hour. 8-OhdG standards were prepared as per 
manufacturer’s instruction. 
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25 μl samples and standards were incubated at 25°C for 1 hour in the 96 well 
plate with 25 μl 1:250 8-OHdG monoclonal antibody. The plate was washed 4 
times with 0.1% (v/v) Tween PBS before incubating for 1 hour at 25 °C with 50 
μl 1:500 goat HRP conjugate. After washing 4 times with 0.1% Tween PBS, 50 
μl TACS-sapphire™ was added and incubated for 5 minutes. 50 μl 0.2 M HCl 
was added to stop the reaction and the plate read at 450 nm using Spectra Max 
250 microplate reader.  
Data analysis was performed using the Trevigen online worksheet. Briefly, the 
mean absorbance of each 8-OHdG standard and a blank was calculated. The 
log of 8-OHdG standard concentrations (nM) was plotted against the relative 
absorbance and the sample 8-OHdG concentrations calculated by interpolation 
from the standard curve.  
6.4.4. Western Blotting  
The assay protocol described in detail in Chapter 3 was used to quantify protein 
expression of hENT1, dCK and CDA in PCO samples.  
Briefly, 20 mg/ml protein samples were denatured at 100 °C for 5 minutes 
before proteins separated electrophorectically using the Mini-PROTEAN Tetra 
cell system. Proteins were transfer to Hybond ECL membrane before blocking. 
Membranes were incubated in primary antibody in TBST with 1% milk at 4 ˚C 
overnight before washing and horseradish peroxidase-conjugated secondary 
antibodies were applied. Table 6.4 - 2. Bound antibodies were detected using 
ECL detection solution and chemiluminescence used to quantify protein 
expression using the Fuji-imager). Total protein was quantified using Ponceau S 
solution. All immune-blotting experiments were carried out in triplicate.  
 
 
Protein 
 
Molecular weight 
(kDa) 
Species Conc 
hENT1 55 Rabbit polyclonal anti-hENT-1 (Abcam, UK) 1:100 
dCK 31 Rabbit polyclonal anti-dCK antibody (Abcam, UK) 1:500 
CDA 16 Rabbit polyclonal anti-CDA (Abcam, UK) 1:100 
 
Table 6.4 - 2:  Antibodies for Western blot 
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6.5. Results 
6.5.1. Cell Lines 
A panel of cell lines paired for defective BRCA1 or BRCA2 function with WT 
(VC8, VC8-BR2, VC8 PIR; UWB1-289 and UWB1-289-BR1) were used in initial 
experiments to assess the effect of HR status upon CNDAC sensitivity. The HR 
status of each cell line was confirmed using the standard HR Rad51 assay, and 
sensitivity to CNDAC was assessed using colony formation assays, Table 6.5 - 
1. Results clearly demonstrated greater sensitivity in cell lines with BRCA 1/2 
mutations and subsequent HR dysfunction in comparison to their matched wild 
type lines for CNDAC, cisplatin and rucaparib, across different paired cell lines, 
Table 6.5 – 1,  
Figure 6.5 - 1. The LC50 for VC8 BRCA2 cell line (HRC) to CNDAC was 656 nM, 
which was 243 fold higher than VC8 cell line (HRD, with an LC50 of 3 nM, p = 
0.0001. The same trend was seen in UWB1-289 paired cell lines with a 7 fold 
increase in LC50 in the BRCA1 WT cell lines, p = 0.0001.  The PARPi resistant 
subclone of the VC8 cell line was partially resistant to rucaparib, with an LC50 
intermediate to its matched VC8 and VC8 BRCA2. This subclone remained 
sensitive to cisplatin with an LC50 of 70 nM and CNDAC with an LC50 of 39 nM 
suggesting that mechanisms, other than the HR pathway, are likely to be 
involved in resistance to cisplatin and CNDAC.  
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Cell Line DNA Repair Status 
Doubling 
Time 
(hours) 
LC50 
CNDAC, nM 
(mean, SD) 
Fold 
resistant 
(HRC/HRD) 
LC50 
Cisplatin, nM 
(mean, SD) 
Fold 
resistant 
(HRC/HRD) 
LC50 
Rucaparib, 
μM 
(mean, SD) 
Fold 
resistant 
(HRC/HRD) 
VC8 BRCA2 deficient (HR-) 39 3 ± 0.7 - 11 (8.3) - 0.6 (0.3) - 
VC8 BR2 BRCA2 corrected (HR+) 25 656 ± 434.7 243 3598 (51.4) 327 384.4 (143.5) 641 
VC8 PIR BRCA2 revertant (HR+) 23 39 ± 4.3 14 70 (61.3) 6 11.8 (4.9) 20 
UWB1 289 BRCA1 defective (HR-) 53 136 ± 71.8 - 5 (0.9) - 0.5 (0.1) - 
UWB1 289 BR1 BRCA1 corrected (HR+) 45 971 ± 708.1 7 1786 (865.7) 1984 68.9 (9.5) 138 
Capan-1 BRCA2 defective (HR-) 77 128 ± 45.3 -  
MX-1 BRCA1/2 defective (HR-) 27 58 ± 39.1 - 
MCF7 BRCA1/2 WT (HR+) 38 408 ± 99.9 7 
 
Table 6.5 - 1: Cell line panel: Growth characteristics and cytotoxicity by CNDAC, rucaparib and cisplatin. Doubling time: Cell proliferation was 
assessed by SRB assay, with six repeats at each time point. Clonogenic survival: cells were treated with cytotoxic agent at various concentrations, as 
indicated, fir 24 hours and survival was determined with colony formation assay. Data are the mean and standard deviation values from three 
independent experiments, with triplicate values for each concentration.Colony formation assays for MX-1, MCF7 and Capan-1 cell lines completed by 
James Murray.  
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Figure 6.5 - 1: Cytotoxicity of CNDAC and cisplatin in cell lines matched for BRCA1/2 mutations. Cells were treated with CNDAC, rucaparib or 
cisplatin at various concentrations, as indicated, for 24 hours and survival determined by colony formation assay. Data are the mean values from 
three independent experiments, with triplicate values for each concentration. Error bars = 95% CI. 
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6.5.2. Assessing Cytotoxicity in PCO Samples  
As described in Chapter 4, the inability of PCO cultures to form colonies in 
standard or agar colony formation assays prevented accurate assessment of 
cytotoxicity using this methodology. Evaluation of numerous alternative assays 
confirmed SRB to be the reproducible and feasible for accurate assessment of 
cytotoxicity in PCOs, Table 6.5 - 2.  
Cell Line 
CNDAC 
Mean ±SD 
GI50 nM 
SRB 
Fold 
increase 
LC50 nM 
Colony 
Fold resistant 
(HRC/HRD) 
VC8 47 ±51 - 3 ±0.7 - 
VC8 BR2 758 ±114 16 656 ±434.7 243 
VC8 PIR 220 ±344 5 39 ±4.3 14 
UWB1-289 41 ±42 - 136 ±71.8 - 
UWB1-289 BR1 129 ±69 3 971 ±708.1 7 
 
Table 6.5 - 2: Comparison of SRB with colony formation in cell lines matched for BRCA 
1/2. Colony formation. Cells were seeded at low density and treated with CNDAC at 
various concentrations for 24 hours. Cell proliferation by SRB assay. Cells were 
seeded at 1000 cells / well and treated with CNDAC at various concentrations for three 
doubling times. Data are the mean values (95% CI) from three independent 
experiments, with triplicate values (colony formation) or six replicates (cell proliferation) 
for each concentration.  
 
 
6.5.3. Sensitivity of PCO to CNDAC, Cisplatin and Rucaparib in 
Relation to HR Status 
54 PCO cultures that had previously been determined as HRC or HRD and 
sensitivity to cisplatin and rucaparib determined (Chapter 4) were evaluated for 
sensitivity to CNDAC. Data are given as percentage control cell growth at a 
single concentration owing to the high proportion of cultures resistant to the 
cytotoxic tested, as previously discussed. Sensitivity, quantified by % survival 
following exposure at a given concentration of cytotoxic agent, is a continuous, 
variable and therefore strict discrimination between cultures, which are sensitive 
and resistant is therefore difficult, Figure 6.5 - 2. 
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Of the 54 PCO cultures tested for sensitivity to CNDAC, cisplatin and rucaparib, 
34 (63%) were HRC and 20 (37%) cultures were HRD. When grouping all HRC 
cultures and comparing to grouped HRD cultures, greater sensitivity to CNDAC 
was seen in the HRD group, Figure 6.5 - 2, Figure 6.5 - 3. Mean percentage 
survival following treatment with 100 μM CNDAC was 63.5% (SD 22.3) in HRC 
cultures and 43.1% (20.1) in HRD cultures, p = 0.0015. The cell line cytotoxicity 
assays confirm that HRD cell lines with a BRCA mutation are more sensitive to 
CNDAC as well as cisplatin and rucaparib. However, the ability of HR status 
alone to reliably determine sensitivity in every culture to CNDAC is not absolute 
with some outliers as observed for cisplatin and rucaparib (Chapter 4).   
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Figure 6.5 - 2: Sensitivity of each PCO culture to CNDAC (A), cisplatin (B), and 
rucaparib (C).1000 cells/well were seeded and treated with various concentrations of 
either rucaparib, CNDAC or cisplatin for 10 days. Cells were fixed before staining with 
SRB and cell density determined by spectrophotometer. Data are the mean of six 
replicates for cell density expressed as a percentage of untreated control at the given 
concentration.     
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Figure 6.5 - 3: Sensitivity to CNDAC, rucaparib and cisplatin stratified by HR status. 
Data from Figure 6.5 - 2 describing sensitivity to CNDAC, Rucaparib and cisplatin using 
SRB cell proliferation assay were grouped into HRC and HRD cultures and analysed 
for significance. T-test was used to compare the mean percentage survival at a given 
concentration of cytotoxic agent (see Y-axis) between the HRD and HRC groupings.  
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This might have been expected as clinically there are highly variable responses 
to chemotherapy agents between patients and a 50% cell survival in a 
cytotoxicity assay may reflect a partial response clinically. To assess the 
relationship between sensitivity across the three agents, correlation studies 
between percentage survival were performed.  
Correlation of Resistance to Cytotoxic Agents  
To further assess the relationship between HR status and sensitivity to the three 
agents tested, sensitivity of each PCO culture was compared across all three 
agents.  
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Figure 6.5 - 4: Correlation studies between percentage survival at given concentrations 
of CNDAC, cisplatin and rucaparib. Percentage survival at given concentrations of 
cytotoxic agent was determined by cell proliferation SRB assays. HRC cultures are 
shown by red circles, HRD by blue circles.  
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Data described in Chapter 4 and summarised in Figure 6.5 - 4, identified a 
relationship between sensitivity to rucaparib and cisplatin with a strong 
correlation between antiproliferative activities of each cytotoxic agent. The 
correlation between CNDAC and rucaparib sensitivity was weak but significant. 
There was however, a stronger correlation between CNDAC and cisplatin, 
Figure 6.5 - 5. Nevertheless, there were some outliers, all of which were HRC. 
Such variable sensitivity in HRC cultures may be due to dysfunction in cellular 
mechanisms conferring cisplatin sensitivity (e.g. reduced glutathione), or 
increased CNDAC resistance mechanisms (e.g., reduced ENTs).  Sensitivity to 
CNDAC in cisplatin resistant cultures (purple circle) may be due to high ENT 
expression or increased cisplatin resistance due to high GSH and/or MRP drug 
efflux pump. Additionally, unexpectedly there were two HRD cultures that were 
clearly resistant to both CNDAC and cisplatin.    
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Figure 6.5 - 5: Correlation of sensitivity of PCO cultures to cisplatin and CNDAC. Mean 
percentage survival at 100 μM CNDAC assessed using SRB cell proliferation assay is 
plotted against percentage survival at 10 μM cisplatin for 54 PCO cultures. Outliers 
resistant to CNDAC but sensitive to cisplatin (green circle); outliers resistant to cisplatin 
but sensitive to CNDAC (purple circle). Red dots denote HRC cultures, blue dots, HRD 
cultures.  
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The ability of HR function to accurately predict sensitivity to multiple agents was 
not 100% predictive. Cultures which were resistance to each agent were 
grouped and the proportions of HRD/HRC calculated, Figure 6.5 – 6. 
 
 
A 
 
B 
 
 
Figure 6.5 - 6: Resistance (A) and sensitivity (B) to CNDAC, cisplatin and rucaparib. 
SRB cell proliferation assays were used to calculate the percentage survival at 100 μM 
CNDAC, 10 μM cisplatin and 100 μM rucaparib.  ≥50% survival of untreated control 
denoted resistance. The percentage of cultures resistant is shown numerically within 
the black Venn diagram The proportion of PCO cultures sensitive to each agent is 
shown in (B). 27.8% of cultures were sensitive to all three agents.   
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Grouping the cultures in this way reveals that there are a proportion of cultures, 
which are resistant to cisplatin that are sensitive to CNDAC (9.3 + 7.4 = 16.7%),  
Figure 6.5 - 6. 7.4% of all PCO cultures tested were resistant to both cisplatin 
and rucaparib but were sensitive to CNDAC showing that CNDAC may have a 
role to play in platinum resistant and PARPi resistant disease. HR function 
alone however is not a reliable discriminator to identify this group of patients 
who may benefit.  
6.5.4. HR and the Prediction of CNDAC Sensitivity 
The ability of HR functional status to accurately predict sensitivity to CNDAC ex 
vivo in PCO cultures was tested by ROC analysis. An AUC of 0.7798 (SE 
0.068) demonstrates a significant association with a p value of 0.0005, Figure 
6.5 - 7. The PPV of HRC to predict resistance was 83.3% with a NPV of 70.8%. 
Sensitivity and specificity were shown to be 0.781 and 0.773 respectively, 
Figure 6.5 - 7. 
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Figure 6.5 - 7: ROC analysis for HR status and CNDAC sensitivity.Sensitivity to 
CNDAC was determined by SRB cell proliferation assay. Greater than 50% survival in 
comparison to untreated control after 10 days exposure to 100 μM CNDAC was used 
to define resistance. An AUC of 0.7798 confirms a significant association between HR 
status and percentage survival.  
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6.5.5. CNDAC in Sequential or Combination Drug Regimes 
These studies were conducted by S Frame (Cyclacel).  
The ability of CNDAC to be incorporated into nucleic acids during DNA repair 
makes them interesting candidates for combination therapy with DNA-damaging 
agents. PCO primary culture data suggests a role for sapacitabine in the 
treatment of ovarian cancer but it is unclear how this should be offered. Many 
new agents used in cancer care are often given in trials at the time of relapse 
following failure of standard therapy. This is unlikely to result in a high rate of 
response and the possibility of providing sapacitabine earlier in the 
management of ovarian cancer either a s a single agent or in combination was 
explored, (Frame, Armour et al. 2012).   
Data demonstrated that CNDAC could be effectively combined with PARPi 
inhibitors in ovarian cell lines or given in sequential treatments, although with 
PARPi, sequential treatments appeared to be better than the concomitant 
treatment schedule, Table 6.5 - 3.  
 
 ED50 CI ED75 CI ED90 CI 
CNDAC then PARPi 0.64 <0.5 0.65 <0.5 0.67 <0.5 
PARPi then CNDAC 0.83 <0.5 0.68 <0.5 0.57 <0.5 
CNDAC plus PARPi 0.81 <0.5 0.75 <0.5 0.72 <0.5 
 
Table 6.5 - 3: CNDAC in combination with PARPi. PEO1 cell lines were seeded at 
1000 cells/well, and treated with CNDAC, PARPi or cisplatin in 3 different schedules. 
For sequential schedules, cells were treated with the first compound for 24 h, followed 
by the second compound for 72 h. For the combination schedule, cells were treated for 
72 h with both compounds. Cell viability was assessed by resazurin assay, and data 
analysed by Calcusyn. The combination index (CI) is a measure of the nature of the 
drug interaction, with CI <0.9 showing a synergistic relationship, CI 0.9-1.1 showing 
additive effect and CI >1.1 showing antagonistic effect. Effective dose values for 50, 75 
and 90% reduction in growth (ED50, ED75 and ED90) for each of the combinations are 
shown (Frame, Armour et al. 2012).  
 
  
 210 
 
6.5.6. Investigation of Alternative DNA Repair Mechanisms as 
Possible Determinants of Sensitivity to CNDAC 
Cell lines with isolated BRCA 1/2 mutations were consistently more sensitive to 
CNDAC in comparison to their paired WT cell lines suggesting HR status could 
be used to enrich the population of patients who are likely to be sensitive to 
CNDAC. However, HR function alone is not entirely predictive of CNDAC 
sensitivity with several outliers identified indicating that other DNA repair 
pathways may be important. 
To identify any other relevant pathways CNDAC sensitivity in matched cell lines 
defective in other DNA repair mechanisms was explored using SRB proliferation 
assays,  
Figure 6.5 - 8. Full details of cell lines are given, in Table 3.4 – 1, Chapter 3 and 
summarised in Table 6.5 - 4.  
 
Cell line Description 
A2780 p53 and MMR-competent  
CP70-B1 p53 mutant, MMR competent (chromosome 3 transfer). A2780 
derivative 
CP70-A2 P53 mutant, MMR defective (transferred chromosome 3 with 
mutant hMLH1). A2780 derivative 
V3 NHEJ defective (DNA-PKCS deficient)  
V3-YAC NHEJ competent (transfected with a yeast artificial chromosome 
(YAC) carrying DNA-PKCS gene) 
AA8 BER competent and NER competent  
EM9 BER defective (XRCC1 mutation)  
UV5 NER defective (ERCC2 mutation)  
 
Table 6.5 - 4: Cell line panel used to explore the contribution of NHEJ, BER, NER, p53 
and MMR in the sensitivity to CNDAC. 
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Figure 6.5 - 8: Cell proliferation by CNDAC (SRB assay) with matched cell lines for NHEJ, BER, and NER DNA repair. Cells were seeded at 1000 
cells/well and treated with CNDAC at various concentrations, as indicated, for three doubling times. Cell density was measured by SRB assay. 
Results shown are the mean (SEM) of three independent experiments, each with six repeats. 
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 GI50 Competent Defective 
Fold 
resistance 
(HRC/HRD)  
P value 
(t-test) 
DNA-PKCS 
(NHEJ) 
 V3-YAC V3   
CNDAC (nM) 120.3 (92.4-157.0) 267.7 (222.4 – 322.1) 0.7 0.0292  * 
Cisplatin (µM) 2.62 (1.69 – 4.06) 3.69 (3.36 – 4.06) 0.7 0.7366  . 
Rucaparib (μM) 48.5 (24.3 – 96.8) 32.9 (6.5 – 167.9) 1.5 0.9272  . 
XRCC1 
(BER) 
 AA8 EM9   
CNDAC (nM) 6970 (4540- 10700) 374.4 (303.6 – 461.7) 18.6 <0.0001  * 
Cisplatin (µM) 18.4 (15.6 – 21.8) 16.7 (11.8 – 23.7) 1.1 0.0003  * 
Rucaparib (μM) 103.2 (85.9 – 124.1) 112.9 (102.4 – 124.5) 0.9 0.5039  . 
ERCC2 
(NER) 
 AA8 UV5   
CNDAC (nM) 6970 (4540- 10700) 147.3 (106.0 – 204.1) 47.3 0.0221  * 
Cisplatin (µM) 18.5 (15.8 – 21.8) 0.72 (0.41 – 1.26) 25.7 <0.0001  * 
Rucaparib (μM) 103.2 (85.9 – 124.1) 47.5 (35.4 – 63.75) 2.2 0.2315  . 
MHLH1 (MMR) 
/ p53 
 
A2780 
MMR comp 
p53 comp 
CP70 A2 
MMR def 
p53 def 
CP70 B1 
MMR comp 
p53 def 
P value 
(ANOVA) 
CNDAC (nM) 187.4 (138.9 – 252.6) 2869 (1713 – 4805) 872.8 (712 – 1070) 0.0002  * 
Cisplatin (µM) 0.10 (0.08 – 0.13) 5.04 (3.69 – 6.90) 1.74(1.12 – 2.71) <0.0001  * 
Rucaparib (μM) 6.5 (4.2 – 10.2) 55.8 (44.3 – 70.4) 10.5 (8.0 – 13.8) <0.0001  * 
 
Table 6.5 - 5: Sensitivity to CNDAC and cisplatin assessed by SRB proliferation assay in cell line panels matched for functional/defective DNA repair 
pathways. Cells were seeded at a density of 1000 cells/well with six replicates per condition and treated with CNDAC at a variety of concentration 
normalised to 1% DMSO, as indicated, for three doubling times. Cell proliferation was assessed by SRB assay. Data are the mean values (95% CI) 
from three independent experiments, with six repeats for each concentration. 
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Cell lines defective in NER, with ERCC2 mutation (UV5) were also significantly 
(nearly 50-fold) more sensitive than their WT (AA8), p=0.0221. Similarly, the 
UV5 cells were 26 fold more sensitive to cisplatin than the matched WT AA8 
cell line, p <0.0001. No significant difference was seen in these paired cell lines 
with rucaparib.  Cell lines with mutant XRCC1 (EM9), defective in BER were 
nearly 20x more sensitive to CNDAC than matched WT, p <0.0001, Table 6.5 – 
5. 
Interestingly, V3 cells (DNA-PKCS deficient) defective in NHEJ was more 
resistant to CNDAC in comparison to its paired competent cell line (V3-YAC) 
p=0.0292. The fold resistance of 2.23 was however less pronounced than that 
seen in other pathways. There was no statistical difference in their sensitivities 
to cisplatin, p=0.7366.  
Comparing CP70 B1 and A2780 cells the presence of p53 mutation appeared to 
result in an approximately 5-fold increase in resistance to both CNDAC and 
cisplatin in comparison to WT, p<0.0001. This requires confirmation by 53 
knockdown, The presence of a mutation in hMLH1 (CP70 A2) conferring 
defective MMR resulted in an additional 3-fold increase in resistance to CNDAC 
and 1.5 fold increase in resistance to cisplatin, p<0.0001, p<0.0001 
respectively.   
With only a modest increase in sensitivity in the MMR defective cells and a 
small fold increase in sensitivity in cell lines with competent NHEJ, these 
pathways were not investigated further. BER and NER defective cell lines were 
significantly more sensitive to CNDAC in comparison to their matched wild type 
cell lines and BER was selected for further evaluation in this study.   
6.5.7. Base Excision Repair  
The data above have demonstrated that a defective BER DNA repair pathway 
confers sensitivity to CNDAC. To test prevention of repair by BER pathway 
results in greater resistance to CNDAC a series of cell proliferation assays were 
conducted with addition of methoxyamine to inhibit BER. 
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Inhibition of BER: Methoxyamine 
Methoxyamine is an alkoxyamine derivative, which is capable of blocking the 
short patch nucleotide BER pathway by reacting with the aldehyde group in the 
acyclic sugar left in the DNA abasic site following removal of a damaged 
nucleotide (Talpaert-Borle 1983, Liuzzi 1985). The methoxyamine-adducted AP 
site is a stable intermediate, refractory to the lyase activity of AP endonuclease 
(Ape1/Ref-1) cleavage and to polymerase (Fortini 1993, Horton 2002). 
Incompletely repaired methoxyamine-blocked AP sites lead to increases in 
SSB, DSB as well as cell death (Taverna 2001, Rinne 2004). Inhibition of BER 
by methoxyamine is a valid pharmacologic strategy to enhance the cytotoxicity 
of a methylating chemotherapeutic agent, such as temozolomide, or to 
overcome temozolomide drug-resistance (Liu 1999, Taverna 2001, Liu 2002). 
Addition of 6 mM of methoxyamine has been shown to increase sensitivity to 
temozolomide in colon cell lines by interruption of BER (Liu 1999).  It was 
hypothesised that the addition of methoxyamine would prevent repair of DNA 
damage by BER and therefore induce resistance in the BER defective cell line 
EM9. 
Methoxyamine is itself a cytotoxic agent with a GI50 of 14.2 mM and 9.4 mM in 
AA8 and EM9 cell lines respectively.  
 Mean (SEM) % cell growth with CNDAC 
and methoxyamine 
AA8 EM9 
M
X
 1 mM 72.4 (2.8) 83.5 (2.1) 
5 mM 60.5 (6.8) 66.6 (6.4) 
20 mM 38.0 (2.9) 48.2 (6.3) 
 
Table 6.5 - 6: Cytotoxic effect of methoxyamine (MX): Percentage survival AA8 and 
EM9 cells with addition of MX.Cells were treated with methoxyamine at 0, 1, 5 and 20 
mM concentrations for 48 hours. Cell proliferation was assessed using SRB assay and 
percentage survival expressed as percentage survival compared to untreated controls.  
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For drug combination assays data were normalised to methoxyamine or vehicle 
alone but the inherent growth inhibition by methoxyamine made sensitisation 
difficult to determine, Figure 6.5 - 9, Table 6.5 - 6. 
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Figure 6.5 - 9: Inhibition of BER using methoxyamine. Cells were treated with CNDAC 
at various concentrations normalised to 1% DMSO, as indicated, for 48 hours (three 
doubling times) with addition of 1, 5 or 20 mM  methoxyamine. Cell proliferation was 
assessed by SRB assay and compared to control cells with CNDAC alone, normalised 
to 1% DMSO or MX alone as appropriate.   
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Methoxyamine at 1 mM did not potentiate sensitivity to CNDAC significantly in 
either AA8 or EM9 cell lines. Effect of the addition of higher doses of MX cannot 
be assessed due to the toxicity of MX.  
Functional BER Assay: 8-OHdG ELISA 
To further explore the relationship of defective BER pathway with sensitivity to 
CNDAC, a functional assay was developed to be used in PCO samples. The 
quantification of 8-OHdG by ELISA testing provides the opportunity to 
characterise PCO cultures as BER competent or defective using extracted 
DNA. AA8 and EM9 cells were assayed in parallel with PCOs to provide BER 
proficient and deficient standards. 
8-OHdG is produced during oxidative DNA damage and is removed by BER. 
Therefore, cells competent in BER (AA8) remove the 8-oxo-dG and have low 
residual levels, whilst cell lines defective in BER (EM9) fail to remove 8-oxo-dG 
and have high residual levels. Trevigen’s competitive ELISA kit quantifies 8-
OHdG in DNA using wells pre-coated with 8-OHdG.  
Functional BER Assessment of PCO Samples 
58 PCO samples, including four samples run with duplicates during separate 
experiments, were processed for baseline 8-OHdG levels. All samples were 
normalised for the concentration of DNA loaded and normalised to EM9 within 
each assay to eliminate inter-assay variability. Higher measurement of 8-OHdG 
indicates BER defect, Figure 6.5 - 10.  
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Figure 6.5 - 10: 8-OHdG baseline levels in PCO samples. DNA extracted from PCO ascitic cell cultures, at a concentration of 1.25 μg/25 μl, was 
added to the Trevigen ELISA plate containing immobilised 8-OHdG before adding 8-OHdG monoclonal antibody followed by HRP with colour 
conjugate and quantifying by spectrophotometry. Sample 8-OHdG concentrations were calculated by interpolation from the standard curve. Cells 
competent in BER (AA8) have low residual levels, whilst cells defective in BER (EM9) have high residual levels. Results for cell lines are the mean 
and SD of three independent experiments.  
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Correlation 8-OHdG Levels with CNDAC Sensitivity  
A negative correlation was seen between 8-OHdG level and percentage 
survival at 100 μM CNDAC with a correlation coefficient of r = -0.3234, 
p=0.0133, suggesting that 8-OHdG may serve as a marker for sensitivity to 
CNDAC, Figure 6.5 - 11.  
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Figure 6.5 - 11: Correlation of 8-OHdG with CNDAC sensitivity.    
 
Analysis of 8-OHdG levels in PCO cultures shows a continuum. There is no 
clear cut off value at which PCO cultures can be easily stratified into BER 
competent and defective groups. In order to explore the ability of an isolated 8-
OHdG level to predict sensitivity to CNDAC a series of cut-off values were 
tested using ROC analysis with percentage survival at 100 μM CNDAC, Table 
6.5 - 7. The mean 8-OHdG levels in AA8 cell line (BER competent) was 0.701 
and that of EM9 cell line (BER defective) was 5.286. Using a low level of 8-
OHdG as the cut-off to allocate PCO cultures into BER competent and defective 
groups results in the best prediction for sensitivity in this dataset to CNDAC with 
an AUC of 0.7639, demonstrating this cut-off as having a fair/good predictor for 
% survival at 100 μM CNDAC, p = 0.0803. However, the ROC analysis does not 
reach significance, and additionally, using a cut-off of 15 ng in this dataset 
would mean that only 4/60 (6.7%) of cultures were BER competent. This may 
be a reflection of the relatively small number of cultures, Figure 6.5 - 12.    
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8-OHdG Cut-off 
Value (ng) 
Number (%) PCO cultures in 
group depending upon cut-
off ROC 
AUC (SE) 
95% CI p 
BER 
competent 
BER 
defective 
1.5 4 56 0.7639 0.6365 to 0.8913 0.0803 
2 13 37 0.5547 0.3802 to 0.7292 0.5508 
3 (median) 30 30 0.5886  0.4405 to 0.7366 0.2467 
4 36 24 0.5114 0.3603 to 0.6625 0.8853 
5 42 18 0.5454 0.3858 to 0.7050 0.5957 
6 48 12 0.5048 0.3154 to 0.6943 0.9805 
7 52 8 0.5056 0.2953 to 0.7159 0.9619 
 
Table 6.5 - 7: Receiver operator curve (ROC) analysis of predictability of 8-OHdG 
values (ng) to predict sensitivity to CNDAC, defined as <50% cell survival after 10day 
exposure to 100 μM CNDAC (determined by SRB assay). .  
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Figure 6.5 - 12: ROC 8-OHdG of 1.5 to predict CNDAC sensitivity. Using 1.5 ng 8-
OHdG to stratify PCO samples tested into BER competent and BER defective groups 
enables accurate prediction of CNDAC sensitivity with an AUC of 0.7639, p=0.0803.  
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Inter-assay Variability 
Sample batches of up to 12 samples were run in parallel each with AA8 and 
EM9 serving as positive and negative controls. There was a 33.5% inter-assay 
coefficient of variation for AA8 and EM9 and 47.9% in PCO samples. Variability 
within the PCO repeats may be a reflection of DNA collected at different 
passages. Using the 8-OHdG cut-off of 1.5 ng interassay variation in PCO did 
not alter BER functional status.  
6.5.8. Interaction of HR and BER Functional Status 
The interaction between HR and BER functional status is not yet known and it is 
not clear if one is more predictive of sensitivity to CNDAC than the other, or of 
their effect upon sensitivity to other novel cytotoxic agents.  
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Figure 6.5 - 13: Incidence of BER and HR dysfunction in PCO cultures with 
corresponding grouped sensitivity to CNDAC. A: HR function determined by Rad51 
assay based upon a >2 fold increase in Rad51 foci following induction of DNA DSB, 
see section 3.6. BER function determined by competitive 8-OHdG ELISA using median 
8-OHdG as differential cut-off. B: percentage survival at 100 μM CNDAC in PCO 
cultures stratified by HR and BER function. Mean and SD of each of the functional 
groups are shown on the graph. 
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Stratifying the PCO cultures according to their combined HR and BER 
functional status reveals greatest sensitivity to CNDAC in those cultures, which 
are defective in both HR and BER, with a mean (SD) % growth at 100 μM 
CNDAC of 44.9 ±11.3, in comparison to cultures with either competent HR or 
BER function alone, ANOVA p = 0.0028, Figure 6.5 - 13.   
 
6.5.9. Investigation of Uptake of CNDAC by Nucleoside 
Transporters Using Inhibitors 
To investigate the relative roles of ENT1 and ENT2 equilibrative nucleoside 
transporters in the sensitivity to CNDAC, dipyridamole (DP) (which inhibits both 
ENT1 and ENT2) and NBMPR (which inhibits ENT1) were used. Cell 
proliferation SRB assays using cell lines paired for BER function (AA8: BER 
competent; EM9: XRCC1 mutation with BER defective) with addition of DP or 
NBMPR at various concentrations were undertaken to explore the effect of ENT 
1/2 inhibition on sensitivity to CNDAC, Figure 6.5. - 14.  
Neither addition of NBMPR nor DP had any effect upon cell growth, (data not 
shown). Both NBMPR and DP significantly protected the hyper-sensitive EM9 
cells from CNDAC and both NBMPR and DP afforded equivalent protection 
from CNDAC in EM9 cells indicating that inhibition of ENT1 is sufficient and 
hence this is likely the predominant uptake mechanism of CNDAC, Table 6.5 - 
8. Since in these experiments the effect of CNDAC on AA8 was modest it was 
not possible to determine if DP or NBMPR were protective but it is likely that the 
same mechanism operated in both cells which may be seen with inhibition of 
uptake at higher concentrations of CNDAC.     
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Figure 6.5 - 14: CNDAC cell proliferation assays using AA8 and EM9 cell lines with 
addition of DP or NBMPR. Cells were treated with CNDAC at various concentrations, 
nnormalised for 1% DMSO as indicated, for 48 hours with addition of 0.1, 1, 10 μM 
NBMPR or 300 nM, 3 μM or 30 μM DP. Cell proliferation was assessed by SRB assay. 
Data are the mean values and SEM from three independent experiments with six 
replicates for each concentration.  
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Mean GI50, µM (fold increase from control) 
AA8 EM9 
Control 697 50.37 
DP 
3 µM 
3874 (5.56) 5689 (112.94) 
NBMPR 
1 µM 
21300 (30.56) 9893 (196.41) 
 
Table 6.5 - 8: Mean GI50 of paired cell lines following exposure to CNDAC with NBMPR 
or DP. Cells were treated with CNDAC at various concentrations with NBMPR or DP, 
as indicated, for 48 hours. Cell proliferation was assessed by SRB assay. Fold 
increase in GI50 from untreated controls was calculated.   
 
6.5.10. Expression of Proteins Implicated in CNDAC 
Sensitivity: ENT, dCK, CDA 
Levels of protein expression of transporters and enzymes involved in resistance 
to nucleoside analogues, such as dCK (activation of CNDAC into CNDAC 
triphosphate), hENT1 (cellular uptake), and CDA (inactivation to CNDAC), were 
determined in a series of western blots using a panel of cell lines and PCO 
samples and correlated with CNDAC cytotoxicity, see Chapter 3 for protocol.  
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Figure 6.5 - 15: Western blot for protein expression of ENT1, CDA, dCK in PCO cultures. Cell lysates from cultured PCO and cell lines were made 
from approximately 1 million cells. Proteins were separated using gel electrophoresis, detected using western blotting and visualised using 
chemiluminescence. Protein levels were normalised to total protein (Ponceau S). Data are from two independent experiments.  
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Variable expression of ENT, CDA and dCK were detected within the PCO 
samples tested. As anticipated, there was a modest negative association of 
CNDAC resistance with dCK expression, indicating that reduced CNDAC 
activation confers resistance. The same negative association was seen with 
ENT1 expression. There was however, no significant correlation between levels 
of expression of any of the proteins tested and sensitivity to CNDAC determined 
by cell proliferation assays. This suggests that although CNDAC may enter the 
cells via ENT1 and is phosphorylated by dCK to form CNDAC triphosphate 
before incorporation into DNA small variations in expression of these proteins is 
not the major determinant of sensitivity to CNDAC.  
Interestingly, ENT1 expression was <0.5 of the normalised protein in 9/17 
(53%) of the PCO tested and in comparison to OVCAR3 cell line, known to 
express low levels of ENT1 (Zhang 2006). It would be expected that this would 
result in poor uptake of CNDAC into the cell and therefore result in resistance to 
CNDAC. This was the case in PCO 230, PCO 231 and PC 238 with percentage 
survival at 100 μM CNDAC of 96.0, 83.3 and 86.4% respectively but PCO 219 
and PCO 175, which also had low expression of ENT1, were sensitive to 
CNDAC with 24.1 and 45.0 % survival at 100 μM CNDAC. It is possible that 
tumours with low ENT have utilised alternative nucleoside transporters that can 
also carry CNDAC into the cell.  As the cell line data demonstrate, there are 
several determinants of sensitivity to CNDAC and it is possible that one or more 
of these mechanisms (reduced dCK, increased CDA, increased HR, NER and 
BER) could confer resistance even if ENT1 was high.    
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6.5.11. BER Gene Expression as a Surrogate for BER Function  
To further evaluate the role of the BER pathway in the sensitivity to CNDAC, 
RNA expression of key components of the pathway (APE1, PARP1, XRCC1, 
Polβ, LIGIII, PNK, PCNA, FEN1, LIGI) were examined and correlated to BER 
function.  
The relative expression of genes involved in DNA BER repair was determined 
by the Oxford genomics centre (Oxford, UK) using Illumina Genome Studio and 
HumanHT 12v4.0 R1 15002873 array, see Chapter 3. 24 PCO samples with a 
range of 8-OHdG levels, reflecting variable BER function were tested. The 
relative expression of each component of the BER DNA repair pathway was 
calculated and differences between the BER competent and BER defective 
groups calculated. Groups were defined using the median 8-OHdG value and 2 
nM.    
No statistically significance difference between RNA expression of any 
component of the BER pathway was seen when between BER functional 
groupings using the median 8-OHdG value as the discriminatory cut-off. 
Significance was seen between the expression of PARP1 and Polε when the 
lower discriminatory value of 2 nM was used, Figure 6.5 - 15. However, no 
correlation between RNA expression and sensitivity to CNDAC was seen. There 
was however correlation between Polβ expression and sensitivity to CNDAC, 
r2=0.09659, approaching significance, p=0.0697. Correlation between sensitivity 
to CNDAC and RNA expression of PARP1, LIG1, and PolƐ was seen.    
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Figure 6.5 - 16: RNA expression of key components of the BER DNA repair pathway in 
PCO grouped by BER status, n=24, (orange = BER competent, Blue = BER defective). 
RNA was extracted from frozen PCO cell pellets and after quantification, the 
HumanHT-12 v4 Expression BeadChip used to detect and quantify more than 47,000 
probes derived from the National Centre for Biotechnology Information Reference 
Sequence (NCBI) RefSeq Release 38 (2009). Labelled cRNA are detected by 
hybridisation to 50-mer probes on the Beadchip. After washing and staining steps using 
the Direct Hybridization Assay, beadchips are scanned on the HiScan or iScan 
systems. Illumina Genome Studio Gene expression software is used to extract relative 
gene expression across samples, clustering them into differential groups. The 
comparative Ct (ΔΔCt) method was used to assess the expression level of components 
of each pathway relative to endogenous controls normalized to the reference panel. 
The fold change differences in expression of each gene between sample categories 
(HRC and HRD; BER competent and BER defective) was calculated. The mean and 
SD of the fold change are plotted with HRC cultures shown in red and HRD shown in 
blue. 
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6.6. Discussion 
6.6.1. Sapacitabine in the Treatment of Ovarian Cancer 
Initial cell line and ex vivo PCO culture work suggests that there is a role for 
CNDAC in the treatment of ovarian cancer. A phase 1 study of sapacitabine and 
seliciclib for advanced solid tumours (NCT00999401), which included 7 patients 
with end stage ovarian cancer, showed response in 2/7 (29%) when provision of 
treatment was not stratified. Based upon cell proliferation assays of primary 
cultures, section 6.5.2, an unstratified approach would result in a response rate 
of 46% (25/54), with less than 50% cell survival following a 10-day treatment 
with 100 μM CNDAC. Exposing patients to the associated morbidity and the 
NHS to the financial costs of ineffective treatment is not ideal. A stratified 
approach aims to enrich the patient population who receive the treatment and 
would at least enable provision of accurate prognostic information to patients 
and, if biomarkers are used to guide actual therapy, this is likely to result in 
higher rates of overall response. Successful stratification is dependent upon 
reliable biomarkers capable of accurately predicting response. This study aimed 
to further our understanding of the potential effect of CNDAC upon ovarian 
cancer as well as explore the use of DDR function as biomarkers of response.  
Cell line studies show greater sensitivity in cell lines with BRCA 1/2 mutations 
and subsequent HR dysfunction in comparison to their matched wild type lines 
for CNDAC, as well as for PARPi and cisplatin. A fold increase ranging from 7 
to 243 was seen between BRCA mutant and BRCA WT across three sets of 
paired cell lines, section 6.5.1. The range of levels of sensitisation in different 
paired cell lines (VC8 were 243 fold and UWB1-289 were 7 fold more sensitive) 
demonstrated that even within a particular defect (BRCA) there is a spectrum of 
sensitivity and this may be a consequence of other genetic and epigenetic 
changes perhaps resulting in dysfunction of other critical pathways. 
Established cell lines provide an invaluable tool for studying biological functions 
at the molecular and cellular level. However, their use has several limitations, 
particularly in ovarian cancer research. We understand that actual ovarian 
cancer frequently harbours multiple interacting mutations within many cellular 
pathways and the isolated defects in cell lines underestimate this complexity. 
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Primary cultures are more accurate in simulating the patient situation more 
closely and were used in this study to ascertain the frequency of response to 
CNDAC in ovarian cancer.  
6.6.2. HR as a Biomarker of Sensitivity to CNDAC 
Each PCO culture was stratified into two groups based upon the Rad51 assay 
for HR function. 34 (63%) were HRC and 20 (37%) cultures were HRD. When 
grouping all HRC cultures and comparing to grouped HRD cultures, greater 
sensitivity to all three agents (CNDAC, rucaparib and cisplatin) was seen in the 
HRD group, Figure 6.5 – 3, with mean % survival following treatment with 100 
μM CNDAC of 63.5% (SD 22.3) in HRC cultures and 43.1% (20.1) in HRD 
cultures, p = 0.0015. The resistance to CNDAC seen in some HRD PCO 
cultures may have developed by dysfunction in another cellular pathway and it 
is important to realise that testing HR function alone will fail to identify some 
patients who may benefit from treatment with CNDAC and may subject some 
patients to treatment without clinical benefit. Although there were some outliers 
with HRD PCO cultures being resistant to CNDAC and HRC cultures showing 
sensitivity, with the use of HR functional status to stratify treatment response 
rate rose to 77% with 17/22 cultures classified as HRD showing response to 
CNDAC. The overall PPV of HRC to predict resistance to CNDAC was 83.3% 
with a NPV of 70.8%. Sensitivity and specificity were shown to be 0.816 and 
0.898 respectively.   
The PCO ex vivo data presented here suggests that response to sapacitabine 
could be anticipated in approximately 50% of tumours when used as a first line 
agent (in PCO samples from chemo-naïve patients) but there is also response 
seen in a proportion of PCO cultures generated from patients following platinum 
therapy and in platinum resistant disease, see section 6.5.3. Of the 38 PCO ex 
vivo cultures classified as sensitive to CNDAC, eight of the donor patients had 
been treated with platinum chemotherapy prior to sample collection and a 
further four patients had innate platinum resistance indicated by clinical 
progression of disease within 6 months of treatment. Additionally response to 
CNDAC was seen in 17 PCO cultures that were resistant to rucaparib. This 
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initial work suggests that sapacitabine may have a role in both platinum 
sensitive and platinum resistant disease.  
As discussed in Chapter 4, the typical population of patients affected by ovarian 
cancer is frequently affected by multiple comorbidities and typically, 
combination treatments would not be tolerated. Sapacitabine can be given as 
an oral preparation and the reported systemic side effects are minimal. It may 
therefore be possible to combine sapacitabine with standard treatments.  
In BER, PARP-1 mediated recruitment of XRCC1 is followed by nucleotide 
replacement and their close relationship within the BER pathway and their cross 
reactivity across thee DDR prompts exploration of the combined effect of 
CNDAC and PARPi.  Work undertaken by project collaborators in cell lines 
aimed to explore the combined effect of CNDAC with PARPi and CNDAC 
platinum if given sequentially or together upon cytotoxicity. CNDAC can be 
effectively combined with PARPi in ovarian cell lines or given in sequential 
treatments, although with PARPi, sequential treatments appeared to be better 
than the concomitant treatment schedule, Table 6.5 - 3. Synergy was also 
observed between CNDAC and cisplatin in a schedule-independent manner in 
non-small cell lung cancer (NSCLC) cell lines, (Frame, Armour et al. 2012). In 
the same series of work, sequential treatments with CNDAC and PARPi 
(irrespective of order) in NSCLC cell lines was also synergistic however 
concomitant treatment with CNDAC and PARPi was antagonistic schedule-
independent manner in non-small cell lung cancer cell lines, (Frame, Armour et 
al. 2012). The synergy observed between CNDAC and rucaparib may be 
explained, at least in part, by the understanding that although CNDAC and 
PARPi induced damage is predominantly repaired by the HR pathway, BER is 
also involved (see section 6.5.6). Induction of damage in both pathways 
simultaneously results in loss of the synthetically lethal ‘backup’ pathway 
resulting in high rates of cell death.  
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6.6.3. Interaction of Other Cellular Pathways in the Sensitivity to 
CNDAC 
Work to date has utilised cell lines with isolated pathway mutations. In primary 
ovarian cancers, multiple coexisting mutations may result in dysfunction of 
several pathways and loss of some elements of one DNA repair pathway may 
be compensated for by increased activity of others. It may therefore be 
important to explore other pathways in addition to HR to understand the key 
pathways involved and identify a possible biomarker of response. It was 
hypothesised that dysfunction in other important pathways in ovarian cancer 
may be responsible for the outliers in response to CNDAC, cisplatin and 
rucaparib in the PCO dataset.  
Cell lines defective in NER due to an ERCC2 mutation (UV5) were 47 fold more 
sensitive than AA8 cells. The increased sensitivity of the NER-defective cells to 
CNDAC was comparable to their cisplatin sensitivity, Figure 6.5 – 8, Table 6.5 - 
5. This is in contrast to work completed by Wang et al which demonstrated that  
cells lacking either XPD (ERCC2), the 3′-helicase, or the 3′-endonuclease XPG 
were equally as sensitive to CNDAC as wild-type cells (Wang 2008). 
Additionally, Wang et al showed that cells deficient in the CSB protein, (which 
initiates TC-NER), exhibited increased sensitivity to CNDAC, whereas cells 
deficient in XPC, (which initiates GG-NER), were slightly resistant relative to 
wild-type cells (Wang 2008). It is not clear why these differences exist but may 
be a reflection of the different paired cell lines and assays used.  ERCC2 is 
involved in both TC- and GG-NER and the greater sensitivity seen in UV5 
compared to AA8 cell lines in this study in comparison to the smaller 5 fold 
difference in TC-NER cell lines previously reported (Wang 2008) may reflect the 
importance of the difference in the initial DNA damage recognition step with 
GG-NER may be the major determinant of CNDAC sensitivity. Multiple studies 
have demonstrated the functional importance of ERCC2 in the repair of cisplatin 
DNA adducts and in cisplatin sensitivity in human ovarian cancer cells in vitro 
(Saldivar 2007) and dysfunction of both NER subpathways may be important in 
the sensitivity of ovarian cancer to CNDAC and the interaction of multiple 
defective pathways in ovarian cancer requires further exploration.  
 233 
 
In this study, the presence of p53 mutation appeared to result in a 4.7 fold 
increase in resistance to CNDAC in comparison to WT, p<0.0001. Addition of 
mutation in hMLH1 (CP70 A2) conferring defective MMR resulted in an 
additional three fold increase in resistance to CNDAC, p<0.0001, reinforcing the 
lack of understanding of the cross-talk between the different pathways and the 
unknown summative effects that dysfunction in more than one pathway may 
have upon sensitivity.  
Cells with defective NHEJ are more proficient in HR repair, and it has been 
suggested that the two DSB DNA repair pathways are in direct competition with 
one another (Neal, Dang et al. 2011). Interestingly, V3 cell line (DNA-PKCS 
deficient) defective in NHEJ was more resistant to CNDAC in comparison to its 
paired competent cell line (V3-YAC) suggesting that NHEJ is not the 
predominant repair mechanism of CNDAC induced DNA damage. Within the 
SRB assays used to investigate the role of NHEJ, cell are however in the phase 
of exponential growth and further investigation of this is essential prior to 
stratification in clinical trials. It is possible that quiescent cell populations, which 
are not in active S phase, in which the NHEJ pathway predominates, will be 
resistant to CNDAC if NHEJ defective. Tumours, which are rapidly growing (in S 
phase), may therefore show more of a response to CNDAC than more slowly 
growing tumours.  It has been shown that DNA-PK can inhibit HR, which is 
dependent upon DNA-PKs enzymic activity modulated by phosphorylation 
(Neal, Dang et al. 2011). Since HR is a determinant of CNDAC sensitivity then a 
mechanism to increase DNA-PK activity may confer sensitivity by obstructing 
HR and should be explored as a combination treatment in HR competent cells.   
Cell lines with mutant XRCC1 (EM9), conferring BER dysfunction were 19 fold 
more sensitive to CNDAC than matched WT (AA8). The differential sensitivity in 
the AA8 and EM9 cell lines suggest a central role of XRCC1 in CNDAC 
sensitivity. This was in contrast to previous work by Wang et al who found that 
XRCC1 defect conferred no difference in sensitivity to CNDAC (Wang 2008). 
Data in this these was repeated by three people independently (Adriana Buskin 
and James Murray) with consistent results.  
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The BER assay described in this work assesses the baseline level of 8-OHdG 
within PCO samples, and aimed to further assess the relationship of BER 
dysfunction with sensitivity to CNDAC. It was hypothesised that 8-OHdG serves 
as a biomarker of BER DNA repair with higher levels of 8-OHdG (indicating 
defective BER) conferring sensitivity to CNDAC. In the small sample of PCO 
cultures tested, a negative correlation was seen between 8-OHdG level and 
percentage survival at 100 μM CNDAC, p=0.0133, Figure 6.5 - 11. However, 
correlation of XRCC1 (RNA) and BER function in PCO samples with sensitivity 
to CNDAC was not seen. 
The variable level of 8-OHdG detected within the PCO samples tested suggests 
that different tumours have variable ability to repair using BER but it is also 
possible that this reflects the different microenvironments of the tumour, with 
variable levels of oxidative stress. To further evaluate the ability of the tumour to 
repair using BER, further experiments to quantify the change in levels of 8-
OHdG following ex-vivo induction of oxidative stress (perhaps with 
temozolomide), alongside untreated controls may provide a more accurate 
assessment. Although additional work is required to validate and develop 
further understanding of the levels of BER in normal cells and the level of 8-
OHdG which discriminates between competent and defective BER, this study 
does however clearly demonstrate the important role of BER in the use of 
CNDAC in ovarian cancer.  
It is perhaps over ambitious to expect that a single marker for a single DNA 
repair pathway will be capable of predicting overall response to cytotoxic agents 
in tumours that we understand to have multiple mutations affecting a number of 
pathways. The development of biomarkers of function of all-important pathways 
in ovarian cancer is important but further work will be required to understand 
which of these pathways are predominant and how they interact. The 243 fold 
increase in mean LC50 between HRD and HRC paired cell lines suggests that 
HR is the predominant pathway of CNDAC DNA damage repair but NER is a 
key determinant of sensitivity as is BER. 
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6.6.4. Cellular Uptake and Metabolism of CNDAC 
Variable expression of ENT, CDA and dCK were detected within the PCO 
samples tested. No correlation was seen however between levels of expression 
of protein with sensitivity to CNDAC determined by cell proliferation assay as 
previously described. This suggests that although CNDAC may enter the cells 
via ENT1 and is phosphorylated by dCK to form CNDAC triphosphate before 
incorporation into DNA small variations in expression of these proteins is not the 
major determinant of sensitivity to CNDAC.  
 
6.7. Conclusions 
 
CNDAC induced damage is mainly repaired by HR and cell lines deficient in HR 
are more sensitive to CNDAC than competent cells. This correlated with 
sensitivity to PARPi and cisplatin. Use of HR functional status may enrich for 
response to sapacitabine but its PPV and NPV are likely to prevent the isolated 
use of HR status to stratify treatment in clinical practice. Investigation of the role 
of alternative DNA repair pathways in the sensitivity to CNDAC using paired cell 
lines confirmed merit in further investigation of the BER pathway. A functional 
assessment of this pathway is possible and may aid in future stratification. In 
reality, it is likely that there are multiple pathways involved in the tumour 
response to each cytotoxic agent and developing an understanding of if there is 
a single predominant pathway with a biomarker or if the function of all pathways 
involved is required to determine sensitivity.  
Knowledge of CNDAC mechanisms identifies tumours that may be sensitive to 
sapacitabine, thus enabling accurate stratification of therapy. It also creates the 
opportunity to overcome resistance to commonly seen with current platinum 
based chemotherapies and identifies synergistic interactions. The work in this 
chapter provides rational for the design of sapacitabine-based clinical trials in 
ovarian cancer.   
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Chapter 7. Circulating Tumour Cells in Ovarian Cancer 
7.1. Introduction 
The first detection of circulating tumour cells (CTCs) was reported more than a 
century ago (Ashworth 1869). More recently, interest in the clinical role of CTCs 
has re-emerged with the development of new technologies.  
CTCs potentially represent a substitute for an invasive tissue biopsy. In contrast 
to functional assessment in tumour biopsies, measuring biomarkers in CTCs 
offers the potential for more frequent, real time monitoring throughout treatment. 
7.1.1. The Origin of CTCs  
CTCs may originate from the primary tumour or from metastases having 
acquired properties enabling migration and survival in the circulation. If CTCs 
are to form metastases, they must also possess the ability to extravasate from 
the circulation and initiate growth in a secondary site (Kalluri 2009, Allan 2010). 
The ability of cancer cells to metastasise depends upon their molecular profile 
as well as the host environment (Coman 1951, Fidler 2008). Epithelial 
mesenchymal transition (EMT) is considered the crucial event in the metastatic 
process and involves disruption of epithelial cell homeostasis and acquisition of 
a migratory mesenchymal phenotype (Thiery 2002, Visvader 2008, Aktas 2009). 
The molecular profile of CTCs cannot therefore be presumed to be the same as 
the original tumour (van de Stolpe et al, 2011).  
Tumour Metastasis  
While the circulatory system is the main route of metastasis in the majority of 
cancers, ovarian cancer predominantly disseminates by transcoelomic spread. 
Tumour cells are shed from the tube/ovary releasing proteins resulting in 
accumulation of ascites that carries floating cancer cells to other intra-peritoneal 
site. This allows deposition and invasion of tumour cells onto peritoneal 
surfaces. Different from other malignancies, distant metastasis formed by 
haematogenous or lymphatic spread, is a late complication and only occurs in 
about one third of patients (Cormio 2003).  
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The Clinical Potential of CTCs 
CTCs offer the potential to change the way in which we diagnose cancers, 
stratify available treatments, monitor patients during and following treatment, 
and provide prognostic information. Research has initially focused on CTC 
enumeration and, as metastatic disease is the cause of death in 90% of cancer 
patients (Pantel 2010), it is unsurprising that the presence of CTCs has been 
linked with poor prognosis in breast, colorectal and prostate cancer (Cohen 
2008, De Bono 2008, Krebs 2011). Whilst provision of prognostic information 
may be of some use to clinicians, the hope for improved survival is dependent 
upon accurate provision of targeted cytotoxic agents, which in turn relies upon 
biomarkers. Current biomarker assays in ovarian cancer rely upon surgical 
resection or invasive biopsies. If CTCs can be identified and used in biomarker 
assays, they offer the potential for non-invasive real time assessment of an 
individual’s cancer. In some cancer types, it has been shown that cells are shed 
from tumours into the peripheral circulation well before metastasis occurs (Liotta 
1974) and therefore detection of CTCs could be important for screening as well 
as for detection of recurrence and evaluation of treatment response (Cristofanilli 
2006, Hayes 2006, Cristofanilli 2007). 
Tumour Microemboli/CTC and WBC Aggregates 
There have been reports of clusters of CTCs detected in patients with advanced 
cancer, which range from 3 to 14 cells (Stott 2010, Hou 2011, Hou 2012). Early 
studies suggest that CTC clusters may be relatively protected from cell death 
and the harsh environment and stresses of the vascular circulations. They may 
also be clinically significant, particularly the number, size or composition of the 
clusters (Wang 2000, Glinsky 2003, Serrano Fernadez 2009, Stott 2010, Hou 
2011, Hou 2012). The presence of clusters may be a better biomarker for 
increased metastatic potential than single CTCs (Wang 2000, Stott 2010, Hou 
2011) 
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7.1.2. Pharmacodynamic Biomarkers Using CTCs 
Bourton et al (2012) have demonstrated identification of γH2AX foci on 
ImageStream in irradiated immortalised human fibroblast cells. Although the 
number of foci detected using the ImageStream was lower than those detected 
in comparable cells using traditional immunofluorescence on fixed cells, the 
relative difference between the different cell lines used was retained and the 
difference between control and irradiated samples was also maintained 
(Bourton 2012). It remains to be seen whether this work can be replicated on 
primary ovarian samples. 
CTCs have also been used as a pharmacodynamic biomarker to study γH2AX 
induction after treatment with DNA damaging agents (Wang 2010, Bourton 
2012). Results from an initial set of patient data suggest that γH2AX levels in 
CTCs may be a more sensitive marker for assessing drug effects in patients 
than total CTC counts alone (Wang 2010). Similar studies evaluating Rad51 foci 
formation and other DNA repair proteins in CTCs are on-going (Yap 2011). 
7.1.3. CTCs vs. Circulating DNA 
Given the many methods and technical challenges that are involved in isolating 
and characterising CTCs assays, the alternative approach of utilising DNA 
isolated directly from blood are appealing. Although the majority of circulating 
extracellular DNA is adsorbed to the surface of leukocytes or erythrocytes, a 
portion can be identified in the plasma, known as plasma DNA or cfDNA 
(Kidess 2013). In light of the current advances in next-generation sequencing 
the availability of cfDNA has ignited interest.  
The presence of small amounts of tumour DNA in the plasma of cancer patients 
was demonstrated several decades ago (Leon 1977). Since then, multiple 
studies have investigated plasma DNA's potential as a biomarker 
(Schwarzenbach 2011). Circulating DNA is thought to originate from lytic, 
apoptotic or necrotic tumour cells or by active secretion from macrophages that 
have phagocytised necrotic cells, or from CTCs themselves (Schwarzenbach 
2011, Payne, Hava et al. 2012). However, cfDNA can also be derived from 
normal cells and therefore cfDNA is also detectable in healthy volunteers, 
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patients without cancer, patients with benign tumours, as well as cancer 
patients. cfDNA is typically analysed together with plasma DNA from normal 
cells. cfDNA fragments represent only a minority of all DNA fragments in the 
circulation but the actual percentage of cfDNA present may vary considerably 
and depends on various parameters including the tumour burden. cfDNA 
isolated from plasma and can be subjected directly to an array for copy number 
analysis, and or mutations at the nucleotide level. This analysis is independent 
of epithelial markers, tumour heterogeneity and evolution. On the other hand, 
CTCs yield information on a cellular level and thus clonality, whereas cfDNA 
reflects an average of all tumour cells releasing DNA into the circulation (Heitzer 
2013). The method selected is likely to therefore depend upon the goal of 
analysis; whether a biomarker is being sought rather than the biology; 
identification of a drug target; investigation of tumour response or mechanisms 
of drug resistance.  
Although analysis of cfDNA may be cheaper and technically less challenging its 
restrictions limit its use in sampling tumour in ovarian cancer for the purposes of 
functional biomarker assessment and this study has focused upon optimisation 
of CTC detection, Table 7.1 - 1. 
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CTC cfDNA 
Equipment Special instrumentation for cell 
identification needed 
None, simple blood collection 
Isolation of CTC or 
cfDNA 
Complex CTC isolation out of 
thousands of cells and complex single-
cell transfer for further processing 
No isolation of cfDNA required; 
instead, standard preparation of 
plasma DNA 
Information on 
heterogeneity and 
clonality 
Yes, if enough CTCs are captured and 
successfully analysed 
No, results represent an average 
from all cells shedding tumour 
DNA into the circulation 
Dependence on 
EpCAM markers 
Yes, for most CTC capture systems, 
such as the CellSearch system. 
EpCAM-independent CTC capture 
systems exist but await validation in 
clinical studies 
Independent of any marker 
Applicability for basic 
metastasis research 
Instrumental, as it enables cell-by-cell 
analyses, generation of cell lines and 
analyses in animal models 
Provides only a snapshot of the 
current status of the tumour 
genome 
Applicability for 
diagnostic or 
monitoring purposes 
Established for CTC enumeration; 
advancements will depend on 
improvements in CTC capturing, 
analysis tools and associated costs 
Appears to be very attractive 
because of the simplicity of 
obtaining plasma DNA; needs to 
be determined in clinical studies 
 
Table 7.1 - 1 Differences between CTC and ctDNA analyses, (Heitzer 2013) 
. 
7.1.4. CTCs in Ovarian Cancer 
There are several reports of the identification of CTCs in ovarian cancer 
patients (Marth 2002, Judson 2003, Wimberger, Heubner et al. 2007, He 2008, 
Fan 2009), which have mainly used cytological detection methods. These 
antibody-based methods resulted in variable CTC detection rates, ranging from 
detection in 12% - 100% of all patients tested. Cellular yields were also variable, 
ranging from 0 - 3118 CTC/ml in one study (He 2008) and as expected, higher 
detection rates have been associated with higher stage of disease (CTC 
present in 100% of stage IV patients tested compared to 35% for stage III) (Sapi 
2002). There have also been reports of metastatic cells in the bone marrow of 
20 - 30% patients with ovarian cancer, providing further evidence for the 
existence of CTCs in at least a proportion of patients (Braun 2001, Marth 2001, 
Marth 2002). 
The study by Marth et al 2002 identified CTCs using immunomagnetic beads 
conjugated to an epithelial glycoprotein (EGP-2 / MOC31). Samples that 
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demonstrated at least two cells with antibody-bound beads were considered 
positive but this was the only criteria used to select a CTC from the other 
nucleated cells in the sample. The study by Judson et al (2003) used 
immunomagnetic beads conjugated to a mixture of epithelial markers (anti-
cytokeratin 8 and 18, TFS02, CK-7, CK-10 and EGFR), following gradient 
separation of the mononuclear cell fraction to enrich tumour cells, and then 
used microscopic evaluation to identify and count CTCs based on specific 
cytoplasmic staining and tumour cell morphology. This study did not include a 
leucocyte specific marker and it is possible that the cells found to be positive for 
one or more of the epithelial antigens were in fact false positive antigen 
expression in apoptotic / activated WBC or contaminated epithelial skin cells.  
The study by Tan et al (2010) describes antibody enrichment of the 
mononuclear cell fraction, following density gradient separation, and 
enumerates epithelial positive (CAM+ and [EPCAM+ or ESA+ or CK+]), CD45 
negative cells. None of the five benign samples tested had detectable CTCs 
and CTC counts ranged from 0 - 149 CTC/ml, with Stage III and IV patients 
exhibiting significantly higher mean counts (41.3 CTC/ml). These antibody-
based methods resulted in CTC detection in a small proportion of patients 
ranging from 12% - 18.7% and the presence of CTC defined by anti-epithelial 
antibody markers alone was not found to correlate with survival or disease 
recurrence.  
One potential explanation for the variation reported is the multiple different 
detection platforms used, which all utilise varying definitions of what constitutes 
a CTC. Of concern, a number of these platforms, including Veridex, have been 
reported to detect objects, classified by their definition as CTCs, in healthy 
volunteer blood or those with non-malignant disease, (Allard and Tibbe 2004, 
Obermayr 2013).  CellSearch™ state that it is only abnormal to have >2 ‘CTC’ 
(Allard and Tibbe 2004).   
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7.1.5. CTC Challenges 
Effective enumeration and characterisation depend upon a reliable method for 
detection. Detection of small populations of CTCs within the large number of 
normal blood cells represents a significant technical challenge.  
Rare Cell Population 
Whole blood contains 4 - 11 x 109/L WBC, 3 - 7 x 1012/L RBC and 150 - 450 x 
109/L platelets. The ideal method for CTC analysis would enable 100% 
detection with no CTC loss. However, imaging and sorting millions of cells is 
unlikely to be clinically reproducible and evidence suggests that enrichment is 
necessary to prevent underestimation of CTCs (Pantel 1999). Enrichment may 
consist of positive selection of CTCs, negative depletion of blood cells or a 
combination of the two methods. The majority of studies have relied on positive 
enrichment using a single tumour cell antigen, most commonly EpCAM (Tibbe 
1999, Nagrath 2007, Riethdorf 2007, Maheswaran 2008, Sequist 2009, Talasaz 
2009, Gleghorn 2010, Stott 2010). The problem with this approach is tumour 
heterogeneity and there are currently no known markers expressed by every 
tumour cell within a given tumour type (Allan 2010). Use of a single antigen is 
likely to result in underestimation of the number of CTCs as well as biased 
selection of a single subpopulation. Negative enrichment options include lysis or 
filtration of RBCs, alongside negative selection of WBCs labelled with specific 
antigens, for example the highly conserved marker CD45 (Goodale 2009).  
CTC Definition  
There is much debate about what constitutes a CTC with various definitions 
being used across different CTC platforms. It seems unlikely that CTCs from 
ovarian cancer will have the same phenotype as CTCs from other tissue types 
and therefore the definition must be cancer-site specific. The Lorentz 
Workshop; CTC Isolation and Diagnostics: Toward Routine Clinical Use, 
created a standard CTC definition combining parameters to increase specificity 
(Van de Stolpe 2011):  
“A nucleated cell larger than 4 µm, expressing epithelial proteins EpCAM and cytokeratins 
8/18/19, while being negative for the leukocyte-specific antigen CD45”. 
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Heterogeneity of CTCs 
We have shown that inter- and intra-tumoural heterogeneity exists within intra-
abdominal ovarian tumour and the same heterogeneity may exist in CTCs. 
Terstappen et al (2000) showed, using retrospective analysis of prostate CTC 
images, that different CTC definitions resulted in different counts with varying 
degrees of clinical significance. The use of a single parameter to define a CTC 
is problematic as no single parameter is essential, or sufficiently distinctive, to 
define a true CTC without overlapping with WBC and/or the presence in healthy 
volunteers (Van de Stolpe 2011).  
EpCAM is widely used in many CTC platforms and is theoretically expressed by 
all epithelial cells. As discussed in this thesis, CTCs may lose their epithelial 
antigens as they undergo EMT. EMT constitutes a spectrum and it therefore 
seems likely that CTCs can express both epithelial and mesenchymal antigens 
to varying degrees, giving rise to heterogeneous CTC populations (Christiansen 
2006).The use of a panel of antigens for the positive detection of CTCs may 
overcome these problems.  
7.1.6. CTC Detection Techniques  
Technologies available can be broadly divided into nucleic acid based and 
cytometric approaches. In the 1990s, nucleic acid based methods 
predominated, relying upon the detection of DNA/RNA sequences differentially 
expressed by tumour cells (Paterlini-Brechot 2007, Alunni-Fabbroni 2010). 
Circulating free DNA may however be released from non-viable cells and 
cytometric techniques examining intact CTCs enables assessment of 
morphology, enumeration of CTCs and has potential for further analysis, Table 
7.1 - 2.  
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Technique Description Enrichment References 
ImageStream, 
Amnis  
High resolution 
immunofluorescent 
microscopy with 
flow cytometry 
See section 7.2.6  
Cells are stained for a panel of antibodies to positively identify 
epithelial tumour cells, whilst simultaneously excluding WBCs 
and un-nucleated objects. 
Negative enrichment of 
RBC +/- WBCs. 
 
CellSearch™, 
Veridex  
Immunological 
selective isolation 
EpCAM antibody coated magnetic beads to select epithelial cells 
subsequently labelled with anti-CK antibody. Negative exclusion 
of anti-CD45 labelled WBC.  
Positive enrichment for 
EpCAM. 
(Cristofanilli 2004, De Bono 2008, 
Krebs 2011) 
Magsweeper  Anti-EpCAM coated magnetic beads dispersed in the sample and 
collected by sweeping rods. 
Positive enrichment for 
EpCAM. 
(Talasaz 2009) 
CTC-Chip  
 
 
Microfluidic 
technologies 
Silicon microchip containing chambers lined with microposts 
coated with EpCAM antibodies with flow patterns to optimise 
cell antibody contact while preserving cell viability. Microfluidics 
push whole blood over the chip to capture EpCAM-positive CTCs, 
which are confirmed to be CTC with CK immunofluorescence.  
Positive enrichment for 
EpCAM. 
(Kobayashi 2005, Nagrath 2007, 
Maheswaran 2008, Sequist 2009, 
Tewes 2009, Gleghorn 2010, Stott 
2010) 
IMEC  Molecular selective 
isolation 
Immunomagnetic bead capture with di-electrophoresis-based 
transport combined with a PCR assay.  
Positive enrichment for 
CTC 
(Stakenborg 2010) 
Isolation by size 
of epithelial 
tumour cells 
(ISET)  
3D microflter 
Filter technologies Filter technique based upon differentiation of CTCs by size using 
an 8 um pore, pressure driven polycarbonate filter (ISET 29) or 3-
dimensional parylene microfilter containing homogeneous 
posers, enabling direct visualisation/analysis on the filter.  
Positive enrichment for 
CTC 
(Vona 2000, Krebs 2011, Zheng 2011) 
 
Epithelial 
immunospot 
(EPISPOT) 
 Antibody-based approach based upon the ELISPOT technology. 
Based upon the identification of cells able to secrete epithelial 
specific or tumour type-specific soluble proteins. 
Positive enrichment for 
CTC  based upon epithelial 
markers (MUC1 – breast; 
PSA-prostate) 
(Alix-Panabieres 2007) 
Table 7.1 - 2: CTC detection technologies. Adapted from (Alunni-Fabbroni 2010). 
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CellSearch™ 
CellSearch™ is FDA approved for CTC detection in patients with metastatic 
breast, colorectal and prostate cancer (Cristofanilli 2004, Cristofanilli 2005, De 
Bono 2008, Plummer, Woll et al. 2008, Miller 2010). Its advantages include its 
semi-automation, reported reproducibility and sensitivity. However, dependence 
upon EpCAM enrichment means CTC subpopulations may go undetected 
(Fischer 2009). Briefly, blood is diluted and incubated with anti-EpCAM antibody 
coated ferrofluid particles. Then, following immunomagnetic enrichment, cells 
are permeabilised and fluorescently labelled using anti-CK antibodies (epithelial 
cells) and anti-CD45 antibody to exclude WBCs (Hou 2009).  
The first publication from CellSearch compared CTC numbers in 964 metastatic 
cancer patients to 145 healthy volunteer and 199 non-malignant disease 
samples (Allard and Tibbe 2004). Only one sample from the non-cancer 
samples had more than 2 CTC/7.5 ml whole blood in comparison to 36% of 
samples from metastatic cancer patients, (range 0 - 23618 CTC/7.5 ml blood) 
(Allard and Tibbe 2004). The presence of CTCs varied widely in samples from 
different carcinomas, with highest frequency in metastatic prostate, unknown 
primary, ovary and breast cancers (Allard and Tibbe 2004). Three seminal 
studies in breast (Cristofanilli 2004), prostate (De Bono 2008) and colorectal 
cancer (Cohen 2008) have subsequently shown that the number of CTCs, over 
a specified cut-off, predicted worse prognosis and a change in CTC number 
following initiation of therapy demonstrated predictive value for survival outcome 
(Krebs 2010).   
7.1.7. ImageStream 
Technology  
ImageStream is a multispectral imaging flow cytometer that produces high-
resolution images of individual cells in flow, allowing assessment of morphology 
as well as intensity and location of fluorochrome labelled antigens. 
ImageStream has five lasers and can collect up to 12 simultaneous images, 
with three lenses and two cameras. The sample is run at up to 5000 
objects/second allowing rapid processing. Inclusion of SpeedBeads in the 
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sample enables hydrodynamic focusing of the cell suspension as well as 
synchronisation of pixel resolution with flow rate, resulting in preservation of 
image quality. Inspire™ data acquisition software is integrated with the 
ImageStream and is used to capture objects defined by cell classifier 
parameters. Sub-populations can then be identified and further characterised 
based on numerous variables using IDEAS Software. These features potentially 
allow for the quantification and characterisation of CTCs as well as 
quantification of nuclear γH2AX and Rad51 foci, offering the potential of 
performing the HR assay on such cells.  
Published Evidence 
Multiple publications have demonstrated the imaging capabilities of the 
ImageStream system but there has been no published work using this 
technology for detection of CTCs in any cancer.   
 
 
7.2. Aims 
 Develop a method for sample preparation of whole blood to positively identify 
ovarian cancer cells from blood cells using cell lines and healthy volunteer 
blood.  
 Develop a method for data handling and analysis of such samples.  
 Develop a method for the accurate identification, quantification and 
characterisation of CTCs from whole blood taken from ovarian cancer 
patients 
 Correlate enumeration of CTCs with stage of disease/PFS/OS 
 Develop a method for application of the HR functional assay based upon 
γH2AX and Rad51 foci formation to cell lines, PCO cultures, and CTC using 
ImageStream. 
 Explore the alternative approach of using ImageStream technology to directly 
characterise and functionally assess the cellular component of malignant 
ascites. 
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7.3. Method Development 
A method was developed for processing whole blood for CTC enumeration and 
characterisation. Prior to ImageStream sample processing, cell suspensions 
required fixation, permeabilisation and antigen labelling. Details of method 
development using cell lines, and PCO cultures are shown in Appendix 8.  
Optimised methods and patient results are shown below.  
7.3.1. Antibody Selection 
Three antigens (EpCAM, CK and CA125) were selected for positive selection of 
CTCs, alongside CD45 to identify WBCs and DRAQ5 as a generic nuclear 
stain. Commercially available fluorochrome conjugated antibodies were 
selected ensuring those with similar emission spectra were in separate cellular 
compartments and ImageStream channels. Fluorochrome-conjugated CA125 
was not available commercially and was manually conjugated, see Appendix 8. 
7.3.2. ImageStream Settings 
Excitation of fluorochromes was achieved with 405, 488, 561 and 642 nm lasers 
and images collected through a 40 x objective. Of the 12 channels, 1 and 9 
were reserved for Brightfield images. The other channels collected emitted light 
over a range of wavelengths between 430 and 745 nm. Only images of objects 
with an area larger than 50 m2 were retained for analysis. ImageStream laser 
settings were manually selected to achieve optimal live image quality with 
identifiable labelling of the corresponding antigens in cell line samples, aiming 
for signal intensity between 100 and 4000, Table 7.3 – 1. 
 
Antibody Concentration Fluorochrome Colour 
Excitation 
Laser 
Intensity Channel 
EpCAM 1:50 AF 488 Green 488 0.5 2 
CA125 1:10 AF595 Orange 561 40 4 
CK 1:20 PE Yellow 488 0.5 3 
DRAQ5 1:50000 DRAQ5 Far-red 658 60 11 
CD45 1:20 V450 Blue 405 20 7 
Table 7.3 - 1: ImageStream laser and channel settings for flourochrome conjugated 
antibodies. 
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Table 7.3 - 2: Characterisation of OVCAR3 cell line using traditional fixed immunofluorescent microscopy and ImageStream. Representative images 
obtained from a single cell are shown in each horizontal panel. The bright field image of the cell shown on the left hand side of each panel allows 
visualisation of the nucleus, plasma membrane and overall cell morphology. The fluorescent detected expression of EpCAM/CK/CA125 are shown. 
The composite images shown on the right hand side of the panels confirm membrane localisation of EpCAM and CA125 as well as cytoplasmic 
localisation of CK. 
Antibody Fixed immunofluorescence ImageStream 
Pancytokeratin 
  
CA125 
  
DRAQ5 nuclear 
stain (FITC 
panCK) 
 
  
EpCAM 
  
Composite 
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7.3.3. Characterisation of OVCAR3 Cell Line and PCO Cultures 
Validation of the final protocol for sample preparation and data analysis was 
undertaken by characterisation of a panel of cell lines (with known antigen 
expression of EpCAM, CK and CA125) as well as assessment of PCO cultures, 
Table 7.3 - 2.  
Cell cultures were trypsinised, cytospun and PBS washed, prior to fixation 
(methanol, -20 °C for 20 minutes). Cells were permeabilised with BD Phosflow 
Perm/Wash Buffer I for 12 hours before incubating with EpCAM, CK, CA125 
and DRAQ 5 antibodies for 12 hours, as above. A population of single, focused 
cells was selected using a scatterplot of area with aspect ratio and histogram of 
gradient root mean square (RMS – an average measure of a dynamic sample), 
Figure 7.3 - 1.  
 
Figure 7.3 - 1: A: Scatterplot showing the area and aspect ratio of OVCAR3 cell line 
sample (incubate with EpCAM, CK, CA125 and DRAQ5) based upon brightfield image 
(MO1). A single cell population can be gated based on these parameters as 
demonstrated here. B: A histogram plot of the gated single, focused cell population 
demonstrating the intensity gradient of immunofluorescent signal of EpCAM (detected 
within Channel 2) in this population. The cut-off denoting positive expression is marked 
by R1 and the cell quantifier function used to calculate the proportion of cells 
expressing the EpCAM antigen. 
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Morphology was studied using the Brightfield images from channels 1 and 9. 
Intensity histograms for EpCAM, CK and CA-125 were drawn and the 
proportion of cells positive defined using parameters set from positive 
(OVCAR3) and negative (A2780) controls, Figure 7.3 - 2.   
 
 
A 
OVCAR 3 
 
 
B 
A2780 
 
 
C 
VC8 
 
 
D 
Cell line Antigen 
Percentage of Cells 
Expressing Antigen 
(%) 
OVCAR 3 
EpCAM 100 
CK 99 
CA125 98 
A2780 
EpCAM 97 
CK 94 
CA125 2 
VC8 
EpCAM 0 
CK 0 
CA125 0 
 
 
Figure 7.3 - 2: ImageStream cell Line characterisation results. A: Cell plot of OVCAR 3 
with a nucleated cell (DRAQ 5 nuclear stain) expressing EpCAM, CK and CA125. B: 
Cell plot of ovarian cell line A2780 showing expression of CK with no expression of 
EpCAM or CA125. C: Cell plot of VC8 lung fibroblast cell line showing nucleated cell 
with no expression of EpCAM, CK or CA125. D: Quantification of antigen expression in 
cell line panel. 
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7.3.4. Retrieval of Spiked ‘CTC’ 
A series of retrieval experiments spiking OVCAR3 cells into healthy volunteer 
whole blood were undertaken.  
Principle of the Assay 
In order to minimise biased selection of subpopulations of CTCs, a method for 
CTC selection was based upon expression of any of a panel of three antigens.   
Method 
Following informed consent, venous blood samples were collected using the 
Vacutainer system. The initial 4 ml of blood drawn was discarded to minimise 
the risk of epithelial skin cell contamination. Blood for analysis was then 
collected in EDTA tubes (no fixative agent) or a single 7.5 ml Transfix tube (with 
fixative). Samples were maintained at room temperature and processed within 
four hours of collection.  
Assay Protocol 
Trypsinised OVCAR3 cells re-suspended in PBS were counted and diluted 
twice by 1 in 10 and the appropriate volume of cells containing 2000, 200, 20 or 
0 cells was added to four 4 ml blood samples equating to 500, 50, 5 and 0 cells 
per ml whole blood. Samples were transferred into 50 ml Falcon tubes, blocked 
in 5% BSA autoMACS solution. Human FcR Blocking Reagent was added 
directly to the blood to a final dilution of 1:40 to prevent non-specific antibody 
binding (Daeron 1997). RBCs were lysed, and all other cells fixed, by incubation 
in BD Phosflow Lyse/Fix Buffer 1:20 (v:v) for 15 min at 37 °C.  Fixed cells were 
collected by centrifugation at 500 g at room temperature for 8 min and 
permeabilised in 1 ml BD Phosflow Perm/Wash Buffer I for 1 hour. Following 
centrifugation cells were resuspended in 100 μl of Perm/Wash Buffer I and 
incubated with 1:20 anti-pan cytokeratin phycoerythrin (PE) for 30 minutes at 
4oC. Membrane antibodies (1:10 anti-CA125 conjugated to Alexa Fluor® 594, 
1:50 anti-EpCAM CD326 Alexa Fluor® 488 and 1:20 anti-CD45 V450) were 
added with nuclear stain (1:50000 DRAQ5) and incubated for 1 h at 4oC. Cells 
were washed in 500 µl of BD Phosflow Perm/Wash Buffer I and centrifuged at 
500 g for 5 min.  
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Experimental samples were divided into 60 µl aliquots and processed alongside 
single-colour controls (SCC), generated from OVCAR3 cells, that had been 
incubated with each antibody separately.  
 
7.3.5. ImageStream Data Analysis Algorithm  
An algorithm for a series of scatter and histogram plots was developed to 
enable identification and enumeration of CTCs based on size, morphology and 
expression of CD45, EpCAM, CK and CA125. CTCs were defined as: 
 
“CK/EpCAM/CA125 positive, CD45 negative with a consistent cellular morphology  
(aspect ratio >0.8; size >WBC; 3-D appearance) and nucleated.  
WBCs were defined as nucleated cells with CD45 expression”. 
 
The first selection was based upon the intensity of the nuclear dye retained by 
the cells,  
Figure 7.3 - 3. The sharp peak above zero contains beads and small particles of 
debris and can be excluded from further analysis. The largest peak of intensity 
between 3 - 4 x 105 typically contains single leukocytes. The second peak of 
intensity between 5 - 8 x 105, which contains malignant cells and doublets of 
white blood cells gating the population of cells at 0.2 x 105, selects these two 
populations for further analysis.  
Subsequent selection aimed to exclude WBC (with expression of only CD45) 
and include other cells expressing EpCAM, cytokeratin and CA125. The 
selection was based upon absence of CD45 expression and presence of 
expression of EpCAM, cytokeratins and CA125.  
Intensity histograms of each of the CTC antigens were created and visual 
inspection of cells within each histogram bar (‘bucket’) enabled discriminatory 
values to be selected for positive and negative expression. Gating varied 
marginally within each experiment due to the variable intensity of 
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immunofluorescence detected. Typically gating a cell population with intensity of 
antigen detection above 3 - 4 x104 resulted in accurate discrimination between 
the presence of antigen but ensured inclusion of even weakly positive cells.  
Three separate dot plots were then configured, plotting intensity of CD45 (y 
axis) against intensity of each of the antigens of interest (EpCAM, CK, CA125), 
see Figure 7.7 – 3B. The gating determined by histogram plot was used to gate 
off cell populations with detected expression of the antigen of interest whilst 
excluding cells, which were only CD45 positive and therefore presumed to be 
WBC. The effectiveness of the discrimination is illustrated in  
Figure 7.3 - 3C; one population of cells expresses CD45 but not EpCAM while 
the second population expresses EpCAM but not CD45. Cell populations that 
express one or more of the epithelial or tumour specific antigens and do not 
express CD45 were selected automatically with the IDEAS Software and 
combined for further visual inspection. The images of each of these cells are 
examined visually to confirm that they have a cellular morphology and that the 
IDEAS Software is able to distinguish the malignant cells from any residual 
haematopoietic cells.  
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Figure 7.3 - 3: CTC analysis algorithm.A: Histogram plot of intensity of 
immunofluorescence of DRAQ5 in all objects detected, identifying the nucleated cell 
fraction; B: Scatterplot of immunofluorescent intensity of CD45 (Channel 7) and 
EpCAM (Channel 2) to enable broad discrimination of haematopoietic and epithelial 
cells (positive expression cut-off of 4x104). Cell populations which are EpCAM or CK or 
CA125 positive were combined to create a second population before the CTC 
population was defined following visual inspection of bright field images (C).  
 
  
All
Cells with positive nuclear stain
6e54e5 8e5 1e60 2e5
Intensity of  nuclear stain (DRAQ5)
100
200
50
0
150
F
re
q
u
e
n
c
y
All
EpCAM positive CD45 negative
CD45 positive EpCAM negative
2e50 6e54e5 8e5
Intensity EpCAM
1e5
0
2e5
3e5
In
te
n
s
it
y
 C
D
4
5
 255 
 
7.3.6. Retrieval Results Without Enrichment  
Despite the ability of the ImageStream flow cytometer to image 5,000 cells per 
second, the large number of leukocytes in whole blood means that analysis of 
each ml of blood takes approximately six hours and produces an enormous 
amount of data for analysis and storage. A standard 8 – 10 ml sample may 
therefore take 4 days to process. Additionally, retrieval in unenriched spiked 
samples across three separate experiments was low with a mean retrieval of 
13% (13.3% of 500 cells, 15.3% of 50 cells and 13.3% of 5 cells), Figure 7.3 - 4. 
Enrichment for non-haematopoietic cells is therefore required before 
identification of CTCs can occur, ensuring that a sufficient volume of whole 
blood could be processed within a reasonable timeframe. 
 
Figure 7.3 - 4: CTC retrieval without WBC enrichment.500, 50 and 5 cells per 1 ml 
were spiked into healthy volunteer blood. Following fixation, permeabilisation and 
incubation with EpCAM, CK, CA125, DRAQ5 and CD45, the percentage retrieval 
following ImageStream processing and data analysis was calculated. Results shown 
are the mean and SD of three independent experiments.  
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7.3.7. Enrichment 
Enrichment may consist of positive selection of CTCs, negative depletion of 
blood cells or a combination of both methods. A series of depletion and retrieval 
experiments were undertaken to evaluate several techniques. Table 7.3 – 3 
summarises the principles of each method as well as the protocol used.  
Positive selection of CTCs involved identification of a universally expressed 
antigen or differential separation based on density. Methods tested gave low 
recovery of spiked CTCs and the cells that were recovered were damaged 
physically as assessed by the images produced (data not shown). Depletion 
methods of haematopoietic cells were therefore evaluated.  
Depletion Method 
4 ml of healthy volunteer blood was depleted of RBCs by incubating the sample 
with 40 ml BD Phosflow Lyse/Fix Buffer for 15 minutes at 37 °C. The sample 
was centrifuged at 500 g for 5 minutes, supernatant discarded and resulting cell 
pellet resuspended in 10 ml PBS. The sample was counted using the Coulter 
counter. Briefly, 100 µl of cell suspension was added to 4900 µl FACS Buffer. 
After mixing well, the mean of three counts was used as the pre-depletion 
count. Following depletion, utilising one of the methods described in Table 7.3 – 
3, the mean of three readings gave the post-depletion count and percentage 
depletion calculated.  
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Method Principle 
 
Protocol 
MACS Antibody directly coupled to magnetic microbead particles is used for 
either positive (EpCAM) or negative (CD45) enrichment. The sample is 
passed through the MiniMACS™ Separator, a high-gradient magnetic 
field, which retains cells labelled with the microbeads. Unlabelled and 
labelled cells can be collected for use in further experiments.  
Following red cell lysis, the cell pellet was resuspended in 500 µl 
MACS buffer solution and incubated with variable quantities of MACS 
CD45 or MACS EpCAM microbeads (50 - 200 µl) at 4 °C for 20 
minutes. The column was prepped with 2 ml MACS buffer, followed by 
the sample, before washing twice with MACS buffer.  
Dynabeads The Dynabeads system is based upon depletion of CD45 positive cells 
using magnetically labelled anti-CD45 antibody. Beads bind to target 
cells during a short incubation. Bead bound cells are separated using a 
DynaMag™ magnet. 
The cell pellet was resuspended in isolation buffer (PBS with 0.1% [v/v] 
BSA, 3 mM EDTA, pH 7.4) and incubated with variable volumes (100 - 
200 µl) of prewashed Dynabeads at 4 °C for 30 minutes before pouring 
off the unbound cellular fraction and counting.       
Magnet In an attempt to avoid the complexities of some of the preceding 
techniques, a simplified method of magnet incubation within a sample 
mixed with MACS CD45 microbeads was explored. This assay relies 
upon the positive exclusion of cells, which express CD45 antigen, using 
magnetically labelled anti-CD45 antibodies.  
The cell pellet was resuspended in 20 ml PBS in a 50 ml falcon tube 
and variable quantities of MACS CD45 microbeads (50 - 200 µl) 
added. An 8 x 30 mm neodymium magnet within a glass FACS tube 
was inserted into the sample and incubated for 1 - 12 hours, 3 times.  
RosetteSep™  
Work done by 
Emma Rouke 
(MRes 2012) 
The RosetteSep™ system combines immunodensity cell isolation 
reagent with a cell processing tube (SepMate™) for cell separation 
directly from whole blood. The RosetteSep® cocktail crosslinks 
unwanted cells to multiple RBCs forming immunorosettes. When 
centrifuged over Ficoll™, the unwanted (rosetted) cells pellet, along with 
RBCs, leaving the CTC fraction untouched at the density medium: 
plasma interface.   
4 ml whole blood was spiked with SKBR3 cells and enriched with the 
RosetteSep CD45
+
 negative selection cocktail, according to 
manufacturer instructions. Briefly, whole blood was incubated with 100 
µl RosetteSep antibody cocktail for 20 minutes at room temperature. 
The blood was then diluted 1:1 with PBS containing 2% FBS, layered 
over Ficoll™ and centrifuged for 20 minutes at 1200 g. The non-
RBC/WBC cell layer was extracted and analysed further with 
ImageStream.  
EasySep™ See section 7.3.7 below  
Table 7.3 – 3: Methods for depletion of white blood cells. 
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EasySep™ 
Principle of the Assay 
The EasySep™ system uses a cocktail of antibodies against CD45 and dextran 
coated magnetic tetrameric complexes to negatively enrich blood samples. 
Incubation in the EasySep™ magnet removes the unwanted CD45 antibody 
bound cells, leaving unbound CTCs in the cellular fraction poured off. 
Assay Protocol 
WBCs were removed with an EasySep™ Human Whole Blood CD45 Depletion 
Kit according to the manufacturer’s instructions (STEMCELL Technologies, 
2013), Figure 7.3 -  5. Briefly, EasySep™ Whole Blood Depletion Cocktail was 
added at 100 μl/ml of sample and incubated at room temperature for 15 
minutes. EasySep™ dextran-coated Magnetic Nanoparticles were then added 
at 50 μl/ml of sample and incubated at room temperature for a further 10 
minutes. The cell suspension was diluted to 5 ml with RoboSep Buffer and 
placed in a “Big Easy” EasySep™ Magnet for 10 minutes. The magnetically 
labelled CD45 cells were held in the tube by the magnetic field and the un-
retained cell fraction (containing non-CD45 cells) was decanted into a clean 
tube by inversion of the sample and magnet. The recovered cells were 
centrifuged at 250 g for 5 min, re-suspended in 1 ml Perm/Wash buffer (10% 
(v/v) with ddH20) for 1 h at room temperature in preparation for antibody 
labelling.  
 
 
 
Figure 7.3 -  5: EasySep™ CD45 depletion of WBC (STEMCELL Technologies, 2013). 
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7.3.8. Enrichment Results 
The concentration of WBCs was counted pre- and post- depletion using the 
methods described in section 7.3.7. Percentage depletion across three separate 
experiments was calculated. Consistent depletion was achieved with 
EasySep™, with a median depletion of 96% (92 - 99%), Figure 7.3 - 6, 
EasySep™ was adopted as the method to be used in further experiments.  
 
A 
 
B 
 
Figure 7.3 - 6: A: Comparison of depletion methods. The mean and range from three 
separate experiments are shown.  B: EasySep™ WBC Depletion. Enrichment for non-
haematopoietic cells.  Cultured malignant cells were added to 4 ml of whole blood and 
cells were incubated with tetrameric antibody complexes against CD45 and dextran-
coated magnetic particles for 1 h and placed in an EasySep™ Big Easy magnet. Cells 
not attracted to the magnet were recovered. The number of leukocytes was counted 
with a haemocytometer prior to and after depletion. Erythrocytes were removed by lysis 
and platelets by centrifugation at 250 g.  
 
7.3.9. Retrieval Results with Enrichment  
Mean percentage retrieval, following enrichment with RosetteSep, was 48% but 
this was highly variable and resulted in substantial debris, which prolonged 
sample running and processing time (data not shown). Retrieval experiments 
were repeated with spiked OVCAR3 cells with the addition of EasySep™ WBC 
depletion. Depletion was consistent and images of the malignant cells and 
residual leukocytes were similar to those shown in  
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Figure 7.3 - 3, confirming minimal damage to the malignant cells by depletion of 
the blood cells. Validation of the methodology on samples from patients with 
oesophageal (Barry Dent), hepatocellular (Laura Ogle) and thyroid (David 
Jamieson) cancers confirmed its utility and indicated that it has comparable or 
greater sensitivity to published methods, Figure 7.3 - 7. The recovery after 
analysis of known numbers of cells by image flow cytometry was 59.2 ± 6.2%. 
This means that the recovery during the red blood cell lysis, white blood cell 
depletion, centrifugation and antibody labelling steps was 61.9% to give an 
overall recovery of 55.2%. The sample processing and analysis time was 
dramatically reduced from in excess of six hours/ml whole blood analysed (see 
Section 7.4.6) for unenriched samples, to approximately one hour per/ml blood 
processed.  
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Figure 7.3 - 7: Retrieval of malignant cells from whole blood.SK-GT-4, Huh-7, ML1 and 
OVCAR 3 cells were added to 5 ml of whole blood to give a final concentration of 500, 
50 and 5 malignant cells per ml. The samples were enriched for malignant cells by 
depletion of blood cells and the residual cells were incubated with fluorescent 
antibodies and nuclear dye and analysed by high-resolution flow cytometry as 
described as described in the Materials and Methods. The mean recoveries of 
malignant cells ± SEM from three experiments are shown. 
  
O e s o p h a g e a l
C e lls / m l
R
e
c
o
v
e
ry
 (
%
)
5 0 0 5 0 5
0
5 0
1 0 0
H e p a t o c e l lu la r
C e lls / m l
R
e
c
o
v
e
ry
 (
%
)
5 0 0 5 0 5
0
5 0
1 0 0
O v a r ia n
C e lls / m l
R
e
c
o
v
e
ry
 (
%
)
5 0 0 5 0 5
0
5 0
1 0 0
T h y r o id
C e lls / m l
R
e
c
o
v
e
ry
 (
%
)
5 0 0 5 0 5
0
5 0
1 0 0
 262 
 
7.4. Results: Ovarian Cancer Patient Sample Results 
Blood samples were collected in Transfix collection tubes for storage up to 24 
hours at 4 °C or in BD Vacutainer EDTA tubes for immediate use from 18 
patients (14 with confirmed ovarian malignancy). Samples were transferred into 
50 ml Falcon tubes, blocked in 5% BSA and FcR Blocking Reagent added. 
RBCs were lysed and WBCs depleted, with EasySep, as above. Cells were 
incubated with anti-pan cytokeratin, followed by anti-CA125, anti-EpCAM, anti-
CD45 antibodies and DRAQ5. Cells were washed before ImageStream 
processing, alongside OVCAR3 single-colour controls.   
7.4.1. Enumeration 
Using the CTC definition in Section 7.3.5, “CK/EpCAM/CA125 positive, CD45 negative 
negative with a consistent cellular morphology (aspect ratio >0.8; size >WBC; 3-D 
D appearance) and nucleated”, CTCs were detected in 9/18 samples tested (7/14 
(7/14 ovarian cancer samples), Table 7.4 - 1. The frequency of ovarian CTCs was 
was highly variable with a median count of 1 CTC per ml blood tested in all samples 
samples and 5.3 CTC per ml in ovarian cancer patients (0 - 47),  
Figure 7.4 - 1A. There was no relationship seen between frequency of CTCs and FIGO 
Stage at presentation or presence of intra- or extra-peritoneal metastases,  
Figure 7.4 - 1B/C. The highest concentration of CTCs (47 per ml) was detected 
in a patient who had completed 4 cycles of dual agent chemotherapy just 4 
weeks earlier, with a significant reduction in tumour volume on CT imaging. 
CTCs from this patient were highly homogeneous. Despite the high frequency 
of CTCs, the patient remains alive and well at 30 months. 
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C 
 
 
Figure 7.4 - 1: CTC frequency and relation to stage of disease and extra-peritoneal 
disease. A: CTC Frequency per ml Whole Blood Tested in PCO samples and non-
ovarian patients; B: CTC frequency by FIGO stage of disease; C: CTC frequency by 
presence of intra- and extra-peritoneal spread of disease
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PCO Age Histology 
FIGO 
Stage 
CA125 
Treatment Prior to CTC 
Sampling Last 
Chemo 
(wks) 
Timing of 
Sample 
Total 
CTC 
No. 
Vol 
blood 
(ml) 
CTC/
ml 
Total No. 
cells 
Total No. 
WBC 
Total No. 
'Other' 
PFS OS 
Diagnosis 
Sample 
Collection 
Surgery Chemo 
235 71 HGSC 2C 254 
 
Complete 6 carboplatin and taxol 208 Relapse 0 8 0 391620 390337 1283 35 68+ 
189 65 HGSC 3C 289 65 None 3 carboplatin ad taxol 4 IDS 0 4 0 216504 213025 3479 28+ 28+ 
201 55 HGSC 3C 678 ND Optimal 
6 carboplatin and 
taxol,  tamoxifen, 
rucaparib 26 Relapse 0 7.5 0 449327 442543 6784 10 36 
206 54 HGSC 3C 1197 562 Optimal 
6 carboplatin and 
taxol, tamoxifen, 
radiotherapy, 3 
carboplatin and taxol   16 Relapse 0 7.5 0 
364817 
363783 
1034 
11 27 
202 52 HGSC 3C 1352 155 None 3 carboplatin and taxol 4 IDS 5 7.5 <1 749676 744384 5292 23 25+ 
214 72 HGSC 3C 571 NA None None NA Presentation 2 8 <1 893092 835670 57422 18+ 18+ 
192 66 HGSC 3C 2425 NA None None NA Presentation 25 8 3 214825 213970 855 4 7 
180 50 HGSC 3C 521 NA None None NA Presentation 12 2 6 355912 343290 12622 11 12+ 
193 66 HGSC 3C 2800 548 None 6 carboplatin and taxol 4 IDS 378 8 47 545300 539053 6247 7 30+ 
181 72 HGSC 4 180 20 None 3 carboplatin and taxol 5 IDS 0 2 0 108252 99384 8868 10 11 
207 63 HGSC 4 371 60 None 3 carboplatin and taxol 6 IDS 0 4 0 197138 184466 12672 5 5 
213 85 HGSC 4 1295 NA None None NA Presentation 48 8 6 279883 271351 8532 4 4 
172 73 HGSC 4 2494 115 Optimal 6 carboplatin and taxol 9 Relapse 19 2 10 22800 18502 4298 8 38+ 
190 75 Mucinous 3C 135 NA None None NA Presentation 3 8 <1 787144 212508 54636 9 11 
195 75 
Pseudomyxoma 
peritonei 
Non-
malignant 30 NA None None NA Presentation 0 8 0 
     
194 59 
Gastric 
adenocarcinoma Metastatic 1000 NA None None NA Presentation 0 8 0 
   
  
198 52 
Gastric 
adenocarcinoma Metastatic 385 NA None None NA Presentation 0 8 0 
     
173 58 
Gastric 
adenocarcinoma Metastatic 164 NA None None NA Presentation 42 2 21 
      
Table 7.4 - 1: Patient demographics and numbers of circulating tumour cells in blood from patients with ovarian cancers. Grey patients with suspected 
ovarian malignancy at time of blood collection but proven to be non-ovarian in origin following histological examination.
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PCO Representative Images of CTC 
172 
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192 
 
193 
 
202 
 
213 
 266 
 
 
214 
 
 
Figure 7.4 - 1: Ovarian cancer CTC. ImageStream. Cell plot of ovarian cancer CTC 
with nucleated cells (DRAQ5 nuclear stain) with variable expression of EpCAM, CK 
and CA125.  
 
7.4.2. Characterisation 
Antigen Expression 
Representative images from all ovarian cancer patients with detectable CTCs are 
shown in  
Figure 7.4 - 1. The different images obtained from a single cell are shown in 
each horizontal panel. The bright field image of the cell shown on the left hand 
side of each panel allows visualisation of the nucleus, plasma membrane and 
overall cell morphology. CTCs detected have variable membrane immuno-
reaction for EpCAM, with some evidence of intracellular vesicular accumulation 
and membrane localisation. The immuno-reaction for the cytokeratins was 
evident in the cytoplasmic compartment of cells. CA125 expression was also 
variable with localisation predominantly in the membrane. The composite 
images shown on the right and confirm localisation of EpCAM and CA125 in the 
membrane and cytokeratin in the cytoplasm. Expression of CD45 was not 
detected in CTCs but many CTC were captured in association with CD45 
expressing WBC. It is unclear if it is by chance that they are captured within the 
same field, whether this is a consequence of the assay protocol or whether this 
is as a result of a true immunological reaction. A summary of the total proportion 
of CTCs expressing EpCAM, CK and CA125 is shown in Figure 7.4 - 2 which 
shows heterogeneity in the expression of all three markers reinforcing the 
importance of a multi-marker panel.  
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Figure 7.4 - 2: CTC characterisation. Proportion of cells with detectable expression of 
EpCAM, CK and CA125. 
 
Are CTCs Representative of Ascitic PCO Cultures? 
It was possible to compare the expression of EpCAM, CK and CA125 in CTCs.  
Comparison of expression of the same antigens in cultured ascites from the 
same patient was possible in 5/8 patients with CTC. Discordance in 
characterisation of CTC and primary tumour culture was present in 9/15 (60%) 
tests. Additionally, heterogeneity in expression of antigens was seen within the 
CTC population from individual patients, Figure 7.4 - 3, further demonstrating 
the intra-tumoural heterogeneity within ovarian cancer.  
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Figure 7.4 - 3: Three representatives CTC from PCO 202. Heterogeneity of EpCAM 
expression with 2/3 cells shown expressing EpCAM and 1/3 with no expression. 
Additionally in two of the cells seen are surrounded by WBC, which may be 
representative of an immune response against CTC. 
 
CTC Size 
Quantification of CTC size using diameter alone results in over- or under-
estimation in elongated cells and is dependent upon orientation. CTC size was 
best assessed using cell area and calculated by IDEAS Software utilising a 
basic cell outline mask (Erode(M01, 1)) and cell area functions.  
Mean cell area across all PCO samples was 61.48 µm2, SD 45.27 µm2. This 
was significantly larger than the mean cell area of WBCs (20.3, SD 1.0), 
p<0.0001, and significantly smaller than ovarian cancer cell line areas (98.5, 
SEM 5.8), p<0.0001.  
The morphologic characteristics exhibited by the captured CTCs were 
consistent with malignant cells, including large cellular size with high 
nuclear:cytoplasmic ratios and visible nucleoli and were similar to that of the 
cultured ovarian cells, Figure 7.4 -  4. CTCs detected were highly 
heterogeneous in their expression of EpCAM, cytokeratins and CA125.  
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Figure 7.4 -  4: CTC area. Area (μm2) of WBC, ovarian cell lines and PCO. Calculated 
from IDEAS software based upon mask/erode function of brightfield images.  
 
 
7.4.3. CTC Enumeration and Survival  
In this small dataset (n=14 ovarian cancer patients) with median frequency of 
5.3 CTC/ml (0 – 47), there was no correlation between CTC frequency and PFS 
or OS with r = -0.2267 (p=0.4165) and r = 0.1192 (p=0.6721) respectively, 
Figure 7.4 -  5. 
 
 
Figure 7.4 -  5: Correlation of CTC frequency/ml with survival. CTC frequency/ml whole 
blood was calculated for each PCO following depletion of RBC and WBC, as previously 
described. CTCs were positively identified following incubation with fluorescent 
antibodies for EpCAM, CK, CA125 and a DRAQ5 nuclear stain. CTC frequency was 
plotted against progression free survival and overall survival (months).  
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7.4.4. Objects of Interest 
There are several populations of circulating objects, which do not fulfil the 
definition for WBCs nor CTCs and have not previously been well described,  
Figure 7.4 -  6.  
Cellular Debris 
Cellular debris (consistently less than 2% of total objects) can be recognised by 
its atypical morphology with non-discriminatory uptake of fluorescence 
antibodies. Quantities of cellular debris were considerably less with use of 
EasySep™ enrichment in comparison to use of other depletion methodologies, 
thereby reducing the time spent on manually sorting cellular debris from true 
CTCs.  
Atypical WBCs 
Within each patient sample, there was a population of cells (3-15% of all WBC) 
whose morphology and size is akin to WBCs but that appeared to express all 
tumour antigens alongside WBC antigens. There are several subtypes of 
WBCs, including those from the myeloid lineage (neutrophils, monocytes, 
eosinophils and basophils) and lymphocytes (including T cells, B cells and 
natural killer cells). Neutrophils are the most abundant WBC, constituting 60 - 
70% of the circulating leukocytes. It is unclear if the cells identified with 
expression of all antigens are one of the other subpopulations of circulating 
WBCs or if they represent activated or apoptotic neutrophils. Another, less 
likely, possibility is that they represent CTCs, which have developed a leucocyte 
phenotype as they adapt to the circulating environment. It has been 
acknowledged that although the majority of leukocytes do not express epithelial 
markers, they have been observed to be EpCAM positive when in an activated 
state (Jung 1998, Sleijfer 2007).  
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Macrophages 
Circulating nucleated cells, which appear to be distinctly different from CTCs 
and WBCs morphologically and which do not express epithelial antigens, may 
represent circulating macrophages (0.5 – 3% of all objects). Tumour-associated 
circulating macrophages have been previously described and are believed to 
facilitate CTC seeding of distant metastases (Adams 2014). This study 
described circulating macrophages in 86% of patients with prostate cancer, 
93% of patients with pancreatic cancer, and 97% of patients with breast cancer 
(Adams 2014). Mean macrophage count was 22/ml whole blood tested in 
patients from all tumour types with stage IV disease, with a mean CTC count in 
the same group of 59.7/ml (Adams 2014). 
Tumour-associated macrophages (TAMs) are found within most tumours and 
have been shown to be prognostic indicators of tumour invasiveness (Shih, 
Yuan et al. 2006). TAMs, recruited to the stroma from circulating monocytes, 
are required for tumour cell intravasation, migration, extravasation and 
angiogenesis (Condeelis 2006, Shih, Yuan et al. 2006). Highly differentiated 
giant circulating macrophage-like cells, with expression of CD14 (macrophage 
antigen) and containing vacuoles of phagocytosed material, have been isolated 
from the peripheral blood of patients with breast, prostate and pancreatic cancer 
(Adams 2014). This cell population, not detected in healthy individuals, has 
been hypothesised to serve as a cellular biomarker of innate immune response 
to the presence of cancer and of cancer aggressiveness and may be useful in 
monitoring chemotherapy-induced responses (Adams 2014).  
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Figure 7.4 -  6: Objects of interest from healthy volunteer sample. A: Cellular debris – 
identifiable by its atypical morphology and saturation for all fluorescence markers. B: 
Atypical WBC, C: Circulating macrophages; see section 7.4.4.  
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Tumour Microemboli/CTC and WBC Aggregates 
There have been reports of clusters of CTCs detected in patients with advanced 
cancer which range from 3 to 14 cells (Stott 2010, Hou 2011, Hou 2012). Early 
studies suggest that CTC clusters may be relatively protected from cell death 
and the harsh environment and stresses of the vascular circulations. They may 
also be clinically significant, particularly the number, size or composition of the 
clusters (Wang 2000, Glinsky 2003, Serrano Fernadez 2009, Stott 2010, Hou 
2011, Hou 2012). The presence of clusters itself has therefore been 
hypothesised to be a biomarker for increased metastatic potential than 
enumeration of single CTCs (Wang 2000, Stott 2010, Hou 2011). However, no 
clusters of CTCs were found with ImageStream in this series and it is unclear if 
the clusters seen in other studies are an artefact of the cell preparation method 
or whether the clusters are disaggregated during the preparation and 
processing for the ImageStream. 
Several samples did however demonstrate clustering of WBC with CTC, Figure 
7.4 -  7.   
 
Figure 7.4 -  7: CTC from PCO 173, 180 and 213 showing CTC surrounded by WBC.  
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7.4.5. Healthy Volunteer Blood without Spiked ‘CTC’ 
It was important to demonstrate that the method did not detect cells in whole 
blood from healthy individuals. Collectively, over fifty healthy volunteer samples 
have been analysed without detection of cells with the morphology shown in 
Figure7.4 - 1 or expression of the markers chosen indicating that the method 
described provides a robust measure of non-haematopoietic cells. Furthermore, 
cellular debris, apoptotic WBCs, non-staining WBCs and circulating 
macrophages have been seen in healthy volunteer blood,  
Figure 7.4 -  6 reinforcing the importance of their exclusion from CTC counts.    
7.4.6. ImageStream HR Assay 
Although enumeration of CTCs in ovarian cancer in this cohort does not have 
prognostic value, characterisation, including functional characterisation of CTCs 
may have more clinical relevance. The homologous recombination repair (HR) 
assay, based upon quantification of nuclear γH2AX and Rad51 foci has been 
shown to be of importance in prediction and prognosis.  
ImageStream HR Assay using Cell Lines 
A panel of cell lines, with known HR status, underwent HR evaluation using 
ImageStream, Figure 7.4 -  8. The optimised ImageStream settings for 
fluorescence intensity, nuclear and foci mask formation as well as counting of 
foci were used.  
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Figure 7.4 -  8: ImageStream assessment of HR function in a panel of cell lines.  
Fold increase from untreated controls in γH2AX and Rad51 foci count are shown in red 
and green respectively. The two fold cut-off of γH2AX foci, above which signifies 
induction of adequate DNA DSB (following 2 Gy IR). The 2-fold increase in Rad51 foci 
count, above which denotes HR competence is shown by a dotted line.    
 
 
Cell lines known to be competent in HR function (OSEC2, OVCAR3, UWB1-
289-BRCA1, VC8-BR2, AA8) showed a greater than 2-fold increase in Rad51 
foci in response to irradiation induced of DNA DSB, assessed using the 
optimised ImageStream methodology, Figure 7.4 -  9. HR defective cell lines 
(UWB1-289 and VC8) had a less than 2-fold increase in Rad51 foci.  
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Figure 7.4 -  9: γH2AX and Rad51 nuclear foci. Representative images from HR assay 
using OSEC2 cell line. Cultured cells were treated with 2 Gy irradiation and 10 μM 
rucaparib to induce DNA DSB, alongside untreated controls. After 24 hours, cells were 
trypsinised and the fixed with methanol before permeabilising with BD Phosflow 
Perm/Wash Buffer. Samples were incubated with primary γH2AX and Rad51 
antibodies for 12 hours at 4 °C followed by corresponding secondary antibodies and 
DRAQ5.  
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γH2AX Fold Increase in PCO Cultures  
The optimised protocol was used to count the γH2AX focus formation in 
irradiated and control PCO samples (n = 4). All irradiated samples showed a 
rise in the mean number of γH2AX foci present, with 3 out of the 4 samples 
achieving a greater than 2-fold increase, Figure 7.4 -  10.   
 
Figure 7.4 -  10: Mean γH2AX  foci count in PCO cultures using ImageStream. 
PCO cultures were irradiated with 2 Gy, trypsinised and fixed at 6 hours alongside un-
irradiated controls. The mean γH2AX foci count using the optimised protocols, 
described above and fold increase from control were calculated. PCO200, PCO205 
and PCO210 irradiated samples all achieved a greater than 2-fold increase.  
 
7.4.7. HR Assay in CTCs 
Principles of the Assay 
The HR assay is based upon quantification of nuclear γH2AX and Rad51 foci in 
response to induction of DNA DSB, section 3.6. ImageStream’s extended depth 
of field function (EDF) enables discrimination of cellular features and more 
precise quantification of nucleic foci. The method for sample processing and 
analysis was optimised using cell lines, before applying to PCO cultures.  
Assay Protocol 
Cultured cell lines were treated with 2 Gy irradiation and 10 μM rucaparib to 
induce DNA DSB, alongside untreated controls. After 24 hours, cells were 
trypsinised and the resulting cell suspension fixed with methanol for 20 minutes 
at -20 °C and then permeabilised with BD Phosflow Perm/Wash Buffer I for 1 
hour at room temperature. Samples were incubated with primary γH2AX and 
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Rad51 antibodies for 12 hours at 4 °C (see Chapter 3 for antibody details). 
Following 3 x 15 minute washes with KCM wash buffer, corresponding 
secondary antibodies and DRAQ5 were added for 1 hour at room temperature. 
Cells were washed and resuspended in PBS before analysis with ImageStream. 
Samples were run at 60x magnification with the EDF filter enabled.  
 
Laser (nm) Intensity Setting 
405 120 (with CD45 antibody) 
488 20 
561 50 
658 150 
785 2.17 
 
Table 7.4 – 2: ImageStreamlaser settings for the HR assay. 
 
Mask Optimisation 
Mask optimisation was undertaken by manual adjustment of mask features and 
visual confirmation of correct outing the fluorescence antigen of interest, see 
Appendix 8.  
Method Optimisation in PCO  
When applied to cell suspensions of trypsinised PCO cultures, the method 
described for HR assessment above resulted in poor intra-nucleic 
permeabilisation and non-specific cytoplasmic staining. Numerous optimisation 
steps were undertaken, Appendix 8. For the final protocol, cells were fixed with 
methanol and permeabilised with 0.1% Triton X-100. Addition of a blocking 
buffer resulted in reduced non-specific antibody binding.  
7.4.8. ImageStream for the Characterisation of Ascites 
Principles of the Assay 
ImageStream, with its ability to simultaneously assess multiple 
immunofluorescent labelled antigens offers a unique opportunity to directly 
characterise the cellular component of ascitic fluid, avoiding the need for cell 
culture. Additionally assessment of the cell suspension avoids culture induced 
selection of subpopulations. Before ascitic samples could be analysed with 
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ImageStream, the cellular components of ascites were filtered from other 
debris. RBCs and WBCs were depleted before the sample was fixed, 
permeabilised and labelled with a panel of immunofluorescent antibodies.  
Characterisation Assay Protocol 
10 ml of ascitic fluid was filtered using a 180 μm nylon filter into a 50 ml Falcon 
tube. Following centrifugation at 50 g for 5 minutes, the cell pellet was 
incubated with BD Phosflow Lyse/Fix Buffer (1:20 v/v) for 15 minutes at 37 °C. 
After centrifugation, the cell pellet was resuspended in 500 μl RoboSep buffer in 
a 14 ml Falcon tube. The sample was then depleted of WBCs with EasySep™ 
Human Whole Blood CD45 Depletion Kit, section 7.3.7. Cells were 
permeabilised with BD Phosflow Perm/Wash Buffer before incubation with 
EpCAM, CK, CA125, CD45 and DRAQ5 antibodies, as previously described 
section 7.3.6.  Cell pellets were resuspended in PBS for ImageStream 
processing.  
HR Assay Protocol 
Two 10 ml of ascitic fluid was filtered into 50 ml Falcon tubes. DNA DSB was 
induced in one sample with 2 Gy irradiation, alongside untreated controls. Two 
hours after irradiation, samples underwent red cell lysis and fixation as 
previously described. Following cell pelleting, 2 ml methanol was added for 20 
minutes at -20 °C before enriching for WBCs with EasySep™ Human Whole 
Blood CD45 Depletion Kit, as above. The cell pellet was blocked in 10% 
blocking buffer for 1 hour, prior to incubation with primary γH2AX and Rad51 
antibodies for 12 hours at 4 °C. Following three washes with KCM wash buffer, 
the sample was incubated with the corresponding secondary antibodies, 
DRAQ5 and CD45 antibodies for 1 hour. Following three further 15 minute 
washes, the cell pellet was resuspended in PBS and processed with 
ImageStream.   
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7.4.9. Ascitic Fluid 
ImageStream has been shown to be efficient at characterising cell lines and 
PCO culture suspensions as well as identifying CTCs. Low numbers of CTCs in 
ovarian cancer are likely to hinder the potential for their use in meaningful 
functional assays and ImageStream was therefore considered for the 
characterisation and functional assessment of fresh ascites.  
Characterisation of the Cellular Components of Ascitic Fluid 
Ascites from seven patients with ovarian cancer was characterised.  
Cellular Classification 
Following exclusion of debris and WBCs that had escaped the depletion 
process, the total number of epithelial and non-epithelial cells within each 10 ml 
ascitic sample was calculated. Non-epithelial cells (no CD45/EpCAM/CK/CA125 
expression) were excluded from further analysis. The concentration and 
proportion of epithelial and non-epithelial cells differed between samples, 
demonstrating a clear inter-patient variability of the ascitic fluid composition, 
Figure 7.4 – 12. 
Division of the epithelial cell population into further subpopulations based upon 
expression of EpCAM, CK, and CA125 demonstrated great inter- and intra-sample 
sample heterogeneity, Figure 7.4 -  11. Collating all samples, 76.9% of epithelial cells 
expressed EpCAM, 26.2% expressed CK and 17.2% expressed CA125. Only 5.4% of 
all epithelial cells co-expressed all three antigens, Figure 7.4 -  12 and   
Figure 7.4 -  13.  
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Figure 7.4 -  11: ImageStream antigen characterisation of PCO ascites. Percentage 
expression of EpCAM, CK and CA125 for each of the seven ascitic samples tested.  
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PCO 
Epithelial Non-Epithelial 
Antigen Expression within 
the epithelial cellular 
component 
PCO 
Epithelial Non-Epithelial 
Antigen Expression within the 
epithelial cellular component 
n (%) in 10ml Ascitic Sample n (%) in 10ml Ascitic Sample 
 
197 
 
236 (56.9) 
 
179 (43.1) 
 
 
202 
 
595 (56.8) 
  
453 (43.2) 
 
199  
410 (22.3) 
 
1428 (77.7) 
 
 
205 
 
5345 (95.9) 
 
229 (4.1) 
 
 
200 
 
1174 (86.8) 
 
179 (13.2) 
 
 
209 
 
146 (9.5) 
 
1391 (90.5) 
 
 
201 
 
683 (63.8) 
 
384 (36.2) 
 
 
Figure 7.4 -  12: ImageStream characterisation of ascitic PCO samples. The sub-populations identified in the epithelial cell population present in 10 ml 
ascitic fluid of patients with EOC.   
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Figure 7.4 -  13: ImageStream cell plot of the major sub-populations of cells identified 
within the ascitic fluid of PCO209. A: EpCAM only. B: CK only. C: CA125 only. D: All. 
E: EpCAM and CK. F: EpCAM and CA125. G: CK and C A-125. 
 
HR Assay Ascites 
Quantification of γH2AX foci was initially attempted in the tumour cell population 
identified within ascitic fluid. Optimisation with addition fixation/permeabilisation 
with methanol alongside RCLB, permeabilisation with 0.1% Triton and addition 
of a blocking buffer resulted in less non-specific binding. In addition, use of a 
nuclear mask excluded non-specific cytoplasmic binding and resulted in 
quantifiable γH2AX foci, Figure 7.4 -  14, indicating that application of the HR 
assay to fresh ascites may be achieved. Time prevented inclusion of Rad51.  
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Figure 7.4 -  14: γH2AX foci in fresh ascites. Fresh ascites was depleted of RBC and 
WBC using Phosflow RCLB and EasySep™ CD45 depletion. The remaining cellular 
component was permeabilised with methanol and 0.1% Triton before blocking and 
incubating with  anti-γH2AX antibody and corresponding fluorescent antibody in a 2 
step process. Foci were counted using IDEAS software.   
 
7.5. Summary 
 It is possible to detect CTCs in ovarian cancer patients 
 CTC enumeration is variable but typically low with no correlation with 
survival 
 CTCs have heterogeneous expression of tumour antigens 
 HR function can be determined using ImageStream  
 Adaptation of CTC methodologies to direct assessment of tumour cells in 
ascites offers the potential for real time assessment of tumour biology with 
minimal intervention. 
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7.6. Discussion 
ImageStream technology has been used in this project for characterisation of 
cell lines, PCO cultures and fresh ascites as well as CTC detection. Before 
sample processing with the ImageStream, cell suspensions were fixed, 
permeabilised and antigens labelled with a panel of antibodies. Initial validation 
of antibody selection and sample preparation was performed using commercial 
cell lines and PCO cultures. Evaluation of depletion methods and retrieval was 
performed using healthy volunteer whole blood spiked with cell lines. Method 
optimisation has been described, followed by the results of patient sample 
assessment. Adapting the HR assay for analysis on the ImageStream, offers 
the potential to simultaneously identify, characterise and functionally assess 
CTCs. HR method optimisation was undertaken using cell line suspensions and 
PCO cultures. Realisation that application of the HR assay to the low number of 
CTCs in ovarian cancer may not be feasible led to exploration of application of 
the assay to cells circulating within ascites.  
An ideal method for analysis of CTCs would be one without enrichment, which 
has the associated risk of CTC depletion. This approach is achievable with 
ImageStream but the time required to process an unenriched sample (more 
than 6 hours per ml blood processed, see section 7.3.6) prevents its routine 
use. CTC detection therefore requires enrichment to reduce the large number of 
haematological cells. The enrichment described is based exclusively on 
depletion of haematological cells, section 7.3.7. Consequently, the method does 
not rely on any single physical or molecular characteristic of the malignant CTC. 
The method has been shown to be simple and reproducible with consistent 
depletion of more than 90% of WBC and patient CTCs detected in samples 
from different tumour types, see section 7.3.9. The recovery after analysis of 
known numbers of cells by ImageStream was 59.2 ± 6.2% (combining data from 
other tumour cell types). Recovery rates of 40-80% achieved in this study are 
comparable with previously described methods (Marth 2002, Judson 2003, 
Wimberger, Heubner et al. 2007, He 2008, Fan 2009). The overall loss from the 
procedure is 44.8%, of which 38.1% is lost during the enrichment and 6.7% 
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during the image collection. The majority of these studies used density gradient 
solutions to isolate a mononuclear cell fraction followed by positive selection of 
CTC using a variety of epithelial antigens, usually in isolation. Few studies have 
reported co-expression of epithelial and leucocyte specific antigens and it is 
possible that many of these studies are in fact enumerating activated or 
apoptotic WBC with non-specific antigen binding.  The study by Tan et al 
however describes antibody enrichment of the mononuclear cell fraction 
following density gradient separation and enumerates epithelial positive (CAM+ 
and [EPCAM+ or ESA+ or CK+]), CD45 negative cells. None of the five benign 
samples tested had detectable CTCs and CTC counts ranged from 0–149 
CTCs/ml with stage III/IV patients exhibiting significantly higher mean counts 
(41.3 CTCs/ml).  
These antibody-based methods resulted in variable CTC detection rates 
ranging from 12%–100% (Marth 2002, Sapi 2002, Allard and Tibbe 2004, 
Ntouroupi 2008, Fan 2009, Obermayr 2013), and cellular yields also tend to be 
variable ranging from 0 to 3118 CTCs/ml in one study (He 2008). The presence 
of CTCs defined by anti-epithelial antibody markers alone has not been found to 
significantly affect survival or disease recurrence.  
Heterogeneity in EpCAM expression in established cell lines (Sieuwerts 2009) 
as well as epithelial ovarian tumours is well documented and it is appreciated 
that this heterogeneity is a likely consequence of EMT. Enrichment based on 
any single molecular characteristic prohibits analysis of CTC heterogeneity. 
In the described method, CTCs were distinguished from residual leukocytes and 
cellular debris by antigen expression of four antigens with a nuclear stain and 
additionally by visual examination of cellular morphology with high quality 
microscopy images. This prevented inclusion and enumeration of activated 
WBC or debris and crucially permits detection of CTC heterogeneity. If CTC 
research is to translate into changes in clinical practice, it is important that the 
specificity of CTC detection is high. The majority of studies define CTCs based 
upon positive and negative antigen expression. In some studies, molecular 
definition is combined with cell morphology. The high resolution imaging that we 
describe allows us to discriminate objects, such as circulating macrophages, 
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that might have been included in enumeration of CTCs had detection relied on a 
lower resolution method. Scrutiny of the high resolution images of these objects 
demonstrate that they are not cells. It has been proposed that some of these 
objects may be apoptotic CTCs or fragmented CTCs but this supposition is 
unproven. We have identified a small number of these objects in healthy 
volunteer samples further supporting the hypothesis that they represent cellular 
debris, possibly created during enrichment. 
In this study CTC were detected in 7/14 ovarian cancer patients tested with a 
median count of 5.3 CTC/ml blood tested (0 - 47). Some published studies have 
reported substantially larger numbers of CTCs (Marth 2002, Judson 2003, 
Wimberger, Heubner et al. 2007, He 2008, Fan 2009), than identified in this 
study or in other reports. It is possible that such high numbers reflect inclusion 
of non-cellular objects and cellular debris in the enumeration. There is no 
consensus definition within the literature as to what constitutes a CTC. In part, 
this reflects the large number of techniques used for their detection. Terstappen 
et al (2000) demonstrated that different definitions of the CTC phenotype 
resulted in different CTC counts with varying degrees of clinical significance 
(Coumans 2010).  
The ability to select different antigens for detection based upon the tumour type 
to be investigated means that our method could be adapted to multiple tumour 
types. Consistent results were obtained between the four tumour types studied 
to date. EpCAM was included within our panel of antigens but could be replaced 
with any other malignant antigen for detection of non-epithelial malignant cells. 
Similarly, as novel biomarkers are discovered, analysis of these could be 
incorporated into this method by inclusion of appropriate antibodies. The 
method also leaves space for the inclusion of pharmacodynamic biomarkers. 
The current focus of CTC research is enumeration of CTCs in patients with 
metastatic disease and the potential association of CTC numbers with 
prognosis or response to systemic therapy. In this small dataset no correlation 
was seen between CTC frequency and PFS or OS, section 7.4.3. The 50% 
retrieval rate, quantified during retrieval experiments, combined with the 
generally small number of CTC detected in this dataset makes tracking of 
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changes in CTC frequency with treatment unreliable. In patients with metastatic 
breast cancer, metastatic colorectal cancer and castration-resistant prostate 
cancer, CTC levels have been shown to be associated with overall survival in 
pre- and on-treatment samples (Cristofanilli 2004, Cristofanilli 2005, Budd 2006, 
Hayes 2006, De Bono 2008, Cohen 2009, Olmos 2009, Tol 2010). These 
tumours do however predominately metastasise haematogenously and CTC 
frequency is therefore considerably higher than those seen in ovarian patients.  
There is considerable interest in the potential to analyse CTCs as a means of 
studying the biology and behaviour of metastatic cancer. Traditionally, 
molecular assessments of tumours are based on tissue biopsies. In the majority 
of cases, these biopsies are from the primary tumour. Metastatic disease is 
frequently more difficult to biopsy and treatment of metastatic disease is 
therefore based on analysis of the original biopsy. There is increasing evidence 
that metastatic disease may differ from the primary tumour. As CTCs are 
thought to represent an interim step in the metastatic process in the majority of 
tumour types, sampling of CTCs may allow a more accurate assessment of the 
metastatic disease without the requirement to invasively biopsy metastatic 
deposits. This is complicated in ovarian cancer. The work described in Chapter 
5 has shown the presence of multiple subpopulations (in terms of antigen 
expression, HR pathway function and response to cytotoxic agents) within 
different areas of intra-peritoneal tumour and it is therefore impossible for the 
CTC population in ovarian cancer to represent the entire tumour. Ovarian 
cancer CTCs may however represent a clinically aggressive subpopulation 
whose biology may reflect extra-peritoneal deposits.  
7.6.1. Why are there so few CTCs in Ovarian Cancer? 
Within 14 ovarian cancer patients the median frequency of CTC detected per ml 
of blood tested was 5.3, ranging from 0 – 47. CTC enumeration in this study, 
alongside other CTC ovarian cancer series have failed to correlate CTC 
frequency with clinical outcome, (Marth 2002, Judson 2003). This is likely to 
reflect the aetiology and natural course of the disease rather than the 
technologies utilised.  
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Ovarian cancer is thought to originate in the distal fallopian tube with tumour 
implanting onto peritoneal surfaces by transcoelomic spread. Even at the 
advanced stage of presentation, haematogenous or lymphatic spread may not 
have occurred with very few tumour cells shed into the circulation. In contrast, 
the majority of other tumours, including prostate and breast, in which CTC 
enumeration has been shown to correlate with prognosis predominately 
metastasise haematogenously. The prognosis of CTC enumeration may 
therefore only be of significance in the subset of malignancies which spread via 
the circulation.  
The biggest limitation of the CTC data set is that blood sampling in this cohort 
has been opportunistic and has sometimes taken place following delivery of 
chemotherapy or at times of disease relapse. Chemotherapy is given 
intravenously and therefore we would expect that any cancer cells within the 
circulation would be the first to die. In fact, the highest frequency of CTCs  was 
detected in a patient who had undergone chemotherapy treatment just 4 weeks 
(with a good clinical response) before sampling and it therefore appears that 
other factors may be more important. The presence and quantity of CTCs may 
not be dependent upon FIGO stage, which essentially describes the distance of 
the metastasis from the pelvis, but perhaps more upon the actual volume of 
disease and its location in respect to major blood vessels?  
In Chapter 4, evidence for EMT in the ovarian cancer patient samples tested 
was presented. Many cultured samples expressed vimentin and lost expression 
of typical epithelial markers (EpCAM and MOC31), section 4.7.4. It was shown 
that this was independent of ex vivo culture and further supported by the 
characterisation profiling of ascitic cells assessed using ImageStream protocol, 
section 7.4.2. Additionally, these data showed that EMT was not universal 
throughout the whole tumour with multiple subpopulations of cells with different 
phenotypes. The process of EMT is dynamic and highly variable and it may be 
that although EMT is thought to take place early in the development of ovarian 
cancer, cells have not yet acquired the ability to invade through the serosal 
surfaces of the intra-abdominal organs or blood vessels and therefore access to 
the circulation is limited. This may not be the case in other cancers from 
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different origins, which may spread predominantly via the circulation and may 
develop the ability to invade blood vessels during their development. Hence, 
this may be one explanation to the reported variability of enumeration of CTCS 
in other tumour types. Additionally, even if tumour cells can access the blood 
stream, survival in this hostile environment is challenging. Preclinical models 
demonstrate that within 24 hours of intravenous administration of tumour cells, 
less than 0.1% of cells remain viable and that less than 0.01% of these 
surviving CTCs can produce metastasis (Fidler 1970).  
Perhaps CTCs in ovarian cancer are in fact plentiful but are rapidly identified by 
the immune system as foreign and are removed promptly before detection is 
possible, Figure 7.4 -  7.   
7.6.2. Can ImageStream Assessment of Ascites make Real Time HR 
Assessment Possible?  
This study shows that identification and characterisation of epithelial tumour 
cells within just 10 ml of patient ascites is possible. Additionally, using the 
principles of the HR assay, we have demonstrated that  DNA damage can be 
estimated in tumour cells within ascites by quantification of γH2AX foci. The 
ability to identify and characterise the multiple subpopulations of cells present in 
ascites using a relatively small volume of ascites is an appealing prospect and 
offers the major advantage of immediate assessment of tumour cells bypassing 
culture and also enabling recognition and assessment of all sub-populations. 
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7.7. Conclusions 
It is clear that CTCs cannot currently replace the diagnostic tests for ovarian 
cancer. Perhaps for ovarian cancer, unlike other malignancies which 
predominantly spread haematogenously, simple enumeration of CTCs is less 
useful owing to their typically low numbers. If it is appreciated that only small 
numbers of ovarian cancer cells are capable of gaining entry into the circulation 
and that an even smaller proportion are capable of survival and initiation of 
distant metastasis, then any CTCs detected are likely to represent one small 
subpopulation. It is therefore unlikely that any characterisation (antigen or 
molecular profiling) of them should be interpreted with care.  
It has been shown that sophisticated molecular testing to determine HR function 
of cell populations using ImageStream technology is possible and although this 
is not feasible with the typical small numbers of CTC detected in ovarian 
cancers, these techniques are adaptable to other tumour types for antigen and 
biological characterisation. Additionally, the technology is applicable to analysis 
of ascitic fluid and the option for a large number of antibodies to be used 
simultaneously in combination with high resolution microscopy allows for very 
accurate identification and localisation of specific target antigens within the cells 
enabling assessment of the multiple subpopulations within ovarian cancer.  
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Chapter 8: Discussion 
 
Ovarian cancer is a complex disease. As we begin to unravel the complexity of 
its aetiology and underlying genetics, the hope of discovering a single 
chemotherapy adjunct to surgery, which is capable of significantly improving 
survival, dissipates. Instead, the developing insight into this mysterious disease 
helps us to strive towards a more realistic goal. A cure for ovarian cancer is 
unlikely unless we can shift the timing of diagnosis to an earlier stage. The 
search for effective screening tools has yet to identify any factors that enable 
accurate identification of early stage disease and therefore we can anticipate 
that women will continue to present with non-specific symptoms at a late stage 
of disease. It is therefore more realistic to, at least initially, aim to turn ovarian 
cancer into a chronic disease rather than the ‘silent killer’, which it is currently 
regarded.  
It is not refuted that surgery plays an essential role in the management of 
ovarian cancer and that this should be undertaken only at a time when complete 
cytoreduction is thought to be achievable. Further discussion of judging the 
timing of surgery and the accuracy of predicting complete cytoreduction is not 
covered within the scope of this thesis.  Polypharmacy of adjuvant 
chemotherapy in the typical population of women affected by ovarian cancer is 
an unrealistic goal owing to the toxic profile of most available agents and the 
typical advanced age of patients, who often have multiple comorbid conditions, 
which limits chemotherapy options. It is perhaps unrealistic to expect a single 
targeted agent to offer the hope of a ‘magic bullet’ for ovarian cancer but it may 
be possible to increase PFS with the use of sequential novel agents, which may 
cumulatively add overall survival benefit.   
An alternative treatment strategy for ovarian cancer is long overdue but 
implementation is massively restricted by our limited ability to accurately predict 
response to treatment and the availability of effective agents. Additionally, for 
alternative treatment strategies to be implemented into routine practice, the 
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importance of the influence of tumour biology upon response to treatment and 
survival needs to be accepted by the clinical team and communicated 
effectively to our patients. 
8.1. Summary of Results 
The aim of this study was to explore the ability of a functional HR assay to 
predict sensitivity to various cytotoxic agents, including CNDAC - a novel 
nucleoside analogue, and the prediction of disease outcome. Additionally, 
project aimed to address the question of the optimal way to sample 
cancer in order to provide accurate, clinically relevant biological 
about an individual’s tumour by exploring sampling of the circulating 
cells as an alternative non-invasive biopsy to the sampling of ascites and 
tumour. A summary of the main objectives and the additional objectives 
during evolution of the project are shown in  
Table 8.1 - 1. 
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Aim 
Results 
Achieved 
Comment 
Characterise PCO cultures 
(antigen expression, growth 
potential, morphology) to further 
understand  validity of ex vivo 
cultures  
Yes Ovarian cancer is highly heterogeneous in terms of 
antigen expression, growth and morphology. 
Selection bias and antigen expression changes 
with the process of ex vivo culture  
Determine HR status of ascitic 
PCO samples and explore 
relationship with sensitivity to 
rucaparib and cisplatin 
Yes HR status of ascites, with ex vivo sensitivity data 
with PF/OS data completed for 56 patients.   
 
Develop a method for culture 
and HR characterisation of solid 
tumour  
Yes Culture success rate of 86%  
Explore spatial heterogeneity  
within an individual’s cancer by 
assessing variability of  
functional HR status  
Yes Heterogeneity exists in terms of antigen 
expression, growth, HR function and sensitivity to 
cytotoxic agents 
Determine the proportion of 
PCO cultures sensitive to 
CNDAC and assess HR status 
as a biomarker of sensitivity 
Yes 46% PCO cultures sensitivity to CNDAC. 
Stratification using HR function is likely to enrich 
for sensitivity to CNDAC. Additionally defective 
BER, is also likely to enrich for sensitivity 
Develop and validate a method 
for accurate identification, 
quantification and 
characterisation of CTCs from 
whole blood  
Yes CTC frequency is variable but typically low with a 
median frequency of 5.3 CTC/ml whole blood 
tested 
Explore relationship of 
enumeration with outcome  
Yes Small numbers but no clear relationship with stage 
or disease outside of the abdomen 
Develop a method for 
application of the HR assay to 
CTCs  
Yes HR assay using ImageStream developed and 
validated on cell lines and PCO samples. Method 
can be applied to ascitic cells and CTCs (in cases 
with greater numbers of CTCs) 
 
Table 8.1 - 1: Summary of objectives and project outcomes 
 
The use of PCO ascitic cultures described in this project has provided a 
valuable resource for the study of ovarian cancer tumour biology. Use of this 
model has many advantages over commercially available cell lines but also has 
several limitations. In this project, we have increased our understanding of the 
effect of culture on the phenotype of the PCO culture in terms of change in 
antigen detection, growth rate and morphology. We now appreciate the inability 
of ascites in isolation to accurately represent the entire tumour without further 
assessment of other areas of the tumour and, additionally, acknowledge the 
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high levels of resources and specialist expertise needed in order to create and 
maintain cultures for biological assessments. In the absence of a simple and 
reproducible alternative, this model should continue to be used to test the 
molecular profile of tumours and, whilst we continue to assess the validity of 
genomic profiling in predicting response, we should incorporate ascites 
assessment into clinical trials.  
This study confirms the high incidence of defective HR within ovarian cancer 
and also provides growing evidence of dysfunction within other DNA repair 
pathways. A functional biomarker utilising live cultured cells remains the most 
reliable way to stratify patients into functional groups, with good evidence that 
this correlates with sensitivity ex vivo and patient outcome (PFS). Irrespective of 
the specific genetic defect, the HR functional assay was able to predict the 
group of women who could potentially benefit from PARP inhibitors. Attempts to 
simplify the functional assay or provide alternative surrogate assays are 
promising but require further evaluation within trials to assess their PPV, NPV 
and application to the clinical setting.  
Additional cytotoxic agents are required if sequential targeted therapies are to 
be given and the sensitivity seen in ex vivo primary cultures in this study 
provides evidence for sapacitabine to progress to phase 1/2 clinical trials in 
ovarian cancer. Incorporation of translational research into these trials will be 
able to further evaluate the usefulness of HR, or perhaps BER, as markers of 
sensitivity.  
We have developed a technique for the successful culture of tumour from solid 
samples and have been able to perform subsequent characterisation and 
assessment of HR function and sensitivity to various cytotoxic agents. The 
greatest challenge that this project has identified is the question of how to 
adequately sample a tumour. We now appreciate the functional heterogeneity of 
ovarian cancer between individual patients, even those with tumours of the 
same histological subtype, and additionally within an individual patient with 
different areas of tumour having different abilities to repair DNA damage and 
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subsequent variable response to cytotoxic agents. Without assessing the intra-
tumoural heterogeneity, it is unrealistic to expect a single assay to accurately 
predict response to any cytotoxic agent and there is a danger that clinical trials 
that do not take this into account may underestimate the actual clinical benefit. 
Development of a novel technique to identify and characterise circulating 
tumour cells (CTCs) has enabled exploration of the ability to sample CTCs as a 
minimally invasive way to sample a tumour and assess its HR functional status. 
The limited number of CTCs identified even in advanced disease limits the use 
of this technique out of the academic setting. Additionally, it is impossible for 
CTCs alone to represent the multiple subpopulations of tumour and although we 
can hypothesise that the cells capable of gaining access and surviving within 
the harsh environment of the circulation are likely to be the most clinically 
aggressive, we as yet have no evidence to confirm this. The adaptation of the 
technique to use ImageStream to assess ascites may however offer the 
opportunity for rapid and detailed characterisation of ascites without labour 
intensive culture.  
It is becoming clear that ovarian cancer is a broad and diverse group of 
diseases and that, even within an individual’s tumour, there exists heterogeneity. 
This heterogeneity may be responsible for determining the variable response to 
chemotherapy seen and the inaccuracy of single biopsy determined biomarkers 
to precisely predict disease response.  
The major outcome from this project is the identification of the need for 
development of sampling regimes and the ability to map tumour according to its 
biological profile. This will require total revision of the definitions of ‘response’ 
and ‘relapse’ and of management pathways.  
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8.2. A New Treatment Strategy for Ovarian Cancer 
If the knowledge of intra-tumoural heterogeneity (ITH) is to be translated into 
clinical practice, it necessitates a new approach to treatment. It is likely that the 
different regions of heterogeneous tumours require treatment with multiple 
targeted agents. As discussed, simultaneous provision of multiple therapies 
ensuring a broad coverage of all subpopulations is not practical in ovarian 
cancer. If chemotherapies cannot be given in combination, sequential provision 
of therapy should be considered with re-stratification at each relapse.  
A combination of debulking surgery paired with the proven most effective 
cytotoxic agent for ovarian cancer, platinum, should remain central to our 
management. Following debulking surgery, whether this is primary surgery or 
interval surgery, all tumours should be sampled and characterised in terms of 
biomarkers indicative of sensitivity to novel targeted cytotoxic agents. In 
particular, any residual tumour that cannot be excised at the time of surgery 
should be sampled, as it is most likely that the residual tumour is the 
subpopulation that will expand and cause relapse/recurrence.  
At the time of relapse, the tumour should be re-biopsied and re-characterised 
with regards to a biomarker panel to enable selection of the targeted cytotoxic 
agent that should be used. This would enable provision of effective therapy 
whilst minimising side effects and, hopefully, improving PFS and OS, Figure 8.2 
- 1.  
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Figure 8.2 - 1: Schematic for the sequential Provision of Targeted Agents following 
Interim Tumour Sampling and Biomarker Testing 
 
Intra-tumour heterogeneity does however add a further complicating factor to 
this concept and a single biopsy will not be sufficient. Multiple biopsies from all 
areas of relapse within the abdomen will be required. This is likely to be best 
achieved laparoscopically, allowing multiple biopsies to be taken whilst 
assessing operability. The role of secondary, tertiary and quaternary surgery 
should not be overlooked, particularly in cases of isolated recurrences.  
The likely key to the successful treatment of the heterogeneous disease of 
ovarian cancer is sequential provision of cytotoxic agents. The current choice of 
cytotoxic agents available for the treatment of ovarian cancer is relatively limited 
and no current treatments have been paired with a reliable biomarker. Future 
treatments need to be selectively cytotoxic to cancer cells with minimal systemic 
side effects. They should work predictably in cancers identified to be sensitive 
to the agent, using a clinically useful assay.   
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8.3. Redefining Ovarian Cancer  
If the way in which we investigate and treat ovarian cancer is evolving then the 
definitions that we currently use for progression and relapse will shortly become 
inapplicable. The current clinical definitions are based upon clinical symptoms 
or multiple measurements of the tumour but are broad and consider the overall 
tumour, Table 8.3 - 1.   
Category Definition 
NCI (Institute 2014) 
Relapse The return of a disease or the signs and symptoms of a disease after a period 
of improvement.  
Recurrence Cancer that has returned usually after a period of time during which the cancer 
could not be detected 
Progression The course of a disease as it becomes worse or spreads in the body 
RECIST (Eisenhauer 2009) 
 Target lesions Non-target lesions 
Complete 
response 
(CR) 
Disappearance of all target lesions. 
Any pathological lymph nodes (target or 
non-target) must have reduced in short 
axis to <10 mm 
Disappearance of all non-target 
lesions and normalisation of 
tumour marker level. All lymph 
nodes must be non-pathological 
in size (<10 mm short axis) 
Partial 
response 
(PR) 
At least a 30% decrease in the sum of 
diameters of target lesions 
 
Non-CR/Non-PD 
Persistence of one or more non-
target lesion(s) and/or 
maintenance of tumour marker 
level above the normal limits 
Stable 
disease (SD) 
Neither sufficient shrinkage to qualify for 
PR nor sufficient increase to qualify for PD 
 
Progressive 
disease (PD) 
At least a 20% increase in the sum of 
diameters of target lesions with an 
absolute increase of at least 5 mm. The 
appearance of one or more new lesions is 
also considered progression. 
Unequivocal progression  
of existing non-target lesions. 
The appearance of one or more 
new lesions is also considered 
progression. 
Table 8.3 - 1: Ovarian Cancer Clinical and Radiological Definitions of Disease 
Response  
 
RECIST (response evaluation criteria in solid tumours) is a set of published 
rules that define responsive, stable or progressive disease during treatment 
(Eisenhauer 2009). The original criteria were published in 2000 by an 
international collaboration, which included the European Organisation for 
Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) of 
the United States and the National Cancer Institute of Cancer Clinical Trials 
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group. RECIST helps to categorise tumours based upon their radiological 
appearance, giving an overall summary of the changes seen. With the 
knowledge of the presence of intra-tumoural heterogeneity and the appreciation 
that distinct areas of tumour are likely to behave differently to a single cytotoxic 
agent, then it is likely that we are to anticipate response in one targeted area 
only. Modification to RECIST or an alternative system may therefore be needed 
to enable description of the individual tumour areas. This method heavily relies 
upon measurement of tumour size from CT imaging and, in fact, alternatives to 
this may need to be considered.  
8.4. Ovarian Cancer Heterogeneity: Implications for Academia 
The provision of clinical samples, with time, will help to unravel the difficulties in 
understanding the importance of adequate sampling of tumour. As the ability to 
molecular profile tumours continues to grow and we begin to understand the 
effects of molecular aberrations on overall function of the cells and subsequent 
response to therapy, then more questions are likely to arise. If multiple 
pathways are dysfunctional, then how will the dysfunctional pathways interact 
and are there ‘dominant’ mutations that are known to be the most important and, 
if present, should dictate management irrespective of their prevalence or 
presence of other mutations? Understanding the interplay of all the important 
pathways in ovarian cancer, alongside the highly variable and influential clinical 
factors, is a sizable and daunting challenge and perhaps unachievable using 
current technologies. This should however be readdressed with the introduction 
of biological programming with artificial intelligence systems (Enshaei 2015). 
8.5. Strengths and Weaknesses  
The mixed nature of the patients, histological subtypes, timing and outcome of 
surgery initially appears to be a limitation of this work as this heterogeneous 
group of patients and samples may not be considered directly comparable. 
However, this may also be one of the greatest strengths of this project as it 
demonstrates that categorisation of tumours based upon histology alone is 
largely unhelpful and does not reliably predict outcome or response to treatment. 
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Categorisation of tumours using functional status of the DDR does however 
appear to enable more accurate prediction of outcomes and should be used to 
inform provision of additional cytotoxic agents.  
One strength of our study, in terms of clinicopathological and survival data, is 
that it was a prospective observational study. Although not randomised, 
clinicians involved in managing the patients were not aware of the HR status of 
cultures. 
The number of women from whom multiple solid tumour biopsies were taken 
may be considered small but the data included demonstrates the variability of 
heterogeneity and provides sufficient pilot data to justify a larger trial. Clearly, 
standardisation of the number and location of biopsies would be needed and 
large numbers of participants would be required for meaningful analysis of the 
effect of heterogeneity upon outcome to be undertaken.  
The work in this study adds to the growing evidence regarding the importance 
of the HR pathway within ovarian cancer and, at present, there are no reliable 
alternatives to the labour intensive functional Rad51 assay. Ongoing efforts to 
identify a reliable and rapid alternative are still needed but require validation 
alongside the functional assay in paired samples from the same tumour site as 
previous genomic signatures may have been falsely excluded due to incorrect 
sampling of heterogeneous tumours. 
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8.6. Future Work 
1. Validation of a genomic sequence for HR function using RNA extracted 
from FFPE tissue matched for biopsy location of solid cultures with HR 
function determined by Rad51 assay (FFPE blocks available). 
2. Development of a database and tissue bank to enable accurate 
documentation and storage of multiple biopsies from multiple sites in 
patients recruited to research.  
3. Continued collection of serial samples from the same patient at different 
time points to explore tumour evolution with time and therapy. 
4. Exploration of the fallopian tube as the site of origin of ovarian/primary 
peritoneal cancer using historical FFPE of STIC lesions. The gene 
signature created from HRD cultures will be applied and used to stratify 
STIC lesions into functional HR groups and correlate with PFS/OS and 
other clinical features. Collaboration with Dr James Bierne (Centre for 
Cancer Research and Cell Biology, Queens University Belfast).  
5. Feasibility of alternative culture methods (splice tumour culture) will be 
tested with solid ovarian tumour to assess if a higher yield of cells will 
result which can be used in a wider variety of assays. This will 
incorporate the per-tumour stroma allowing the impact of this to be 
assessed in terms of growth.  
6. Studying protein expression by IHC in the tumour incorporated into FFPE 
has failed to identify a marker capable of reliably predicting HR functional 
status (although tumour biopsies have been compared to HR status of 
ascites, not a solid tissue culture from the corresponding area of tumour 
from which the biopsy was taken). Assessment of the stroma alongside 
tumour can be undertaken in FFPE tissues already available to explore 
the ability of a stromal score to predict HR function of tumour. 
7. Further quantification of BER dysfunction in ovarian cancer with 
exploration of manipulation of activating/deactivating agents as well as 
APE1 inhibitors.    
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8. The low number of CTCs detected in ovarian cancer alongside the 
heterogeneous nature of the disease, limit the validity of any biological 
assessment performed upon CTCs. Instead of studying molecular 
biology of these cells, the response to treatment will be assessed in real 
time by assessing the impact of cytotoxic agents on CTC cell cycle.  For 
examples, platinum is known to induce G2 arrest. CTC blood sample 
obtained pre-chemo can be compared to a sample collected during 
chemo and any changes in cell cycle assessed. This may be an early 
indicator of likely response alongside enumeration.  
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Appendix 6: Detailed Patient Demographics 
PCO 
Date of 
Collection 
Age (yrs) 
FIGO 
Stage 
Histological subtype 
Pre-op 
CA125 
(U/L) 
Surgery Cytoreduction NACT Adjuvant Chemo 
PFS OS 
(months) 
138 12/10/2011 70 3C HGSC 1412 Primary Suboptimal NA 6 x carbo/taxol 29 30 
139 21/10/2011 77 4 Endometrioid/Clear 1445 Primary Optimal NA NA 9 9 
142 31/10/2011 62 3C 
HGSC 
/Endometrioid/Clear 
896 Primary Optimal NA NA 2 2 
143 21/11/2011 46 3C HGSC 1465 Primary Optimal NA 6 x carbo/taxol 10 10 
144 02/12/2011 60 1A Endometrioid/Clear 1317 Primary Optimal NA 6 x carbo/taxol 29 36 
154 22/02/2012 78 3C Carcinosarcoma 618 Primary Complete NA NA 10 10 
155 22/02/2012 55 NA 
Appendix 
adenocarcinoma 
117 Primary Optimal NA FOLFOX 14 18 
156 27/02/2012 49 4 HGSC 1320 IDS Optimal 4 x carbo/taxol 1 x carbo/taxol 9 13 
157 02/03/2012 58 3C HGSC 500 Primary Suboptimal NA 
6 x carbo/taxol; 
tamoxifen 
11 12 
158 05/03/2012 68 3C HGSC 780 Primary Optimal NA 4 x carboplatin 4 4 
162 23/04/2012 68 3C HGSC 186 Primary Optimal NA 6 x carbo/taxol 18 31 
163 02/05/2012 77 3C HGSC 500 Primary Optimal NA 5 x carbo/taxol 14 31 
167 18/06/2012 63 3C 
HG Neuroendocrine 
tumour 
600 Primary Optimal NA Cisplatin/etoposide 7 7 
168 19/06/2012 66 3C HGSC 1500 Primary Complete NA 6 x carbo/taxol 14 29 
169 13/07/2012 72 3C HGSC 176 IDS Optimal 3 x carbo/taxol 3 x carbo/taxol 10 11 
170 03/08/2012 73 3C HGSC 10000 IDS Suboptimal 4 x carbo/taxol 
2 x carbo/taxol; 
bevacizumab 
20 27 
171 22/08/2012 75 3C HGSC 1285 IDS Optimal 4 x carbo/taxol 2 x carbo/taxol 24 31 
174 12/09/2012 45 3A Endometrioid 552 Primary Complete NA 
6 x carbo, 2 x 
taxol, 4 x docetaxol 
15 26 
175 12/09/2012 66 3B Clear cell 250 Primary Optimal NA 5 x carbo/taxol 6 8 
177 16/10/2012 46 3C HGSC 6 IDS Optimal 4 x carbo/taxol 2 x carbo/taxol 13 23 
179 09/11/2012 66 4 HGSC 800 IDS Optimal 4 x carbo/taxol 2 x carbo/taxol 12 1117 
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180 19/11/2012 50 3C HGSC 521 IDS Optimal 3 x carbo/taxol 3 x carbo/taxol 11 12 
181 19/11/2012 72 3C HGSC 180 IDS Optimal 3 x carbo/taxol 3 x carbo/taxol 10 11 
182 23/11/2012 61 3C HGSC 286 IDS Complete 3 x carbo/taxol 
3 x carbo/taxol; 
tamoxifen; 5 x 
rucaparib 
11 38 
183 28/11/2012 82 2C HGSC 6388 Primary Complete NA 4 x carbo/taxol 19 21 
184 05/12/2012 73 3C HGSC 10,000 IDS Suboptimal 4 x carbo/taxol 2 x carbo/taxol 21 28 
185 07/01/2013 58 4 HGSC 500 IDS Complete 4 x carbo/taxol 2 x carbo/taxol 10 13 
186 09/01/2013 47 3C HGSC 74 Primary Complete NA 6 x carbo/taxol 7 9 
187 10/01/2013 71 3C HGSC 2013 Primary Optimal NA 6 x carbo/taxol 12 20 
190 28/01/2013 75 3C Mucinous 135 Primary Complete NA 6 x carbo/taxol 9 11 
191 31/01/2013 75 3C HGSC 346 Primary Optimal NA 6x carbo/taxol 12 16 
192 06/02/2013 66 3C Endometrioid/Clear 2425 Primary Optimal NA 3 x carbo/taxol 4 7 
194 25/02/2013 59 NA 
Adenocarcinoma (enteric 
type) in mature teratoma 
1000 Primary Suboptimal NA NA 2 2 
197 06/03/2013 63 3C HGSC 2000 primary Optimal NA 6 x carboplatin 21 21 
199 09/12/1949 63 3C HGSC 69 primary Complete NA NA 26 66 
200 20/03/2013 59 3C HGSC 602 IDS Optimal 4 x carbo/taxol 2 x carbo/taxol 10 20 
201 20/03/2013 55 3C HGSC 678 primary Optimal NA 
6 x carbo/taxol; 
tamoxifen; 
rucaparib 
10 36 
202 27/03/2013 52 3C HGSC 1352 IDS Optimal ICON8 3 x carbo/taxol 23 25 
205 15/04/2013 67 1C Clear  203 Primary Complete NA 6 x carbo/taxol 12 18 
209 26/04/2013 52 3C HGSC 419 Primary Optimal 4 x carbo/taxol 2 x carbo/taxol 5 9 
210 04/05/2013 63 3C HGSC 420 Primary Optimal NA 6 x carbo/taxol 21 21 
211 04/05/2013 53 3C HGSC 869 Primary Optimal NA 6 x carbo/taxol 20 20 
213 10/05/2013 85 4 HGSC 1295 NA NA NA NA 4 4 
217 31/05/2013 81 3C HGSC 2738 IDS Optimal 6 x carbo/taxol NA 5 8 
218 31/05/2013 62 3C HGSC 150 Primary Optimal NA 6 x carbo/taxol 35 43 
219 03/06/2013 60 3C HGSC 1445 IDS Optimal 4 x carbo/taxol 2 x carboplatin 4 13 
221 05/06/2013 72 2C Carcinosarcoma 1000 IDS Optimal 4 x carbo/taxol 2 x carbo/taxol 14 21 
222 07/06/2013 47 3C HGSC 6 IDS optimal 4 x carbo/taxol 2 x carbo/taxol 13 25 
223 05/07/2013 43 3C HGSC 2074 Primary Optimal NA 3 x carbo/taxol 17 17 
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224 12/07/2013 70 3C HGSC 325 Primary optimal NA 5 x carbo/taxol 8 9 
225 15/07/2013 48 3C HGSC 2852 Primary Optimal NA 
6 x carbo/taxol; 
bevacizumab 
8 15 
226 24/07/2013 83 3C Low grade serous 1964 Primary Optimal NA Tamoxifen 3 9 
227 26/07/2013 63 3C HGSC 8430 Primary Suboptimal NA 6 x carbo/taxol 16 16 
228 12/08/2013 59 4 HGSC 2349 Primary Optimal NA 6 x carbo/taxol 12 15 
229 11/09/2013 71 4 HGSC 6521 Primary Optimal NA 
2 x carbo/taxol; 4 x 
carboplatin 
13 14 
230 11/09/2013 41 3C HGSC/Clear cell 1743 Primary Optimal NA 6 x carbo/taxol 11 14 
231 01/10/2013 69 3C HGSC 388 NA NA 6 x carbo/taxol NA 11 13 
233 02/10/2013 69 4 HGSC 8407 IDS Suboptimal 6 x carbo/taxol NA 13 14 
234 02/10/2013 60 3C HGSC 1252 IDS Optimal 4 x carbo/taxol 2 x carboplatin 4 13 
238 25/10/2013 76 3C HGSC 1317 IDS Suboptimal 4 x carbo/taxol 
2 x carbo/taxol; 
bevacizumab 
15 15 
239 25/10/2013 77 3C HGSC 4361 NA NA 
no chemo (too 
frail) 
NA 1 1 
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PCO Morphology 
Antigen Characterisation (immuofluorescent panel) 
FFPE 
IHC 
Doubling 
time 
HR BER GI50 (SRB proliferation assay) % Survival at * (SRB proliferation assay) 
CK EpCAM CA125 MOC31 D240 Vimentin CA125 (hrs) (Rad51) (8-OHdG) 
Rucaparib 
(μM) 
CNDAC 
(μM) 
Cisplatin 
(μM) 
Rucaparib 
(*100μM) 
CNDAC 
(*100μM) 
Cisplatin 
(*10μM) 
221 Mes + + - - - + - 105.0 Comp 50.54 26.6 >100 >10 37.4 54.9 67.8 
231 Cob + - - - - + +   Comp 34.16 17.6 >100 >10 31.4 83.3 91.8 
184 Mes + + + + - + + 280.5 Comp 34.16 60.3 >100 >10 25.8 58.4 60.2 
230 Cob + - - - - + + 65.1 Comp 18.07 34.6 >100 7.8 35.7 96.0 45.6 
229 Cob + - - - - + ND 80.6 Comp 14.44 >100 >100 8.8 56.3 94.2 47.3 
187 Cob + + + + - + ND 153.1 Comp 10.62 21.7 >100 8.4 22.3 61.0 42.9 
154 Cob + - + - - + ND 93.3 Comp 8.50 >100 >100 >10 55.7 55.9 49.4 
170 Cob + - + - - + + 211.2 Comp 7.83 53.1 >100 >10 23.2 63.5 48.6 
209 Cob + - + - - + + 148.4 Comp 5.40 >100 2.5 >10 63.4 20.3 76.7 
202 Cob + - - - - + + 87.5 Comp 3.63 0.0 0.6 >10 86.7 13.4 105.5 
142 Cob + + + ND ND ND ND 130.2 Comp 3.42 14.3 >100 0.6 34.4 79.1 10.7 
175 Cob + - + + - + ND 91.3 Comp 3.20 45.5 42.8 >10 45.0 45.0 53.8 
177 Mes + patchy + + - + ND 112.6 Comp 3.15 >100 >100 >10 64.9 72.4 72.4 
181 Cob + - - ND - + + 111.4 Comp 3.13 >100 >100 >10 59.8 61.6 93.1 
186 Cob + - + - - + ND ND Comp 3.13 ND ND >10 ND ND 79.1 
185 Cob + + + + - + ND ND Comp 3.00 ND ND >10 ND ND 86.4 
182 Cob + + + + - + + 125.8 Comp 2.98 >100 42.9 4.7 55.5 48.4 41.1 
225 Cob + - - - - + + 123.6 Comp 2.92 10.3 >100 >10 32.9 58.9 42.0 
139 Mes + ND ND ND ND ND ND ND Comp 2.88 73.4 11.6 6.6 38.9 29.2 49.6 
157 Cob + ND + ND ND ND ND 310.7 Comp 2.87 >100 >100 >10 61.3 91.1 74.0 
138 Mes + - - ND ND ND + ND Comp 2.68 5.5 37.2 >10 34.4 46.7 53.8 
192 Cob + - patchy - - + + 232.4 Comp 2.62 >100 >100 >10 102.1 67.3 98.0 
224 Cob + - patchy - - + ND 90.3 Comp 2.52 7.8 >100 8.0 20.6 61.9 38.0 
194 Cob + - patchy - - + - 79.3 Comp 2.13 12.6 >100 >10 24.7 73.7 53.2 
174 Cob + - + - - + - 35.0 Comp 2.05 >100 >100 >10 58.6 70.0 75.6 
167 Cob + ND - ND ND + - 115.7 Comp 1.89 >100 >100 4.6 76.3 74.0 36.6 
180 Cob + - + - - + + 206.9 Comp 1.61 >100 >100 >10 116.0 92.1 109.7 
169 Cob + - - ND - + + 111.4 Comp 1.61 >100 >100 >10 59.8 61.6 93.1 
168 Mes + - + ND ND + ND 127.7 Comp 1.61 >100 30.3 >10 46.7 38.6 71.1 
227 Cob + - patchy - - + + 131.1 Def 11.18 72.4 8.7 2.1 49.8 27.2 35.4 
210 Cob + - - - - + + 135.0 Def 10.91 84.2 6.8 >10 48.2 12.8 53.5 
222 Cob + + patchy + - + ND 268.5 Def 7.23 14.6 28.3 0.6 42.1 45.0 26.2 
226 Cob + - patchy patchy - + ND 160.5 Def 4.25 14.6 28.3 2.3 42.1 45.0 31.9 
144 Cob + - + - - + +   Def 3.46 58.9 34.9 3.6 42.1 38.5 36.1 
211 Cob + - patchy - - + ND 97.6 Def 3.43 >100 >100 9.9 62.2 61.0 50.6 
219 Cob + - + - - + + 83.0 Def 2.85 2.2 14.4 4.6 21.6 24.1 35.7 
197 Cob + - - - - + + 95.3 Def 2.79 >100 53.9 >10 50.9 45.0 57.7 
191 Cob + + + + - + + 277.9 Def 2.71 26.4 27.8 3.4 43.9 46.8 48.8 
213 Cob + - - - - + ND 98.2 Def 2.70 2.4 58.2 6.0 28.4 44.5 45.1 
183 Mes + - + - - + + 193.6 Def 2.43 10.9 18.5 >10 33.7 34.8 51.0 
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179 Mes + + + + - + + 134.3 Def 2.16 14.6 >100 >10 42.1 53.6 61.7 
190 Cob + - patchy - - + - 112.5 Def 2.12 35.0 1.5 3.2 40.1 17.9 34.0 
234 Mes + + - - - + + 196.8 Comp ND >100 >100 >10 90.2 96.3 94.1 
199 Cob + - patchy - - + ND 486.7 Comp ND >100 >100 >10 82.9 103.6 106.2 
233 Cob + - - - - + ND 303.1 Comp ND >100 >100 >10 81.3 73.6 67.5 
171 Cob + - + ND ND ND ND 273.7 Comp ND >100 >100 >10 77.7 63.5 60.3 
201 Cob + - - + - + ND 272.8 Comp ND >100 >100 >10 63.1 67.3 96.7 
205 Cob + pathy + - - + ND 118.5 Comp ND >100 12.8 >10 55.8 34.3 61.7 
162 Cob + ND + ND ND ND ND ND Comp ND 52.6 ND ND 33.6 ND ND 
163 Mes + ND + ND ND ND ND ND Comp ND 27.5 ND ND 30.2 ND ND 
239 Cob + - - - - + + 200.7 Comp ND 24.6 >100 >10 29.8 55.1 82.9 
238 Cob + - patchy - - + ND 110.9 Def ND 78.7 >100 >10 45.8 86.4 93.0 
143 Cob + - - ND ND ND + 87.5 Def ND 72.3 39.0 9.1 38.5 42.5 47.6 
158 Cob + ND + ND ND ND + 148.7 Def ND 13.4 >100 >10 38.3 97.3 84.5 
223 Cob + - patchy - - + + 129.3 Def ND 1.3 >100 >10 37.1 59.3 67.5 
217 Cob + - + - - + ND 178.3 Def ND 47.1 13.6 0.9 36.2 26.9 32.4 
200 Cob + + + + - + + 312.4 Def ND 0.4 0.5 1.4 34.5 23.9 46.2 
218 Cob + + patchy + - + + 284.2 Def ND 1.2 1.5 0.2 33.8 29.4 24.3 
156 Mes + - + + - + + 168.7 Def ND 11.1 44.2 1.9 33.7 45.0 34.8 
228 Mes + - + + - + ND 168.7 Def ND 10.9 18.5 2.8 33.7 34.8 27.3 
155 Cob +   -       - ND Def ND 0.0 ND ND 21.5 ND ND 
 
Morphology: Cob = cobblestone; Mes = mesenchymal. ND = Not done. GI50 and % survival determined by SRB cell proliferation assays.  
PCO cultures are ordered by HR status (HRC = Red; HRD= Blue), then by BER status (BERC = Orange; BERD = Pale blue), then by sensitivity to 
rucaparib, CNDAC and cisplatin (Resistant = hatched red, sensitive = hatched green).   
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Appendix 7: Solid Tumour Case Series 
PCO 
Age  
(year
s) 
CA125 
(U/L) 
Histological 
subtype 
FIGO 
Stage  
Surgery Sample 
timing 
(pre-post 
chemo) 
NACT Post-op chemotherapy 
PFS OS 
Primary / 
IDS 
Debulking 
outcome 
(months) 
155 55 117 Adenocarcinoma  3C Primary Optimal Pre NA FOLFOX 15 18 
156 49 1320 HGSC 4 IDS Optimal Post 4 carbotaxol 1 carbotaxol 5 8 
157 58 500 HGSC 3C Primary Suboptimal Pre NA 6 carbotaxol, tamoxifen 10 12 
158 68 780 HGSC 3C Primary Optimal Pre NA 6 carboplatin (>22) (>22) 
162 68 186 HGSC 3C Primary Optimal Pre NA 6 carbotaxol (>21) (>21) 
163 77 500 HGSC 3C Primary Optimal Pre NA 5 carbotaxol 13 (>20) 
167 63 600 Neuroendocrine 3C Primary Optimal Pre NA Cisplatin, etoposide 6 7 
168 66 1500 HGSC 3C Primary Complete Pre NA 6 carbotaxol 14 (>15) 
174 45 552 Endometrioid 3A Primary Complete Pre NA 6 carboplatin, 2 placlitazol, 4 
docetaxol 
(>16) (>16) 
175 66 250 Clear cell 3B Primary Optimal Pre NA 5 carbotaxol 5 8 
179 66 57 HGSC 4 IDS Optimal Post 4 carbotaxol 2 carbotaxol 8 (>14) 
180 50 521 HGSC 3C IDS Optimal Post 3 carbotaxol 3 carbotaxol 8 (>9) 
181 72 176 HGSC 3C IDS Optimal  Post 3 carbotaxol 3 carbotaxol 5 7 
183 82 6388 HGSC 2C Primary Complete Pre NA 4 carboplatin (>13) (>13) 
184 73 9740 HGSC 4 IDS Suboptimal Post 4 carbotaxol 2 carbotaxol (>16) (>16) 
185 58 500 HGSC 4 IDS Complete Post 4 carbotaxol 2 carbotaxol (>9) (>9) 
186 47 74 HGSC 3C Primary Complete Pre NA 6 carbotaxol (>9) (>9) 
192 66 2425 Clear cell 3C Primary Optimal Pre NA 3 carbotaxol 4 7 
200 59 602 HGSC 3C IDS Optimal Post 4 carbotaxol 2 carbotaxol (>6) (>6) 
201 55 678 HGSC 3C Primary** Optimal Pre NA 6 carbotaxol, tamoxifen, 
rucaparib 
11 36 
209 52 419 HGSC 3C IDS* Optimal Post 4 carbotaxol 2 carbotaxol (>7) (>7) 
217 81 2738 HGSC 3C No surgery Post 3 carbotaxol 6 carbotaxol (>7) (>7) 
223 43 2074 HGSC 3C Primary Optimal Pre NA 3 carbotaxol (>6) (>6) 
226 83 1964 Low grade serous 3C Primary Optimal Pre NA Tamoxifen (>6) (>6) 
228 59 2349 HGSC 4 Primary Optimal Pre NA 6 carbotaxol (>6) (>6) 
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Appendix 8: CTC Method Development  
Sample preparation methods were evaluated by assessing uniformity and 
consistency of fluorochrome staining for both cell surface and intracellular 
antigens in comparison to parallel experiments using traditional fixed cell 
immunofluorescent microscopy. 
CA125 Antibody Fluorochrome Conjugation  
The APEX™ antibody labelling kit was used to covalently bind AlexaFlour-594 
to anti-CA125 antibody, as per manufacturer’s instructions (Life Technologies, 
2013). Briefly, the hydrated resin filled APEX tip was incubated for 2 hours 
with 10 μg of IgG CA125 antibody and 10 μl of fluorochrome dye solution 
before washing twice with 50 μl wash buffer. Conjugated antibody was eluted 
with 40 μl elution buffer and stored with 10 μl neutralisation buffer at -20 °C.  
Uniformity and intensity of antigen detection, using conjugated CA125 
antibody, was compared to a 2-step process using traditional 
immunofluorescent microscopy and ImageStream cell suspensions. 
Consistent results (n = 5) were seen and the method adopted for all 
ImageStream characterisation.  
  
 318 
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B 
 
C 
 
D 
 
 
Figure 9.1 – 1: CA125 conjugation validation. A: Immunofluoresent microscopy 
showing PCO 142 stained with anti-CA125 conjugated with AF594. B: PCO 142 
stained with anti-CA125 and secondary AF594 in a 2-step process. C: ImageStream 
assessment of % of OVCAR 3 cells with detected expression of CA125 using 
conjugated CA125 at variable concentrations as indicated. D: ImageStream images 
of OVCAR 3 cells using 1:10, 1:20 and 1:50 concentration. 
 
Fixation and Permeabilisation 
OVCAR3 cells were trypsinised and PBS washed prior to fixation. All cells 
were permeabilised with BD Phosflow Perm/Wash Buffer I for 12 hours before 
incubating with EpCAM, CK, CA125 and DRAQ 5 antibodies for 12 hours. 
Five fixatives were investigated, Table 9.1 - 1. Methanol fixation resulted in 
consistent detection of both surface and intracellular antigens and was 
adopted for use in cell line experiments. Comparable results were achieved 
with BD Phosflow Lyse/Fix Buffer and this was adopted for use in blood 
sample processing due to simultaneous fixation and lysis of RBC.  
C o n ju g a te d  C A 1 2 5
A n tib o d y  C o n c e n tra t io n
%
1 :5 1 :1 0 1 :2 0 1 :5 0 F ix e d  IF
0
2 0
4 0
6 0
8 0
1 0 0
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Fixative Method Results 
Methanol 2 ml 100% methanol 
at -20 °C for 20 minutes 
Preservation of cell morphology, surface, 
intracellular and nuclear antigens. Good cell 
recovery. 
Paraformaldehyde   2 ml 0.4% at 4 °C for 20 
minutes 
Preservation of cell morphology, surface and 
internal antigens as well as good cell recovery. 
BD Phosflow Lyse/Fix 
buffer 
1:20 (2 ml PBS: 40 ml 
buffer) at 37 °C for 15 
minutes  
Preservation of cell morphology, surface and 
internal antigens as well as good cell recovery. 
Simultaneous red cell lysis.  
Acetone 
 
2 ml 80% at -20 °C for 20 
minutes  
Shrinking effect with distortion of cellular 
morphology. 
Acetone/Methanol 2 ml v:v at 4 °C Shrinking effect with distortion of cellular 
morphology. 
 Table 9.1 - 1: Optimisation of cell suspension fixation.  
 
Nuclear Foci Mask Optimisation 
Mask optimisation was undertaken by manual adjustment of mask features 
and visual confirmation of correct outing the fluorescence antigen of interest, 
Table 9.2 - 1. Two reviewers independently ranked 5 mask options and three 
were selected for further assessment. The method for accurate quantification 
of foci using IDEAS Software was optimised by counting γH2AX foci in a 
series of OSEC2 cells, fixed at varying times, following induction of DSB by 
irradiation. Using the various nuclear mask and spot count functions, 
ImageStream counts were compared to counts obtained in parallel samples 
assessed with conventional IF microscopy, counted with ImageJ Software and 
to a series counted manually, Figure 9.2 - 1. 
A 
 
B  Rad51 foci mask
 
γH2AX foci mask
 
Nuclear mask
 
 
Figure 9.2 - 1: HR assay optimisation of nuclear, γH2AX and Rad51 foci masks 
DRAQ5 and γH2AX antibody labelling on an OSEC2 cell and their respective 
optimised masks. 
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Figure 9.3 - 1: γH2AX focus dose response comparing three ImageStream masks 
with traditional immunofluorescent microscopy and manual counting.   
Fold increase of mean γH2AX focus count in OSEC2 cells, fixed at various time 
points following induction of DS DNA with 2 Gy irradiation, in comparison to control. 
The results are from parallel experiments comparing traditional IF microscopy to 
ImageStream. 
 
Foci Count 
Method 
 
ImageStream settings 
 
Correlation with IF 
count 
r p 
Spot (Peak) Spot Count [Peak(M03,Ch03, Bright, 50)] 0.7738 0.0142* 
Threshold (80) Threshold(M03, Ch03, 80) 0.8947 0.0065** 
Peak (20) Peak(M03,Ch03, Bright 50)  0.7127 0.0722 
Spot (5.5:1) Spot(M03,Ch03,Bright 5.5,1) 0.5298 0.2213 
Manual Count NA 0.7616 0.0466* 
 
Table 9.2 - 1: Imagestream IDEAS settings for Rad51 foci HR assay. 
 
Positive correlation was seen between the fold increases from control 
between conventional IF results and results using ImageStream Spot (Peak) 
and Threshold functions. Additionally, Spot (Peak) function gave the most 
accurate outline of actual foci confirmed visually and was used as the 
optimum mask for γH2AX foci quantification and these settings used for the 
analysis of all further experimental samples.  
The same analysis was repeated for Rad51 foci and Spot Count [Peak(Ch02, 
Bright, 50)] used for further analysis.  
C o n tr o l AS AP 1 2 4 6 1 0
0
5
1 0
 H 2 A X  fo c i fo ld  in c re a s e :
Im a g e s tre a m  v s  IF  m ic ro s c o p y  v s  M a n u a l c o u n t
T im e  to  fix a t io n  (h o u rs )
F
o
ld
 i
n
c
r
e
a
s
e
 f
r
o
m
 c
o
n
tr
o
l
IF  M ic ro s c o p y
Im a g e S tre a m
S p o t  (P e a k )
Im a g e s tre a m
T h re s h o ld  (8 0 )
Im a g e S tre a m
P e a k  (2 0 )
M a n u a l c o u n t
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Data Analysis  
A population of single focused cells was gated for further analysis before 
creating a nuclear mask based upon intensity of DRAQ5 nuclear stain  
[Fill(Intensity(M11, Ch11, 400-4095)]. This was combined with a peak 
intensity mask [γH2AX: Peak(Ch03, Bright, 20) or Rad51: [Peak(Ch02, Bright, 
50)] to identify the foci and combined with the Spot function used to quantify 
foci. The mean Spot Count was used to calculate the fold-increase between 
the irradiated and control samples.  
Dose Response Curve 
To further validate ImageStream assessed focus count, a series of OVCAR3 
cells were irradiated at varying doses of IR and γH2AX focus quantified. Mean 
foci count per cell assessed using ImageStream was compared with mean 
foci count per cell counted using ImageJ and IF. Poor correlation was seen 
and this lack of correlation of actual focus count between the two methods is 
in keeping with previous published work (Bourton 2012). Alternative 
methodologies for quantification of foci were explored. The change in 
proportion of cells counted with mean foci counts above a threshold level of 5, 
10 or 15 foci per cell from control was compared to traditional IF and strong 
correlation seen between ImageStream assessment of the proportion of cells 
foci count >15 and traditional counting methods using ImageJ, r = 0.9094, 
p<0.0001. This counting method was adopted for further experiments.  
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Figure 9.4 - 1: γH2AX foci following irradiation at different doses. Assessment of 
count using ImageStream.  
 
Method Optimisation in PCO  
When applied to cell suspensions of trypsinised PCO cultures, the method 
described for HR assessment above resulted in poor intra-nucleic 
permeabilisation and non-specific cytoplasmic staining. Numerous 
optimisation steps were undertaken, Figure 9.5 - 1. 
  
 H 2 A X  fo c i d o s e  re s p o n s e  to  IR
F
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l
C o n tr o l 1 2 3 4 5 1 0
0
5
1 0
1 5
M e a n  c o u n t/c e ll
IS
P ro p o rt io n  c e lls  > 5  fo c i/c e ll
P ro p o rt io n  c e lls  > 1 0  fo c i/c e ll
P ro p o rt io n  c e lls  > 1 5  fo c i/c e ll
Ir ra d ia t io n  (G y )
M e a n  c o u n t/c e ll
IF
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Figure 9.5 - 1: HR method pptimisation in PCO cultures. Demonstrating the 
experiments undertaken to optimise the protocol for the identification of γH2AX foci in 
PCO cultures using ImageStream. Cells were irradiated at 2 Gy and labelled with 
γH2AX and DRAQ5 antibodies. The optimisation steps made in each experiment are 
highlighted in red. 
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